Hercules Capital (HTGC) 10-Q 2 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 27, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Central Index Key	0001280784
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		130,149,104
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	814-00702
Entity Tax Identification Number	74-3113410
Entity Address, Address Line One	400 Hamilton Ave
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	289-3060
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MD
Document Quarterly Report	true
Document Transition Report	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Shares, par value $0.001 per share
Trading Symbol	HTGC
Security Exchange Name	NYSE
6.25% Notes Due 2033
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2033
Trading Symbol	HCXY
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF ASSE

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2022		Dec. 31, 2021
Assets
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	$ 2,825,738		$ 2,434,522
Cash and cash equivalents	57,065		133,115
Restricted cash (amounts related to a VIE $8,346 and $0, respectively)	8,346		3,150
Interest receivable	25,494		17,365
Right of use asset	5,672		6,761
Other assets	2,207		5,100
Total assets	2,924,522		2,600,013
Liabilities
Debt (net of debt issuance costs - Note 5; amounts related to a VIE $147,810 and $0, respectively)	1,521,220		1,236,303
Accounts payable and accrued liabilities	34,492		47,781
Operating lease liability	6,092		7,382
Total liabilities	1,561,804		1,291,466
Net assets consist of:
Common stock, par value	131		117
Capital in excess of par value	1,288,341		1,091,907
Total distributable earnings	74,246		216,523
Total net assets	(1,362,718)		(1,308,547)
Total liabilities and net assets	$ 2,924,522		$ 2,600,013
Shares of common stock outstanding ($0.001 par value and 200,000,000 authorized)	130,191		116,619
Net asset value per share	$ 10.47		$ 11.22
Investment, Unaffiliated Issuer [Member]
Assets
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	$ 2,745,413		$ 2,351,560
Investment, Affiliated Issuer, Controlled [Member]
Assets
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	80,325	[1]	73,504	[2]
Investment, Affiliated Issuer, Noncontrolled [Member]
Assets
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	$ 0		$ 9,458	[2]
[1] All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

CONSOLIDATED STATEMENTS OF AS_2

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investment cost	$ 2,869,469	$ 2,390,984
Restricted cash (amounts related to a VIE $8,346 and $0, respectively)	8,346	3,150
Net of debt issuance costs	$ 1,521,220	$ 1,236,303
Common stock, par value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Investment, Unaffiliated Issuer [Member]
Investment cost	$ 2,782,220	$ 2,293,398
Investment, Affiliated Issuer, Controlled [Member]
Investment cost	87,249	84,039
Investment, Affiliated Issuer, Noncontrolled [Member]
Investment cost	0	13,547
VIE
Investment cost	236,826	0
Restricted cash (amounts related to a VIE $8,346 and $0, respectively)	8,346	0
Net of debt issuance costs	$ 147,810	$ 0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended				9 Months Ended
		Sep. 30, 2022		Sep. 30, 2021		Sep. 30, 2022		Sep. 30, 2021
Investment income:
Total interest income		$ 81,408		$ 63,312		$ 212,391		$ 188,400
Fee Income		2,821		6,881		9,110		20,111
Gross Investment Income, Operating, Total		84,229		70,193		221,501		208,511
Operating expenses:
Interest expense, debt		14,499	[1]	13,069	[1]	38,844	[2]	42,309	[1]
Loan fees		2,183		1,674		5,517		6,694
General and administrative		4,364		4,085		12,504		11,749
Investment Income, Operating, Tax Expense (Benefit)		1,602		2,395		4,135		5,579
Total gross operating expenses		36,090		33,441		101,916		102,372
Expenses allocated to the Adviser Subsidiary		1,863		1,337		6,335		3,474
Employee compensation:
Compensation and benefits		10,968		8,898		30,357		27,051
Employee benefits and share-based compensation		2,474		3,320		10,559		8,990
Employee compensation		13,442		12,218		40,916		36,041
Total net operating expenses		34,227		32,104		95,581		98,898
Net investment income		50,002		38,089		125,920		109,613
Net realized gain (loss):
Loss on debt extinguishment		0		(1,702)		(3,686)		(1,702)
Realized Investment Gains (Losses), Total		5,289		21,111		775		14,599
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		(2,089)		(35,651)		(87,147)		46,231
Total net realized gain (loss) and net change in unrealized appreciation (depreciation)		3,200		(14,540)		(86,372)		60,830
Net increase (decrease) in net assets resulting from operations		$ 53,202		$ 23,549		$ 39,548		$ 170,443
Net investment income before investment gains and losses per common share:
Net investment income before investment gains and losses per common share: Basic		$ 0.39		$ 0.33		$ 1.01		$ 0.95
Change in net assets resulting from operations per common share:
Basic		0.41		0.20		0.31		1.47
Diluted		$ 0.41		$ 0.20		$ 0.30		$ 1.46
Weighted average shares outstanding
Basic		127,484		114,805		123,379		114,590
Diluted		129,334		116,239		124,767		115,550
Distributions paid per common share:
Basic	[3]							$ 0.09
Common Stock [Member]
Distributions paid per common share:
Basic		$ 0.50		$ 0.39		$ 1.46		$ 1.15
Investment, Affiliated Issuer [Member]
Investment income:
Gross Investment Income, Operating, Total						$ 4,694	[4]	$ 2,946	[5]
Net realized gain (loss):
Realized Investment Gains (Losses), Total						1,758		(62,143)
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)						7,700		56,893
Investment, Unaffiliated Issuer [Member]
Investment income:
Total interest income		$ 80,146		$ 62,239		207,747		185,497
Fee Income		2,803		6,861		9,059		20,068
Net realized gain (loss):
Realized Investment Gains (Losses), Total		7,303		22,813		2,703		78,444
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		(4,149)		(31,759)		(94,847)		(10,662)
Investment, Affiliated Issuer, Controlled [Member]
Investment income:
Total interest income		1,181		1,072		3,440		2,900
Fee Income		18		20		51		43
Gross Investment Income, Operating, Total						3,490	[4]	2,943	[5]
Net realized gain (loss):
Realized Investment Gains (Losses), Total						0		0
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		(2,571)		(3,774)		3,611		(7,327)
Investment, Affiliated Issuer, Noncontrolled [Member]
Investment income:
Total interest income		81		1		1,204		3
Gross Investment Income, Operating, Total						1,204	[4]	3	[5]
Net realized gain (loss):
Realized Investment Gains (Losses), Total		(2,014)		0		1,758		(62,143)
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		$ 4,631		$ (118)		$ 4,089		$ 64,220
[1] Interest expense includes amortization of original issue discounts for the three months ended September 30, 2021 of $ 41 thousand, $ 168 thousand, and $ 6 thousand, for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes for the nine months ended September 30, 2021 , $ 123 thousand, $ 504 thou sand, and $ 6 thousand for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes amortization of original issue discounts for the three months ended September 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the nine months ended September 30, 2022 , $ 23 thousand, $ 112 thousand, $ 125 thousand, $ 349 thousand, and $ 51 thousand related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Includes distributions on unvested restricted stock awards. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2022		Sep. 30, 2021		Sep. 30, 2022		Sep. 30, 2021		Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Beginning Balance	$ (1,327,740)		$ (1,356,358)		$ (1,308,547)		$ (1,291,704)
Common Stock Value	131				131					$ 117
Capital in excess of par value	1,242,618		1,163,910		1,091,907		1,158,198
Distributable Earnings (loss)	84,994		192,332		216,523		133,391
Net increase in net assets resulting from operations	53,202		23,549		39,548		170,443
Public offering, net of offering expenses	42,854		(10)		189,958		(208)
Issuance of common stock due to stock option exercises	266		180		720		3,813
Retired shares from net issuance and for restricted stock vesting	(176)		(52)		(208)		(1,141)
Distributions reinvested in common stock	$ 949		$ 947		$ 2,895		$ 3,057
Distributions reinvested in common stock (Shares)	62,726		55,413		184,197		189,356
Distributions	$ (63,950)		$ (45,190)		$ (181,825)		$ (133,143)
Stock-based compensation (1)	2,495	[1]	2,622	[2]	8,333	[1]	7,785	[2]
Capital in excess of par value	1,288,341		1,166,725		1,288,341		1,166,725
Distributable Earnings (loss)	74,246		170,691		74,246		170,691
Ending Balance	$ (1,362,718)		$ (1,337,532)		$ (1,362,718)		$ (1,337,532)
Ending Balance (Shares)	130,191,000		115,925,000		130,191,000		115,925,000
Restricted Stock
Retired shares from net issuance and for restricted stock vesting	$ (662)		$ (872)		$ (5,250)		$ (4,778)
Common Stock
Beginning Balance (Shares)	127,285,000		115,867,000		116,619,000		114,726,000
Common Stock Value	$ 131		$ 116		$ 131		$ 116		$ 128	$ 117	$ 116	$ 115
Public offering, net of offering expenses	$ 3				$ 12
Public offering, net of offering expenses (Shares)	2,866,000				11,787,000
Issuance of common stock due to stock option exercises (Shares)	22,000		14,000		59,000		277,000
Retired shares from net issuance and for restricted stock vesting (Shares)	(12,000)		(3,000)		(14,000)		(65,000)
Issuance of common stock under restricted stock plan					$ 1		$ 1
Issuance of common stock under restricted stock plan (Shares)	23,000		38,000		811,000		998,000
Distributions reinvested in common stock (Shares)	63,000		55,000		184,000		189,000
Issuance of common stock from conversion of 2022 Convertible Notes					$ 1
Issuance of common stock from conversion of 2022 Convertible Notes					981,000
Distributions	$ (63,421)		$ (44,770)		$ (180,114)		$ (131,829)
Ending Balance (Shares)	130,191,000		115,925,000		130,191,000		115,925,000
Common Stock | Restricted Stock
Retired shares from net issuance and for restricted stock vesting (Shares)	(56,000)		(46,000)		(236,000)		(200,000)
Capital in Excess of Par Value
Public offering, net of offering expenses	$ 42,851		$ (10)		$ 189,946		$ (208)
Issuance of common stock due to stock option exercises	266		180		720		3,813
Retired shares from net issuance and for restricted stock vesting	(176)		(52)		(208)		(1,141)
Issuance of common stock under restricted stock plan					(1)		(1)
Distributions reinvested in common stock	949		947		2,895		3,057
Issuance of common stock from conversion of 2022 Convertible Notes					(1)
Stock-based compensation (1)	2,495	[1]	2,622	[2]	8,333	[1]	7,785	[2]
Capital in Excess of Par Value | Restricted Stock
Retired shares from net issuance and for restricted stock vesting	(662)		(872)		(5,250)		(4,778)
Distributable Earnings (Loss)
Net increase in net assets resulting from operations	53,202		23,549		39,548		170,443
Distributions	$ (63,950)		$ (45,190)		$ (181,825)		$ (133,143)
[1] Stock-based compensation includes $ 36 thousand and $ 113 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2022 , respectively. Stock-based compensation includes $ 36 thousand and $ 86 thousand of restricted stock and option expense related to director compensation for the three and nine months ended September 30, 2021 , respectively.

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement Of Stockholders Equity [Abstract]
APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition	$ 36	$ 36	$ 113	$ 86

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Cash flows used in operating activities:
Net Income (Loss) Attributable to Parent		$ 39,548	$ 170,443
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Payments for Purchase of Investment, Operating Activity		(1,097,812)	(1,033,189)
Fundings assigned to Adviser Funds		247,848	107,793
Net unrealized (appreciation) depreciation		87,147	(46,231)
Realized Gain (Loss), Investment and Derivative, Operating, after Tax		(4,461)	(16,301)
Interest Income, Operating, Paid in Kind		(14,888)	(8,105)
Change In Loan Income Net Of Collection		(18,398)	21,730
Unearned fees related to unfunded commitments		19,412	(2,367)
Non-Cash Realized Loss Extinguishment Debt		3,378	1,702
Amortization of debt issuance costs		4,051	4,957
Depreciation and amortization		160	255
Stock-based compensation and amortization of restricted stock grants (1)	[1]	8,333	7,785
Change in operating assets and liabilities:
Interest receivable		(8,039)	1,218
Other assets		(1,196)	2,380
Accrued liabilities		(14,856)	(680)
Net cash provided by (used in) operating activities		(359,881)	28,681
Cash flows used in investing activities:
Purchases of capital equipment		(86)	(12)
Net cash used in investing activities		(86)	(12)
Cash flows provided by (used in) financing activities:
Issuance of common stock		192,011	0
offering expenses		(2,053)	(208)
Retirement of employee shares, net		(4,738)	(2,106)
Distributions paid		(178,930)	(130,086)
Issuance of debt		1,169,237	1,396,406
Repayment of debt		(878,198)	(1,272,712)
Debt issuance costs		(6,581)	(4,830)
Fees paid for credit facilities and debentures		(1,635)	(3,395)
Net cash provided by (used in) financing activities		289,113	(16,931)
Net increase (decrease) in cash, cash equivalents, and restricted cash		(70,854)	11,738
Cash, cash equivalents, and restricted cash at beginning of period		136,265	237,622
Cash, cash equivalents, and restricted cash at end of period		65,411	249,360
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Income Taxes Paid, Net, Total		7,341	3,731
Interest paid		44,382	44,985
Distributions reinvested		2,895	3,057
Convertible Note Discounts - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion (Amortization) of Discounts and Premiums, Investments		112	504
Discounts - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion (Amortization) of Discounts and Premiums, Investments		(2,996)	(2,737)
Exit Fees - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion (Amortization) of Discounts and Premiums, Investments		364	17,364
Debt Investment [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Proceeds from Disposition of Investment, Operating Activity		378,109	738,321
Equity and Warrant Investments [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Proceeds from Disposition of Investment, Operating Activity		$ 14,303	$ 98,567
[1] Stock-based compensation includes $ 113 thousand and $ 86 thousand of restricted stock and option expense related to director compensation for the nine months ended September 30, 2022 and 2021 , respectively.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Statement Of Cash Flows [Abstract]
Restricted stock and option expense related to director compensation	$ 36	$ 36	$ 113	$ 86
Cash and cash equivalents	57,065	235,851	57,065	235,851	$ 133,115
Restricted cash (amounts related to a VIE $8,346 and $0, respectively)	8,346	13,509	8,346	13,509	3,150
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows	$ 65,411	$ 249,360	$ 65,411	$ 249,360	$ 136,265	$ 237,622

CONSOLIDATED SCHEDULE OF INVEST

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands

9 Months Ended

12 Months Ended

Sep. 30, 2022 USD ($) shares

Dec. 31, 2021 USD ($) shares

Sep. 30, 2022 GBP (£) shares

Dec. 31, 2021 GBP (£) shares

Sep. 30, 2021 USD ($)

Dec. 31, 2020 USD ($)

Investment Holdings [Line Items]

Investment cost

$ 2,869,469,000

$ 2,390,984,000

Investments at Fair Value

2,825,738,000

2,434,522,000

Equity

Investment Holdings [Line Items]

Investment cost

150,539,000

[1]

142,219,000

[2]

Investments at Fair Value

134,134,000

184,710,000

Warrant Investment

Investment Holdings [Line Items]

Investment cost

31,148,000

[1]

27,147,000

[2]

Investments at Fair Value

27,159,000

38,399,000

Investments in Securities [Member]

Investment Holdings [Line Items]

Investment cost

[2]

2,388,952,000

Investments at Fair Value

2,432,708,000

Investment [Member]

Investment Holdings [Line Items]

Investment cost

[2]

2,390,984,000

Investments at Fair Value

2,434,522,000

Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1]

3,139,000

Investments at Fair Value

3,046,000

Senior Secured

Investment Holdings [Line Items]

Investments at Fair Value

2,607,006,000

$ 2,156,709,000

Senior Secured | Blue Sprig Pediatrics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Kind

4.45%

4.45%

Total Investments Before Cash And Cash Equivalent [Member]

Investment Holdings [Line Items]

Investment cost

[1],[3]

2,869,469,000

Investments at Fair Value

2,825,738,000

Total Investments with Cash and Cash Equivalents

Investment Holdings [Line Items]

Investment cost

[1],[3]

2,894,469,000

Investments at Fair Value

[3]

2,850,738,000

Total investments In Securities

Investment Holdings [Line Items]

Investment cost

[1]

2,866,330,000

Investments at Fair Value

2,822,692,000

Cash and Cash Equivalents | G S Financial Square Government Fund

Investment Holdings [Line Items]

Investment cost

[1]

25,000,000

Investments at Fair Value

25,000,000

Money Market Funds [Member]

Investment Holdings [Line Items]

Investment cost

[1],[3]

25,000,000

Investments at Fair Value

[3]

25,000,000

Debt Investments

Investment Holdings [Line Items]

Investment cost

2,684,643,000

[1]

$ 2,219,586,000

[2]

Investments at Fair Value

2,661,399,000

2,209,599,000

Unsecured

Investment Holdings [Line Items]

Investments at Fair Value

54,393,000

52,890,000

Communications & Networking

Investment Holdings [Line Items]

Investments at Fair Value

101,094,000

105,490,000

Communications & Networking | Equity

Investment Holdings [Line Items]

Investment cost

[2]

1,230,000

Investments at Fair Value

6,260,000

Communications & Networking | Warrant Investment

Investment Holdings [Line Items]

Investment cost

541,000

[1]

418,000

[2]

Investments at Fair Value

140,000

0

Communications & Networking | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

98,596,000

[1]

97,088,000

[4]

Investments at Fair Value

100,954,000

99,230,000

Communications & Networking | Aryaka Networks, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

123,000

Investments at Fair Value

$ 140,000

Investment, Acquisition Date

[5]

Jun. 28, 2022

Shares | shares

229,611

229,611

Communications & Networking | Peerless Network Holdings, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

[2]

1,230,000

Investments at Fair Value

$ 6,260,000

Shares | shares

1,138,328

1,138,328

Communications & Networking | Peerless Network Holdings, Inc. | Equity | Preferred Series A

Investment Holdings [Line Items]

Investment cost

[2]

$ 1,230,000

Investments at Fair Value

$ 6,242,000

Investment, Acquisition Date

[6]

Apr. 11, 2008

Shares | shares

1,135,000

1,135,000

Communications & Networking | Peerless Network Holdings, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 0

Investments at Fair Value

$ 18,000

Investment, Acquisition Date

[6]

Oct. 21, 2020

Shares | shares

3,328

3,328

Communications & Networking | Spring Mobile Solutions, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 418,000

[1]

$ 418,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Apr. 19, 2013

[5]

Apr. 19, 2013

[6]

Shares | shares

2,834,375

2,834,375

2,834,375

2,834,375

Communications & Networking | Senior Secured | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-07

2026-07

Investment, Basis Spread, Variable Rate

[7]

3.25%

3.25%

Investment, Interest Rate, Floor

[7]

6.75%

6.75%

Investment, Interest Rate, Paid in Kind

[7]

1.05%

1.05%

Principal Amount

[8],[9],[10]

$ 5,009,000

Investment cost

[1],[8],[9],[10]

4,943,000

Investments at Fair Value

[8],[9],[10]

$ 4,943,000

Communications & Networking | Senior Secured | Cytracom Holdings LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

2025-02

2025-02

Investment, Basis Spread, Variable Rate

9.31%

[7]

9.31%

[11]

9.31%

[7]

9.31%

[11]

Investment, Interest Rate, Floor

10.31%

[7]

10.31%

[11]

10.31%

[7]

10.31%

[11]

Principal Amount

$ 8,933,000

[10],[12],[13]

$ 9,000,000

[14],[15],[16]

Investment cost

8,776,000

[1],[10],[12],[13]

8,802,000

[4],[14],[15],[16]

Investments at Fair Value

$ 8,728,000

[10],[12],[13]

$ 8,725,000

[14],[15],[16]

Communications & Networking | Senior Secured | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-06

2024-06

2024-06

2024-06

Investment Interest Rate

[11]

3.25%

3.25%

Investment, Basis Spread, Variable Rate

4.90%

[7]

4.90%

[11]

4.90%

[7]

4.90%

[11]

Investment, Interest Rate, Floor

8.15%

[7]

8.15%

[11]

8.15%

[7]

8.15%

[11]

Investment, Interest Rate, Paid in Kind

1.25%

[7]

1.25%

[11]

1.25%

[7]

1.25%

[11]

Interest Rate and Floor

[11]

3.25%

3.25%

Principal Amount

$ 84,314,000

[9],[12],[17],[18],[19]

$ 88,542,000

[20],[21]

Investment cost

84,877,000

[1],[9],[12],[17],[18],[19]

88,286,000

[4],[20],[21]

Investments at Fair Value

$ 87,283,000

[9],[12],[17],[18],[19]

90,505,000

[20],[21]

Communications & Networking | Senior Secured | Exit Fee | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.55%

3.55%

Interest Rate and Floor

[7]

3.55%

3.55%

Communications & Networking | Senior Secured | Exit Fee | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.20%

3.20%

Interest Rate and Floor

[7]

3.20%

3.20%

Communications & Networking | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 98,596,000

[1]

97,088,000

[4]

Investments at Fair Value

100,954,000

99,230,000

Consumer & Business Products

Investment Holdings [Line Items]

Investments at Fair Value

25,497,000

28,099,000

Consumer & Business Products | Equity

Investment Holdings [Line Items]

Investment cost

561,000

[1]

128,000

[2]

Investments at Fair Value

185,000

447,000

Consumer & Business Products | Warrant Investment

Investment Holdings [Line Items]

Investment cost

1,712,000

[1]

2,145,000

[2]

Investments at Fair Value

1,122,000

4,354,000

Consumer & Business Products | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

[4]

23,162,000

Investment cost

[1]

23,774,000

Investments at Fair Value

24,190,000

23,298,000

Consumer & Business Products | Grove Collaborative, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[22]

433,000

Investments at Fair Value

[5],[22]

$ 127,000

Investment, Acquisition Date

[5]

Apr. 30, 2021

Shares | shares

[5],[22]

61,300

61,300

Consumer & Business Products | Grove Collaborative, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

433,000

Investments at Fair Value

$ 326,000

Investment, Acquisition Date

[6]

Apr. 30, 2021

Shares | shares

83,625

83,625

Consumer & Business Products | Penumbra Brands, LLC (p.k.a. Gadget Guard) | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 228,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Jun. 03, 2014

Shares | shares

1,662,441

1,662,441

Consumer & Business Products | TechStyle, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 128,000

[1]

$ 128,000

[2]

Investments at Fair Value

$ 58,000

$ 447,000

Investment, Acquisition Date

Apr. 30, 2010

[5]

Apr. 30, 2010

[6]

Shares | shares

42,989

42,989

42,989

42,989

Consumer & Business Products | TechStyle, Inc. | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

[1]

$ 1,101,000

Investments at Fair Value

$ 365,000

Investment, Acquisition Date

[5]

Jul. 16, 2013

Shares | shares

206,185

206,185

Consumer & Business Products | Gadget Guard, LLC | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 228,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[5]

Jun. 03, 2014

Shares | shares

1,662,441

1,662,441

Consumer & Business Products | The Neat Company | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 365,000

[1]

$ 365,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Aug. 13, 2014

[5]

Aug. 13, 2014

[6]

Shares | shares

54,054

54,054

54,054

54,054

Consumer & Business Products | Whoop, Inc. | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 18,000

[1]

$ 18,000

[2]

Investments at Fair Value

$ 757,000

$ 1,847,000

Investment, Acquisition Date

Jun. 27, 2018

[5]

Jun. 27, 2018

[6]

Shares | shares

686,270

686,270

686,270

686,270

Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

[2]

$ 1,101,000

Investments at Fair Value

$ 2,181,000

Investment, Acquisition Date

[6]

Jul. 16, 2013

Shares | shares

206,185

206,185

Consumer & Business Products | Senior Secured | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-04

2025-04

2025-04

2025-04

Investment Interest Rate

[11]

6.75%

6.75%

Investment, Basis Spread, Variable Rate

5.50%

[7]

5.50%

[11]

5.50%

[7]

5.50%

[11]

Investment, Interest Rate, Floor

8.75%

[7]

8.75%

[11]

8.75%

[7]

8.75%

[11]

Interest Rate and Floor

[11]

6.75%

6.75%

Principal Amount

$ 23,520,000

[8]

$ 23,520,000

[23]

Investment cost

23,774,000

[1],[8]

23,162,000

[4],[23]

Investments at Fair Value

$ 24,190,000

[8]

23,298,000

[23]

Consumer & Business Products | Senior Secured | Exit Fee | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

8.75%

8.75%

Interest Rate and Floor

[7]

8.75%

8.75%

Consumer & Business Products | Debt Investments

Investment Holdings [Line Items]

Principal Amount

[4]

23,162,000

Investment cost

[1]

$ 23,774,000

Investments at Fair Value

24,190,000

23,298,000

Diversified Financial Services

Investment Holdings [Line Items]

Investments at Fair Value

72,061,000

65,073,000

Diversified Financial Services | Equity

Investment Holdings [Line Items]

Investment cost

28,444,000

[1]

28,041,000

[2]

Investments at Fair Value

38,022,000

32,608,000

Diversified Financial Services | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

[4]

403,000

Investments at Fair Value

403,000

Diversified Financial Services | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

36,545,000

[1]

33,335,000

[4]

Investments at Fair Value

34,039,000

32,062,000

Diversified Financial Services | Gibraltar Business Capital, LLC | Equity

Investment Holdings [Line Items]

Investment cost

28,006,000

[1]

28,006,000

[2]

Investments at Fair Value

$ 15,623,000

$ 20,618,000

Shares | shares

11,432,752

11,432,752

11,432,752

11,432,752

Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Preferred Series A

Investment Holdings [Line Items]

Investment cost

$ 26,122,000

[1],[24]

$ 26,122,000

[2],[25]

Investments at Fair Value

$ 14,489,000

[24]

$ 19,393,000

[25]

Investment, Acquisition Date

Mar. 01, 2018

[5]

Mar. 01, 2018

[6],[25]

Shares | shares

10,602,752

[24]

10,602,752

[25]

10,602,752

[24]

10,602,752

[25]

Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,884,000

[1],[24]

$ 1,884,000

[2],[25]

Investments at Fair Value

$ 1,134,000

[24]

$ 1,225,000

[25]

Investment, Acquisition Date

Mar. 01, 2018

[5]

Mar. 01, 2018

[6],[25]

Shares | shares

830,000

[24]

830,000

[25]

830,000

[24]

830,000

[25]

Diversified Financial Services | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

$ 25,000,000

$ 25,000,000

Investment cost

24,545,000

[1]

24,485,000

[4]

Investments at Fair Value

22,039,000

23,212,000

Diversified Financial Services | Hercules Adviser LLC | Equity | Member Units

Investment Holdings [Line Items]

Investment cost

35,000

[1],[24]

35,000

[2],[25]

Investments at Fair Value

$ 21,945,000

[24]

$ 11,990,000

[25]

Investment, Acquisition Date

Mar. 26, 2021

[5]

Mar. 26, 2021

[6],[25]

Shares | shares

1

[24]

1

[25]

1

[24]

1

[25]

Diversified Financial Services | Newfront Insurance Holdings, Inc. | Equity | Preferred Series D-2

Investment Holdings [Line Items]

Investment cost

[1]

$ 403,000

Investments at Fair Value

$ 454,000

Investment, Acquisition Date

[5]

Sep. 30, 2021

Shares | shares

210,282

210,282

Diversified Financial Services | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 36,545,000

[1]

$ 33,738,000

[4]

Investments at Fair Value

$ 34,039,000

$ 32,465,000

Diversified Financial Services | Unsecured | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

Principal Amount

[25]

$ 15,000,000

Diversified Financial Services | Unsecured | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-06

2025-06

Investment, Interest Rate, Paid in Cash

[7]

5%

5%

Principal Amount

[24]

$ 12,000,000

Investment cost

[1],[24]

12,000,000

Investments at Fair Value

[24]

$ 12,000,000

Diversified Financial Services | Unsecured 14.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

Investment, Interest Rate, Paid in Cash

14.50%

[7]

14.50%

[11],[25]

14.50%

[7]

14.50%

[11],[25]

Principal Amount

[24]

$ 15,000,000

Investment cost

14,701,000

[1],[24]

$ 14,662,000

[4],[25]

Investments at Fair Value

$ 13,033,000

[24]

$ 13,818,000

[25]

Diversified Financial Services | Unsecured 11.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

2026-09

2026-09

Investment, Interest Rate, Paid in Cash

11.50%

[7]

11.50%

[11],[25]

11.50%

[7]

11.50%

[11],[25]

Principal Amount

$ 10,000,000

[24]

$ 10,000,000

[25]

Investment cost

9,844,000

[1],[24]

9,823,000

[4],[25]

Investments at Fair Value

9,006,000

[24]

$ 9,394,000

[25]

Diversified Financial Services | Unsecured 5.00 % | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-05

2023-05

Investment, Interest Rate, Paid in Cash

[11],[25]

5%

5%

Principal Amount

[25]

$ 8,850,000

Investment cost

[4],[25]

8,850,000

Investments at Fair Value

[25]

$ 8,850,000

Diversified Financial Services | Convertible Debt | Newfront Insurance Holdings, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-08

2022-08

Investment, Interest Rate, Floor

[11],[26]

0.19%

0.19%

Investment, Interest Rate, Paid in Kind

[11],[26]

0.19%

0.19%

Principal Amount

[26]

$ 403,000

Investment cost

[4],[26]

403,000

Investments at Fair Value

[26]

403,000

Investment Funds And Vehicles

Investment Holdings [Line Items]

Investment cost

[2]

2,032,000

Investments at Fair Value

1,814,000

Investment Funds And Vehicles | Forbion Growth Opportunities Fund I C V

Investment Holdings [Line Items]

Investment cost

[2],[15],[27],[28]

2,032,000

Investments at Fair Value

[15],[27],[28]

$ 1,814,000

Investment, Acquisition Date

[6],[27],[28]

Nov. 16, 2020

Surgical Devices

Investment Holdings [Line Items]

Investments at Fair Value

1,536,000

$ 1,029,000

Surgical Devices | Equity

Investment Holdings [Line Items]

Investment cost

1,941,000

[1]

1,941,000

[2]

Investments at Fair Value

0

543,000

Surgical Devices | Warrant Investment

Investment Holdings [Line Items]

Investment cost

152,000

[1]

206,000

[2]

Investments at Fair Value

1,536,000

486,000

Surgical Devices | Gynesonics, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

1,941,000

[1]

1,941,000

[2]

Investments at Fair Value

$ 0

$ 543,000

Shares | shares

9,595,178

9,595,178

9,595,178

9,595,178

Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 712,000

[1]

$ 712,000

[2]

Investments at Fair Value

$ 0

$ 81,000

Investment, Acquisition Date

Feb. 08, 2013

[5]

Feb. 08, 2013

[6]

Shares | shares

1,991,157

1,991,157

1,991,157

1,991,157

Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 250,000

[1]

$ 250,000

[2]

Investments at Fair Value

$ 0

$ 9,000

Investment, Acquisition Date

Jan. 18, 2007

[5]

Jan. 18, 2007

[6]

Shares | shares

219,298

219,298

219,298

219,298

Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 282,000

[1]

$ 282,000

[2]

Investments at Fair Value

$ 0

$ 26,000

Investment, Acquisition Date

Jun. 16, 2010

[5]

Jun. 16, 2010

[6]

Shares | shares

656,538

656,538

656,538

656,538

Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

$ 429,000

[1]

$ 429,000

[2]

Investments at Fair Value

$ 0

$ 131,000

Investment, Acquisition Date

Jul. 14, 2015

[5]

Jul. 14, 2015

[6]

Shares | shares

2,786,367

2,786,367

2,786,367

2,786,367

Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series F

Investment Holdings [Line Items]

Investment cost

$ 118,000

[1]

$ 118,000

[2]

Investments at Fair Value

$ 0

$ 123,000

Investment, Acquisition Date

Dec. 18, 2018

[5]

Dec. 18, 2018

[6]

Shares | shares

1,523,693

1,523,693

1,523,693

1,523,693

Surgical Devices | Gynesonics, Inc. | Equity | Series F One Preferred Stock

Investment Holdings [Line Items]

Investment cost

$ 150,000

[1]

$ 150,000

[2]

Investments at Fair Value

$ 0

$ 173,000

Investment, Acquisition Date

Dec. 18, 2018

[5]

Dec. 18, 2018

[6]

Shares | shares

2,418,125

2,418,125

2,418,125

2,418,125

Surgical Devices | Gynesonics, Inc. | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 13,000

[1]

$ 67,000

[2]

Investments at Fair Value

$ 0

$ 6,000

Investment, Acquisition Date

Dec. 05, 2012

[5]

Feb. 08, 2012

[6]

Shares | shares

33,670

151,123

33,670

151,123

Surgical Devices | TransMedics Group, Inc. (p.k.a Transmedics, Inc.) | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 139,000

[1],[5]

$ 139,000

[2],[6]

Investments at Fair Value

$ 1,536,000

[5]

$ 480,000

[6]

Investment, Acquisition Date

Nov. 07, 2012

[5]

Nov. 07, 2012

Shares | shares

64,440

[5]

64,440

[6]

64,440

[5]

64,440

[6]

Drug Discovery & Development

Investment Holdings [Line Items]

Investments at Fair Value

$ 1,091,827,000

$ 967,383,000

Drug Discovery & Development | Equity

Investment Holdings [Line Items]

Investment cost

42,548,000

[1]

33,401,000

[2]

Investments at Fair Value

32,844,000

24,860,000

Drug Discovery & Development | Warrant Investment

Investment Holdings [Line Items]

Investment cost

7,709,000

[1]

7,393,000

[2]

Investments at Fair Value

4,074,000

4,745,000

Drug Discovery & Development | Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1]

2,758,000

Investments at Fair Value

2,665,000

Drug Discovery & Development | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

16,378,000

[1]

20,036,000

[4]

Investments at Fair Value

16,093,000

20,036,000

Drug Discovery & Development | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

1,039,957,000

[1]

916,421,000

[2]

Investments at Fair Value

1,036,151,000

915,928,000

Drug Discovery & Development | Chemocentryx, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

1,000,000

[1],[5],[29]

1,000,000

[2],[6],[27]

Investments at Fair Value

$ 891,000

[5],[29]

$ 628,000

[6],[27]

Investment, Acquisition Date

Jun. 15, 2020

[5]

Jun. 15, 2020

[6],[27]

Shares | shares

17,241

[5],[29]

17,241

[6],[27]

17,241

[5],[29]

17,241

[6],[27]

Drug Discovery & Development | Akero Therapeutics, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 1,000,000

Investments at Fair Value

[5],[29]

$ 1,310,000

Investment, Acquisition Date

[5]

Sep. 19, 2022

Shares | shares

[5],[29]

38,461

38,461

Drug Discovery & Development | Akero Therapeutics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[29]

$ 56,000

Investments at Fair Value

[5],[29]

$ 398,000

Investment, Acquisition Date

[5]

Jun. 15, 2022

Shares | shares

[5],[29]

18,360

18,360

Drug Discovery & Development | Albireo Pharma, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1],[5],[29]

$ 1,000,000

[2],[6],[27]

Investments at Fair Value

$ 484,000

[5],[29]

$ 582,000

[6],[27]

Investment, Acquisition Date

Sep. 14, 2020

[5]

Sep. 14, 2020

[6],[27]

Shares | shares

25,000

[5],[29]

25,000

[6],[27]

25,000

[5],[29]

25,000

[6],[27]

Drug Discovery & Development | Albireo Pharma, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 61,000

[1],[5],[29]

$ 61,000

[2],[6],[27]

Investments at Fair Value

$ 26,000

[5],[29]

$ 42,000

[6],[27]

Investment, Acquisition Date

Jun. 08, 2020

[5]

Jun. 08, 2020

[6],[27]

Shares | shares

5,311

[5],[29]

5,311

[6],[27]

5,311

[5],[29]

5,311

[6],[27]

Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,715,000

[1],[5]

$ 1,715,000

[2],[6]

Investments at Fair Value

$ 1,565,000

[5]

$ 892,000

[6]

Investment, Acquisition Date

Jul. 31, 2011

[5]

Jul. 31, 2011

[6]

Shares | shares

190,179

[5]

190,179

[6]

190,179

[5]

190,179

[6]

Drug Discovery & Development | Axsome Therapeutics, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[19],[22],[29]

$ 4,165,000

Investments at Fair Value

[5],[19],[22],[29]

$ 5,360,000

Investment, Acquisition Date

[5]

May 09, 2022

Shares | shares

[5],[19],[22],[29]

127,021

127,021

Drug Discovery & Development | Axsome Therapeutics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 880,000

[1],[5],[19],[29]

$ 681,000

[2],[6],[27]

Investments at Fair Value

$ 783,000

[5],[19],[29]

$ 142,000

[6],[27]

Investment, Acquisition Date

Sep. 25, 2020

[5]

Sep. 25, 2020

[6],[27]

Shares | shares

40,396

[5],[19],[22],[29]

15,541

[6],[27]

40,396

[5],[19],[22],[29]

15,541

[6],[27]

Drug Discovery & Development | Bicycle Therapeutics PLC | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,871,000

[1],[5],[29],[30]

$ 1,871,000

[2],[6],[27],[28]

Investments at Fair Value

$ 2,282,000

[5],[29],[30]

$ 5,971,000

[6],[27],[28]

Investment, Acquisition Date

Oct. 05, 2020

[5]

Oct. 05, 2020

[6],[27],[28]

Shares | shares

98,100

[5],[29],[30]

98,100

[6],[27],[28]

98,100

[5],[29],[30]

98,100

[6],[27],[28]

Drug Discovery & Development | BridgeBio Pharma, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 2,255,000

[1],[5]

$ 2,255,000

[2],[6]

Investments at Fair Value

$ 2,299,000

[5]

$ 3,859,000

[6]

Investment, Acquisition Date

Jun. 21, 2018

[5]

Jun. 21, 2018

[6]

Shares | shares

231,329

[5]

231,329

[6]

231,329

[5]

231,329

[6]

Drug Discovery & Development | Cellarity, Inc. | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 287,000

[1],[31]

$ 287,000

[2],[32]

Investments at Fair Value

$ 370,000

[31]

$ 287,000

[32]

Investment, Acquisition Date

Dec. 08, 2021

[5]

Dec. 08, 2021

[6]

Shares | shares

100,000

[31]

100,000

[32]

100,000

[31]

100,000

[32]

Drug Discovery & Development | Century Therapeutics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 37,000

[1],[5]

$ 37,000

[2],[6]

Investments at Fair Value

$ 16,000

[5]

$ 64,000

[6]

Investment, Acquisition Date

Sep. 14, 2020

[5]

Sep. 14, 2020

[6]

Shares | shares

16,112

[5]

16,112

[6]

16,112

[5]

16,112

[6]

Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3

Investment Holdings [Line Items]

Investment cost

[1],[29],[30]

$ 72,000

Investments at Fair Value

[29],[30]

$ 31,000

Investment, Acquisition Date

[5]

Dec. 30, 2021

Shares | shares

[29],[30]

133,692

133,692

Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3 Class C

Investment Holdings [Line Items]

Investment cost

[2],[27],[28]

$ 64,000

Investments at Fair Value

[27],[28]

$ 64,000

Investment, Acquisition Date

[6],[27],[28]

Dec. 30, 2021

Shares | shares

[27],[28]

84,714

84,714

Drug Discovery & Development | Hibercell, Inc. | Equity | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 4,250,000

[1],[31]

$ 4,250,000

[2],[32]

Investments at Fair Value

$ 2,917,000

[31]

$ 3,264,000

[32]

Investment, Acquisition Date

May 07, 2021

[5]

May 07, 2021

[6]

Shares | shares

3,466,840

[31]

3,466,840

[32]

3,466,840

[31]

3,466,840

[32]

Drug Discovery & Development | HilleVax, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

$ 4,000,000

Investments at Fair Value

[5]

$ 4,021,000

Investment, Acquisition Date

[5]

May 03, 2022

Shares | shares

[5]

235,295

235,295

Drug Discovery & Development | Humanigen, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 800,000

[1],[5],[29]

$ 800,000

[2],[6],[27]

Investments at Fair Value

$ 8,000

[5],[29]

$ 161,000

[6],[27]

Investment, Acquisition Date

Mar. 31, 2021

[5]

Mar. 31, 2021

[6],[27]

Shares | shares

43,243

[5],[29]

43,243

[6],[27]

43,243

[5],[29]

43,243

[6],[27]

Drug Discovery & Development | Kaleido Biosciences, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 1,000,000

Investments at Fair Value

[6]

$ 207,000

Investment, Acquisition Date

[6]

Feb. 10, 2021

Shares | shares

[6]

86,585

86,585

Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[29]

$ 177,000

Investments at Fair Value

[5],[29]

$ 214,000

Investment, Acquisition Date

[5]

May 09, 2022

Shares | shares

[5],[29]

10,131

10,131

Drug Discovery & Development | Phathom Pharmaceuticals, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 848,000

[1],[5],[19],[29],[31]

$ 848,000

[2],[6],[27],[32]

Investments at Fair Value

$ 113,000

[5],[19],[29],[31]

$ 307,000

[6],[21],[27],[32]

Investment, Acquisition Date

Sep. 17, 2021

[5]

Sep. 17, 2021

[6],[27]

Shares | shares

64,687

[5],[19],[29],[31]

64,687

[6],[21],[27],[32]

64,687

[5],[19],[29],[31]

64,687

[6],[21],[27],[32]

Drug Discovery & Development | Provention Bio, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

$ 281,000

Investments at Fair Value

[5]

$ 224,000

Investment, Acquisition Date

[5]

Sep. 15, 2022

Shares | shares

[5]

111,934

111,934

Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment

Investment Holdings [Line Items]

Investments at Fair Value

[31]

$ 18,000

Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[1],[31]

$ 20,000

Investment, Acquisition Date

[5]

Mar. 23, 2022

Shares | shares

[31]

475,510

475,510

Drug Discovery & Development | Scynexis, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 296,000

[1],[5]

$ 188,000

[2],[6]

Investments at Fair Value

$ 47,000

[5]

$ 142,000

[6]

Investment, Acquisition Date

May 14, 2021

[5]

May 14, 2021

[6]

Shares | shares

106,035

[5]

90,887

[6]

106,035

[5]

90,887

[6]

Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[29]

$ 2,100,000

Investments at Fair Value

[5],[29]

$ 2,663,000

Investment, Acquisition Date

[5]

May 05, 2022

Shares | shares

[5],[29]

155,555

155,555

Drug Discovery & Development | TG Therapeutics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,033,000

[1],[5],[18],[29]

$ 1,033,000

[2],[6],[27],[33]

Investments at Fair Value

$ 335,000

[5],[18],[29]

$ 2,172,000

[6],[27],[33]

Investment, Acquisition Date

Feb. 28, 2019

[5]

Feb. 28, 2019

[6],[27]

Shares | shares

231,613

[5],[18],[29]

231,613

[6],[27],[33]

231,613

[5],[18],[29]

231,613

[6],[27],[33]

Drug Discovery & Development | Uni Qure B V | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 332,000

[1],[5],[19],[29],[30]

$ 332,000

[2],[6],[21],[27],[28]

Investments at Fair Value

$ 322,000

[5],[19],[29],[30]

$ 356,000

[6],[21],[27],[28]

Investment, Acquisition Date

Jan. 31, 2019

[5]

Jan. 31, 2019

[6],[27],[28]

Shares | shares

17,175

[5],[19],[29],[30]

17,175

[6],[21],[27],[28]

17,175

[5],[19],[29],[30]

17,175

[6],[21],[27],[28]

Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 3,000,000

[1]

$ 3,000,000

[2]

Investments at Fair Value

$ 3,622,000

$ 4,650,000

Investment, Acquisition Date

Dec. 11, 2020

[5]

Dec. 11, 2020

[6]

Shares | shares

510,308

510,308

510,308

510,308

Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investments at Fair Value

$ 242,000

Investment, Acquisition Date

[5]

Jun. 15, 2020

Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Units

Investment Holdings [Line Items]

Investment cost

[1]

$ 256,000

Shares | shares

102,216

102,216

Drug Discovery & Development | X Four Pharmaceuticals Inc | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 2,522,000

[1],[5]

$ 1,641,000

[2],[6]

Investments at Fair Value

$ 1,901,000

[5]

$ 454,000

[6]

Investment, Acquisition Date

Nov. 26, 2019

[5]

Nov. 26, 2019

[6]

Shares | shares

1,111,519

[5]

198,277

[6]

1,111,519

[5]

198,277

[6]

Drug Discovery & Development | X Four Pharmaceuticals Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 792,000

[1],[5]

$ 673,000

[2],[6]

Investments at Fair Value

$ 628,000

[5]

$ 2,000

[6]

Investment, Acquisition Date

Mar. 18, 2019

[5]

Mar. 18, 2019

[6]

Shares | shares

1,021,576

[5]

108,334

[6]

1,021,576

[5]

108,334

[6]

Drug Discovery & Development | Applied Molecular Transport | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 42,000

[1],[5],[29]

$ 42,000

[2],[6],[27]

Investments at Fair Value

$ 1,000

[5],[29]

$ 14,000

[6],[27]

Investment, Acquisition Date

Apr. 06, 2021

[5]

Apr. 06, 2021

[6],[27]

Shares | shares

1,000

[5],[29]

1,000

[6],[27]

1,000

[5],[29]

1,000

[6],[27]

Drug Discovery & Development | Avalo Therapeutics, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1],[5]

$ 1,000,000

[2],[6]

Investments at Fair Value

$ 33,000

[5]

$ 202,000

[6]

Investment, Acquisition Date

Aug. 19, 2014

[5]

Aug. 19, 2014

[6]

Shares | shares

9,924

[5]

119,087

[6]

9,924

[5]

119,087

[6]

Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,367,000

[1],[5],[29]

$ 1,367,000

[2],[6],[27]

Investments at Fair Value

$ 474,000

[5],[29]

$ 223,000

[6],[27]

Investment, Acquisition Date

Feb. 13, 2019

[5]

Feb. 13, 2019

[6],[27]

Shares | shares

70,796

[5],[29]

70,796

[6],[27]

70,796

[5],[29]

70,796

[6],[27]

Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6],[27]

$ 178,000

Investments at Fair Value

[6],[27]

$ 3,000

Investment, Acquisition Date

[6],[27]

Jun. 08, 2017

Shares | shares

[6],[27]

61,273

61,273

Drug Discovery & Development | Dare Biosciences, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1],[5]

$ 1,000,000

[2],[6]

Investments at Fair Value

$ 14,000

[5]

$ 27,000

[6]

Investment, Acquisition Date

Jan. 08, 2015

[5]

Jan. 08, 2015

[6]

Shares | shares

13,550

[5]

13,550

[6]

13,550

[5]

13,550

[6]

Drug Discovery & Development | Dynavax Technologies | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 550,000

[1],[5],[29]

$ 550,000

[2],[6],[27]

Investments at Fair Value

$ 209,000

[5],[29]

$ 281,000

[6],[27]

Investment, Acquisition Date

Jul. 22, 2015

[5]

Jul. 22, 2015

[6],[27]

Shares | shares

20,000

[5],[29]

20,000

[6],[27]

20,000

[5],[29]

20,000

[6],[27]

Drug Discovery & Development | NorthSea Therapeutics | Equity | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 2,000,000

[1],[29],[30]

$ 2,000,000

[2],[27],[28]

Investments at Fair Value

$ 1,515,000

[29],[30]

$ 2,000,000

[27],[28]

Investment, Acquisition Date

Dec. 15, 2021

[5]

Dec. 15, 2021

[6],[27],[28]

Shares | shares

983

[29],[30]

983

[27],[28]

983

[29],[30]

983

[27],[28]

Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 2,744,000

[1],[5]

$ 2,744,000

[2],[6]

Investments at Fair Value

$ 196,000

[5]

$ 343,000

[6]

Investment, Acquisition Date

Feb. 26, 2007

[5]

Feb. 26, 2007

[6]

Shares | shares

76,362

[5]

76,362

[6]

76,362

[5]

76,362

[6]

Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 520,000

[1],[5]

$ 546,000

[2],[6]

Investments at Fair Value

$ 72,000

[5]

$ 427,000

[6]

Investment, Acquisition Date

Aug. 01, 2018

[5]

Jun. 27, 2017

[6]

Shares | shares

426,866

[5]

432,240

[6]

426,866

[5]

432,240

[6]

Drug Discovery & Development | Rocket Pharmaceuticals, Ltd. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,500,000

[1],[5]

$ 1,500,000

[2],[6]

Investments at Fair Value

$ 15,000

[5]

$ 21,000

[6]

Investment, Acquisition Date

Aug. 22, 2007

[5]

Aug. 22, 2007

[6]

Shares | shares

944

[5]

944

[6]

944

[5]

944

[6]

Drug Discovery & Development | Savara, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 203,000

[1],[5]

$ 202,000

[2],[6]

Investments at Fair Value

$ 17,000

[5]

$ 14,000

[6]

Investment, Acquisition Date

Aug. 11, 2015

[5]

Aug. 11, 2015

[6]

Shares | shares

11,119

[5]

11,119

[6]

11,119

[5]

11,119

[6]

Drug Discovery & Development | Sio Gene Therapies, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,269,000

[1],[5]

$ 1,269,000

[2],[6],[27]

Investments at Fair Value

$ 4,000

[5]

$ 21,000

[6],[27]

Investment, Acquisition Date

Feb. 02, 2017

[5]

Feb. 02, 2017

[6],[27]

Shares | shares

16,228

[5]

16,228

[6],[27]

16,228

[5]

16,228

[6],[27]

Drug Discovery & Development | Tricida, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 863,000

[1],[5]

$ 863,000

[2],[6]

Investments at Fair Value

$ 721,000

[5]

$ 658,000

[6]

Investment, Acquisition Date

Feb. 28, 2018

[5]

Feb. 28, 2018

[6]

Shares | shares

68,816

[5]

68,816

[6]

68,816

[5]

68,816

[6]

Drug Discovery & Development | Tricida, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 280,000

[1],[5]

$ 280,000

[2],[6]

Investments at Fair Value

$ 22,000

[5]

$ 20,000

[6]

Investment, Acquisition Date

Mar. 27, 2019

[5]

Mar. 27, 2019

[6]

Shares | shares

31,352

[5]

31,352

[6]

31,352

[5]

31,352

[6]

Drug Discovery & Development | ADMA Biologics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 295,000

[1],[5]

$ 295,000

[2],[6]

Investments at Fair Value

$ 2,000

[5]

$ 1,000

[6]

Investment, Acquisition Date

Dec. 21, 2012

[5]

Dec. 21, 2012

[6]

Shares | shares

89,750

[5]

89,750

[6]

89,750

[5]

89,750

[6]

Drug Discovery & Development | Brickell Biotech, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 119,000

Investments at Fair Value

[6]

$ 0

Investment, Acquisition Date

[6]

Feb. 18, 2016

Shares | shares

[6]

9,005

9,005

Drug Discovery & Development | Dermavant Sciences Ltd. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 101,000

[1],[18],[29],[30]

$ 101,000

[2],[27],[33]

Investments at Fair Value

$ 104,000

[18],[29],[30]

$ 354,000

[27],[33]

Investment, Acquisition Date

May 31, 2019

[5]

May 31, 2019

[6],[27]

Shares | shares

223,642

[18],[29],[30]

223,642

[27],[33]

223,642

[18],[29],[30]

223,642

[27],[33]

Drug Discovery & Development | Evofem Biosciences, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 266,000

[1],[5]

$ 266,000

[2],[6]

Investments at Fair Value

$ 0

[5]

$ 0

[6]

Investment, Acquisition Date

Jun. 11, 2014

[5]

Jun. 11, 2014

[6]

Shares | shares

520

[5]

7,806

[6]

520

[5]

7,806

[6]

Drug Discovery & Development | Myovant Sciences, Ltd. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 460,000

[1],[5],[29],[30]

$ 460,000

[2],[6],[27]

Investments at Fair Value

$ 429,000

[5],[29],[30]

$ 267,000

[6],[27]

Investment, Acquisition Date

Oct. 16, 2017

[5]

Oct. 16, 2017

[6],[27]

Shares | shares

73,710

[5],[29],[30]

73,710

[6],[27]

73,710

[5],[29],[30]

73,710

[6],[27]

Drug Discovery & Development | Stealth Bio Therapeutics Corp. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 158,000

[1],[5],[29],[30]

$ 158,000

[2],[6],[27]

Investments at Fair Value

$ 0

[5],[29],[30]

$ 0

[6],[27]

Investment, Acquisition Date

Jun. 30, 2017

[5]

Jun. 30, 2017

[6],[27]

Shares | shares

500,000

[5],[29],[30]

500,000

[6],[27]

500,000

[5],[29],[30]

500,000

[6],[27]

Drug Discovery & Development | Yumanity Therapeutics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 110,000

[1],[5]

$ 110,000

[2],[6]

Investments at Fair Value

$ 0

[5]

$ 3,000

[6]

Investment, Acquisition Date

Dec. 20, 2019

[5]

Dec. 20, 2019

[6]

Shares | shares

15,414

[5]

15,414

[6]

15,414

[5]

15,414

[6]

Drug Discovery & Development | Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.) | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

$ 119,000

Investments at Fair Value

[5]

$ 0

Investment, Acquisition Date

[5]

Feb. 18, 2016

Shares | shares

[5]

200

200

Drug Discovery & Development | Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1],[10],[29],[30]

$ 2,353,000

Investments at Fair Value

[10],[29],[30]

$ 2,291,000

Investment, Acquisition Date

[5]

Nov. 16, 2020

Drug Discovery & Development | Forbion Growth Opportunities Fund I I C V | Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1],[10],[29],[30]

$ 405,000

Investments at Fair Value

[10],[29],[30]

$ 374,000

Investment, Acquisition Date

[5]

Jun. 23, 2022

Drug Discovery & Development | Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) | Warrant Investment | Common Units

Investment Holdings [Line Items]

Investment cost

[2]

$ 256,000

Investments at Fair Value

$ 441,000

Investment, Acquisition Date

[6]

Jun. 15, 2020

Shares | shares

102,216

102,216

Drug Discovery & Development | Acacia Pharma Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 304,000

[1],[29],[30]

$ 305,000

[2],[6],[27],[28]

Investments at Fair Value

$ 0

[29],[30]

$ 6,000

[6],[27],[28]

Investment, Acquisition Date

Jun. 29, 2018

[5]

Jun. 29, 2018

[6],[27],[28]

Shares | shares

201,330

[29],[30]

201,330

[6],[27],[28]

201,330

[29],[30]

201,330

[6],[27],[28]

Drug Discovery & Development | Genocea Biosciences Inc | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 2,000,000

Investments at Fair Value

[6]

$ 32,000

Investment, Acquisition Date

[6]

Nov. 20, 2014

Shares | shares

[6]

27,933

27,933

Drug Discovery & Development | Genocea Biosciences Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 165,000

Investments at Fair Value

[6]

$ 1,000

Investment, Acquisition Date

[6]

Apr. 24, 2018

Shares | shares

[6]

41,176

41,176

Drug Discovery & Development | Motif Bio P L C | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[27]

$ 282,000

Investments at Fair Value

[27]

$ 0

Investment, Acquisition Date

[6],[27]

Jan. 27, 2020

Shares | shares

[27]

121,337,041

121,337,041

Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-12

2022-12

2022-12

2022-12

Investment Interest Rate

[11],[27]

6.25%

6.25%

Investment, Basis Spread, Variable Rate

3.30%

[7]

3.30%

[11],[27]

3.30%

[7]

3.30%

[11],[27]

Investment, Interest Rate, Floor

8.05%

[7]

8.05%

[11],[27]

8.05%

[7]

8.05%

[11],[27]

Interest Rate and Floor

[11],[27]

6.25%

6.25%

Principal Amount

$ 11,451,000

[17],[29]

$ 18,951,000

[27]

Investment cost

12,677,000

[1],[17],[29]

20,036,000

[4],[27]

Investments at Fair Value

$ 12,780,000

[17],[29]

$ 20,036,000

[27]

Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

2025-02

2025-02

Investment Interest Rate

[11],[27]

7.15%

7.15%

Investment, Basis Spread, Variable Rate

3.25%

[7]

3.25%

[11],[27]

3.25%

[7]

3.25%

[11],[27]

Investment, Interest Rate, Floor

8.50%

[7]

8.50%

[11],[27]

8.50%

[7]

8.50%

[11],[27]

Interest Rate and Floor

[11],[27]

7.15%

7.15%

Principal Amount

$ 5,000,000

[17],[29]

$ 5,000,000

[27]

Investment cost

5,214,000

[1],[17],[29]

5,161,000

[2],[27]

Investments at Fair Value

$ 5,408,000

[17],[29]

$ 5,070,000

[27]

Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2023-06

2023-06

Investment, Basis Spread, Variable Rate

[7]

4.30%

4.30%

Investment, Interest Rate, Floor

[7]

9.80%

9.80%

Principal Amount

[17],[29],[30]

$ 3,077,000

Investment cost

[1],[17],[29],[30]

3,701,000

Investments at Fair Value

[17],[29],[30]

$ 3,313,000

Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-06

2023-06

Investment Interest Rate

[11],[27],[28]

6.95%

6.95%

Investment, Basis Spread, Variable Rate

[11],[27],[28]

4.30%

4.30%

Investment, Interest Rate, Floor

[11],[27],[28]

9.80%

9.80%

Interest Rate and Floor

[11],[27],[28]

6.95%

6.95%

Principal Amount

[27],[28]

$ 5,000,000

Investment cost

[2],[27],[28]

5,500,000

Investments at Fair Value

[27],[28]

$ 5,459,000

Drug Discovery & Development | Senior Secured | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-01

2027-01

Investment, Basis Spread, Variable Rate

[7]

3.65%

3.65%

Investment, Interest Rate, Floor

[7]

7.65%

7.65%

Principal Amount

[10],[29]

$ 5,000,000

Investment cost

[1],[10],[29]

4,966,000

Investments at Fair Value

[10],[29]

$ 4,983,000

Drug Discovery & Development | Senior Secured | Albireo Pharma, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-07

2024-07

Investment Interest Rate

[11],[27]

6.95%

6.95%

Investment, Basis Spread, Variable Rate

[11],[27]

5.90%

5.90%

Investment, Interest Rate, Floor

[11],[27]

9.15%

9.15%

Interest Rate and Floor

[11],[27]

6.95%

6.95%

Principal Amount

[14],[27]

$ 10,000,000

Investment cost

[4],[14],[27]

10,229,000

Investments at Fair Value

[14],[27]

$ 10,268,000

Drug Discovery & Development | Senior Secured | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

Investment, Basis Spread, Variable Rate

[7]

3.65%

3.65%

Investment, Interest Rate, Floor

[7]

8.40%

8.40%

Principal Amount

[10]

$ 15,000,000

Investment cost

[1],[10]

14,858,000

Investments at Fair Value

[10]

$ 14,858,000

Drug Discovery & Development | Senior Secured | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-10

2023-10

2023-10

2023-10

Investment Interest Rate

[11]

6.95%

6.95%

Investment, Basis Spread, Variable Rate

3.10%

[7]

3.10%

[11]

3.10%

[7]

3.10%

[11]

Investment, Interest Rate, Floor

8.60%

[7]

8.60%

[11]

8.60%

[7]

8.60%

[11]

Interest Rate and Floor

[11]

6.95%

6.95%

Principal Amount

$ 15,000,000

[12]

$ 15,000,000

Investment cost

15,817,000

[1],[12]

15,639,000

[4]

Investments at Fair Value

$ 15,608,000

[12]

$ 15,653,000

Drug Discovery & Development | Senior Secured | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-04

2024-04

2024-04

2024-04

Investment Interest Rate

[11]

9.75%

9.75%

Investment, Basis Spread, Variable Rate

6.50%

[7]

6.50%

[11]

6.50%

[7]

6.50%

[11]

Investment, Interest Rate, Floor

[7]

9.75%

9.75%

Interest Rate and Floor

[11]

9.75%

9.75%

Principal Amount

$ 15,609,000

[17]

$ 20,000,000

Investment cost

16,450,000

[1],[17]

20,416,000

[4]

Investments at Fair Value

$ 16,308,000

[17]

$ 20,339,000

Drug Discovery & Development | Senior Secured | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-08

2026-08

Investment, Basis Spread, Variable Rate

[7]

4.55%

4.55%

Investment, Interest Rate, Floor

[7]

8.55%

8.55%

Principal Amount

[10],[29],[30]

$ 10,500,000

Investment cost

[1],[10],[29],[30]

10,467,000

Investments at Fair Value

[10],[29],[30]

$ 10,467,000

Drug Discovery & Development | Senior Secured | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-09

2024-09

2024-09

2024-09

Investment, Basis Spread, Variable Rate

6.40%

[7]

6.40%

[11]

6.40%

[7]

6.40%

[11]

Investment, Interest Rate, Floor

9.65%

[7]

9.65%

[11]

9.65%

[7]

9.65%

[11]

Principal Amount

$ 40,000,000

[12],[31]

$ 40,000,000

[14],[32]

Investment cost

41,439,000

[1],[12],[31]

40,842,000

[4],[14],[32]

Investments at Fair Value

$ 41,374,000

[12],[31]

$ 40,776,000

[14],[32]

Drug Discovery & Development | Senior Secured | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-10

2026-10

2026-10

2026-10

Investment Interest Rate

[11],[27]

5.82%

5.82%

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

[11],[27]

5.70%

[7]

5.70%

[11],[27]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11],[27]

8.95%

[7]

8.95%

[11],[27]

Interest Rate and Floor

[11],[27]

5.82%

5.82%

Principal Amount

$ 81,725,000

[10],[12],[18],[19],[29]

$ 50,000,000

[27],[33]

Investment cost

81,388,000

[1],[10],[12],[18],[19],[29]

49,542,000

[4],[27],[33]

Investments at Fair Value

$ 79,295,000

[10],[12],[18],[19],[29]

$ 48,859,000

[27],[33]

Drug Discovery & Development | Senior Secured | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-07

2024-10

2025-07

2024-10

Investment Interest Rate

[11],[27],[28]

5%

5%

Investment, Basis Spread, Variable Rate

4.55%

[7]

5.60%

[11],[27],[28]

4.55%

[7]

5.60%

[11],[27],[28]

Investment, Interest Rate, Floor

8.05%

[7]

8.85%

[11],[27],[28]

8.05%

[7]

8.85%

[11],[27],[28]

Interest Rate and Floor

[11],[27],[28]

5%

5%

Principal Amount

$ 11,500,000

[12],[18],[29],[30]

$ 24,000,000

[14],[15],[27],[28],[33]

Investment cost

11,724,000

[1],[12],[18],[29],[30]

24,271,000

[4],[14],[15],[27],[28],[33]

Investments at Fair Value

$ 11,619,000

[12],[18],[29],[30]

$ 24,454,000

[14],[15],[27],[28],[33]

Drug Discovery & Development | Senior Secured | BiomX, INC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-09

2025-09

2025-09

2025-09

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

[11],[27],[28]

5.70%

[7]

5.70%

[11],[27],[28]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11],[27],[28]

8.95%

[7]

8.95%

[11],[27],[28]

Principal Amount

$ 9,000,000

[12],[29],[30]

$ 9,000,000

[14],[27],[28]

Investment cost

9,125,000

[1],[12],[29],[30]

8,980,000

[4],[14],[27],[28]

Investments at Fair Value

$ 9,004,000

[12],[29],[30]

$ 8,980,000

[14],[27],[28]

Drug Discovery & Development | Senior Secured | BridgeBio Pharma, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-11

2026-11

2026-11

2026-11

Investment, Interest Rate, Paid in Cash

9%

[7]

9%

[11]

9%

[7]

9%

[11]

Investment Interest Rate

[11]

2%

2%

Interest Rate and Floor

[11]

2%

2%

Principal Amount

$ 37,022,000

[9],[17],[18]

$ 38,000,000

Investment cost

36,694,000

[1],[9],[17],[18]

37,462,000

[4]

Investments at Fair Value

$ 33,561,000

[9],[17],[18]

$ 37,462,000

Drug Discovery & Development | Senior Secured | Cellarity, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-06

2026-06

2026-06

2026-06

Investment Interest Rate

[11]

3.75%

3.75%

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

[11]

5.70%

[7]

5.70%

[11]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11]

8.95%

[7]

8.95%

[11]

Interest Rate and Floor

[11]

3.75%

3.75%

Principal Amount

$ 30,000,000

[17],[31]

$ 30,000,000

[32]

Investment cost

29,734,000

[1],[17],[31]

29,422,000

[4],[32]

Investments at Fair Value

$ 29,943,000

[17],[31]

$ 29,422,000

[32]

Drug Discovery & Development | Senior Secured | Century Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-04

2024-04

2024-04

2024-04

Investment Interest Rate

[11]

3.95%

3.95%

Investment, Basis Spread, Variable Rate

6.30%

[7]

6.30%

[11]

6.30%

[7]

6.30%

[11]

Investment, Interest Rate, Floor

9.55%

[7]

9.55%

[11]

9.55%

[7]

9.55%

[11]

Interest Rate and Floor

[11]

3.95%

3.95%

Principal Amount

$ 10,000,000

[12]

$ 10,000,000

[14]

Investment cost

10,197,000

[1],[12]

10,075,000

[4],[14]

Investments at Fair Value

$ 10,261,000

[12]

$ 10,361,000

[14]

Drug Discovery & Development | Senior Secured | Codiak Biosciences, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-10

2025-10

2025-10

2025-10

Investment Interest Rate

[11]

5.50%

5.50%

Investment, Basis Spread, Variable Rate

5%

[7]

5%

[11]

5%

[7]

5%

[11]

Investment, Interest Rate, Floor

8.25%

[7]

8.25%

[11]

8.25%

[7]

8.25%

[11]

Interest Rate and Floor

[11]

5.50%

5.50%

Principal Amount

$ 25,000,000

[12]

$ 25,000,000

[14]

Investment cost

25,681,000

[1],[12]

25,459,000

[2],[14]

Investments at Fair Value

$ 25,076,000

[12]

$ 25,316,000

[14]

Drug Discovery & Development | Senior Secured | Corium, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

2026-09

2026-09

Investment Interest Rate

[11]

7.75%

7.75%

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

[11]

5.70%

[7]

5.70%

[11]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11]

8.95%

[7]

8.95%

[11]

Interest Rate and Floor

[11]

7.75%

7.75%

Principal Amount

$ 132,675,000

[17],[19]

$ 91,500,000

[21]

Investment cost

133,069,000

[1],[17],[19]

90,997,000

[2],[21]

Investments at Fair Value

$ 135,828,000

[17],[19]

$ 90,997,000

[21]

Drug Discovery & Development | Senior Secured | Eloxx Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-04

2025-04

2025-04

2025-04

Investment Interest Rate

[11]

6.25%

6.25%

Investment, Basis Spread, Variable Rate

[7]

6.25%

6.25%

Investment, Interest Rate, Floor

9.50%

[7]

9.50%

[11]

9.50%

[7]

9.50%

[11]

Interest Rate and Floor

[11]

6.25%

6.25%

Principal Amount

$ 12,500,000

[31]

$ 12,500,000

[32]

Investment cost

12,673,000

[1],[31]

12,443,000

[2],[32]

Investments at Fair Value

$ 12,408,000

[31]

$ 12,443,000

[32]

Drug Discovery & Development | Senior Secured | enGene, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-07

2025-07

2025-07

2025-07

Investment Interest Rate

[11],[27],[28]

6.35%

6.35%

Investment, Basis Spread, Variable Rate

5%

[7]

5%

[11],[27],[28]

5%

[7]

5%

[11],[27],[28]

Investment, Interest Rate, Floor

[11],[27],[28]

8.25%

8.25%

Interest Rate and Floor

[11],[27],[28]

6.35%

6.35%

Principal Amount

$ 11,000,000

[17],[29],[30]

$ 7,000,000

[27],[28]

Investment cost

10,994,000

[1],[17],[29],[30]

6,858,000

[2],[27],[28]

Investments at Fair Value

$ 10,918,000

[17],[29],[30]

$ 6,858,000

[27],[28]

Drug Discovery & Development | Senior Secured | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-11

2026-11

Investment, Basis Spread, Variable Rate

[7]

4.05%

4.05%

Investment, Interest Rate, Floor

[7]

7.55%

7.55%

Principal Amount

[10]

$ 15,000,000

Investment cost

[1],[10]

14,958,000

Investments at Fair Value

[10]

$ 14,241,000

Drug Discovery & Development | Senior Secured | G1 Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-11

2026-11

2026-11

2026-11

Investment Interest Rate

[11],[27]

9.86%

9.86%

Investment, Basis Spread, Variable Rate

5.90%

[7]

5.90%

[11],[27]

5.90%

[7]

5.90%

[11],[27]

Investment, Interest Rate, Floor

9.15%

[7]

9.15%

[11],[27]

9.15%

[7]

9.15%

[11],[27]

Interest Rate and Floor

[11],[27]

9.86%

9.86%

Principal Amount

$ 58,125,000

[10],[12],[18],[31]

$ 58,125,000

[14],[15],[27],[32],[33]

Investment cost

58,472,000

[1],[10],[12],[18],[31]

57,873,000

[2],[14],[15],[27],[32],[33]

Investments at Fair Value

$ 58,006,000

[10],[12],[18],[31]

$ 57,874,000

[14],[15],[27],[32],[33]

Drug Discovery & Development | Senior Secured | Geron Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-10

2024-10

2024-10

2024-10

Investment Interest Rate

[11],[27]

6.55%

6.55%

Investment, Basis Spread, Variable Rate

5.75%

[7]

5.75%

[11],[27]

5.75%

[7]

5.75%

[11],[27]

Investment, Interest Rate, Floor

9%

[7]

9%

[11],[27]

9%

[7]

9%

[11],[27]

Interest Rate and Floor

[11],[27]

6.55%

6.55%

Principal Amount

$ 18,500,000

[17],[18],[29]

$ 32,500,000

[27],[33]

Investment cost

19,003,000

[1],[17],[18],[29]

32,704,000

[2],[27],[33]

Investments at Fair Value

$ 19,059,000

[17],[18],[29]

$ 32,744,000

[27],[33]

Drug Discovery & Development | Senior Secured | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-07

2027-07

Investment, Basis Spread, Variable Rate

[7]

3.15%

3.15%

Investment, Interest Rate, Floor

[7]

7.15%

7.15%

Investment, Interest Rate, Paid in Kind

[7]

2%

2%

Principal Amount

[9],[10]

$ 15,037,000

Investment cost

[1],[9],[10]

14,989,000

Investments at Fair Value

[9],[10]

$ 14,989,000

Drug Discovery & Development | Senior Secured | Hibercell, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-05

2025-05

2025-05

2025-05

Investment Interest Rate

[11]

4.95%

4.95%

Investment, Basis Spread, Variable Rate

5.40%

[7]

5.40%

[11]

5.40%

[7]

5.40%

[11]

Investment, Interest Rate, Floor

8.65%

[7]

8.65%

[11]

8.65%

[7]

8.65%

[11]

Interest Rate and Floor

[11]

4.95%

4.95%

Principal Amount

$ 17,000,000

[17],[31]

$ 17,000,000

[32]

Investment cost

17,244,000

[1],[17],[31]

17,041,000

[2],[32]

Investments at Fair Value

$ 17,225,000

[17],[31]

$ 17,014,000

[32]

Drug Discovery & Development | Senior Secured | HilleVax, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-05

2027-05

Investment, Basis Spread, Variable Rate

[7]

1.05%

1.05%

Investment, Interest Rate, Floor

[7]

4.55%

4.55%

Investment, Interest Rate, Paid in Kind

[7]

2.85%

2.85%

Principal Amount

[9],[10],[31]

$ 4,043,000

Investment cost

[1],[9],[10],[31]

4,043,000

Investments at Fair Value

[9],[10],[31]

$ 4,044,000

Drug Discovery & Development | Senior Secured | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-08

2027-08

Investment, Basis Spread, Variable Rate

[7]

4%

4%

Investment, Interest Rate, Floor

[7]

8.75%

8.75%

Principal Amount

[10],[29]

$ 24,750,000

Investment cost

[1],[10],[29]

24,530,000

Investments at Fair Value

[10],[29]

$ 24,531,000

Drug Discovery & Development | Senior Secured | Humanigen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

Investment Interest Rate

[11],[26],[27]

6.75%

6.75%

Investment, Basis Spread, Variable Rate

[11],[26],[27]

5.50%

5.50%

Investment, Interest Rate, Floor

[11],[26],[27]

8.75%

8.75%

Interest Rate and Floor

[11],[26],[27]

6.75%

6.75%

Principal Amount

[26],[27]

$ 20,000,000

Investment cost

[2],[26],[27]

20,235,000

Investments at Fair Value

[26],[27]

$ 19,985,000

Drug Discovery & Development | Senior Secured | Kaleido Biosciences, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-01

2024-01

Investment Interest Rate

[11]

7.55%

7.55%

Investment, Basis Spread, Variable Rate

[11]

6.10%

6.10%

Investment, Interest Rate, Floor

[11]

9.35%

9.35%

Interest Rate and Floor

[11]

7.55%

7.55%

Principal Amount

[33]

$ 22,500,000

Investment cost

[2],[33]

23,505,000

Investments at Fair Value

[33]

$ 23,384,000

Drug Discovery & Development | Senior Secured | Locus Biosciences, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-07

2025-07

2025-07

2025-07

Investment Interest Rate

[11]

4.95%

4.95%

Investment, Basis Spread, Variable Rate

6.10%

[7]

6.10%

[11]

6.10%

[7]

6.10%

[11]

Investment, Interest Rate, Floor

9.35%

[7]

9.35%

[11]

9.35%

[7]

9.35%

[11]

Interest Rate and Floor

[11]

4.95%

4.95%

Principal Amount

$ 8,000,000

[31]

$ 8,000,000

[32]

Investment cost

8,084,000

[1],[31]

7,977,000

[2],[32]

Investments at Fair Value

$ 8,062,000

[31]

$ 7,900,000

[32]

Drug Discovery & Development | Senior Secured | Madrigal Pharmaceutical, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-05

2026-05

Investment, Basis Spread, Variable Rate

[7]

3.95%

3.95%

Investment, Interest Rate, Floor

[7]

7.45%

7.45%

Principal Amount

[29]

$ 34,000,000

Investment cost

[1],[29]

33,807,000

Investments at Fair Value

[29]

$ 33,807,000

Drug Discovery & Development | Senior Secured | Phathom Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-10

2026-10

2026-10

2026-10

Investment Interest Rate

[11],[27]

7.50%

7.50%

Investment, Basis Spread, Variable Rate

2.25%

[7]

2.25%

[11],[27]

2.25%

[7]

2.25%

[11],[27]

Investment, Interest Rate, Floor

5.50%

[7]

5.50%

[11],[27]

5.50%

[7]

5.50%

[11],[27]

Investment, Interest Rate, Paid in Kind

3.35%

[7]

3.35%

[11],[27]

3.35%

[7]

3.35%

[11],[27]

Interest Rate and Floor

[11],[27]

7.50%

7.50%

Principal Amount

$ 93,978,000

[9],[10],[18],[19],[29],[31]

$ 87,116,000

[15],[20],[21],[27],[32],[33]

Investment cost

93,948,000

[1],[9],[10],[18],[19],[29],[31]

86,075,000

[2],[15],[20],[21],[27],[32],[33]

Investments at Fair Value

$ 94,006,000

[9],[10],[18],[19],[29],[31]

$ 86,075,000

[15],[20],[21],[27],[32],[33]

Drug Discovery & Development | Senior Secured | Provention Bio, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

Investment, Basis Spread, Variable Rate

[7]

2.70%

2.70%

Investment, Interest Rate, Floor

[7]

8.20%

8.20%

Principal Amount

$ 25,000,000

Investment cost

[1]

24,552,000

Investments at Fair Value

$ 24,552,000

Drug Discovery & Development | Senior Secured | Redshift Bioanalytics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-01

2026-01

Investment, Basis Spread, Variable Rate

[7]

4.25%

4.25%

Investment, Interest Rate, Floor

[7]

7.50%

7.50%

Principal Amount

[31]

$ 5,000,000

Investment cost

[1],[31]

4,936,000

Investments at Fair Value

[31]

$ 4,935,000

Drug Discovery & Development | Senior Secured | Scynexis, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

2025-03

2025-03

Investment Interest Rate

[11]

3.95%

3.95%

Investment, Basis Spread, Variable Rate

5.80%

[7]

5.80%

[11]

5.80%

[7]

5.80%

[11]

Investment, Interest Rate, Floor

9.05%

[7]

9.05%

[11]

9.05%

[7]

9.05%

[11]

Interest Rate and Floor

[11]

3.95%

3.95%

Principal Amount

$ 18,667,000

[17],[18]

$ 16,000,000

Investment cost

18,592,000

[1],[17],[18]

15,826,000

[2]

Investments at Fair Value

$ 18,524,000

[17],[18]

$ 15,778,000

Drug Discovery & Development | Senior Secured | Seres Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-10

2023-11

2024-10

2023-11

Investment Interest Rate

[11]

4.85%

4.85%

Investment, Basis Spread, Variable Rate

6.40%

[7]

4.40%

[11]

6.40%

[7]

4.40%

[11]

Investment, Interest Rate, Floor

9.65%

[7]

9.65%

[11]

9.65%

[7]

9.65%

[11]

Interest Rate and Floor

[11]

4.85%

4.85%

Principal Amount

$ 37,500,000

[17],[18]

$ 24,051,000

Investment cost

38,509,000

[1],[17],[18]

24,777,000

[2]

Investments at Fair Value

$ 38,657,000

[17],[18]

$ 25,183,000

Drug Discovery & Development | Senior Secured | Syndax Pharmaceutics Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-04

2024-04

Investment Interest Rate

[11]

4.99%

4.99%

Investment, Basis Spread, Variable Rate

[11]

6%

6%

Investment, Interest Rate, Floor

[11]

9.25%

9.25%

Interest Rate and Floor

[11]

4.99%

4.99%

Principal Amount

[15],[33]

$ 20,000,000

Investment cost

[2],[15],[33]

20,646,000

Investments at Fair Value

[15],[33]

$ 20,653,000

Drug Discovery & Development | Senior Secured | Tarsus Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-02

2027-02

Investment, Basis Spread, Variable Rate

[7]

5.20%

5.20%

Investment, Interest Rate, Floor

[7]

8.45%

8.45%

Principal Amount

[10],[17],[29]

$ 8,250,000

Investment cost

[1],[10],[17],[29]

8,255,000

Investments at Fair Value

[10],[17],[29]

$ 8,388,000

Drug Discovery & Development | Senior Secured | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-01

2026-01

2026-01

2026-01

Investment Interest Rate

[11],[27]

5.95%

5.95%

Investment, Basis Spread, Variable Rate

2.15%

[7]

2.15%

[11],[27]

2.15%

[7]

2.15%

[11],[27]

Investment, Interest Rate, Floor

5.40%

[7]

5.40%

[11],[27]

5.40%

[7]

5.40%

[11],[27]

Investment, Interest Rate, Paid in Kind

[7]

3.45%

3.45%

Interest Rate and Floor

[11],[27]

5.95%

5.95%

Principal Amount

$ 47,567,000

[9],[12],[18],[29]

$ 51,450,000

[27]

Investment cost

47,267,000

[1],[9],[12],[18],[29]

50,470,000

[2],[27]

Investments at Fair Value

$ 47,137,000

[9],[12],[18],[29]

$ 50,470,000

[27]

Drug Discovery & Development | Senior Secured | Uni Qure B V | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-12

2025-12

2025-12

2025-12

Investment Interest Rate

[11],[27],[28]

7.28%

7.28%

Investment, Basis Spread, Variable Rate

4.70%

[7]

4.70%

[11],[27],[28]

4.70%

[7]

4.70%

[11],[27],[28]

Investment, Interest Rate, Floor

7.95%

[7]

7.95%

[11],[27],[28]

7.95%

[7]

7.95%

[11],[27],[28]

Interest Rate and Floor

[11],[27],[28]

7.28%

7.28%

Principal Amount

$ 70,000,000

[12],[18],[19],[29],[30]

$ 77,500,000

[14],[21],[27],[28],[33]

Investment cost

72,015,000

[1],[12],[18],[19],[29],[30]

78,755,000

[2],[14],[21],[27],[28],[33]

Investments at Fair Value

$ 73,205,000

[12],[18],[19],[29],[30]

$ 78,755,000

[14],[21],[27],[28],[33]

Drug Discovery & Development | Senior Secured | Unity Biotechnology Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-08

2024-08

2024-08

2024-08

Investment Interest Rate

[11],[26]

6.25%

6.25%

Investment, Basis Spread, Variable Rate

6.10%

[7]

6.10%

[11],[26]

6.10%

[7]

6.10%

[11],[26]

Investment, Interest Rate, Floor

9.35%

[7]

9.35%

[11],[26]

9.35%

[7]

9.35%

[11],[26]

Interest Rate and Floor

[11],[26]

6.25%

6.25%

Principal Amount

$ 20,000,000

[17]

$ 22,701,000

[26]

Investment cost

20,990,000

[1],[17]

23,293,000

[2],[26]

Investments at Fair Value

$ 20,844,000

[17]

$ 23,627,000

[26]

Drug Discovery & Development | Senior Secured | Valo Health L L C | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-05

2024-05

2024-05

2024-05

Investment Interest Rate

[11]

3.85%

3.85%

Investment, Basis Spread, Variable Rate

6.45%

[7]

6.45%

[11]

6.45%

[7]

6.45%

[11]

Investment, Interest Rate, Floor

9.70%

[7]

9.70%

[11]

9.70%

[7]

9.70%

[11]

Interest Rate and Floor

[11]

3.85%

3.85%

Principal Amount

$ 9,583,000

[12],[17]

$ 11,500,000

[14]

Investment cost

9,805,000

[1],[12],[17]

11,547,000

[2],[14]

Investments at Fair Value

$ 9,760,000

[12],[17]

$ 11,492,000

[14]

Drug Discovery & Development | Senior Secured | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-10

2026-10

Investment, Basis Spread, Variable Rate

[7]

4.20%

4.20%

Investment, Interest Rate, Floor

[7]

7.45%

7.45%

Principal Amount

[10],[17],[29]

$ 2,000,000

Investment cost

[1],[10],[17],[29]

2,004,000

Investments at Fair Value

[10],[17],[29]

$ 1,969,000

Drug Discovery & Development | Senior Secured | X Four Pharmaceuticals Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-07

2024-07

2024-07

2024-07

Investment Interest Rate

[11]

8.80%

8.80%

Investment, Basis Spread, Variable Rate

3.75%

[7]

3.75%

[11]

3.75%

[7]

3.75%

[11]

Investment, Interest Rate, Floor

8.75%

[7]

8.75%

[11]

8.75%

[7]

8.75%

[11]

Interest Rate and Floor

[11]

8.80%

8.80%

Principal Amount

$ 32,500,000

[12],[17],[18]

$ 32,500,000

[14],[33]

Investment cost

33,464,000

[1],[12],[17],[18]

34,140,000

[2],[14],[33]

Investments at Fair Value

$ 33,291,000

[12],[17],[18]

$ 34,085,000

[14],[33]

Drug Discovery & Development | Senior Secured | Yumanity Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-01

2024-01

Investment Interest Rate

[11]

5.92%

5.92%

Investment, Basis Spread, Variable Rate

[11]

4%

4%

Investment, Interest Rate, Floor

[11]

8.75%

8.75%

Interest Rate and Floor

[11]

5.92%

5.92%

Principal Amount

$ 12,732,000

Investment cost

[2]

13,256,000

Investments at Fair Value

$ 13,187,000

Drug Discovery & Development | Senior Secured | Center for Breakthrough Medicines Holdings, LLC [Member] | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-05

2023-05

Investment Interest Rate

[11]

7.50%

7.50%

Investment, Basis Spread, Variable Rate

[11]

5.50%

5.50%

Investment, Interest Rate, Floor

[11]

8.75%

8.75%

Interest Rate and Floor

[11]

7.50%

7.50%

Principal Amount

$ 5,000,000

Investment cost

[4]

5,005,000

Investments at Fair Value

$ 5,005,000

Drug Discovery & Development | Senior Secured | Floor Rate | enGene, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Floor

[7]

8.25%

8.25%

Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.25%

6.25%

Interest Rate and Floor

[7]

6.25%

6.25%

Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.15%

7.15%

Interest Rate and Floor

[7]

7.15%

7.15%

Drug Discovery & Development | Senior Secured | Exit Fee | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

9.95%

9.95%

Interest Rate and Floor

[7]

9.95%

9.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.85%

5.85%

Interest Rate and Floor

[7]

5.85%

5.85%

Drug Discovery & Development | Senior Secured | Exit Fee | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.30%

5.30%

Interest Rate and Floor

[7]

5.30%

5.30%

Drug Discovery & Development | Senior Secured | Exit Fee | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.95%

6.95%

Interest Rate and Floor

[7]

6.95%

6.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

6.95%

[7]

6.95%

[11]

6.95%

[7]

6.95%

[11]

Interest Rate and Floor

6.95%

[7]

6.95%

[11]

6.95%

[7]

6.95%

[11]

Drug Discovery & Development | Senior Secured | Exit Fee | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.95%

6.95%

Interest Rate and Floor

[7]

6.95%

6.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

6.95%

[7]

6.95%

[11]

6.95%

[7]

6.95%

[11]

Interest Rate and Floor

6.95%

[7]

6.95%

[11]

6.95%

[7]

6.95%

[11]

Drug Discovery & Development | Senior Secured | Exit Fee | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.31%

5.31%

Interest Rate and Floor

[7]

5.31%

5.31%

Drug Discovery & Development | Senior Secured | Exit Fee | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5%

5%

Interest Rate and Floor

[7]

5%

5%

Drug Discovery & Development | Senior Secured | Exit Fee | BiomX, INC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

6.55%

[7]

6.55%

[11],[27],[28]

6.55%

[7]

6.55%

[11],[27],[28]

Interest Rate and Floor

6.55%

[7]

6.55%

[11],[27],[28]

6.55%

[7]

6.55%

[11],[27],[28]

Drug Discovery & Development | Senior Secured | Exit Fee | BridgeBio Pharma, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

2%

2%

Interest Rate and Floor

[7]

2%

2%

Drug Discovery & Development | Senior Secured | Exit Fee | Cellarity, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.75%

3.75%

Interest Rate and Floor

[7]

3.75%

3.75%

Drug Discovery & Development | Senior Secured | Exit Fee | Century Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Codiak Biosciences, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.50%

5.50%

Interest Rate and Floor

[7]

5.50%

5.50%

Drug Discovery & Development | Senior Secured | Exit Fee | Corium, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.75%

7.75%

Interest Rate and Floor

[7]

7.75%

7.75%

Drug Discovery & Development | Senior Secured | Exit Fee | Eloxx Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

6.55%

[7]

6.55%

[11]

6.55%

[7]

6.55%

[11]

Interest Rate and Floor

6.55%

[7]

6.55%

[11]

6.55%

[7]

6.55%

[11]

Drug Discovery & Development | Senior Secured | Exit Fee | enGene, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.35%

6.35%

Interest Rate and Floor

[7]

6.35%

6.35%

Drug Discovery & Development | Senior Secured | Exit Fee | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.50%

5.50%

Interest Rate and Floor

[7]

5.50%

5.50%

Drug Discovery & Development | Senior Secured | Exit Fee | G1 Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

9.86%

9.86%

Interest Rate and Floor

[7]

9.86%

9.86%

Drug Discovery & Development | Senior Secured | Exit Fee | Geron Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.55%

6.55%

Interest Rate and Floor

[7]

6.55%

6.55%

Drug Discovery & Development | Senior Secured | Exit Fee | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.75%

5.75%

Interest Rate and Floor

[7]

5.75%

5.75%

Drug Discovery & Development | Senior Secured | Exit Fee | Hibercell, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Drug Discovery & Development | Senior Secured | Exit Fee | HilleVax, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.15%

7.15%

Interest Rate and Floor

[7]

7.15%

7.15%

Drug Discovery & Development | Senior Secured | Exit Fee | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.25%

4.25%

Interest Rate and Floor

[7]

4.25%

4.25%

Drug Discovery & Development | Senior Secured | Exit Fee | Locus Biosciences, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Madrigal Pharmaceutical, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.35%

5.35%

Interest Rate and Floor

[7]

5.35%

5.35%

Drug Discovery & Development | Senior Secured | Exit Fee | Phathom Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.50%

7.50%

Interest Rate and Floor

[7]

7.50%

7.50%

Drug Discovery & Development | Senior Secured | Exit Fee | Provention Bio, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.60%

6.60%

Interest Rate and Floor

[7]

6.60%

6.60%

Drug Discovery & Development | Senior Secured | Exit Fee | Redshift Bioanalytics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.80%

3.80%

Interest Rate and Floor

[7]

3.80%

3.80%

Drug Discovery & Development | Senior Secured | Exit Fee | Scynexis, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Seres Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.98%

4.98%

Interest Rate and Floor

[7]

4.98%

4.98%

Drug Discovery & Development | Senior Secured | Exit Fee | Tarsus Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.75%

4.75%

Interest Rate and Floor

[7]

4.75%

4.75%

Drug Discovery & Development | Senior Secured | Exit Fee | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.95%

5.95%

Interest Rate and Floor

[7]

5.95%

5.95%

Drug Discovery & Development | Senior Secured | Exit Fee | Uni Qure B V | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.28%

7.28%

Interest Rate and Floor

[7]

7.28%

7.28%

Drug Discovery & Development | Senior Secured | Exit Fee | Unity Biotechnology Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.25%

6.25%

Interest Rate and Floor

[7]

6.25%

6.25%

Drug Discovery & Development | Senior Secured | Exit Fee | Valo Health L L C | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.85%

3.85%

Interest Rate and Floor

[7]

3.85%

3.85%

Drug Discovery & Development | Senior Secured | Exit Fee | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.76%

4.76%

Interest Rate and Floor

[7]

4.76%

4.76%

Drug Discovery & Development | Senior Secured | Exit Fee | X Four Pharmaceuticals Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

8.80%

8.80%

Interest Rate and Floor

[7]

8.80%

8.80%

Drug Discovery & Development | Senior Secured | Cap Rate | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

10.90%

10.90%

Interest Rate and Floor

[7]

10.90%

10.90%

Drug Discovery & Development | Senior Secured | Cap Rate | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

15%

15%

Interest Rate and Floor

[7]

15%

15%

Drug Discovery & Development | Senior Secured | Cap Rate | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

10.70%

10.70%

Interest Rate and Floor

[7]

10.70%

10.70%

Drug Discovery & Development | Senior Secured | Cap Rate | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

9.05%

9.05%

Interest Rate and Floor

[7]

9.05%

9.05%

Drug Discovery & Development | Senior Secured | Cap Rate | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

8.80%

8.80%

Interest Rate and Floor

[7]

8.80%

8.80%

Drug Discovery & Development | Senior Secured | Cap Rate | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

8.65%

8.65%

Interest Rate and Floor

[7]

8.65%

8.65%

Drug Discovery & Development | Senior Secured | Cap Rate | HilleVax, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.05%

6.05%

Interest Rate and Floor

[7]

6.05%

6.05%

Drug Discovery & Development | Senior Secured | Cap Rate | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

10.25%

10.25%

Interest Rate and Floor

[7]

10.25%

10.25%

Drug Discovery & Development | Senior Secured | Cap Rate | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

8.95%

8.95%

Interest Rate and Floor

[7]

8.95%

8.95%

Drug Discovery & Development | Senior Secured Tranche A [Member] | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Kind

[11],[27]

3.45%

3.45%

Drug Discovery & Development | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 1,056,335,000

[1]

$ 936,457,000

[2]

Investments at Fair Value

1,052,244,000

935,964,000

Drug Delivery

Investment Holdings [Line Items]

Investments at Fair Value

90,000

368,000

Drug Delivery | Equity

Investment Holdings [Line Items]

Investment cost

3,638,000

[1]

3,638,000

[2]

Investments at Fair Value

305,000

Drug Delivery | Warrant Investment

Investment Holdings [Line Items]

Investment cost

465,000

[1]

465,000

[2]

Investments at Fair Value

0

63,000

Drug Delivery | AcelRx Pharmaceuticals, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

1,329,000

[1],[5]

1,329,000

[2],[6]

Investments at Fair Value

$ 37,000

[5]

$ 99,000

[6]

Investment, Acquisition Date

Dec. 10, 2018

[5]

Dec. 10, 2018

[6]

Shares | shares

176,730

[5]

176,730

[6]

176,730

[5]

176,730

[6]

Drug Delivery | Aytu BioScience, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,500,000

[1],[5]

$ 1,500,000

[2],[6]

Investments at Fair Value

$ 3,000

[5]

$ 18,000

[6]

Investment, Acquisition Date

Mar. 28, 2014

[5]

Mar. 28, 2014

[6]

Shares | shares

13,600

[5]

13,600

[6]

13,600

[5]

13,600

[6]

Drug Delivery | BioQ Pharma Incorporated | Equity | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 500,000

[1]

$ 500,000

[2]

Investments at Fair Value

$ 43,000

$ 168,000

Investment, Acquisition Date

Dec. 08, 2015

[5]

Dec. 08, 2015

[6]

Shares | shares

165,000

165,000

165,000

165,000

Drug Delivery | BioQ Pharma Incorporated | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000

[1]

$ 1,000

[2]

Investments at Fair Value

$ 0

$ 62,000

Investment, Acquisition Date

Oct. 27, 2014

[5]

Oct. 27, 2014

[6]

Shares | shares

459,183

459,183

459,183

459,183

Drug Delivery | PDS Biotechnology Corporation | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

$ 309,000

Investments at Fair Value

[5]

$ 7,000

Investment, Acquisition Date

[5]

Apr. 06, 2015

Shares | shares

[5]

2,498

2,498

Drug Delivery | PDS Biotechnology Corporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 390,000

[1],[5]

$ 390,000

[2],[6]

Investments at Fair Value

$ 0

[5]

$ 1,000

[6]

Investment, Acquisition Date

Aug. 28, 2014

[5]

Aug. 28, 2014

[6]

Shares | shares

3,929

[5]

3,929

[6]

3,929

[5]

3,929

[6]

Drug Delivery | Aerami Therapeutics Holdings, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 74,000

[1]

$ 74,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Sep. 30, 2015

[5]

Sep. 30, 2015

[6]

Shares | shares

110,882

110,882

110,882

110,882

Drug Delivery | PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.) | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 309,000

Investments at Fair Value

[6]

$ 20,000

Investment, Acquisition Date

[6]

Apr. 06, 2015

Shares | shares

[6]

2,498

2,498

Healthcare Services Other

Investment Holdings [Line Items]

Investments at Fair Value

$ 203,599,000

$ 121,003,000

Healthcare Services Other | Equity

Investment Holdings [Line Items]

Investment cost

6,782,000

[1]

6,781,000

[2]

Investments at Fair Value

3,198,000

7,364,000

Healthcare Services Other | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[1]

697,000

Investments at Fair Value

521,000

Healthcare Services Other | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

156,619,000

[1]

113,724,000

[2]

Investments at Fair Value

155,925,000

113,639,000

Healthcare Services Other | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Investment cost

[1]

43,955,000

Investments at Fair Value

43,955,000

Healthcare Services Other | Carbon Health Technologies, Inc. | Equity | Preferred Series C

Investment Holdings [Line Items]

Investment cost

1,688,000

[1]

1,687,000

[2]

Investments at Fair Value

$ 836,000

$ 1,864,000

Investment, Acquisition Date

Mar. 30, 2021

[5]

Mar. 30, 2021

[6]

Shares | shares

217,880

217,880

217,880

217,880

Healthcare Services Other | Elation Health, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 583,000

Investments at Fair Value

$ 501,000

Investment, Acquisition Date

[5]

Sep. 12, 2022

Shares | shares

362,837

362,837

Healthcare Services Other | 23andMe, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 5,094,000

[1],[5]

$ 5,094,000

[2],[6]

Investments at Fair Value

$ 2,362,000

[5]

$ 5,500,000

[6]

Investment, Acquisition Date

Mar. 11, 2019

[5]

Mar. 11, 2019

[6]

Shares | shares

825,732

[5]

825,732

[6]

825,732

[5]

825,732

[6]

Healthcare Services Other | Vida Health, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 114,000

Investments at Fair Value

$ 20,000

Investment, Acquisition Date

[5]

Mar. 28, 2022

Shares | shares

100,618

100,618

Healthcare Services Other | Senior Secured | Better Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-08

2025-08

2025-08

2025-08

Investment Interest Rate

5.95%

5.95%

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

5.70%

[7]

5.70%

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

8.95%

[7]

8.95%

Interest Rate and Floor

5.95%

5.95%

Principal Amount

$ 12,000,000

[31]

$ 8,000,000

[15],[32]

Investment cost

12,093,000

[1],[31]

7,966,000

[2],[15],[32]

Investments at Fair Value

$ 11,996,000

[31]

$ 7,966,000

[15],[32]

Healthcare Services Other | Senior Secured | Blue Sprig Pediatrics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-11

2026-11

2026-11

2026-11

Investment, Basis Spread, Variable Rate

5%

[7]

5%

5%

[7]

5%

Investment, Interest Rate, Floor

6%

[7]

6%

6%

[7]

6%

Investment, Interest Rate, Paid in Kind

[7]

4.45%

4.45%

Principal Amount

$ 40,949,000

[9],[10],[12],[17]

$ 25,022,000

[15],[20]

Investment cost

40,403,000

[1],[9],[10],[12],[17]

24,653,000

[2],[15],[20]

Investments at Fair Value

$ 39,332,000

[9],[10],[12],[17]

$ 24,653,000

[15],[20]

Healthcare Services Other | Senior Secured | Carbon Health Technologies, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

2025-03

2025-03

Investment Interest Rate

4.61%

4.61%

Investment, Basis Spread, Variable Rate

5.60%

[7]

5.60%

5.60%

[7]

5.60%

Investment, Interest Rate, Floor

8.85%

[7]

8.85%

8.85%

[7]

8.85%

Interest Rate and Floor

4.61%

4.61%

Principal Amount

$ 46,125,000

[8],[10],[12],[17],[18]

$ 46,125,000

[15],[23]

Investment cost

46,399,000

[1],[8],[10],[12],[17],[18]

45,964,000

[2],[15],[23]

Investments at Fair Value

$ 46,158,000

[8],[10],[12],[17],[18]

$ 45,964,000

[15],[23]

Healthcare Services Other | Senior Secured | Equality Health, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-02

2026-02

2026-02

2026-02

Investment Interest Rate

1.55%

1.55%

Investment, Basis Spread, Variable Rate

6.25%

[7]

6.25%

6.25%

[7]

6.25%

Investment, Interest Rate, Floor

9.50%

[7]

9.50%

9.50%

[7]

9.50%

Investment, Interest Rate, Paid in Kind

[7]

1.55%

1.55%

Interest Rate and Floor

1.55%

1.55%

Principal Amount

$ 53,388,000

[9],[18]

$ 35,444,000

[15],[20],[33]

Investment cost

52,928,000

[1],[9],[18]

35,141,000

[2],[15],[20],[33]

Investments at Fair Value

$ 53,644,000

[9],[18]

35,056,000

[15],[20],[33]

Healthcare Services Other | Senior Secured | Elation Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-03

2026-03

Investment, Basis Spread, Variable Rate

[7]

4.25%

4.25%

Investment, Interest Rate, Floor

[7]

9%

9%

Investment, Interest Rate, Paid in Kind

[7]

1.95%

1.95%

Principal Amount

[8],[10]

$ 5,000,000

Investment cost

[1],[8],[10]

4,796,000

Investments at Fair Value

[8],[10]

$ 4,795,000

Healthcare Services Other | Senior Secured | Oak Street Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Basis Spread, Variable Rate

[7]

2.45%

2.45%

Investment, Interest Rate, Floor

[7]

7.95%

7.95%

Principal Amount

[10],[29]

$ 44,250,000

Healthcare Services Other | Senior Secured | Oak Street Health, Inc. | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-10

2027-10

Investment, Interest Rate, Paid in Kind

[7]

1%

1%

Investment cost

[1],[10],[29]

$ 43,955,000

Investments at Fair Value

[10],[29]

$ 43,955,000

Healthcare Services Other | Senior Secured | Exit Fee | Better Therapeutics, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.95%

5.95%

Interest Rate and Floor

[7]

5.95%

5.95%

Healthcare Services Other | Senior Secured | Exit Fee | Carbon Health Technologies, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.61%

4.61%

Interest Rate and Floor

[7]

4.61%

4.61%

Healthcare Services Other | Senior Secured | Exit Fee | Elation Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Healthcare Services Other | Senior Secured | Cap Rate | Oak Street Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

9.45%

9.45%

Interest Rate and Floor

[7]

9.45%

9.45%

Healthcare Services Other | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 200,574,000

[1]

113,724,000

[2]

Investments at Fair Value

199,880,000

113,639,000

Information Services

Investment Holdings [Line Items]

Investments at Fair Value

59,735,000

74,417,000

Information Services | Equity

Investment Holdings [Line Items]

Investment cost

4,440,000

[1]

4,440,000

[2]

Investments at Fair Value

7,579,000

9,414,000

Information Services | Warrant Investment

Investment Holdings [Line Items]

Investment cost

680,000

[1]

645,000

[2]

Investments at Fair Value

416,000

557,000

Information Services | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

52,386,000

[1]

64,773,000

[2]

Investments at Fair Value

51,740,000

64,446,000

Information Services | Capella Space Corp. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

207,000

[1],[31]

207,000

[2],[32]

Investments at Fair Value

$ 50,000

[31]

$ 139,000

[32]

Investment, Acquisition Date

Oct. 21, 2021

[5]

Oct. 21, 2021

[6]

Shares | shares

176,200

[31]

176,200

[32]

176,200

[31]

176,200

[32]

Information Services | Signal Media Limited | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[29],[30]

$ 35,000

Investments at Fair Value

[29],[30]

$ 21,000

Investment, Acquisition Date

[5]

Jun. 29, 2022

Shares | shares

[29],[30]

94,857

94,857

Information Services | Yipit, LLC | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

$ 3,825,000

[1]

$ 3,825,000

[2]

Investments at Fair Value

$ 2,648,000

$ 3,825,000

Investment, Acquisition Date

Dec. 30, 2021

[5]

Dec. 30, 2021

[6]

Shares | shares

41,021

41,021

41,021

41,021

Information Services | Planet Labs, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 615,000

[1],[5]

$ 615,000

[2]

Investments at Fair Value

$ 2,975,000

[5]

$ 3,369,000

Investment, Acquisition Date

Jun. 21, 2019

[5]

Jun. 21, 2019

[6]

Shares | shares

547,880

[5]

547,880

547,880

[5]

547,880

Information Services | Zeta Global Corp. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 0

[1],[5]

$ 0

[2],[6],[34]

Investments at Fair Value

$ 1,956,000

[5]

$ 2,220,000

[6],[34]

Investment, Acquisition Date

Nov. 20, 2007

[5]

Nov. 20, 2007

[6]

Shares | shares

295,861

[5]

295,861

[6],[34]

295,861

[5]

295,861

[6],[34]

Information Services | I N M O B I Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 82,000

[1],[29],[30]

$ 82,000

[2],[27]

Investments at Fair Value

$ 0

[29],[30]

$ 0

[27]

Investment, Acquisition Date

Nov. 19, 2014

[5]

Nov. 19, 2014

[6],[27]

Shares | shares

65,587

[29],[30]

65,587

[27]

65,587

[29],[30]

65,587

[27]

Information Services | NetBase Solutions, Inc. | Warrant Investment | Preferred Series 1

Investment Holdings [Line Items]

Investment cost

$ 356,000

[1]

$ 356,000

[2]

Investments at Fair Value

$ 345,000

$ 418,000

Investment, Acquisition Date

Aug. 22, 2017

[5]

Aug. 22, 2017

[6]

Shares | shares

60,000

60,000

60,000

60,000

Information Services | Senior Secured | Capella Space Corp. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-11

2024-11

2024-11

2024-11

Investment Interest Rate

4%

4%

Investment, Basis Spread, Variable Rate

5%

[7]

5%

5%

[7]

5%

Investment, Interest Rate, Floor

8.25%

[7]

8.25%

8.25%

[7]

8.25%

Investment, Interest Rate, Paid in Kind

1.10%

[7]

1.10%

1.10%

[7]

1.10%

Interest Rate and Floor

4%

4%

Principal Amount

$ 20,193,000

[8],[9],[31]

$ 20,025,000

[20],[23],[32]

Investment cost

20,302,000

[1],[8],[9],[31]

19,751,000

[2],[20],[23],[32]

Investments at Fair Value

$ 20,219,000

[8],[9],[31]

$ 19,424,000

[20],[23],[32]

Information Services | Senior Secured | Signal Media Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-06

2025-06

Investment, Basis Spread, Variable Rate

[7]

5.50%

5.50%

Investment, Interest Rate, Floor

[7]

9%

9%

Principal Amount

[10],[29],[30]

$ 750,000

Investment cost

[1],[10],[29],[30]

739,000

Investments at Fair Value

[10],[29],[30]

$ 739,000

Information Services | Senior Secured | Yipit, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

2026-09

2026-09

Investment, Basis Spread, Variable Rate

9.08%

[7]

9.08%

9.08%

[7]

9.08%

Investment, Interest Rate, Floor

10.08%

[7]

10.08%

10.08%

[7]

10.08%

Principal Amount

$ 31,875,000

[10],[13]

$ 45,900,000

[15],[16]

Investment cost

31,345,000

[1],[10],[13]

45,022,000

[2],[15],[16]

Investments at Fair Value

$ 30,782,000

[10],[13]

45,022,000

[15],[16]

Information Services | Senior Secured | Exit Fee | Capella Space Corp. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7%

7%

Interest Rate and Floor

[7]

7%

7%

Information Services | Senior Secured | Exit Fee | Signal Media Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.45%

3.45%

Interest Rate and Floor

[7]

3.45%

3.45%

Information Services | Senior Secured | Cap Rate | Signal Media Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

12%

12%

Interest Rate and Floor

[7]

12%

12%

Information Services | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 52,386,000

[1]

64,773,000

[2]

Investments at Fair Value

51,740,000

64,446,000

Internet Consumer And Business Services

Investment Holdings [Line Items]

Investments at Fair Value

489,968,000

395,506,000

Internet Consumer And Business Services | Equity

Investment Holdings [Line Items]

Investment cost

22,058,000

[1]

22,151,000

[2]

Investments at Fair Value

15,377,000

35,331,000

Internet Consumer And Business Services | Warrant Investment

Investment Holdings [Line Items]

Investment cost

6,110,000

[1]

4,992,000

[2]

Investments at Fair Value

5,800,000

10,212,000

Internet Consumer And Business Services | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

82,481,000

[1]

22,164,000

[2]

Investments at Fair Value

82,481,000

22,164,000

Internet Consumer And Business Services | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

384,097,000

[1]

341,001,000

[2]

Investments at Fair Value

365,957,000

327,799,000

Internet Consumer And Business Services | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Investment cost

[1]

21,252,000

Investments at Fair Value

20,354,000

Internet Consumer And Business Services | Fulfil Solutions Inc [Member] | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

325,000

Investments at Fair Value

$ 199,000

Investment, Acquisition Date

[5]

Jul. 29, 2022

Shares | shares

84,995

84,995

Internet Consumer And Business Services | SeatGeek, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 842,000

[1],[19]

842,000

[2]

Investments at Fair Value

$ 1,692,000

[19]

$ 1,140,000

Investment, Acquisition Date

Jun. 12, 2019

[5]

Jun. 12, 2019

[6]

Shares | shares

1,379,761

[19]

1,379,761

1,379,761

[19]

1,379,761

Internet Consumer And Business Services | Carwow LTD | Equity | Preferred Series D-4

Investment Holdings [Line Items]

Investment cost

$ 1,151,000

[1],[29],[30]

$ 1,151,000

[2],[27],[28]

Investments at Fair Value

$ 216,000

[29],[30]

$ 608,000

[27],[28]

Investment, Acquisition Date

Dec. 15, 2021

[5]

Dec. 15, 2021

[6],[27],[28]

Shares | shares

199,742

[29],[30]

199,742

[27],[28]

199,742

[29],[30]

199,742

[27],[28]

Internet Consumer And Business Services | Carwow LTD | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 164,000

[1],[29],[30]

$ 164,000

[2],[27],[28]

Investments at Fair Value

$ 33,000

[29],[30]

$ 160,000

[27],[28]

Investment, Acquisition Date

Dec. 14, 2021

[5]

Dec. 14, 2021

[6],[27],[28]

Shares | shares

174,163

[29],[30]

174,163

[27],[28]

174,163

[29],[30]

174,163

[27],[28]

Internet Consumer And Business Services | Convoy, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[19]

$ 974,000

Investments at Fair Value

[19]

$ 582,000

Investment, Acquisition Date

[5]

Mar. 30, 2022

Shares | shares

[19]

165,456

165,456

Internet Consumer And Business Services | Rhino Labs Incorporation | Equity | Preferred Series B-2

Investment Holdings [Line Items]

Investment cost

[1]

$ 1,000,000

Investments at Fair Value

$ 866,000

Investment, Acquisition Date

[5]

Jan. 24, 2022

Shares | shares

7,063

7,063

Internet Consumer And Business Services | Rhino Labs Incorporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 470,000

[1],[31]

$ 470,000

[2],[32]

Investments at Fair Value

$ 344,000

[31]

$ 77,000

[32]

Investment, Acquisition Date

Mar. 12, 2021

[5]

Mar. 12, 2021

[6]

Shares | shares

13,106

[31]

13,106

[32]

13,106

[31]

13,106

[32]

Internet Consumer And Business Services | Skyword, Inc. | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 83,000

[1]

$ 83,000

[2]

Investments at Fair Value

$ 2,000

$ 7,000

Investment, Acquisition Date

Aug. 23, 2019

[5]

Aug. 23, 2019

[6]

Shares | shares

444,444

444,444

444,444

444,444

Internet Consumer And Business Services | Tectura Corporation | Equity

Investment Holdings [Line Items]

Investment cost

$ 900,000

[1]

$ 900,000

[2]

Investments at Fair Value

$ 0

$ 0

Shares | shares

415,994,863

415,994,863

415,994,863

415,994,863

Internet Consumer And Business Services | Tectura Corporation | Equity | Preferred Series BB

Investment Holdings [Line Items]

Investment cost

$ 0

[1],[24]

$ 0

[2],[25]

Investments at Fair Value

$ 0

[24]

$ 0

[25]

Investment, Acquisition Date

Jun. 06, 2016

[5]

Jun. 06, 2016

[6],[25]

Shares | shares

1,000,000

[24]

1,000,000

[25]

1,000,000

[24]

1,000,000

[25]

Internet Consumer And Business Services | Tectura Corporation | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 900,000

[1],[24]

$ 900,000

[2],[25]

Investments at Fair Value

$ 0

[24]

$ 0

[25]

Investment, Acquisition Date

May 23, 2018

[5]

May 23, 2018

[6],[25]

Shares | shares

414,994,863

[24]

414,994,863

[25]

414,994,863

[24]

414,994,863

[25]

Internet Consumer And Business Services | Tectura Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

$ 31,953,000

$ 31,953,000

Investment cost

21,513,000

[1]

21,513,000

[2]

Investments at Fair Value

8,318,000

8,269,000

Internet Consumer And Business Services | Thumbtack, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

844,000

[1]

552,000

[2]

Investments at Fair Value

$ 459,000

$ 786,000

Investment, Acquisition Date

May 01, 2018

[5]

May 01, 2018

[6]

Shares | shares

267,225

190,953

267,225

190,953

Internet Consumer And Business Services | Veem, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 126,000

Investments at Fair Value

$ 48,000

Investment, Acquisition Date

[5]

Mar. 31, 2022

Shares | shares

98,428

98,428

Internet Consumer And Business Services | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

$ 10,041,000

Investments at Fair Value

10,022,000

Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[1]

155,000

Investments at Fair Value

$ 405,000

Shares | shares

79,083

79,083

Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

[1],[19],[29],[30]

$ 129,000

Investments at Fair Value

[19],[29],[30]

$ 399,000

Investment, Acquisition Date

[5]

Feb. 11, 2021

Shares | shares

[19],[29],[30]

77,215

77,215

Internet Consumer And Business Services | Worldremit Group Limited | Warrant Investment | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[1],[19],[29],[30]

$ 26,000

Investments at Fair Value

[19],[29],[30]

$ 6,000

Investment, Acquisition Date

[5]

Aug. 27, 2021

Shares | shares

[19],[29],[30]

1,868

1,868

Internet Consumer And Business Services | Houzz, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 20,000

[1]

$ 20,000

[2]

Investments at Fair Value

$ 1,000

$ 116,000

Investment, Acquisition Date

Oct. 29, 2019

[5]

Oct. 29, 2019

[6]

Shares | shares

529,661

529,661

529,661

529,661

Internet Consumer And Business Services | Black Crow AI, Inc. affiliates | Equity | Preferred Series Seed

Investment Holdings [Line Items]

Investment cost

[2],[35]

$ 1,000,000

Investments at Fair Value

[35]

$ 1,120,000

Investment, Acquisition Date

[6],[35]

Mar. 24, 2021

Shares | shares

[35]

872,797

872,797

Internet Consumer And Business Services | Black Crow AI, Inc. affiliates | Equity | Preferred Note

Investment Holdings [Line Items]

Investment cost

$ 3,000,000

[1],[36]

$ 3,000,000

[2]

Investments at Fair Value

$ 3,000,000

[36]

$ 3,000,000

Investment, Acquisition Date

Mar. 24, 2021

[5]

Mar. 24, 2021

[6]

Shares | shares

3

[36]

3

3

[36]

3

Internet Consumer And Business Services | Contentful Global, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

$ 638,000

[1]

$ 638,000

[2]

Investments at Fair Value

$ 924,000

$ 1,894,000

Shares | shares

149,500

149,500

149,500

149,500

Internet Consumer And Business Services | Contentful Global, Inc. | Equity | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 500,000

[1],[29],[30]

$ 500,000

[2],[27],[28]

Investments at Fair Value

$ 685,000

[29],[30]

$ 1,388,000

[27],[28]

Investment, Acquisition Date

Nov. 20, 2018

[5]

Nov. 20, 2018

[6],[27],[28]

Shares | shares

108,500

[29],[30]

108,500

[27],[28]

108,500

[29],[30]

108,500

[27],[28]

Internet Consumer And Business Services | Contentful Global, Inc. | Equity | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 138,000

[1],[29],[30]

$ 138,000

[2],[27],[28]

Investments at Fair Value

$ 239,000

[29],[30]

$ 506,000

[27],[28]

Investment, Acquisition Date

Dec. 22, 2020

[5]

Dec. 22, 2020

[6],[27],[28]

Shares | shares

41,000

[29],[30]

41,000

[27],[28]

41,000

[29],[30]

41,000

[27],[28]

Internet Consumer And Business Services | DoorDash, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 945,000

[1],[5]

$ 945,000

[2],[6]

Investments at Fair Value

$ 4,055,000

[5]

$ 12,209,000

[6]

Investment, Acquisition Date

Dec. 20, 2018

[5]

Dec. 20, 2018

[6]

Shares | shares

81,996

[5]

81,996

[6]

81,996

[5]

81,996

[6]

Internet Consumer And Business Services | Lyft Inc | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 5,263,000

[1],[5]

$ 5,263,000

[2],[6]

Investments at Fair Value

$ 1,327,000

[5]

$ 4,305,000

[6]

Investment, Acquisition Date

Dec. 26, 2018

[5]

Dec. 26, 2018

[6]

Shares | shares

100,738

[5]

100,738

[6]

100,738

[5]

100,738

[6]

Internet Consumer And Business Services | Nerdy Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1],[5],[22]

$ 1,000,000

[2],[6]

Investments at Fair Value

$ 209,000

[5],[22]

$ 450,000

[6]

Investment, Acquisition Date

Sep. 17, 2021

[5]

Sep. 17, 2021

[6]

Shares | shares

100,000

[5],[22]

100,000

[6]

100,000

[5],[22]

100,000

[6]

Internet Consumer And Business Services | Nextdoor.com, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 4,854,000

[1],[5]

$ 4,854,000

[2],[6],[34]

Investments at Fair Value

$ 2,844,000

[5]

$ 6,624,000

[6],[34]

Investment, Acquisition Date

Aug. 01, 2018

[5]

Aug. 01, 2018

[6]

Shares | shares

1,019,255

[5]

1,019,255

[6],[34]

1,019,255

[5]

1,019,255

[6],[34]

Internet Consumer And Business Services | OfferUp, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

$ 2,295,000

[1]

$ 2,295,000

[2]

Investments at Fair Value

$ 577,000

$ 2,471,000

Shares | shares

394,790

394,790

394,790

394,790

Internet Consumer And Business Services | OfferUp, Inc. | Equity | Preferred Series A

Investment Holdings [Line Items]

Investment cost

$ 1,663,000

[1]

$ 1,663,000

[2]

Investments at Fair Value

$ 418,000

$ 1,791,000

Investment, Acquisition Date

Oct. 25, 2016

[5]

Oct. 25, 2016

[6]

Shares | shares

286,080

286,080

286,080

286,080

Internet Consumer And Business Services | OfferUp, Inc. | Equity | Preferred Series A-1

Investment Holdings [Line Items]

Investment cost

$ 632,000

[1]

$ 632,000

[2]

Investments at Fair Value

$ 159,000

$ 680,000

Investment, Acquisition Date

Oct. 25, 2016

[5]

Oct. 25, 2016

[6]

Shares | shares

108,710

108,710

108,710

108,710

Internet Consumer And Business Services | Oportun | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 577,000

[1],[5]

$ 577,000

[2],[6]

Investments at Fair Value

$ 211,000

[5]

$ 980,000

[6]

Investment, Acquisition Date

Jun. 28, 2013

[5]

Jun. 28, 2013

[6]

Shares | shares

48,365

[5]

48,365

[6]

48,365

[5]

48,365

[6]

Internet Consumer And Business Services | Reischling Press, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 15,000

[1]

$ 15,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Jul. 31, 2020

[5]

Jul. 31, 2020

[6]

Shares | shares

1,163

1,163

1,163

1,163

Internet Consumer And Business Services | Savage X Holding, LLC | Equity | Class A Units

Investment Holdings [Line Items]

Investment cost

$ 13,000

[1]

$ 13,000

[2]

Investments at Fair Value

$ 179,000

$ 71,000

Investment, Acquisition Date

Apr. 30, 2010

[5]

Apr. 30, 2010

[6]

Shares | shares

42,137

42,137

42,137

42,137

Internet Consumer And Business Services | Savage X Holding, LLC | Warrant Investment | Class A Units

Investment Holdings [Line Items]

Investment cost

[1]

$ 0

Investments at Fair Value

$ 875,000

Investment, Acquisition Date

[5]

Jun. 27, 2014

Shares | shares

206,185

206,185

Internet Consumer And Business Services | TFG Holding, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 89,000

[1]

$ 89,000

[2]

Investments at Fair Value

$ 95,000

$ 216,000

Investment, Acquisition Date

Apr. 30, 2010

[5]

Apr. 30, 2010

[6]

Shares | shares

42,989

42,989

42,989

42,989

Internet Consumer And Business Services | TFG Holding, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 0

Investments at Fair Value

$ 17,000

Investment, Acquisition Date

[5]

Jun. 27, 2014

Shares | shares

206,185

206,185

Internet Consumer And Business Services | Uber Technologies, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 318,000

[1],[5]

$ 318,000

[2],[6]

Investments at Fair Value

$ 874,000

[5]

$ 1,383,000

[6]

Investment, Acquisition Date

Dec. 01, 2020

[5]

Dec. 01, 2020

[6]

Shares | shares

32,991

[5]

32,991

[6]

32,991

[5]

32,991

[6]

Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment

Investment Holdings [Line Items]

Investment cost

$ 860,000

[1]

$ 860,000

[2]

Investments at Fair Value

$ 258,000

$ 382,000

Shares | shares

3,611,537

3,611,537

3,611,537

3,611,537

Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series A

Investment Holdings [Line Items]

Investment cost

$ 782,000

[1],[18]

$ 782,000

[2],[33]

Investments at Fair Value

$ 120,000

[18]

$ 171,000

[33]

Investment, Acquisition Date

Jun. 30, 2016

[5]

Jun. 30, 2016

[6]

Shares | shares

1,800,000

[18]

1,800,000

[33]

1,800,000

[18]

1,800,000

[33]

Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 62,000

[1],[18]

$ 62,000

[2],[33]

Investments at Fair Value

$ 69,000

[18]

$ 90,000

[33]

Investment, Acquisition Date

Aug. 01, 2018

[5]

Aug. 01, 2018

[6]

Shares | shares

1,211,537

[18]

1,211,537

[33]

1,211,537

[18]

1,211,537

[33]

Internet Consumer And Business Services | Snagajobcom Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 16,000

[1],[18]

$ 16,000

[2],[33]

Investments at Fair Value

$ 69,000

[18]

$ 121,000

[33]

Investment, Acquisition Date

Apr. 20, 2020

[5]

Apr. 20, 2020

[6]

Shares | shares

600,000

[18]

600,000

[33]

600,000

[18]

600,000

[33]

Internet Consumer And Business Services | Aria Systems, Inc. | Warrant Investment | Preferred Series G

Investment Holdings [Line Items]

Investment cost

$ 74,000

[1]

$ 74,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

May 22, 2015

[5]

May 22, 2015

[6]

Shares | shares

231,535

231,535

231,535

231,535

Internet Consumer And Business Services | Cloudpay, Inc. | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 54,000

[1],[29],[30]

$ 54,000

[2],[27],[28]

Investments at Fair Value

$ 310,000

[29],[30]

$ 348,000

[27],[28]

Investment, Acquisition Date

Apr. 10, 2018

[5]

Apr. 10, 2018

[6],[27],[28]

Shares | shares

6,763

[29],[30]

6,763

[27],[28]

6,763

[29],[30]

6,763

[27],[28]

Internet Consumer And Business Services | First Insight, Inc. | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

$ 95,000

[1]

$ 96,000

[2]

Investments at Fair Value

$ 35,000

$ 105,000

Investment, Acquisition Date

May 10, 2018

[5]

May 10, 2018

[6]

Shares | shares

75,917

75,917

75,917

75,917

Internet Consumer And Business Services | Landing Holdings Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 116,000

[1],[31]

$ 116,000

[2],[32]

Investments at Fair Value

$ 117,000

[31]

$ 141,000

[32]

Investment, Acquisition Date

Mar. 12, 2021

[5]

Mar. 12, 2021

[6]

Shares | shares

11,806

[31]

11,806

[32]

11,806

[31]

11,806

[32]

Internet Consumer And Business Services | Lendio, Inc. | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 39,000

[1]

$ 39,000

[2]

Investments at Fair Value

$ 35,000

$ 84,000

Investment, Acquisition Date

Mar. 29, 2019

[5]

Mar. 29, 2019

[6]

Shares | shares

127,032

127,032

127,032

127,032

Internet Consumer And Business Services | RumbleON, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 88,000

[1],[5]

$ 88,000

[2],[6]

Investments at Fair Value

$ 1,000

[5]

$ 33,000

[6]

Investment, Acquisition Date

Apr. 30, 2018

[5]

Apr. 30, 2018

[6]

Shares | shares

5,139

[5]

5,139

[6]

5,139

[5]

5,139

[6]

Internet Consumer And Business Services | ShareThis, Inc. | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 547,000

[1]

$ 547,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Dec. 14, 2012

[5]

Dec. 14, 2012

[6]

Shares | shares

493,502

493,502

493,502

493,502

Internet Consumer And Business Services | The Faction Group LLC | Warrant Investment | Preferred Series AA

Investment Holdings [Line Items]

Investment cost

$ 234,000

[1],[7]

$ 234,000

[2]

Investments at Fair Value

$ 387,000

$ 650,000

Investment, Acquisition Date

Nov. 03, 2014

[5]

Nov. 03, 2014

[6]

Shares | shares

8,076

8,076

8,076

8,076

Internet Consumer And Business Services | Xometry, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2],[6]

$ 47,000

Investments at Fair Value

[6]

$ 3,038,000

Investment, Acquisition Date

[6]

May 09, 2018

Shares | shares

[6]

87,784

87,784

Internet Consumer And Business Services | Interactions Corporation | Warrant Investment | Series G Three Preferred Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 204,000

Investments at Fair Value

$ 505,000

Investment, Acquisition Date

[6]

Jun. 16, 2015

Shares | shares

68,187

68,187

Internet Consumer And Business Services | Brigade Group, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 93,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Mar. 01, 2013

Shares | shares

9,023

9,023

Internet Consumer And Business Services | Logic Source | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

[2]

$ 30,000

Investments at Fair Value

$ 210,000

Investment, Acquisition Date

[6]

Mar. 21, 2016

Shares | shares

79,625

79,625

Internet Consumer And Business Services | Tapjoy, Inc. | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

[2]

$ 317,000

Investments at Fair Value

$ 443,000

Investment, Acquisition Date

[6]

Jul. 01, 2014

Shares | shares

748,670

748,670

Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[2]

$ 155,000

Investments at Fair Value

$ 1,987,000

Shares | shares

79,083

79,083

Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

[2],[21],[27],[28]

$ 129,000

Investments at Fair Value

[21],[27],[28]

$ 1,962,000

Investment, Acquisition Date

[6],[27],[28]

Feb. 11, 2021

Shares | shares

[21],[27],[28]

77,215

77,215

Internet Consumer And Business Services | Zepz (p.k.a. Worldremit Group Limited) | Warrant Investment | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[2],[21],[27],[28]

$ 26,000

Investments at Fair Value

[21],[27],[28]

$ 25,000

Investment, Acquisition Date

[6],[27],[28]

Aug. 27, 2021

Shares | shares

[21],[27],[28]

1,868

1,868

Internet Consumer And Business Services | Senior Secured | Salary.com, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-09

2027-09

Investment, Basis Spread, Variable Rate

[7]

8%

8%

Investment, Interest Rate, Floor

[7]

9%

9%

Investment cost

[1],[13]

$ 17,640,000

Investments at Fair Value

[13]

$ 17,640,000

Internet Consumer And Business Services | Senior Secured | SeatGeek, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2023-06

2023-06

Investment, Basis Spread, Variable Rate

[7]

5%

5%

Investment, Interest Rate, Floor

[7]

10.50%

10.50%

Investment, Interest Rate, Paid in Kind

[7]

0.50%

0.50%

Principal Amount

[9],[12],[17],[18],[19]

$ 60,838,000

Investment cost

[1],[9],[12],[17],[18],[19]

60,529,000

Investments at Fair Value

[9],[12],[17],[18],[19]

$ 60,529,000

Internet Consumer And Business Services | Senior Secured | SeatGeek, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-05

2023-06

2026-05

2023-06

Investment, Basis Spread, Variable Rate

7%

[7]

5%

[11]

7%

[7]

5%

[11]

Investment, Interest Rate, Floor

10.50%

[7]

10.50%

[11]

10.50%

[7]

10.50%

[11]

Investment, Interest Rate, Paid in Kind

0.50%

[7]

0.50%

[11]

0.50%

[7]

0.50%

[11]

Principal Amount

$ 25,040,000

[9],[12],[17],[18],[19]

$ 60,607,000

[20]

Investment cost

24,869,000

[1],[9],[12],[17],[18],[19]

59,983,000

[2],[20]

Investments at Fair Value

$ 25,591,000

[9],[12],[17],[18],[19]

$ 60,316,000

[20]

Internet Consumer And Business Services | Senior Secured | App Direct Incorporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-04

2024-08

2026-04

2024-08

Investment Interest Rate

[11]

7.95%

7.95%

Investment, Basis Spread, Variable Rate

5.50%

[7]

5.90%

[11]

5.50%

[7]

5.90%

[11]

Investment, Interest Rate, Floor

8.75%

[7]

9.15%

[11]

8.75%

[7]

9.15%

[11]

Interest Rate and Floor

[11]

7.95%

7.95%

Principal Amount

$ 30,790,000

[10],[18]

$ 30,790,000

Investment cost

31,733,000

[1],[10],[18]

31,416,000

[2]

Investments at Fair Value

$ 31,991,000

[10],[18]

$ 32,248,000

Internet Consumer And Business Services | Senior Secured | Carwow LTD | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-12

2024-12

2024-12

2024-12

Investment Interest Rate

[11],[27],[28]

4.95%

4.95%

Investment, Basis Spread, Variable Rate

4.70%

[7]

4.70%

[11],[27],[28]

4.70%

[7]

4.70%

[11],[27],[28]

Investment, Interest Rate, Floor

7.95%

[7]

7.95%

[11],[27],[28]

7.95%

[7]

7.95%

[11],[27],[28]

Investment, Interest Rate, Paid in Kind

1.45%

[7]

1.45%

[11],[27],[28]

1.45%

[7]

1.45%

[11],[27],[28]

Interest Rate and Floor

[11],[27],[28]

4.95%

4.95%

Principal Amount

$ 21,021,000

[9],[29],[30]

£ 18,798

[9],[29],[30]

£ 21,250

[20],[27],[28]

Investment cost

$ 25,845,000

[1],[9],[29],[30]

$ 28,632,000

[2],[20],[27],[28]

Investments at Fair Value

[20],[27],[28]

$ 28,632,000

Internet Consumer And Business Services | Senior Secured | Convoy, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-03

2026-03

Investment, Basis Spread, Variable Rate

[7]

3.20%

3.20%

Investment, Interest Rate, Floor

[7]

6.45%

6.45%

Investment, Interest Rate, Paid in Kind

[7]

1.95%

1.95%

Principal Amount

[8],[9],[19]

$ 73,623,000

Investment cost

[1],[8],[9],[19]

72,447,000

Investments at Fair Value

[8],[9],[19]

$ 73,092,000

Internet Consumer And Business Services | Senior Secured | Jobandtalent USA, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

Investment, Basis Spread, Variable Rate

[7]

8.86%

8.86%

Investment, Interest Rate, Floor

[7]

9.75%

9.75%

Principal Amount

[29],[30]

$ 14,000,000

Investment cost

[1],[29],[30]

13,802,000

Investments at Fair Value

[29],[30]

$ 13,865,000

Internet Consumer And Business Services | Senior Secured | Nextroll, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2023-07

2022-06

2023-07

2022-06

Investment Interest Rate

[11]

3.50%

3.50%

Investment, Basis Spread, Variable Rate

[11]

3.75%

3.75%

Investment, Interest Rate, Floor

[11]

7%

7%

Investment, Interest Rate, Paid in Kind

[11]

2.95%

2.95%

Interest Rate and Floor

[11]

3.50%

3.50%

Principal Amount

$ 22,046,000

[9],[18]

$ 21,555,000

[20],[23],[33]

Investment cost

21,952,000

[1],[9],[18]

22,164,000

[2],[20],[23],[33]

Investments at Fair Value

$ 21,952,000

[9],[18]

$ 22,164,000

[20],[23],[33]

Internet Consumer And Business Services | Senior Secured | Nextroll, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.75%

7.75%

Investment, Basis Spread, Variable Rate

[7]

3.75%

3.75%

Investment, Interest Rate, Paid in Kind

[7]

2.95%

2.95%

Interest Rate and Floor

[7]

7.75%

7.75%

Internet Consumer And Business Services | Senior Secured | Rhino Labs Incorporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-03

2024-03

2024-03

2024-03

Investment, Basis Spread, Variable Rate

5.50%

[7]

5.50%

[11]

5.50%

[7]

5.50%

[11]

Investment, Interest Rate, Floor

8.75%

[7]

8.75%

[11]

8.75%

[7]

8.75%

[11]

Investment, Interest Rate, Paid in Kind

2.25%

[7]

2.25%

[11]

2.25%

[7]

2.25%

[11]

Principal Amount

$ 16,407,000

[9],[31]

$ 16,136,000

[20],[32]

Investment cost

16,180,000

[1],[9],[31]

15,765,000

[2],[20],[32]

Investments at Fair Value

$ 16,331,000

[9],[31]

$ 15,876,000

[20],[32]

Internet Consumer And Business Services | Senior Secured | R V Share Limited Liability Company | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-12

2026-12

2026-12

2026-12

Investment, Basis Spread, Variable Rate

5.50%

[7]

5.50%

[11]

5.50%

[7]

5.50%

[11]

Investment, Interest Rate, Floor

6.50%

[7]

6.50%

[11]

6.50%

[7]

6.50%

[11]

Investment, Interest Rate, Paid in Kind

4%

[7]

4%

[11]

4%

[7]

4%

[11]

Principal Amount

$ 20,489,000

[9],[10],[17],[31]

$ 15,000,000

[15],[32]

Investment cost

20,138,000

[1],[9],[10],[17],[31]

14,701,000

[2],[15],[32]

Investments at Fair Value

$ 20,130,000

[9],[10],[17],[31]

$ 14,701,000

[15],[32]

Internet Consumer And Business Services | Senior Secured | Skyword, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-09

2024-09

2024-09

2024-09

Investment Interest Rate

[11]

4%

4%

Investment, Basis Spread, Variable Rate

3.88%

[7]

3.88%

[11]

3.88%

[7]

3.88%

[11]

Investment, Interest Rate, Floor

9.38%

[7]

9.38%

[11]

9.38%

[7]

9.38%

[11]

Investment, Interest Rate, Paid in Kind

1.90%

[7]

1.90%

[11]

1.90%

[7]

1.90%

[11]

Interest Rate and Floor

[11]

4%

4%

Principal Amount

$ 12,607,000

[9],[17]

$ 12,426,000

[20]

Investment cost

12,922,000

[1],[9],[17]

12,665,000

[2],[20]

Investments at Fair Value

$ 12,708,000

[9],[17]

$ 12,521,000

[20]

Internet Consumer And Business Services | Senior Secured | Thumbtack, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-04

2023-09

2026-04

2023-09

Investment Interest Rate

[11]

3.95%

3.95%

Investment, Basis Spread, Variable Rate

4.95%

[7]

3.45%

[11]

4.95%

[7]

3.45%

[11]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11]

8.95%

[7]

8.95%

[11]

Investment, Interest Rate, Paid in Kind

1.50%

[7]

1.50%

[11]

1.50%

[7]

1.50%

[11]

Interest Rate and Floor

[11]

3.95%

3.95%

Principal Amount

$ 10,065,000

[9],[10],[18]

$ 25,618,000

[20],[33]

Investment cost

9,985,000

[1],[9],[10],[18]

25,965,000

[2],[20],[33]

Investments at Fair Value

9,938,000

[9],[10],[18]

$ 26,372,000

[20],[33]

Internet Consumer And Business Services | Senior Secured | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

[1]

$ 9,891,000

Internet Consumer And Business Services | Senior Secured | Worldremit Group Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

2025-02

2025-02

Investment Interest Rate

[11],[27],[28]

3%

3%

Investment, Basis Spread, Variable Rate

9.25%

[7]

9.25%

[11],[27],[28]

9.25%

[7]

9.25%

[11],[27],[28]

Investment, Interest Rate, Floor

10.25%

[7]

10.25%

[11],[27],[28]

10.25%

[7]

10.25%

[11],[27],[28]

Interest Rate and Floor

[11],[27],[28]

3%

3%

Principal Amount

$ 94,500,000

[8],[12],[18],[19],[29],[30]

$ 103,000,000

[21],[23],[27],[28],[33]

Investment cost

94,115,000

[1],[8],[12],[18],[19],[29],[30]

101,674,000

[2],[21],[23],[27],[28],[33]

Investments at Fair Value

$ 92,293,000

[8],[12],[18],[19],[29],[30]

$ 100,472,000

[21],[23],[27],[28],[33]

Internet Consumer And Business Services | Senior Secured | E Pay Policy Holdings L L C | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-12

2024-12

Investment, Basis Spread, Variable Rate

[11]

8.50%

8.50%

Investment, Interest Rate, Floor

[11]

9.50%

9.50%

Principal Amount

[14],[15]

$ 8,169,000

Investment cost

[2],[14],[15]

8,011,000

Investments at Fair Value

[14],[15]

$ 7,967,000

Internet Consumer And Business Services | Senior Secured | Logic Source | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-07

2027-07

Investment, Basis Spread, Variable Rate

[7]

8.93%

8.93%

Investment, Interest Rate, Floor

[7]

9.93%

9.93%

Principal Amount

[10]

$ 13,300,000

Investment cost

[1],[10]

13,017,000

Investments at Fair Value

[10]

$ 13,017,000

Internet Consumer And Business Services | Senior Secured | Exit Fee | App Direct Incorporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

9.70%

9.70%

Interest Rate and Floor

[7]

9.70%

9.70%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Carwow LTD | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Convoy, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.55%

4.55%

Interest Rate and Floor

[7]

4.55%

4.55%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Jobandtalent USA, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3%

3%

Interest Rate and Floor

[7]

3%

3%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Nextroll, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

1.95%

1.95%

Interest Rate and Floor

[7]

1.95%

1.95%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Skyword, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4%

4%

Interest Rate and Floor

[7]

4%

4%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Thumbtack, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Internet Consumer And Business Services | Senior Secured | Exit Fee | Worldremit Group Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3%

3%

Interest Rate and Floor

[7]

3%

3%

Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-07

2024-07

2024-07

2024-07

Investment, Interest Rate, Paid in Kind

5%

[7]

5%

[11],[25],[37]

5%

[7]

5%

[11],[25],[37]

Principal Amount

$ 10,680,000

[9],[24],[38]

$ 10,680,000

[20],[25],[37]

Investment cost

240,000

[1],[9],[24],[38]

240,000

[2],[20],[25],[37]

Investments at Fair Value

$ 0

[9],[24],[38]

$ 0

[20],[25],[37]

Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

Investment, Basis Spread, Variable Rate

[7]

4%

4%

Investment, Interest Rate, Floor

[7]

7.25%

7.25%

Investment, Interest Rate, Paid in Kind

[7]

1.25%

1.25%

Principal Amount

[9],[17]

$ 5,027,000

Investment cost

[1],[9],[17]

4,959,000

Investments at Fair Value

[9],[17]

$ 4,967,000

Internet Consumer And Business Services | Senior Secured Tranche A [Member] | Exit Fee | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-07

2024-07

2024-07

2024-07

Investment, Interest Rate, Paid in Cash

8.25%

[7]

8.25%

[11],[25],[37]

8.25%

[7]

8.25%

[11],[25],[37]

Principal Amount

$ 8,250,000

[24]

$ 8,250,000

[25],[37]

Investment cost

8,250,000

[1],[24]

8,250,000

[2],[25],[37]

Investments at Fair Value

$ 8,250,000

[24]

$ 8,250,000

[25],[37]

Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

Investment, Basis Spread, Variable Rate

[7]

4.70%

4.70%

Investment, Interest Rate, Floor

[7]

7.95%

7.95%

Investment, Interest Rate, Paid in Kind

[7]

1.50%

1.50%

Principal Amount

$ 5,014,000

Investment cost

[1]

4,932,000

Investments at Fair Value

$ 5,055,000

Internet Consumer And Business Services | Senior Secured Tranche B [Member] | Exit Fee | Veem, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Internet Consumer And Business Services | Senior Secured Tranche C [Member] | Tectura Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-07

2024-07

2024-07

2024-07

Investment, Interest Rate, Paid in Kind

5%

[7]

5%

[11],[25],[37]

5%

[7]

5%

[11],[25],[37]

Principal Amount

$ 13,023,000

[9],[24],[38]

$ 13,023,000

[20],[25],[37]

Investment cost

13,023,000

[1],[9],[24],[38]

13,023,000

[2],[20],[25],[37]

Investments at Fair Value

68,000

[9],[24],[38]

19,000

[20],[25],[37]

Internet Consumer And Business Services | Debt Investments

Investment Holdings [Line Items]

Investment cost

487,830,000

[1]

363,165,000

[2]

Investments at Fair Value

468,792,000

$ 349,963,000

Internet Consumer And Business Services | Convertible Debt | Salary.com, LLC | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Investments at Fair Value

[13]

$ 18,000

Internet Consumer And Business Services | Convertible Debt | Houzz, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2028-05

2028-05

Investment, Interest Rate, Paid in Kind

[11],[26]

5.50%

5.50%

Principal Amount

[20],[26]

$ 20,676,000

Investment cost

[2],[20],[26]

20,676,000

Investments at Fair Value

[20],[26]

20,425,000

Internet Consumer And Business Services | Convertible Debt | Houzz, Inc. | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2028-05

2028-05

Investment, Interest Rate, Paid in Kind

[7]

5.50%

5.50%

Principal Amount

[9],[39]

$ 21,252,000

Investment cost

[1],[9],[39]

21,252,000

Investments at Fair Value

[9],[39]

20,354,000

Manufacturing Technology | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[1]

726,000

Investments at Fair Value

4,338,000

Manufacturing Technology | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

15,902,000

[1]

14,995,000

[2]

Investments at Fair Value

16,045,000

$ 14,995,000

Manufacturing Technology | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

[1]

23,597,000

Investments at Fair Value

23,509,000

Manufacturing Technology | Bright Machines, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

151,000

Investments at Fair Value

$ 320,000

Investment, Acquisition Date

[5]

Mar. 31, 2022

Shares | shares

196,335

196,335

Manufacturing Technology | MacroFab, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 528,000

Investments at Fair Value

$ 603,000

Investment, Acquisition Date

[5]

Mar. 23, 2022

Shares | shares

1,111,111

1,111,111

Manufacturing Technology | Xometry, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

$ 47,000

Investments at Fair Value

[5]

$ 3,415,000

Investment, Acquisition Date

[5]

May 09, 2018

Shares | shares

[5]

87,784

87,784

Manufacturing Technology | Senior Secured | Bright Machines, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-11

2022-11

2022-11

2022-11

Investment Interest Rate

[11]

6.95%

6.95%

Investment, Basis Spread, Variable Rate

5.70%

[7]

5.70%

[11]

5.70%

[7]

5.70%

[11]

Investment, Interest Rate, Floor

8.95%

[7]

8.95%

[11]

8.95%

[7]

8.95%

[11]

Interest Rate and Floor

[11]

6.95%

6.95%

Principal Amount

$ 15,000,000

[8],[12]

$ 15,000,000

[23]

Investment cost

15,902,000

[1],[8],[12]

14,995,000

[2],[23]

Investments at Fair Value

$ 16,045,000

[8],[12]

14,995,000

[23]

Manufacturing Technology | Senior Secured | MacroFab, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-03

2026-03

Investment Interest Rate

[7]

7.60%

7.60%

Investment, Basis Spread, Variable Rate

[7]

4.35%

4.35%

Investment, Interest Rate, Paid in Kind

[7]

1.25%

1.25%

Interest Rate and Floor

[7]

7.60%

7.60%

Principal Amount

[9],[18]

$ 17,083,000

Investment cost

[1],[9],[18]

16,616,000

Investments at Fair Value

[9],[18]

$ 16,469,000

Manufacturing Technology | Senior Secured | Ouster, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-05

2026-05

Investment, Basis Spread, Variable Rate

[7]

6.15%

6.15%

Investment, Interest Rate, Floor

[7]

9.40%

9.40%

Principal Amount

[10],[17],[29]

$ 7,000,000

Investment cost

[1],[10],[17],[29]

6,981,000

Investments at Fair Value

[10],[17],[29]

$ 7,040,000

Manufacturing Technology | Senior Secured | Exit Fee | Bright Machines, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

6.95%

6.95%

Interest Rate and Floor

[7]

6.95%

6.95%

Manufacturing Technology | Senior Secured | Exit Fee | MacroFab, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Manufacturing Technology | Senior Secured | Exit Fee | Ouster, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

7.45%

7.45%

Interest Rate and Floor

[7]

7.45%

7.45%

Manufacturing Technology | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 39,499,000

[1]

14,995,000

[2]

Investments at Fair Value

39,554,000

14,995,000

Medical Devices & Equipment

Investment Holdings [Line Items]

Investments at Fair Value

17,421,000

12,612,000

Medical Devices & Equipment | Equity

Investment Holdings [Line Items]

Investment cost

2,953,000

[1]

3,991,000

[2]

Investments at Fair Value

2,143,000

10,538,000

Medical Devices & Equipment | Warrant Investment

Investment Holdings [Line Items]

Investment cost

2,035,000

[1]

2,483,000

[2]

Investments at Fair Value

443,000

2,074,000

Medical Devices & Equipment | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

[1]

14,927,000

Investments at Fair Value

14,835,000

Medical Devices & Equipment | Lucira Health, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5]

110,000

Investments at Fair Value

[5]

$ 0

Investment, Acquisition Date

[5]

Feb. 04, 2022

Shares | shares

[5]

59,642

59,642

Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity

Investment Holdings [Line Items]

Investment cost

$ 250,000

[1]

250,000

[2]

Investments at Fair Value

$ 400,000

$ 565,000

Shares | shares

5,180,000

5,180,000

5,180,000

5,180,000

Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity | Preferred Series A-2

Investment Holdings [Line Items]

Investment cost

$ 250,000

[1],[24]

$ 250,000

[2],[25]

Investments at Fair Value

$ 391,000

[24]

$ 500,000

[25]

Investment, Acquisition Date

Oct. 15, 2021

[5]

Oct. 15, 2021

[6],[25]

Shares | shares

5,000,000

[24]

5,000,000

[25]

5,000,000

[24]

5,000,000

[25]

Medical Devices & Equipment | Coronado Aesthetics, LLC | Equity | Common Units

Investment Holdings [Line Items]

Investment cost

$ 0

[1],[24]

$ 0

[2],[25]

Investments at Fair Value

$ 9,000

[24]

$ 65,000

[25]

Investment, Acquisition Date

Oct. 15, 2021

[5]

Oct. 15, 2021

[6],[25]

Shares | shares

180,000

[24]

180,000

[25]

180,000

[24]

180,000

[25]

Medical Devices & Equipment | Flowonix Medical Incorporated | Equity | Preferred Series AA

Investment Holdings [Line Items]

Investment cost

$ 1,500,000

[1]

$ 1,500,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Nov. 03, 2014

[5]

Nov. 03, 2014

[6]

Shares | shares

221,893

221,893

221,893

221,893

Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment

Investment Holdings [Line Items]

Investment cost

$ 714,000

[1]

$ 714,000

[2]

Investments at Fair Value

$ 0

$ 0

Shares | shares

836,752

881,131

836,752

881,131

Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment | Preferred Series BB

Investment Holdings [Line Items]

Investment cost

$ 352,000

[1]

$ 351,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Sep. 21, 2018

[5]

Sep. 21, 2018

[6]

Shares | shares

725,806

725,806

725,806

725,806

Medical Devices & Equipment | Flowonix Medical Incorporated | Warrant Investment | Preferred Series AA

Investment Holdings [Line Items]

Investment cost

$ 362,000

[1],[18]

$ 363,000

[2],[33]

Investments at Fair Value

$ 0

[18]

$ 0

[33]

Investment, Acquisition Date

Nov. 03, 2014

[5]

Nov. 03, 2014

[6]

Shares | shares

110,946

[18]

155,325

[33]

110,946

[18]

155,325

[33]

Medical Devices & Equipment | Gelesis, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

[2]

$ 1,003,000

Investments at Fair Value

$ 9,772,000

Shares | shares

662,071

662,071

Medical Devices & Equipment | Gelesis, Inc. | Equity | Preferred Series A-1

Investment Holdings [Line Items]

Investment cost

[2]

$ 503,000

Investments at Fair Value

$ 3,593,000

Investment, Acquisition Date

[6]

Dec. 30, 2011

Shares | shares

243,432

243,432

Medical Devices & Equipment | Gelesis, Inc. | Equity | Preferred Series A-2

Investment Holdings [Line Items]

Investment cost

[2]

$ 500,000

Investments at Fair Value

$ 2,828,000

Investment, Acquisition Date

[6]

Dec. 31, 2011

Shares | shares

191,626

191,626

Medical Devices & Equipment | Gelesis, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 871,000

[1],[5]

$ 0

[2]

Investments at Fair Value

$ 1,611,000

[5]

$ 3,351,000

Investment, Acquisition Date

Nov. 30, 2009

[5]

Nov. 30, 2009

[6]

Shares | shares

1,490,700

[5]

227,013

1,490,700

[5]

227,013

Medical Devices & Equipment | ViewRay, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 332,000

[1],[5]

$ 333,000

[2],[6]

Investments at Fair Value

$ 132,000

[5]

$ 201,000

[6]

Investment, Acquisition Date

Dec. 16, 2013

[5]

Dec. 16, 2013

[6]

Shares | shares

36,457

[5]

36,457

[6]

36,457

[5]

36,457

[6]

Medical Devices & Equipment | Aspire Bariatrics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 455,000

[1]

$ 455,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Jan. 28, 2015

[5]

Jan. 28, 2015

[6]

Shares | shares

22,572

22,572

22,572

22,572

Medical Devices & Equipment | Intuity Medical, Inc. | Warrant Investment | Preferred Series B-1

Investment Holdings [Line Items]

Investment cost

$ 294,000

[1]

$ 294,000

[2]

Investments at Fair Value

$ 30,000

$ 264,000

Investment, Acquisition Date

Dec. 29, 2017

[5]

Dec. 29, 2017

[6]

Shares | shares

3,076,323

3,076,323

3,076,323

3,076,323

Medical Devices & Equipment | Outset Medical, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 401,000

[1],[5]

$ 401,000

[2],[6]

Investments at Fair Value

$ 413,000

[5]

$ 1,797,000

[6]

Investment, Acquisition Date

Sep. 27, 2013

[5]

Sep. 27, 2013

[6]

Shares | shares

62,794

[5]

62,794

[6]

62,794

[5]

62,794

[6]

Medical Devices & Equipment | Tela Bio, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 61,000

[1],[5]

$ 61,000

[2],[6]

Investments at Fair Value

$ 0

[5]

$ 13,000

[6]

Investment, Acquisition Date

Mar. 31, 2017

[5]

Mar. 31, 2017

[6]

Shares | shares

15,712

[5]

15,712

[6]

15,712

[5]

15,712

[6]

Medical Devices & Equipment | Medrobotics Corporation | Equity

Investment Holdings [Line Items]

Investment cost

[2]

$ 905,000

Investments at Fair Value

$ 0

Shares | shares

374,703

374,703

Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[2]

$ 250,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Sep. 12, 2013

Shares | shares

136,798

136,798

Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series F

Investment Holdings [Line Items]

Investment cost

[2]

$ 155,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Oct. 22, 2014

Shares | shares

73,971

73,971

Medical Devices & Equipment | Medrobotics Corporation | Equity | Preferred Series G

Investment Holdings [Line Items]

Investment cost

[2]

$ 500,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Oct. 16, 2015

Shares | shares

163,934

163,934

Medical Devices & Equipment | Medrobotics Corporation | Warrant Investment | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[2]

$ 370,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Mar. 13, 2013

Shares | shares

455,539

455,539

Medical Devices & Equipment | SonaCare Medical, LLC | Warrant Investment | Preferred Series A

Investment Holdings [Line Items]

Investment cost

[2]

$ 188,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Sep. 28, 2012

Shares | shares

6,464

6,464

Medical Devices & Equipment | Senior Secured | Lucira Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-02

2026-02

Investment, Basis Spread, Variable Rate

[7]

5.50%

5.50%

Investment, Interest Rate, Floor

[7]

8.75%

8.75%

Principal Amount

[17]

$ 15,000,000

Investment cost

[1],[17]

14,927,000

Investments at Fair Value

[17]

$ 14,835,000

Medical Devices & Equipment | Senior Secured | Exit Fee | Lucira Health, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.25%

5.25%

Interest Rate and Floor

[7]

5.25%

5.25%

Medical Devices & Equipment | Debt Investments

Investment Holdings [Line Items]

Investment cost

[1]

$ 14,927,000

Investments at Fair Value

14,835,000

Semiconductors

Investment Holdings [Line Items]

Investments at Fair Value

20,621,000

$ 22,498,000

Semiconductors | Equity

Investment Holdings [Line Items]

Investment cost

160,000

[1]

160,000

[2]

Investments at Fair Value

259,000

725,000

Semiconductors | Warrant Investment

Investment Holdings [Line Items]

Investment cost

850,000

[1]

850,000

[2]

Investments at Fair Value

715,000

2,701,000

Semiconductors | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

19,492,000

[1]

19,072,000

[2]

Investments at Fair Value

19,647,000

19,072,000

Semiconductors | Fungible, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

751,000

[1],[31]

751,000

[2],[32]

Investments at Fair Value

$ 77,000

[31]

$ 751,000

[32]

Investment, Acquisition Date

Dec. 16, 2021

[5]

Dec. 16, 2021

[6]

Shares | shares

800,000

[31]

800,000

[32]

800,000

[31]

800,000

[32]

Semiconductors | Achronix Semiconductor Corporation | Equity | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 160,000

[1]

$ 160,000

[2]

Investments at Fair Value

$ 259,000

$ 725,000

Investment, Acquisition Date

Jul. 01, 2011

[5]

Jul. 01, 2011

[6]

Shares | shares

277,995

277,995

277,995

277,995

Semiconductors | Achronix Semiconductor Corporation | Warrant Investment | Preferred Series D-2

Investment Holdings [Line Items]

Investment cost

$ 99,000

[1]

$ 99,000

[2]

Investments at Fair Value

$ 638,000

$ 1,950,000

Investment, Acquisition Date

Jun. 26, 2015

[5]

Jun. 26, 2015

[6]

Shares | shares

750,000

750,000

750,000

750,000

Semiconductors | Senior Secured | Fungible, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-12

2024-12

2024-12

2024-12

Investment Interest Rate

[11]

4.95%

4.95%

Investment, Basis Spread, Variable Rate

5%

[7]

5%

[11]

5%

[7]

5%

[11]

Investment, Interest Rate, Floor

8.25%

[7]

8.25%

[11]

8.25%

[7]

8.25%

[11]

Interest Rate and Floor

[11]

4.95%

4.95%

Principal Amount

$ 20,000,000

[8],[31]

$ 20,000,000

[23],[32]

Investment cost

19,492,000

[1],[8],[31]

19,072,000

[2],[23],[32]

Investments at Fair Value

$ 19,647,000

[8],[31]

19,072,000

[23],[32]

Semiconductors | Senior Secured | Exit Fee | Fungible, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Semiconductors | Debt Investments

Investment Holdings [Line Items]

Investment cost

[2]

19,072,000

Investments at Fair Value

$ 19,647,000

19,072,000

Software

Investment Holdings [Line Items]

Investments at Fair Value

680,216,000

585,622,000

Software | Equity

Investment Holdings [Line Items]

Investment cost

24,006,000

[1]

23,905,000

[2]

Investments at Fair Value

24,997,000

45,087,000

Software | Warrant Investment

Investment Holdings [Line Items]

Investment cost

7,639,000

[1]

5,594,000

[2]

Investments at Fair Value

6,217,000

11,133,000

Software | Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1]

381,000

Investments at Fair Value

381,000

Software | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

10,691,000

[1]

68,743,000

[2]

Investments at Fair Value

10,691,000

68,287,000

Software | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

614,819,000

[1]

437,659,000

[2]

Investments at Fair Value

615,863,000

441,115,000

Software | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Investment cost

22,066,000

[1]

19,851,000

[2]

Investments at Fair Value

22,066,000

20,000,000

Software | Automation Anywhere, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

448,000

Investments at Fair Value

$ 437,000

Investment, Acquisition Date

[5]

Sep. 23, 2022

Shares | shares

254,778

254,778

Software | Cutover, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[29],[30]

$ 26,000

Investments at Fair Value

[29],[30]

$ 25,000

Investment, Acquisition Date

[5]

Sep. 21, 2022

Shares | shares

[29],[30]

102,898

102,898

Software | Liberty Zim Co-Invest L.P. | Investment Funds & Vehicles [Member]

Investment Holdings [Line Items]

Investment cost

[1],[29],[30]

$ 381,000

Investments at Fair Value

[29],[30]

$ 381,000

Investment, Acquisition Date

[5]

Jul. 21, 2022

Software | Delphix Corp. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,594,000

[1]

1,594,000

[2],[21]

Investments at Fair Value

$ 2,306,000

$ 3,275,000

[21]

Investment, Acquisition Date

Oct. 08, 2019

[5]

Oct. 08, 2019

[6]

Shares | shares

718,898

718,898

[21]

718,898

718,898

[21]

Software | Pymetrics, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 77,000

Investments at Fair Value

$ 218,000

Investment, Acquisition Date

[6]

Sep. 15, 2020

Shares | shares

150,943

150,943

Software | 3GTMS, LLC | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1]

$ 1,000,000

[2]

Investments at Fair Value

$ 675,000

$ 985,000

Investment, Acquisition Date

Aug. 09, 2021

[5]

Aug. 09, 2021

[6]

Shares | shares

1,000,000

1,000,000

1,000,000

1,000,000

Software | Brain Corporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 165,000

[1],[31]

$ 165,000

[2],[32]

Investments at Fair Value

$ 61,000

[31]

$ 132,000

[32]

Investment, Acquisition Date

Oct. 04, 2021

[5]

Oct. 04, 2021

[6]

Shares | shares

194,629

[31]

194,629

[32]

194,629

[31]

194,629

[32]

Software | CloudBolt Software, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 117,000

[1]

$ 117,000

[2]

Investments at Fair Value

$ 2,000

$ 85,000

Investment, Acquisition Date

Sep. 30, 2020

[5]

Sep. 30, 2020

[6]

Shares | shares

211,342

211,342

211,342

211,342

Software | Dashlane, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 353,000

[1]

$ 404,000

[2]

Investments at Fair Value

$ 120,000

$ 415,000

Investment, Acquisition Date

Mar. 11, 2019

[5]

Mar. 11, 2019

[6]

Shares | shares

453,641

560,536

453,641

560,536

Software | Demandbase, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 545,000

[1]

$ 404,000

[2]

Investments at Fair Value

$ 140,000

$ 443,000

Investment, Acquisition Date

Aug. 02, 2021

[5]

Aug. 02, 2021

[6]

Shares | shares

727,047

483,248

727,047

483,248

Software | Eigen Technologies Ltd. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[29],[30]

$ 8,000

Investments at Fair Value

[29],[30]

$ 8,000

Investment, Acquisition Date

[5]

Apr. 13, 2022

Shares | shares

[29],[30]

522

522

Software | Esme Learning Solutions, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 198,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[5]

Jan. 27, 2022

Shares | shares

56,765

56,765

Software | Mixpanel, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 252,000

[1]

$ 252,000

[2]

Investments at Fair Value

$ 233,000

$ 906,000

Investment, Acquisition Date

Sep. 30, 2020

[5]

Sep. 30, 2020

[6]

Shares | shares

82,362

82,362

82,362

82,362

Software | Nuvolo Technologies Corporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 172,000

[1]

$ 88,000

[2]

Investments at Fair Value

$ 190,000

$ 283,000

Investment, Acquisition Date

Mar. 29, 2019

[5]

Mar. 29, 2019

[6]

Shares | shares

70,000

50,000

70,000

50,000

Software | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

$ 20,498,000

Investment cost

$ 21,030,000

[1]

20,533,000

[2]

Investments at Fair Value

22,014,000

20,406,000

Software | Tact.ai Technologies, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

206,000

[1]

206,000

[2]

Investments at Fair Value

$ 90,000

$ 162,000

Investment, Acquisition Date

Feb. 13, 2020

[5]

Feb. 13, 2020

[6]

Shares | shares

1,041,667

1,041,667

1,041,667

1,041,667

Software | Udacity, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 218,000

[1]

$ 218,000

[2]

Investments at Fair Value

$ 21,000

$ 345,000

Investment, Acquisition Date

Sep. 25, 2020

[5]

Sep. 25, 2020

[6]

Shares | shares

486,359

486,359

486,359

486,359

Software | VideoAmp, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[31]

$ 1,275,000

Investments at Fair Value

[31]

$ 416,000

Investment, Acquisition Date

[5]

Jan. 21, 2022

Shares | shares

[31]

152,048

152,048

Software | Zimperium, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[2]

$ 72,000

Investments at Fair Value

$ 56,000

Investment, Acquisition Date

[6]

Jul. 02, 2021

Shares | shares

20,563

20,563

Software | SingleStore, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

$ 2,280,000

[1]

$ 2,279,000

[2]

Investments at Fair Value

$ 1,428,000

$ 2,479,000

Shares | shares

633,939

633,939

633,939

633,939

Software | SingleStore, Inc. | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

$ 2,000,000

[1]

$ 2,000,000

[2]

Investments at Fair Value

$ 1,278,000

$ 2,239,000

Investment, Acquisition Date

Nov. 25, 2020

[5]

Nov. 25, 2020

[6]

Shares | shares

580,983

580,983

580,983

580,983

Software | SingleStore, Inc. | Equity | Preferred Series F

Investment Holdings [Line Items]

Investment cost

$ 280,000

[1]

$ 279,000

[2]

Investments at Fair Value

$ 150,000

$ 240,000

Investment, Acquisition Date

Aug. 12, 2021

[5]

Aug. 12, 2021

[6]

Shares | shares

52,956

52,956

52,956

52,956

Software | SingleStore, Inc. | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 103,000

[1]

$ 103,000

[2]

Investments at Fair Value

$ 258,000

$ 704,000

Investment, Acquisition Date

Apr. 28, 2020

[5]

Apr. 28, 2020

[6]

Shares | shares

312,596

312,596

312,596

312,596

Software | CapLinked, Inc. | Equity | Preferred Series A-3

Investment Holdings [Line Items]

Investment cost

$ 51,000

[1]

$ 51,000

[2]

Investments at Fair Value

$ 5,000

$ 65,000

Investment, Acquisition Date

Oct. 26, 2012

[5]

Oct. 26, 2012

[6]

Shares | shares

53,614

53,614

53,614

53,614

Software | Docker, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 4,284,000

[1]

$ 4,284,000

[2]

Investments at Fair Value

$ 494,000

$ 3,000

Investment, Acquisition Date

Nov. 29, 2018

[5]

Nov. 29, 2018

[6]

Shares | shares

20,000

20,000

20,000

20,000

Software | Druva Holdings, Inc. | Equity

Investment Holdings [Line Items]

Investment cost

$ 1,300,000

[1]

$ 1,300,000

[2]

Investments at Fair Value

$ 1,758,000

$ 2,916,000

Shares | shares

552,461

552,461

552,461

552,461

Software | Druva Holdings, Inc. | Equity | Preferred Series 3

Investment Holdings [Line Items]

Investment cost

$ 300,000

[1]

$ 300,000

[2]

Investments at Fair Value

$ 330,000

$ 529,000

Investment, Acquisition Date

Aug. 24, 2017

[5]

Aug. 24, 2017

[6]

Shares | shares

93,620

93,620

93,620

93,620

Software | Druva Holdings, Inc. | Equity | Preferred Series 2

Investment Holdings [Line Items]

Investment cost

$ 1,000,000

[1]

$ 1,000,000

[2]

Investments at Fair Value

$ 1,428,000

$ 2,387,000

Investment, Acquisition Date

Oct. 22, 2015

[5]

Oct. 22, 2015

[6]

Shares | shares

458,841

458,841

458,841

458,841

Software | HighRoads, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 307,000

[1]

$ 307,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Jan. 18, 2013

[5]

Jan. 18, 2013

[6]

Shares | shares

190

190

190

190

Software | Lightbend, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 265,000

[1]

$ 265,000

[2]

Investments at Fair Value

$ 14,000

$ 5,000

Investment, Acquisition Date

Dec. 04, 2020

[5]

Dec. 04, 2020

[6]

Shares | shares

38,461

38,461

38,461

38,461

Software | Lightbend, Inc. | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 131,000

[1]

$ 131,000

[2]

Investments at Fair Value

$ 1,000

$ 0

Investment, Acquisition Date

Feb. 14, 2018

[5]

Feb. 14, 2018

[6]

Shares | shares

89,685

89,685

89,685

89,685

Software | Palantir Technologies | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 8,670,000

[1],[5]

$ 8,670,000

[2],[6]

Investments at Fair Value

$ 11,531,000

[5]

$ 25,828,000

[6]

Investment, Acquisition Date

Sep. 23, 2020

[5]

Sep. 23, 2020

[6]

Shares | shares

1,418,337

[5]

1,418,337

[6]

1,418,337

[5]

1,418,337

[6]

Software | Sprinklr, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 3,748,000

[1],[5]

$ 3,749,000

[2],[6]

Investments at Fair Value

$ 6,454,000

[5]

$ 11,109,000

[6]

Investment, Acquisition Date

Mar. 22, 2017

[5]

Mar. 22, 2017

[6]

Shares | shares

700,000

[5]

700,000

[6]

700,000

[5]

700,000

[6]

Software | Verana Health, Inc. | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

$ 2,000,000

[1]

$ 2,000,000

[2]

Investments at Fair Value

$ 1,171,000

$ 1,697,000

Investment, Acquisition Date

Jul. 08, 2021

[5]

Jul. 08, 2021

[6]

Shares | shares

952,562

952,562

952,562

952,562

Software | Bitsight Technologies Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 284,000

[1]

$ 284,000

[2]

Investments at Fair Value

$ 597,000

$ 1,272,000

Investment, Acquisition Date

Nov. 18, 2020

[5]

Nov. 18, 2020

[6]

Shares | shares

29,691

29,691

29,691

29,691

Software | Cloudian Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 71,000

[1]

$ 71,000

[2]

Investments at Fair Value

$ 17,000

$ 33,000

Investment, Acquisition Date

Nov. 06, 2018

[5]

Nov. 06, 2018

[6]

Shares | shares

477,454

477,454

477,454

477,454

Software | Dronedeploy Incorporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 278,000

Investments at Fair Value

$ 307,000

Investment, Acquisition Date

[5]

Jun. 30, 2022

Shares | shares

95,911

95,911

Software | Evernote Corporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 107,000

[1]

$ 106,000

[2]

Investments at Fair Value

$ 15,000

$ 65,000

Investment, Acquisition Date

Sep. 30, 2016

[5]

Sep. 30, 2016

[6]

Shares | shares

62,500

62,500

62,500

62,500

Software | Poplicus Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 0

[1]

$ 0

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

May 28, 2014

[5]

May 28, 2014

[6]

Shares | shares

132,168

132,168

132,168

132,168

Software | Reltio Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 215,000

[1]

$ 215,000

[2]

Investments at Fair Value

$ 296,000

$ 637,000

Investment, Acquisition Date

Jun. 30, 2020

[5]

Jun. 30, 2020

[6]

Shares | shares

69,120

69,120

69,120

69,120

Software | Sign Post Inc | Warrant Investment | Series Junior 1 Preferred

Investment Holdings [Line Items]

Investment cost

$ 314,000

[1]

$ 314,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Jan. 13, 2016

[5]

Jan. 13, 2016

[6]

Shares | shares

474,019

474,019

474,019

474,019

Software | Zero Fox Inc | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[22]

$ 101,000

Investments at Fair Value

[5],[22]

$ 1,467,000

Investment, Acquisition Date

[5]

May 07, 2020

Shares | shares

[5],[22]

289,992

289,992

Software | Zero Fox Inc | Warrant Investment | Preferred Series C-1

Investment Holdings [Line Items]

Investment cost

[2]

$ 101,000

Investments at Fair Value

$ 603,000

Investment, Acquisition Date

[6]

May 07, 2020

Shares | shares

648,350

648,350

Software | Couchbase Inc | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 462,000

[1],[5]

$ 462,000

[2],[6],[34]

Investments at Fair Value

$ 563,000

[5]

$ 1,343,000

[6],[34]

Investment, Acquisition Date

Apr. 25, 2019

[5]

Apr. 25, 2019

[6]

Shares | shares

105,350

[5]

105,350

[6],[34]

105,350

[5]

105,350

[6],[34]

Software | D N Anexus Inc | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 97,000

[1]

$ 97,000

[2]

Investments at Fair Value

$ 114,000

$ 102,000

Investment, Acquisition Date

Mar. 21, 2014

[5]

Mar. 21, 2014

[6]

Shares | shares

909,091

909,091

909,091

909,091

Software | Fuze, Inc. | Warrant Investment | Preferred Series F

Investment Holdings [Line Items]

Investment cost

[2]

$ 89,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Jun. 30, 2017

Shares | shares

256,158

256,158

Software | Rapid Miner Inc | Warrant Investment | Preferred Series C-1

Investment Holdings [Line Items]

Investment cost

[2]

$ 24,000

Investments at Fair Value

$ 54,000

Investment, Acquisition Date

[6]

Nov. 28, 2017

Shares | shares

4,982

4,982

Software | Senior Secured | Automation Anywhere, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-09

2027-09

Investment, Basis Spread, Variable Rate

[7]

4.25%

4.25%

Investment, Interest Rate, Floor

[7]

9%

9%

Principal Amount

[8],[10]

$ 19,600,000

Investment cost

[1],[8],[10]

19,008,000

Investments at Fair Value

[8],[10]

$ 19,008,000

Software | Senior Secured | Constructor.io Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-07

2027-07

Investment, Basis Spread, Variable Rate

[7]

8.44%

8.44%

Investment, Interest Rate, Floor

[7]

9.44%

9.44%

Principal Amount

[10],[13]

$ 4,688,000

Investment cost

[1],[10],[13]

4,569,000

Investments at Fair Value

[10],[13]

$ 4,569,000

Software | Senior Secured | Omeda Holdings, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-07

2027-07

Investment, Basis Spread, Variable Rate

[7]

8.05%

8.05%

Investment, Interest Rate, Floor

[7]

9.05%

9.05%

Principal Amount

[10],[13]

$ 7,500,000

Investment cost

[1],[10],[13]

7,251,000

Investments at Fair Value

[10],[13]

$ 7,251,000

Software | Senior Secured | Cutover, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-10

2025-10

Investment, Basis Spread, Variable Rate

[7]

5.20%

5.20%

Investment, Interest Rate, Floor

[7]

9.95%

9.95%

Principal Amount

[29],[30]

$ 5,000,000

Investment cost

[1],[29],[30]

4,927,000

Investments at Fair Value

[29],[30]

$ 4,927,000

Software | Senior Secured | Delphix Corp. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-02

2023-02

Investment Interest Rate

[11]

5%

5%

Investment, Basis Spread, Variable Rate

[11]

5.50%

5.50%

Investment, Interest Rate, Floor

[11]

10.25%

10.25%

Interest Rate and Floor

[11]

5%

5%

Principal Amount

[21],[23],[33]

$ 60,000,000

Investment cost

[2],[21],[23],[33]

61,736,000

Investments at Fair Value

[21],[23],[33]

$ 62,345,000

Software | Senior Secured | Khoros (p.k.a Lithium Technologies) | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-10

2022-10

Investment, Basis Spread, Variable Rate

[11]

8%

8%

Investment, Interest Rate, Floor

[11]

9%

9%

Principal Amount

[15]

$ 56,208,000

Investment cost

[2],[15]

55,834,000

Investments at Fair Value

[15]

$ 55,834,000

Software | Senior Secured | Khoros (p.k.a Lithium Technologies) | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-01

2024-01

Principal Amount

[10]

$ 56,208,000

Investment cost

[1],[10]

56,028,000

Investments at Fair Value

[10]

$ 55,958,000

Software | Senior Secured | Pymetrics, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-10

2022-10

Investment Interest Rate

[11]

4%

4%

Investment, Basis Spread, Variable Rate

[11]

5.50%

5.50%

Investment, Interest Rate, Floor

[11]

8.75%

8.75%

Investment, Interest Rate, Paid in Kind

[11]

1.75%

1.75%

Interest Rate and Floor

[11]

4%

4%

Principal Amount

[20]

$ 9,667,000

Investment cost

[2],[20]

9,845,000

Investments at Fair Value

[20]

$ 9,845,000

Software | Senior Secured | 3GTMS, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

2025-02

2025-02

Investment, Basis Spread, Variable Rate

9.28%

[7]

9.28%

[11]

9.28%

[7]

9.28%

[11]

Investment, Interest Rate, Floor

10.28%

[7]

10.28%

[11]

10.28%

[7]

10.28%

[11]

Principal Amount

$ 10,808,000

[10],[12],[13]

$ 10,000,000

[15],[16]

Investment cost

10,660,000

[1],[10],[12],[13]

9,812,000

[2],[15],[16]

Investments at Fair Value

$ 10,496,000

[10],[12],[13]

$ 9,656,000

[15],[16]

Software | Senior Secured | Agilence, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-10

2026-10

2026-10

2026-10

Investment, Basis Spread, Variable Rate

9%

[7]

9%

[11]

9%

[7]

9%

[11]

Investment, Interest Rate, Floor

10%

[7]

10%

[11]

10%

[7]

10%

[11]

Principal Amount

$ 9,330,000

[10],[13],[18]

$ 9,400,000

[15]

Investment cost

9,100,000

[1],[10],[13],[18]

9,138,000

[2],[15]

Investments at Fair Value

$ 8,880,000

[10],[13],[18]

$ 9,138,000

[15]

Software | Senior Secured | Annex Cloud | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-02

2027-02

Investment, Basis Spread, Variable Rate

[7]

9%

9%

Investment, Interest Rate, Floor

[7]

10%

10%

Principal Amount

[10],[17]

$ 8,500,000

Investment cost

[1],[10],[17]

8,282,000

Investments at Fair Value

[10],[17]

$ 8,148,000

Software | Senior Secured | Brain Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-04

2025-04

2025-04

2025-04

Investment Interest Rate

[11]

3.95%

3.95%

Investment, Basis Spread, Variable Rate

3.70%

[7]

3.70%

[11]

3.70%

[7]

3.70%

[11]

Investment, Interest Rate, Floor

6.95%

[7]

6.95%

[11]

6.95%

[7]

6.95%

[11]

Investment, Interest Rate, Paid in Kind

1%

[7]

1%

[11]

1%

[7]

1%

[11]

Interest Rate and Floor

[11]

3.95%

3.95%

Principal Amount

$ 20,116,000

[9],[10],[17],[31]

$ 10,016,000

[15],[20],[32]

Investment cost

20,101,000

[1],[9],[10],[17],[31]

9,943,000

[2],[15],[20],[32]

Investments at Fair Value

$ 20,196,000

[9],[10],[17],[31]

$ 9,943,000

[15],[20],[32]

Software | Senior Secured | Campaign Monitor Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-11

2025-11

2025-11

2025-11

Investment, Basis Spread, Variable Rate

8.90%

[7]

7.90%

[11]

8.90%

[7]

7.90%

[11]

Investment, Interest Rate, Floor

9.90%

[7]

11.15%

[11]

9.90%

[7]

11.15%

[11]

Principal Amount

$ 33,000,000

[8],[17]

$ 33,000,000

[23]

Investment cost

32,546,000

[1],[8],[17]

32,459,000

[2],[23]

Investments at Fair Value

$ 32,944,000

[8],[17]

$ 33,000,000

[23]

Software | Senior Secured | Catchpoint Systems, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-06

2026-06

Investment, Basis Spread, Variable Rate

[7]

8.76%

8.76%

Investment, Interest Rate, Floor

[7],[10],[13]

9.76%

9.76%

Principal Amount

[13]

$ 10,200,000

Investment cost

[1],[13]

10,034,000

Investments at Fair Value

[13]

$ 10,043,000

Software | Senior Secured | Ceros, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

2026-09

2026-09

Investment, Basis Spread, Variable Rate

8.89%

[7]

8.89%

[11]

8.89%

[7]

8.89%

[11]

Investment, Interest Rate, Floor

9.89%

[7],[10],[13]

9.89%

[11]

9.89%

[7],[10],[13]

9.89%

[11]

Principal Amount

$ 19,855,000

[10],[13]

$ 17,978,000

[15],[16]

Investment cost

19,420,000

[1],[10],[13]

17,474,000

[2],[15],[16]

Investments at Fair Value

$ 19,482,000

[10],[13]

$ 17,474,000

[15],[16]

Software | Senior Secured | CloudBolt Software, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-10

2024-10

2024-10

2024-10

Investment Interest Rate

[11]

2.95%

2.95%

Investment, Basis Spread, Variable Rate

6.70%

[7]

6.70%

[11]

6.70%

[7]

6.70%

[11]

Investment, Interest Rate, Floor

9.95%

[7]

9.95%

[11]

9.95%

[7]

9.95%

[11]

Interest Rate and Floor

[11]

2.95%

2.95%

Principal Amount

$ 10,000,000

[8],[12],[18]

$ 10,000,000

[14],[23],[33]

Investment cost

10,021,000

[1],[8],[12],[18]

9,923,000

[2],[14],[23],[33]

Investments at Fair Value

$ 10,014,000

[8],[12],[18]

$ 10,035,000

[14],[23],[33]

Software | Senior Secured | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-03

2025-03

Investment, Basis Spread, Variable Rate

[7]

4.50%

4.50%

Investment, Interest Rate, Floor

[7]

8.25%

8.25%

Investment, Interest Rate, Paid in Kind

[7]

1.95%

1.95%

Principal Amount

[9],[12]

$ 10,095,000

Investment cost

[1],[9],[12]

10,058,000

Investments at Fair Value

[9],[12]

$ 9,882,000

Software | Senior Secured | Cybermaxx Intermediate Holdings, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-08

2026-08

2026-08

2026-08

Investment, Basis Spread, Variable Rate

9.28%

[7]

9.28%

[11]

9.28%

[7]

9.28%

[11]

Investment, Interest Rate, Floor

10.28%

[7]

10.28%

[11]

10.28%

[7]

10.28%

[11]

Principal Amount

$ 7,980,000

[10],[17]

$ 8,000,000

[15]

Investment cost

7,808,000

[1],[10],[17]

7,801,000

[2],[15]

Investments at Fair Value

$ 7,732,000

[10],[17]

$ 7,801,000

[15]

Software | Senior Secured | Dashlane, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-07

2025-07

2025-07

2025-07

Investment Interest Rate

[11]

7.10%

7.10%

Investment, Basis Spread, Variable Rate

3.05%

[7]

3.05%

[11]

3.05%

[7]

3.05%

[11]

Investment, Interest Rate, Floor

7.55%

[7]

7.55%

[11]

7.55%

[7]

7.55%

[11]

Investment, Interest Rate, Paid in Kind

1.10%

[7]

1.10%

[11]

1.10%

[7]

1.10%

[11]

Interest Rate and Floor

[11]

7.10%

7.10%

Principal Amount

$ 31,841,000

[8],[9],[10],[12],[17]

$ 20,719,000

[14],[15],[20],[23]

Investment cost

32,186,000

[1],[8],[9],[10],[12],[17]

21,807,000

[2],[14],[15],[20],[23]

Investments at Fair Value

$ 31,580,000

[8],[9],[10],[12],[17]

$ 21,734,000

[14],[15],[20],[23]

Software | Senior Secured | Demandbase, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-08

2025-08

2025-08

2025-08

Investment, Basis Spread, Variable Rate

2.25%

[7]

5.25%

[11]

2.25%

[7]

5.25%

[11]

Investment, Interest Rate, Floor

5.50%

[7]

8.50%

[11]

5.50%

[7]

8.50%

[11]

Investment, Interest Rate, Paid in Kind

[7]

3%

3%

Principal Amount

$ 28,288,000

[8],[9],[10],[17]

$ 16,875,000

[15],[23]

Investment cost

28,010,000

[1],[8],[9],[10],[17]

16,463,000

[2],[15],[23]

Investments at Fair Value

$ 28,187,000

[8],[9],[10],[17]

$ 16,463,000

[15],[23]

Software | Senior Secured | Eigen Technologies Ltd. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-04

2025-04

Investment, Basis Spread, Variable Rate

[7]

5.10%

5.10%

Investment, Interest Rate, Floor

[7]

8.35%

8.35%

Principal Amount

[29],[30]

$ 3,750,000

Investment cost

[1],[29],[30]

3,730,000

Investments at Fair Value

[29],[30]

$ 3,726,000

Software | Senior Secured | Enmark Systems, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-09

2026-09

2026-09

2026-09

Investment, Basis Spread, Variable Rate

6.83%

[7]

6.83%

[11]

6.83%

[7]

6.83%

[11]

Investment, Interest Rate, Floor

7.83%

[7]

7.83%

[11]

7.83%

[7]

7.83%

[11]

Investment, Interest Rate, Paid in Kind

2.19%

[7]

2.19%

[11]

2.19%

[7]

2.19%

[11]

Principal Amount

$ 8,178,000

[9],[10],[12],[13]

$ 8,000,000

[14],[15],[16]

Investment cost

8,001,000

[1],[9],[10],[12],[13]

7,798,000

[2],[14],[15],[16]

Investments at Fair Value

$ 7,948,000

[9],[10],[12],[13]

$ 7,798,000

[14],[15],[16]

Software | Senior Secured | Esentire, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-05

2024-05

2024-05

2024-05

Investment, Basis Spread, Variable Rate

9.96%

[7]

9.96%

[11],[27],[28]

9.96%

[7]

9.96%

[11],[27],[28]

Investment, Interest Rate, Floor

10.96%

[7]

10.96%

[11],[27],[28]

10.96%

[7]

10.96%

[11],[27],[28]

Principal Amount

$ 8,468,000

[12],[13],[29],[30]

$ 21,000,000

[14],[16],[27],[28]

Investment cost

8,380,000

[1],[12],[13],[29],[30]

20,699,000

[2],[14],[16],[27],[28]

Investments at Fair Value

$ 8,425,000

[12],[13],[29],[30]

$ 20,750,000

[14],[16],[27],[28]

Software | Senior Secured | Esme Learning Solutions, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

Investment, Basis Spread, Variable Rate

[7]

5.50%

5.50%

Investment, Interest Rate, Floor

[7]

8.75%

8.75%

Investment, Interest Rate, Paid in Kind

[7]

1.50%

1.50%

Principal Amount

[9]

$ 5,045,000

Investment cost

[1],[9]

4,890,000

Investments at Fair Value

[9]

$ 4,270,000

Software | Senior Secured | Gryphon Networks Corp. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-01

2026-01

2026-01

2026-01

Investment, Basis Spread, Variable Rate

9.69%

[7]

9.69%

[11]

9.69%

[7]

9.69%

[11]

Investment, Interest Rate, Floor

10.69%

[7]

10.69%

[11]

10.69%

[7]

10.69%

[11]

Principal Amount

$ 5,232,000

[10],[12]

$ 5,232,000

[14],[15]

Investment cost

5,125,000

[1],[10],[12]

5,106,000

[2],[14],[15]

Investments at Fair Value

$ 5,258,000

[10],[12]

$ 5,088,000

[14],[15]

Software | Senior Secured | Ikon Science Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-10

2024-10

2024-10

2024-10

Investment, Basis Spread, Variable Rate

9%

[7]

9%

[11],[27],[28]

9%

[7]

9%

[11],[27],[28]

Investment, Interest Rate, Floor

[7]

10%

10%

Principal Amount

$ 6,650,000

[10],[13],[29],[30]

$ 6,913,000

[15],[16],[27],[28]

Investment cost

6,510,000

[1],[10],[13],[29],[30]

6,719,000

[2],[15],[16],[27],[28]

Investments at Fair Value

$ 6,572,000

[10],[13],[29],[30]

$ 6,767,000

[15],[16],[27],[28]

Software | Senior Secured | Imperva, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-01

2027-01

Investment, Basis Spread, Variable Rate

[7]

8.75%

8.75%

Investment, Interest Rate, Floor

[7]

7.75%

7.75%

Principal Amount

[8]

$ 20,000,000

Investment cost

[1],[8]

19,869,000

Investments at Fair Value

[8]

$ 20,000,000

Software | Senior Secured | Imperva, Inc. | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-01

2027-01

Investment, Basis Spread, Variable Rate

[11]

7.75%

7.75%

Investment, Interest Rate, Floor

[11]

8.75%

8.75%

Principal Amount

[23]

$ 20,000,000

Investment cost

[2],[23]

19,851,000

Investments at Fair Value

[23]

$ 20,000,000

Software | Senior Secured | Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2023-07

2023-07

Investment, Basis Spread, Variable Rate

[7]

10.15%

10.15%

Investment, Interest Rate, Floor

[7]

11.15%

11.15%

Principal Amount

[13]

$ 10,819,000

Investment cost

[1],[13]

10,691,000

Investments at Fair Value

[13]

$ 10,691,000

Software | Senior Secured | Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.) | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-07

2023-07

Investment, Basis Spread, Variable Rate

8%

[7]

10.14%

[11]

8%

[7]

10.14%

[11]

Investment, Interest Rate, Floor

9%

[7]

11.14%

[11]

9%

[7]

11.14%

[11]

Principal Amount

[16]

$ 8,571,000

Investment cost

[2],[16]

8,403,000

Investments at Fair Value

[16]

$ 8,375,000

Software | Senior Secured | Logicworks | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-01

2024-01

2024-01

2024-01

Investment Interest Rate

[7]

0.75%

0.75%

Investment, Basis Spread, Variable Rate

7.50%

[7]

7.50%

[11]

7.50%

[7]

7.50%

[11]

Investment, Interest Rate, Floor

[11]

10.75%

10.75%

Interest Rate and Floor

[7]

0.75%

0.75%

Principal Amount

$ 14,500,000

[18]

$ 10,000,000

[15],[33]

Investment cost

14,373,000

[1],[18]

9,862,000

[2],[15],[33]

Investments at Fair Value

$ 14,356,000

[18]

$ 9,965,000

[15],[33]

Software | Senior Secured | Mixpanel, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-08

2024-08

2024-08

2024-08

Investment Interest Rate

[11]

3%

3%

Investment, Basis Spread, Variable Rate

4.70%

[7]

4.70%

[11]

4.70%

[7]

4.70%

[11]

Investment, Interest Rate, Floor

7.95%

[7]

7.95%

[11]

7.95%

[7]

7.95%

[11]

Investment, Interest Rate, Paid in Kind

1.80%

[7]

1.80%

[11]

1.80%

[7]

1.80%

[11]

Interest Rate and Floor

[11]

3%

3%

Principal Amount

$ 20,713,000

[8],[9]

$ 20,431,000

[20],[23],[33]

Investment cost

20,755,000

[1],[8],[9]

20,292,000

[2],[20],[23],[33]

Investments at Fair Value

$ 21,554,000

[8],[9]

$ 21,030,000

[20],[23],[33]

Software | Senior Secured | Mobile Solutions Services | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-12

2025-12

2025-12

2025-12

Investment, Basis Spread, Variable Rate

9.06%

[7]

9.87%

[11]

9.06%

[7]

9.87%

[11]

Investment, Interest Rate, Floor

10.06%

[7]

10.87%

[11]

10.06%

[7]

10.87%

[11]

Principal Amount

$ 17,668,000

[10],[13]

$ 19,074,000

[15],[16]

Investment cost

17,283,000

[1],[10],[13]

18,575,000

[2],[15],[16]

Investments at Fair Value

$ 16,984,000

[10],[13]

$ 18,834,000

[15],[16]

Software | Senior Secured | Nuvolo Technologies Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-07

2025-07

2025-07

2025-07

Investment Interest Rate

[11]

1.75%

1.75%

Investment, Basis Spread, Variable Rate

5.25%

[7]

7.70%

[11]

5.25%

[7]

7.70%

[11]

Investment, Interest Rate, Floor

8.50%

[7]

10.95%

[11]

8.50%

[7]

10.95%

[11]

Interest Rate and Floor

[11]

1.75%

1.75%

Principal Amount

$ 17,500,000

[8],[10],[17],[18]

$ 15,000,000

[23],[33]

Investment cost

17,525,000

[1],[8],[10],[17],[18]

14,967,000

[2],[23],[33]

Investments at Fair Value

17,586,000

[8],[10],[17],[18]

$ 15,017,000

[23],[33]

Software | Senior Secured | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Principal Amount

$ 20,662,000

Software | Senior Secured | Riviera Partners LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-04

2027-04

Investment, Basis Spread, Variable Rate

[7]

7.53%

7.53%

Investment, Interest Rate, Floor

[7]

8.53%

8.53%

Principal Amount

[10],[13]

$ 26,184,000

Investment cost

[1],[10],[13]

25,595,000

Investments at Fair Value

[10],[13]

$ 25,595,000

Software | Senior Secured | ShadowDragon, LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-12

2026-12

2026-12

2026-12

Investment, Basis Spread, Variable Rate

9%

[7]

9%

[11]

9%

[7]

9%

[11]

Investment, Interest Rate, Floor

10%

[7]

10%

[11]

10%

[7]

10%

[11]

Principal Amount

$ 6,000,000

[13]

$ 6,000,000

[15],[16]

Investment cost

5,849,000

[1],[13]

5,828,000

[2],[15],[16]

Investments at Fair Value

$ 5,780,000

[13]

$ 5,828,000

[15],[16]

Software | Senior Secured | Tact.ai Technologies, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-02

2024-02

2024-02

2024-02

Investment Interest Rate

[11]

5.50%

5.50%

Investment, Basis Spread, Variable Rate

4%

[7]

4%

[11]

4%

[7]

4%

[11]

Investment, Interest Rate, Floor

8.75%

[7]

8.75%

[11]

8.75%

[7]

8.75%

[11]

Investment, Interest Rate, Paid in Kind

2%

[7]

2%

[11]

2%

[7]

2%

[11]

Interest Rate and Floor

[11]

5.50%

5.50%

Principal Amount

$ 5,009,000

[9]

$ 5,185,000

[20]

Investment cost

5,213,000

[1],[9]

5,305,000

[2],[20]

Investments at Fair Value

$ 4,885,000

[9]

$ 5,245,000

[33]

Software | Senior Secured | ThreatConnect, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2026-05

2026-05

2026-05

2026-05

Investment, Basis Spread, Variable Rate

9%

[7]

9%

[11]

9%

[7]

9%

[11]

Investment, Interest Rate, Floor

10%

[7]

10%

[11]

10%

[7]

10%

[11]

Principal Amount

$ 11,060,000

[10],[13],[18]

$ 11,144,000

[15],[16],[33]

Investment cost

10,791,000

[1],[10],[13],[18]

10,831,000

[2],[15],[16],[33]

Investments at Fair Value

$ 10,832,000

[10],[13],[18]

$ 10,859,000

[15],[16],[33]

Software | Senior Secured | Udacity, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-09

2024-09

2024-09

2024-09

Investment Interest Rate

[11]

3%

3%

Investment, Basis Spread, Variable Rate

4.50%

[7]

4.50%

[11]

4.50%

[7]

4.50%

[11]

Investment, Interest Rate, Floor

7.75%

[7]

7.75%

[11]

7.75%

[7]

7.75%

[11]

Investment, Interest Rate, Paid in Kind

2%

[7]

2%

[11]

2%

[7]

2%

[11]

Interest Rate and Floor

[11]

3%

3%

Principal Amount

$ 51,675,000

[9],[18]

$ 50,895,000

[20],[33]

Investment cost

51,851,000

[1],[9],[18]

50,646,000

[2],[20],[33]

Investments at Fair Value

$ 52,330,000

[9],[18]

$ 51,722,000

[20],[33]

Software | Senior Secured | VideoAmp, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-02

2025-02

Investment, Basis Spread, Variable Rate

[7]

3.70%

3.70%

Investment, Interest Rate, Floor

[7]

6.95%

6.95%

Investment, Interest Rate, Paid in Kind

[7]

1.25%

1.25%

Principal Amount

[8],[9],[31]

$ 62,987,000

Investment cost

[1],[8],[9],[31]

62,056,000

Investments at Fair Value

[8],[9],[31]

$ 62,467,000

Software | Senior Secured | Zimperium, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2027-05

2024-07

2027-05

2024-07

Investment, Basis Spread, Variable Rate

8.31%

[7]

8.95%

[11]

8.31%

[7]

8.95%

[11]

Investment, Interest Rate, Floor

9.31%

[7]

9.95%

[11]

9.31%

[7]

9.95%

[11]

Principal Amount

$ 16,313,000

[10],[13]

$ 15,633,000

[16],[33]

Investment cost

15,984,000

[1],[10],[13]

15,347,000

[2],[16],[33]

Investments at Fair Value

$ 15,984,000

[10],[13]

$ 15,347,000

[16],[33]

Software | Senior Secured | Alchemer LLC | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2028-05

2028-05

Investment, Basis Spread, Variable Rate

[7]

7.89%

7.89%

Investment, Interest Rate, Floor

[7]

8.89%

8.89%

Principal Amount

[10],[13]

$ 15,125,000

Investment cost

[1],[10],[13]

14,778,000

Investments at Fair Value

[10],[13]

$ 14,778,000

Software | Senior Secured | Dispatch Technologies, Inc. | Greater than 5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2028-04

2028-04

Investment, Basis Spread, Variable Rate

[7]

8.01%

8.01%

Investment, Interest Rate, Floor

[7]

8.76%

8.76%

Principal Amount

[10],[13]

$ 7,500,000

Investment cost

[1],[10],[13]

7,288,000

Investments at Fair Value

[10],[13]

$ 7,288,000

Software | Senior Secured | Reltio Inc | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-07

2023-07

Investment Interest Rate

[11]

4.95%

4.95%

Investment, Basis Spread, Variable Rate

[11]

5.70%

5.70%

Investment, Interest Rate, Floor

[11]

8.95%

8.95%

Investment, Interest Rate, Paid in Kind

[11]

1.70%

1.70%

Interest Rate and Floor

[11]

4.95%

4.95%

Principal Amount

[20],[23]

$ 10,248,000

Investment cost

[2],[20],[23]

10,336,000

Investments at Fair Value

[20],[23]

$ 10,542,000

Software | Senior Secured | Regent Education | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-01

2022-01

Investment, Interest Rate, Paid in Cash

[11],[37]

10%

10%

Investment Interest Rate

[11],[37]

7.94%

7.94%

Investment, Interest Rate, Paid in Kind

[11],[37]

2%

2%

Interest Rate and Floor

[11],[37]

7.94%

7.94%

Principal Amount

[20],[37]

$ 2,951,000

Investment cost

[2],[20],[37]

3,064,000

Investments at Fair Value

[20],[37]

$ 2,608,000

Software | Senior Secured | Cloud 9 Software | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-04

2024-04

Investment, Basis Spread, Variable Rate

[11]

8.20%

8.20%

Investment, Interest Rate, Floor

[11]

9.20%

9.20%

Principal Amount

[33]

$ 9,953,000

Investment cost

[2],[33]

9,856,000

Investments at Fair Value

[33]

$ 9,953,000

Software | Senior Secured | Floor Rate | Ikon Science Limited | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Floor

[11],[27],[28]

10%

10%

Software | Senior Secured | Exit Fee | Automation Anywhere, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

2.50%

2.50%

Interest Rate and Floor

[7]

2.50%

2.50%

Software | Senior Secured | Exit Fee | Cutover, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Software | Senior Secured | Exit Fee | Brain Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Software | Senior Secured | Exit Fee | CloudBolt Software, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.45%

3.45%

Interest Rate and Floor

[7]

3.45%

3.45%

Software | Senior Secured | Exit Fee | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Software | Senior Secured | Exit Fee | Dashlane, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.95%

4.95%

Interest Rate and Floor

[7]

4.95%

4.95%

Software | Senior Secured | Exit Fee | Demandbase, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5%

5%

Investment, Interest Rate, Floor

[11]

2%

2%

Interest Rate and Floor

[7]

5%

5%

Software | Senior Secured | Exit Fee | Eigen Technologies Ltd. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

2.95%

2.95%

Interest Rate and Floor

[7]

2.95%

2.95%

Software | Senior Secured | Exit Fee | Esme Learning Solutions, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3%

3%

Interest Rate and Floor

[7]

3%

3%

Software | Senior Secured | Exit Fee | Mixpanel, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3%

3%

Interest Rate and Floor

[7]

3%

3%

Software | Senior Secured | Exit Fee | Nuvolo Technologies Corporation | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

2.04%

2.04%

Interest Rate and Floor

[7]

2.04%

2.04%

Software | Senior Secured | Exit Fee | Tact.ai Technologies, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.50%

5.50%

Interest Rate and Floor

[7]

5.50%

5.50%

Software | Senior Secured | Exit Fee | Udacity, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3%

3%

Interest Rate and Floor

[7]

3%

3%

Software | Senior Secured | Exit Fee | VideoAmp, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

5.25%

5.25%

Interest Rate and Floor

[7]

5.25%

5.25%

Software | Senior Secured | Cap Rate | Copper CRM, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

10.25%

10.25%

Interest Rate and Floor

[7]

10.25%

10.25%

Software | Senior Secured Tranche A [Member] | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-11

2023-11

2023-11

2023-11

Investment Interest Rate

[11]

4.50%

4.50%

Investment, Basis Spread, Variable Rate

4.75%

[7]

4.75%

[11]

4.75%

[7]

4.75%

[11]

Investment, Interest Rate, Floor

8%

[7]

8%

[11]

8%

[7]

8%

[11]

Investment, Interest Rate, Paid in Kind

0.50%

[7]

0.50%

[11]

0.50%

[7]

0.50%

[11]

Interest Rate and Floor

[11]

4.50%

4.50%

Principal Amount

$ 7,486,000

[9]

$ 7,457,000

[20]

Investment cost

7,657,000

[1],[9]

7,528,000

[2],[20]

Investments at Fair Value

$ 7,975,000

[9]

$ 7,314,000

[20]

Software | Senior Secured Tranche A [Member] | Exit Fee | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Software | Senior Secured Tranche B [Member] | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2023-11

2023-11

2023-11

2023-11

Investment Interest Rate

[11]

4.50%

4.50%

Investment, Basis Spread, Variable Rate

5.25%

[7]

5.25%

[11]

5.25%

[7]

5.25%

[11]

Investment, Interest Rate, Floor

8.50%

[7]

8.50%

[11]

8.50%

[7]

8.50%

[11]

Investment, Interest Rate, Paid in Kind

1.35%

[7]

1.35%

[11]

1.35%

[7]

1.35%

[11]

Interest Rate and Floor

[11]

4.50%

4.50%

Principal Amount

$ 13,176,000

[9],[31]

$ 13,041,000

[20],[32]

Investment cost

13,373,000

[1],[9],[31]

13,005,000

[2],[20],[32]

Investments at Fair Value

$ 14,039,000

[9],[31]

13,092,000

[20],[32]

Software | Senior Secured Tranche B [Member] | Exit Fee | Pollen, Inc. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

4.50%

4.50%

Interest Rate and Floor

[7]

4.50%

4.50%

Software | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 647,576,000

[1]

526,253,000

[2]

Investments at Fair Value

648,620,000

529,402,000

Sustainable And Renewable Technology

Investment Holdings [Line Items]

Investments at Fair Value

15,683,000

39,387,000

Sustainable And Renewable Technology | Equity

Investment Holdings [Line Items]

Investment cost

11,508,000

[1]

12,412,000

[2]

Investments at Fair Value

8,406,000

11,228,000

Sustainable And Renewable Technology | Warrant Investment

Investment Holdings [Line Items]

Investment cost

792,000

[1]

950,000

[2]

Investments at Fair Value

373,000

1,034,000

Sustainable And Renewable Technology | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

[2]

120,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[6]

Jun. 20, 2013

Shares | shares

471,327

471,327

Sustainable And Renewable Technology | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment cost

[2]

$ 19,659,000

Investments at Fair Value

6,904,000

19,625,000

Sustainable And Renewable Technology | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment cost

7,109,000

[1]

7,500,000

[2]

Investments at Fair Value

7,500,000

Sustainable And Renewable Technology | Impossible Foods, Inc. | Equity | Series E One Preferred Stock

Investment Holdings [Line Items]

Investment cost

2,000,000

[1]

2,000,000

[2]

Investments at Fair Value

$ 2,438,000

$ 3,430,000

Investment, Acquisition Date

May 10, 2019

[5]

May 10, 2019

[6]

Shares | shares

188,611

188,611

188,611

188,611

Sustainable And Renewable Technology | Impossible Foods, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[11]

9%

9%

Investment, Basis Spread, Variable Rate

[11]

3.95%

3.95%

Investment, Interest Rate, Floor

[11]

8.95%

8.95%

Interest Rate and Floor

[11]

9%

9%

Sustainable And Renewable Technology | Ampion, PBC. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

$ 53,000

Investments at Fair Value

$ 42,000

Investment, Acquisition Date

[5]

Apr. 15, 2022

Shares | shares

18,472

18,472

Sustainable And Renewable Technology | Pineapple Energy LLC | Equity | Class A Units

Investment Holdings [Line Items]

Investment cost

[2],[35]

$ 4,767,000

Investments at Fair Value

[35]

$ 591,000

Investment, Acquisition Date

[6],[35]

Dec. 10, 2020

Shares | shares

[35]

3,000,000

3,000,000

Sustainable And Renewable Technology | Pineapple Energy LLC | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

[1],[5],[22]

$ 3,153,000

Investments at Fair Value

[5],[22]

$ 243,000

Investment, Acquisition Date

[5]

Dec. 10, 2020

Shares | shares

[5],[22]

304,486

304,486

Sustainable And Renewable Technology | Pineapple Energy LLC | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Cash

[11],[26],[35]

10%

10%

Sustainable And Renewable Technology | Pineapple Energy LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Kind

[11],[35],[37]

10%

10%

Sustainable And Renewable Technology | Modumetal, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 500,000

[1]

$ 500,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Jun. 01, 2015

[5]

Jun. 01, 2015

[6]

Shares | shares

1,035

1,035

1,035

1,035

Sustainable And Renewable Technology | NantEnergy, LLC | Equity | Common Units

Investment Holdings [Line Items]

Investment cost

$ 102,000

[1]

$ 102,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Aug. 31, 2013

[5]

Aug. 31, 2013

[6]

Shares | shares

59,665

59,665

59,665

59,665

Sustainable And Renewable Technology | Pivot Bio, Inc. | Equity | Preferred Series D

Investment Holdings [Line Items]

Investment cost

$ 4,500,000

[1]

$ 4,500,000

[2]

Investments at Fair Value

$ 2,571,000

$ 3,164,000

Investment, Acquisition Date

Jun. 28, 2021

[5]

Jun. 28, 2021

[6]

Shares | shares

593,080

593,080

593,080

593,080

Sustainable And Renewable Technology | Proterra, Inc. | Equity | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 542,000

[1],[5]

$ 543,000

[2],[6]

Investments at Fair Value

$ 2,280,000

[5]

$ 4,043,000

[6]

Investment, Acquisition Date

May 28, 2015

[5]

May 28, 2015

[6]

Shares | shares

457,841

[5]

457,841

[6]

457,841

[5]

457,841

[6]

Sustainable And Renewable Technology | Halio Inc

Investment Holdings [Line Items]

Investments at Fair Value

$ 111,000

Sustainable And Renewable Technology | Halio Inc | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[1]

$ 218,000

Shares | shares

456,883

456,883

Sustainable And Renewable Technology | Halio Inc | Warrant Investment | Preferred Series A

Investment Holdings [Line Items]

Investment cost

[1]

$ 155,000

Investments at Fair Value

$ 83,000

Investment, Acquisition Date

[5]

Apr. 22, 2014

Shares | shares

325,000

325,000

Sustainable And Renewable Technology | Halio Inc | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

[1]

$ 63,000

Investments at Fair Value

$ 28,000

Investment, Acquisition Date

[5]

Apr. 07, 2015

Shares | shares

131,883

131,883

Sustainable And Renewable Technology | Agrivida Inc | Warrant Investment | Preferred Series D

Investment Holdings [Line Items]

Investment cost

[1]

$ 120,000

Investments at Fair Value

$ 0

Investment, Acquisition Date

[5]

Jun. 20, 2013

Shares | shares

471,327

471,327

Sustainable And Renewable Technology | Fulcrum Bioenergy Inc | Equity | Preferred Series C-1

Investment Holdings [Line Items]

Investment cost

[1]

$ 711,000

Investments at Fair Value

$ 874,000

Investment, Acquisition Date

[5]

Sep. 13, 2012

Shares | shares

187,265

187,265

Sustainable And Renewable Technology | Fulcrum Bioenergy Inc | Warrant Investment | Preferred Series C-1

Investment Holdings [Line Items]

Investment cost

$ 64,000

[1]

$ 274,000

[2]

Investments at Fair Value

$ 220,000

$ 699,000

Investment, Acquisition Date

Apr. 30, 2013

[5]

Sep. 13, 2012

[6]

Shares | shares

93,632

280,897

93,632

280,897

Sustainable And Renewable Technology | Polyera Corporation | Warrant Investment | Preferred Series C

Investment Holdings [Line Items]

Investment cost

$ 337,000

[1]

$ 338,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Dec. 11, 2012

[5]

Dec. 11, 2012

[6]

Shares | shares

311,612

311,609

311,612

311,609

Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment

Investment Holdings [Line Items]

Investment cost

[2]

$ 218,000

Investments at Fair Value

$ 335,000

Shares | shares

456,883

456,883

Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment | Preferred Series A

Investment Holdings [Line Items]

Investment cost

[2]

$ 155,000

Investments at Fair Value

$ 249,000

Investment, Acquisition Date

[6]

Apr. 22, 2014

Shares | shares

325,000

325,000

Sustainable And Renewable Technology | Halio Inc P K Kinestral Technologies Inc | Warrant Investment | Preferred Series B

Investment Holdings [Line Items]

Investment cost

[2]

$ 63,000

Investments at Fair Value

$ 86,000

Investment, Acquisition Date

[6]

Apr. 07, 2015

Shares | shares

131,883

131,883

Sustainable And Renewable Technology | Senior Secured | Impossible Foods, Inc. | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-07

2022-07

Principal Amount

[33]

$ 15,022,000

Investment cost

[2],[33]

19,379,000

Investments at Fair Value

[33]

$ 19,378,000

Sustainable And Renewable Technology | Senior Secured | Ampion, PBC. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2025-05

2025-05

Investment, Basis Spread, Variable Rate

[7]

4.70%

4.70%

Investment, Interest Rate, Floor

[7]

7.95%

7.95%

Investment, Interest Rate, Paid in Kind

[7]

1.45%

1.45%

Principal Amount

[9],[17]

$ 4,022,000

Investment cost

[1],[9],[17]

3,953,000

Investments at Fair Value

[9],[17]

$ 3,943,000

Sustainable And Renewable Technology | Senior Secured | Pineapple Energy LLC | Debt Investments Under 1 Year Maturity

Investment Holdings [Line Items]

Maturity Date

2022-01

2022-01

Principal Amount

[15],[26],[35]

$ 280,000

Investment cost

[2],[15],[26],[35]

280,000

Investments at Fair Value

[15],[26],[35]

$ 247,000

Sustainable And Renewable Technology | Senior Secured | Pineapple Energy LLC | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Maturity Date

2024-12

2023-12

2024-12

2023-12

Investment, Interest Rate, Paid in Kind

[7]

10%

10%

Principal Amount

$ 3,156,000

[9]

$ 7,500,000

[15],[20],[35],[37]

Investment cost

3,156,000

[1],[9]

7,500,000

[2],[15],[20],[35],[37]

Investments at Fair Value

$ 2,961,000

[9]

7,500,000

[15],[20],[35],[37]

Sustainable And Renewable Technology | Senior Secured | Exit Fee | Ampion, PBC. | Debt Investments 1-5 Years Maturity

Investment Holdings [Line Items]

Investment Interest Rate

[7]

3.95%

3.95%

Interest Rate and Floor

[7]

3.95%

3.95%

Sustainable And Renewable Technology | Debt Investments

Investment Holdings [Line Items]

Investment cost

$ 7,109,000

[1]

27,159,000

[2]

Investments at Fair Value

6,904,000

27,125,000

Media/Content/Info | Warrant Investment

Investment Holdings [Line Items]

Investment cost

348,000

[1]

348,000

[2]

Investments at Fair Value

0

0

Media/Content/Info | Zoom Media Group, Inc. | Warrant Investment | Preferred Series A

Investment Holdings [Line Items]

Investment cost

348,000

[1]

348,000

[2]

Investments at Fair Value

$ 0

$ 0

Investment, Acquisition Date

Dec. 21, 2012

[5]

Dec. 21, 2012

[6]

Shares | shares

1,204

1,204

1,204

1,204

Electronics & Computer Hardware

Investment Holdings [Line Items]

Investments at Fair Value

$ 2,498,000

$ 1,040,000

Electronics & Computer Hardware | Equity

Investment Holdings [Line Items]

Investment cost

[1]

1,500,000

Investments at Fair Value

1,034,000

Electronics & Computer Hardware | Warrant Investment

Investment Holdings [Line Items]

Investment cost

692,000

[1]

658,000

[2]

Investments at Fair Value

1,464,000

1,040,000

Electronics & Computer Hardware | Locus Robotics Corporation | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

[1]

34,000

Investments at Fair Value

$ 27,000

Investment, Acquisition Date

[5]

Jun. 21, 2022

Shares | shares

8,511

8,511

Electronics & Computer Hardware | Skydio, Inc. | Equity | Preferred Series E

Investment Holdings [Line Items]

Investment cost

[1]

$ 1,500,000

Investments at Fair Value

$ 1,034,000

Investment, Acquisition Date

[5]

Mar. 08, 2022

Shares | shares

248,900

248,900

Electronics & Computer Hardware | Skydio, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 557,000

[1]

557,000

[2]

Investments at Fair Value

$ 1,153,000

$ 422,000

Investment, Acquisition Date

Nov. 08, 2021

[5]

Nov. 08, 2021

[6]

Shares | shares

622,255

124,451

622,255

124,451

Electronics & Computer Hardware | 908 Devices, Inc. | Warrant Investment | Common Stock

Investment Holdings [Line Items]

Investment cost

$ 101,000

[1],[5]

$ 101,000

[2],[6]

Investments at Fair Value

$ 284,000

[5]

$ 618,000

[6]

Investment, Acquisition Date

Mar. 15, 2017

[5]

Mar. 15, 2017

[6]

Shares | shares

49,078

[5]

49,078

[6]

49,078

[5]

49,078

[6]

Investment, Affiliated Issuer, Controlled [Member]

Investment Holdings [Line Items]

Investment cost

$ 87,249,000

$ 84,039,000

Investments at Fair Value

80,325,000

[40]

$ 73,504,000

[41]

$ 65,835,000

$ 57,400,000

Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital, LLC

Investment Holdings [Line Items]

Investments at Fair Value

[42]

37,662,000

40,737,000

Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser LLC

Investment Holdings [Line Items]

Investments at Fair Value

[42]

33,945,000

16,804,000

Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation

Investment Holdings [Line Items]

Investments at Fair Value

[42]

8,318,000

8,294,000

Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics, LLC

Investment Holdings [Line Items]

Investments at Fair Value

[42]

400,000

Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche A [Member] | Pineapple Energy LLC

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Kind

10%

10%

Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche B [Member] | Pineapple Energy LLC

Investment Holdings [Line Items]

Investment, Interest Rate, Paid in Cash

10%

10%

Principal Amount

$ 280,000

Investment, Affiliated Issuer, Noncontrolled [Member]

Investment Holdings [Line Items]

Investment cost

0

13,547,000

Investments at Fair Value

0

9,458,000

[41]

9,712,000

8,340,000

Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy LLC

Investment Holdings [Line Items]

Investment cost

12,547,000

Investments at Fair Value

0

[42],[43]

8,338,000

[41]

8,469,000

[42]

Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow AI, Inc. affiliates

Investment Holdings [Line Items]

Investments at Fair Value

[42]

0

[43]

1,243,000

Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche A [Member] | Pineapple Energy LLC

Investment Holdings [Line Items]

Principal Amount

7,500,000

Investment cost

7,500,000

Investments at Fair Value

[41]

7,500,000

Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology | Senior Secured Tranche B [Member] | Pineapple Energy LLC

Investment Holdings [Line Items]

Investment cost

280,000

Investments at Fair Value

[41]

247,000

Investment, Affiliated Issuer [Member]

Investment Holdings [Line Items]

Investment cost

87,249,000

97,586,000

Investments at Fair Value

$ 80,325,000

[40]

$ 82,962,000

[41]

$ 75,547,000

$ 65,740,000

[1] Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $ 68.4 million, $ 110.0 million and $ 41.6 million, respectively. The tax cost of investments is $ 2.9 billion. Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $ 121.0 million, $ 75.7 million, and $ 45.3 million, respectively. The tax cost of investments is $ 2.4 billion. Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Except for warrants in 27 publicly traded companies and common stock in 42 publicly traded companies, all investments are restricted as of September 30, 2022 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”). Except for warrants in 26 publicly traded companies and common stock in 36 publicly traded companies, all investments are restricted as of December 31, 2021 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Board. Interest rate PRIME represents 6.25 % as of September 30, 2022. 1-month LIBOR, 3-month LIBOR and 6-month LIBOR represent 3.1427 % , 3.7547 % , and 4.2320 % , respectively, as of September 30, 2022 . Denotes second lien senior secured debt. Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of September 30, 2022 (Refer to “Note 11 - Commitments and Contingencies”). Interest rate PRIME represents 3.25 % as of December 31, 2021. 1-month LIBOR, 3-month LIBOR, and 6-month LIBOR represent, 0.14 %, 0.24 %, and 0.26 %, respectively, as of December 31, 2021. Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition. Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2021. Refer to “Note 11 — Commitments and Contingencies”. Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition. Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”). Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”). Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of September 30, 2022 . Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2021. Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933 (“Securities Act”) and may be deemed to be “restricted securities” under the Securities Act. Denotes second lien senior secured debt. Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. Denotes that all or a portion of the debt investment is convertible debt. Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets. Non-U.S. company or the company’s principal place of business is outside the United States. Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets. Non-U.S. company or the company’s principal place of business is outside the United States. Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company. Denotes that all or a portion of the investment in this portfolio company is held by HC IV, the Company’s wholly owned SBIC subsidiary. Denotes that all or a portion of the investment is pledged as collateral under the Union Bank Facility (as defined in “Note 5 — Debt”). Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933 (“Securities Act”) and may be deemed to be “restricted securities” under the Securities Act. Affiliate investment as defined under the 1940 Act in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities. Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of September 30, 2022 , the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $ 3.0 million. Debt is on non-accrual status as of December 31, 2021, and is therefore considered non-income producing. Note that only the PIK portion is on non-accrual for the Company’s debt investment in Tectura Corporation and Pineapple Energy LLC. Debt is on non-accrual status as of September 30, 2022, and is therefore considered non-income producing. Note that as of September 30, 2022 , only the PIK, or payment-in-kind, portion is on non-accrual for the Company’s debt investment in Tectura Corporation. Denotes that all or a portion of the debt investment is convertible debt. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021 , there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act.

CONSOLIDATED SCHEDULE OF INVE_2

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical) $ in Thousands		Sep. 30, 2022 USD ($) Firm		Dec. 31, 2021 USD ($) Firm
Investment Holdings [Line Items]
Tax basis of investments, gross, unrealized appreciation		$ 68,400		$ 121,000
Tax basis of investments, gross, unrealized depreciation		110,000		75,700
Tax basis of investments, unrealized appreciation (depreciation), net		41,600		45,300
Tax basis of investments, cost for income tax purposes		2,900,000		2,400,000
Investment Owned At Cost		2,869,469		2,390,984
Investment Owned At Fair Value		2,825,738		2,434,522
Black Crow AI, Inc. affiliates
Investment Holdings [Line Items]
Investment Owned Balance Principal Amount				$ 3,000
Promissory Notes [Member] | Black Crow AI, Inc. affiliates
Investment Holdings [Line Items]
Investment Owned Balance Principal Amount		$ 3,000
PRIME
Investment Holdings [Line Items]
Interest rate		6.25%		3.25%
1-month LIBOR
Investment Holdings [Line Items]
Interest rate		3.1427%		0.14%
3-month LIBOR
Investment Holdings [Line Items]
Interest rate		3.7547%		0.24%
6-month LIBOR
Investment Holdings [Line Items]
Interest rate		4.232%		0.26%
Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	1.99%
Investment Owned At Fair Value		$ 27,159		$ 38,399
Warrant | Fair Value Inputs Level1 [Member]
Investment Holdings [Line Items]
Number of publicly traded companies | Firm		27		26
Total Investments Before Cash And Cash Equivalent [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	207.36%
Investment Owned At Cost	[1],[2]	$ 2,869,469
Investment Owned At Fair Value		$ 2,825,738
Total investments In Securities
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	207.14%
Investment Owned At Cost	[2]	$ 2,866,330
Investment Owned At Fair Value		$ 2,822,692
Total Investments with Cash and Cash Equivalents
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	209.19%
Investment Owned At Cost	[1],[2]	$ 2,894,469
Investment Owned At Fair Value	[1]	$ 2,850,738
Money Market Funds [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	1.83%
Investment Owned At Cost	[1],[2]	$ 25,000
Investment Owned At Fair Value	[1]	$ 25,000
Investment Funds And Vehicles [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.22%
Common Stock
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 93,096		$ 115,271
Common Stock | Fair Value Inputs Level1 [Member]
Investment Holdings [Line Items]
Number of publicly traded companies | Firm		42		36
Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		9.84%	[1]	14.12%	[3]
Investment Owned At Cost		$ 150,539	[2]	$ 142,219	[4]
Investment Owned At Fair Value		134,134		$ 184,710
Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			2.93%
Investment Owned At Cost		31,148	[2]	$ 27,147	[4]
Investment Owned At Fair Value		$ 27,159		$ 38,399
Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		195.30%	[1]	168.86%	[3]
Investments in Securities [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			185.91%
Investment Owned At Cost	[4]			$ 2,388,952
Investment Owned At Fair Value				$ 2,432,708
Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.14%
Investment Owned At Cost	[2]	$ 3,139
Investment Owned At Fair Value		3,046
Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			186.05%
Investment Owned At Cost	[4]			$ 2,390,984
Investment Owned At Fair Value				2,434,522
Phathom Pharmaceuticals, Inc. | Royalty Contract
Investment Holdings [Line Items]
Investment Owned At Cost		4,600
Investment Owned At Fair Value		4,300
Internet Consumer And Business Services
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 489,968		$ 395,506
Internet Consumer And Business Services | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.43%
Internet Consumer And Business Services | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		1.13%	[1]	2.70%	[3]
Investment Owned At Cost		$ 22,058	[2]	$ 22,151	[4]
Investment Owned At Fair Value		15,377		$ 35,331
Internet Consumer And Business Services | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.78%
Investment Owned At Cost		6,110	[2]	$ 4,992	[4]
Investment Owned At Fair Value		$ 5,800		$ 10,212
Internet Consumer And Business Services | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		34.40%		26.74%	[3]
Surgical Devices
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 1,536		$ 1,029
Surgical Devices | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.11%
Surgical Devices | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0%	[1]	0.04%	[3]
Investment Owned At Cost		$ 1,941	[2]	$ 1,941	[4]
Investment Owned At Fair Value		0		$ 543
Surgical Devices | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.04%
Investment Owned At Cost		152	[2]	$ 206	[4]
Investment Owned At Fair Value		$ 1,536		$ 486
Media/Content/Info | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0%
Media/Content/Info | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0%
Investment Owned At Cost		$ 348	[2]	$ 348	[4]
Investment Owned At Fair Value		0		0
Consumer & Business Products
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 25,497		$ 28,099
Consumer & Business Products | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.08%
Consumer & Business Products | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.01%	[1]	0.03%	[3]
Investment Owned At Cost		$ 561	[2]	$ 128	[4]
Investment Owned At Fair Value		185		$ 447
Consumer & Business Products | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.33%
Investment Owned At Cost		1,712	[2]	$ 2,145	[4]
Investment Owned At Fair Value		$ 1,122		$ 4,354
Consumer & Business Products | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		1.78%	[1]	1.78%	[3]
Diversified Financial Services
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 72,061		$ 65,073
Diversified Financial Services | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		2.79%	[1]	2.49%	[3]
Investment Owned At Cost		$ 28,444	[2]	$ 28,041	[4]
Investment Owned At Fair Value		$ 38,022		$ 32,608
Diversified Financial Services | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		2.50%	[1]	2.48%	[3]
Electronics & Computer Hardware
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 2,498		$ 1,040
Electronics & Computer Hardware | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.11%
Electronics & Computer Hardware | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.08%
Investment Owned At Cost	[2]	$ 1,500
Investment Owned At Fair Value		1,034
Electronics & Computer Hardware | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.08%
Investment Owned At Cost		692	[2]	$ 658	[4]
Investment Owned At Fair Value		1,464		1,040
Healthcare Services Other
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 203,599		$ 121,003
Healthcare Services Other | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.04%
Healthcare Services Other | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.23%	[1]	0.56%	[3]
Investment Owned At Cost		$ 6,782	[2]	$ 6,781	[4]
Investment Owned At Fair Value		3,198		$ 7,364
Healthcare Services Other | Warrant Investment
Investment Holdings [Line Items]
Investment Owned At Cost	[2]	697
Investment Owned At Fair Value		$ 521
Healthcare Services Other | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		14.67%	[1]	8.68%	[3]
Drug Delivery
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 90		$ 368
Drug Delivery | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0%
Drug Delivery | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.01%	[1]	0.02%	[3]
Investment Owned At Cost		$ 3,638	[2]	$ 3,638	[4]
Investment Owned At Fair Value				$ 305
Drug Delivery | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0%
Investment Owned At Cost		465	[2]	$ 465	[4]
Investment Owned At Fair Value		0		63
Communications & Networking
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 101,094		$ 105,490
Communications & Networking | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.01%
Communications & Networking | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.48%
Investment Owned At Cost	[4]			$ 1,230
Investment Owned At Fair Value				$ 6,260
Communications & Networking | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3],[5]			0%
Investment Owned At Cost		$ 541	[2]	$ 418	[4]
Investment Owned At Fair Value		$ 140		$ 0
Communications & Networking | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		7.41%	[1]	7.58%	[3]
Drug Discovery & Development
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 1,091,827		$ 967,383
Drug Discovery & Development | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.30%
Drug Discovery & Development | Investment Funds And Vehicles [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.20%
Drug Discovery & Development | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		2.41%	[1]	1.90%	[3]
Investment Owned At Cost		$ 42,548	[2]	$ 33,401	[4]
Investment Owned At Fair Value		32,844		$ 24,860
Drug Discovery & Development | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.36%
Investment Owned At Cost		7,709	[2]	$ 7,393	[4]
Investment Owned At Fair Value		$ 4,074		$ 4,745
Drug Discovery & Development | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		77.22%	[1]	71.53%	[3]
Drug Discovery & Development | Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment Owned At Cost	[2]	$ 2,758
Investment Owned At Fair Value		2,665
Medical Devices & Equipment
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 17,421		$ 12,612
Medical Devices & Equipment | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.03%
Medical Devices & Equipment | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.16%	[1]	0.81%	[3]
Investment Owned At Cost		$ 2,953	[2]	$ 3,991	[4]
Investment Owned At Fair Value		2,143		$ 10,538
Medical Devices & Equipment | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.16%
Investment Owned At Cost		2,035	[2]	$ 2,483	[4]
Investment Owned At Fair Value		$ 443		2,074
Medical Devices & Equipment | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	1.09%
Sustainable And Renewable Technology
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 15,683		$ 39,387
Sustainable And Renewable Technology | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.03%
Sustainable And Renewable Technology | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.62%	[1]	0.86%	[3]
Investment Owned At Cost		$ 11,508	[2]	$ 12,412	[4]
Investment Owned At Fair Value		8,406		$ 11,228
Sustainable And Renewable Technology | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.08%
Investment Owned At Cost		792	[2]	$ 950	[4]
Investment Owned At Fair Value		$ 373		$ 1,034
Sustainable And Renewable Technology | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.51%	[1]	2.07%	[3]
Software
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 680,216		$ 585,622
Software | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.46%
Software | Investment Funds And Vehicles [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.03%
Software | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		1.83%	[1]	3.45%	[3]
Investment Owned At Cost		$ 24,006	[2]	$ 23,905	[4]
Investment Owned At Fair Value		24,997		$ 45,087
Software | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.85%
Investment Owned At Cost		7,639	[2]	$ 5,594	[4]
Investment Owned At Fair Value		$ 6,217		$ 11,133
Software | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		47.60%	[1]	40.46%	[3]
Software | Investment Funds & Vehicles [Member]
Investment Holdings [Line Items]
Investment Owned At Cost	[2]	$ 381
Investment Owned At Fair Value		381
Semiconductors
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 20,621		$ 22,498
Semiconductors | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.05%
Semiconductors | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.02%	[1]	0.06%	[3]
Investment Owned At Cost		$ 160	[2]	$ 160	[4]
Investment Owned At Fair Value		259		$ 725
Semiconductors | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.21%
Investment Owned At Cost		850	[2]	$ 850	[4]
Investment Owned At Fair Value		$ 715		$ 2,701
Semiconductors | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		1.44%	[1]	1.46%	[3]
Manufacturing Technology | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.32%
Manufacturing Technology | Warrant Investment
Investment Holdings [Line Items]
Investment Owned At Cost	[2]	$ 726
Investment Owned At Fair Value		$ 4,338
Manufacturing Technology | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		2.90%	[1]	1.15%	[3]
Information Services
Investment Holdings [Line Items]
Investment Owned At Fair Value		$ 59,735		$ 74,417
Information Services | Warrant
Investment Holdings [Line Items]
Investment owned, percent of net assets	[1]	0.03%
Information Services | Equity
Investment Holdings [Line Items]
Investment owned, percent of net assets		0.56%	[1]	0.72%	[3]
Investment Owned At Cost		$ 4,440	[2]	$ 4,440	[4]
Investment Owned At Fair Value		7,579		$ 9,414
Information Services | Warrant Investment
Investment Holdings [Line Items]
Investment owned, percent of net assets	[3]			0.04%
Investment Owned At Cost		680	[2]	$ 645	[4]
Investment Owned At Fair Value		$ 416		$ 557
Information Services | Debt Investment [Member]
Investment Holdings [Line Items]
Investment owned, percent of net assets		3.80%	[1]	4.93%	[3]
[1] Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $ 68.4 million, $ 110.0 million and $ 41.6 million, respectively. The tax cost of investments is $ 2.9 billion. Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $ 121.0 million, $ 75.7 million, and $ 45.3 million, respectively. The tax cost of investments is $ 2.4 billion. Except for warrants in 26 publicly traded companies and common stock in 36 publicly traded companies, all investments are restricted as of December 31, 2021 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s Board.

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003. The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a Regulated Investment Company (“RIC”) under Subchapter M of the Code (see “Note 6 - Income Taxes”). The Company does not currently use Commodity Futures Trading Commission (“CFTC”) derivatives. However, to the extent that it uses CFTC derivatives in the future, it intends to do so below prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a "commodity pool operator" under the CEA. Hercules Capital IV, L.P. (“HC IV”) is our wholly owned Delaware limited partnership that was formed in December 2010. HC IV received a license to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020. SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC (“HTM”), is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV. The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). These subsidiaries are taxable entities and are not consolidated with Hercules for income tax purposes. The Company's taxable subsidiaries may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. In May 2020, Hercules Adviser LLC (the “Adviser Subsidiary”) was formed as a wholly owned Delaware limited liability subsidiary of the Company to provide investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary receives fee income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions. Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and Variable Interest Entities (“VIE”) for which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. As of September 30, 2022, the Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The Company held no interests in a VIE as of December 31, 2021 . The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit. Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company. Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. As of September 30, 2022, approximately 96.6 % of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820. Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2022, the Company held $ 679 thousa nd (Cost basis $ 726 thousand) of foreign cash. As of December 31, 2021, the Company held $ 95 thousand (Cost basis $ 93 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to our 2031 Asset-Backed Notes (refer to “Note 5 – Debt”). Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivables. Escrow Receivables Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. As of both September 30, 2022 and December 31, 2021, there were no material past due escrow receivables. The approximate fair value in accordance with ASC Topic 820 of the escrow receivable balance as of September 30, 2022 and December 31, 2021 was $ 1.3 million and $ 0.6 million, respectively. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right of use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”. Income Recognition The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal. Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $ 53.6 million of unamortized fees as of September 30, 2022, of which approximately $ 42.1 million was included as an offset to the cost basis of its current debt investments and approximately $ 11.5 million was deferred contingent upon the occurrence of a funding or milestone. As of December 31, 2021, the Company had approximately $ 42.9 million of unamortized fees, of which approximately $ 36.5 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $ 6.4 million was deferred contingent upon the occurrence of a funding or milestone. The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default, waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $ 0.5 million and $ 1.7 million in one-time fee income during the three months ended September 30, 2022 and 2021, respectively. The Company recorded approximately $ 1.3 million and $ 6.2 million in one-time fee income during the nine months ended September 30, 2022 and 2021, respectively. In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of September 30, 2022, the Company had approximately $ 36.5 million in exit fees receivable, of which approximately $ 32.0 million was included as a component of the cost basis of its current debt investments and approximately $ 4.5 million was a deferred receivable related to expired commitments. As of December 31, 2021, the Company had approximately $ 35.0 million in exit fees receivable, of which approximately $ 29.6 million was included as a component of the cost basis of its current debt investments and approximately $ 5.4 million was a deferred receivable related to expired commitments. The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $ 4.9 million and $ 2.9 million in PIK income during the three months ended September 30, 2022 and 2021, respectively. The Company recorded approximately $ 14.9 million and $ 8.1 million in PIK income during the nine months ended September 30, 2022 and 2021, respectively. To maintain the Company’s RIC status for taxation purposes, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three and nine months ended September 30, 2022 and 2021 . Equity Offering Expenses The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities. Debt The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpai

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2022 and December 31, 2021. (in thousands) Balance as of Quoted Prices in Significant Significant Description 2022 (Level 1) (Level 2) (Level 3) Cash equivalents Money Market Fund $ 25,000 $ 25,000 $ — $ — Other assets Escrow Receivables $ 1,282 $ — $ — $ 1,282 Investments Senior Secured Debt $ 2,607,006 $ — $ — $ 2,607,006 Unsecured Debt 54,393 — — 54,393 Preferred Stock 41,038 — — 41,038 Common Stock 93,096 58,319 7,175 27,602 Warrants 27,159 — 9,520 17,639 $ 2,822,692 $ 58,319 $ 16,695 $ 2,747,678 Investment Funds & Vehicles measured at Net Asset Value (1) 3,046 Total Investments excluding cash equivalents $ 2,825,738 Total Investments including cash equivalents $ 2,850,738 (in thousands) Balance as of Quoted Prices in Significant Significant Description 2021 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 561 $ — $ — $ 561 Investments Senior Secured Debt $ 2,156,709 $ — $ — $ 2,156,709 Unsecured Debt 52,890 — — 52,890 Preferred Stock 69,439 — — 69,439 Common Stock 115,271 84,460 8,843 21,968 Warrants 38,399 — 10,922 27,477 $ 2,432,708 $ 84,460 $ 19,765 $ 2,328,483 Investment Funds & Vehicles measured at Net Asset Value (1) 1,814 Total Investments excluding cash equivalents $ 2,434,522 Total Investments including cash equivalents $ 2,434,522 (1) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities. The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2022 and 2021. (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (3) Gross (3) Balance as of Investments Senior Secured Debt $ 2,156,709 $ ( 1,883 ) $ ( 11,377 ) $ 854,978 $ ( 73,500 ) $ ( 314,417 ) $ — $ ( 3,504 ) $ 2,607,006 Unsecured Debt 52,890 — ( 1,880 ) 3,383 — — — — 54,393 Preferred Stock 69,439 7,966 ( 22,458 ) 3,614 ( 11,101 ) — — ( 6,422 ) 41,038 Common Stock 21,968 ( 74 ) 9,462 — ( 19 ) — 207 ( 3,942 ) 27,602 Warrants 27,477 992 ( 13,795 ) 6,127 ( 3,162 ) — — — 17,639 Other Assets Escrow Receivable 561 401 ( 328 ) 1,148 ( 500 ) — — — 1,282 Total $ 2,329,044 $ 7,402 $ ( 40,376 ) $ 869,250 $ ( 88,282 ) $ ( 314,417 ) $ 207 $ ( 13,868 ) $ 2,748,960 (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (4) Gross (4) Balance as of Investments Senior Secured Debt $ 2,079,465 $ ( 3,744 ) $ 7,066 $ 884,833 $ — $ ( 754,373 ) $ — $ — $ 2,213,247 Unsecured Debt 14,970 — ( 1,194 ) 36,519 — — — — 50,295 Preferred Stock 58,981 — 54,508 13,954 ( 61,732 ) — — ( 1,267 ) 64,444 Common Stock 27,398 ( 60,904 ) 15,592 4,371 60,900 — — ( 16,025 ) 31,332 Warrants 21,483 2,584 9,043 1,854 ( 4,630 ) — — ( 1,769 ) 28,565 Other Assets Escrow Receivable 65 584 ( 1,515 ) 2,473 ( 1,036 ) — — — 571 Total $ 2,202,362 $ ( 61,480 ) $ 83,500 $ 944,004 $ ( 6,498 ) $ ( 754,373 ) $ — $ ( 19,061 ) $ 2,388,454 (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the ac companying Consolidated Statements of Operations. (3) Transfers out of Level 3 during the nine months ended September 30, 2022 related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the nine months ended September 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares. (4) Transfers out of Level 3 during the nine months ended September 30, 2021, related to the initial public offerings of Proterra, Inc., 23andMe, Inc., Sprinklr, Inc., Century Therapeutics, Couchbase, Inc., and Xometry, Inc. There was no activity related to transfers into Level 3 during the nine months ended September 30, 2021 . (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. For the nine months ended September 30, 2022, approximately $ 23.2 million in net unrealized depreciation and $ 9.5 million in net unrealized appreciation relating to assets still held at the reporting date were recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $ 12.2 million and $ 13.4 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. For the nine months ended September 30, 2021, approximately $ 6.5 million in net unrealized depreciation and $ 15.6 million in net unrealized appreciation were recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets nine months ended September 30, 2021, approximately $ 0.4 million and $ 8.0 million in net unrealized appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2022 and December 31, 2021. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 37,851 Originated Within 4-6 Months Origination Yield 9.28 % - 10.26 % 10.16 % 982,922 Market Comparable Companies Hypothetical Market Yield 10.48 % - 18.10 % 13.17 % Premium/(Discount) ( 0.75 )% - 1.50 % 0.02 % Technology 43,732 Originated Within 4-6 Months Origination Yield 9.90 % - 12.53 % 10.41 % 910,488 Market Comparable Companies Hypothetical Market Yield 11.72 % - 17.52 % 14.22 % Premium/(Discount) ( 0.75 )% - 1.50 % 0.16 % 20,354 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.83 % 4,270 Liquidation (3) Probability weighting of alternative outcomes 15.00 % - 55.00 % 46.57 % Sustainable and Renewable Technology 2,961 Market Comparable Companies Hypothetical Market Yield 13.67 %- 13.67 % 13.67 % Premium/(Discount) 0.75 %- 0.75 % 0.75 % Medical Devices 14,835 Originated Within 4-6 Months Origination Yield 14.84 % - 14.84 % 14.84 % Premium/(Discount) 0.50 % - 0.50 % 0.50 % Lower Middle Market 25,595 Originated Within 4-6 Months Origination Yield 9.67 % - 9.67 % 9.67 % 308,155 Market Comparable Companies Hypothetical Market Yield 12.71 % - 17.82 % 13.94 % Premium/(Discount) ( 2.00 )% - 1.50 % ( 0.38 )% 8,318 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 130,945 Debt Investments originated within 3 months 77,801 Imminent Payoffs (4) 93,172 Debt Investments Maturing in Less than One Year $ 2,661,399 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” industries. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services, Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Fair Value as of Valuation Techniques/Methodologies Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 206,461 Originated Within 4-6 Months Origination Yield 11.23 % - 12.84 % 11.40 % 451,587 Market Comparable Companies Hypothetical Market Yield 9.69 % - 13.89 % 11.34 % Premium/(Discount) ( 0.50 )% - 0.75 % 0.06 % Technology 109,904 Originated Within 4-6 Months Origination Yield 11.12 % - 11.68 % 11.39 % 654,320 Market Comparable Companies Hypothetical Market Yield 8.98 % - 14.54 % 11.64 % Premium/(Discount) ( 0.50 )% - 0.75 % 0.12 % 2,608 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 50.00 % 40.48 % 20,425 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 35.00 % 32.95 % Sustainable and Renewable Technology 247 Convertible Note Analysis Probability weighting of alternative outcomes 40.00 % - 60.00 % 51.84 % 7,500 Expected Realizable Value (4) Probability weighting of alternative outcomes 100 % - 100 % 100.00 % Lower Middle Market 3,100 Originated Within 4-6 Months Origination Yield 5.17 % - 5.17 % 5.17 % 81,566 Market Comparable Companies Hypothetical Market Yield 12.23 % - 16.01 % 13.22 % Premium/(Discount) 0.00 % - 1.50 % 0.43 % 90,504 Expected Realizable Value (4) Probability weighting of alternative outcomes 30.00 % - 70.00 % 57.74 % Hypothetical Market Yield 10.64 % - 10.64 % 10.64 % Premium/(Discount) ( 1.00 )% - ( 1.00 )% ( 1.00 )% 8,269 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 441,524 Debt Investments originated within 3 months 131,584 Debt Investments Maturing in Less than One Year $ 2,209,599 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” industries. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services, Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 29,721 Market Comparable Companies EBITDA Multiple (2) 11.5 x - 11.5 x 11.5 x Revenue Multiple (2) 0.6 x - 15.4 x 6.6 x Tangible Book Value Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 7.19 % - 32.68 % 20.53 % 13,397 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.29 )% - 7.80 % ( 16.68 )% 21,945 Discounted Cash Flow Discount Rate (7) 17.08 % - 28.80 % 23.32 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 84.00 % - 84.00 % 84.00 % 3,577 Other (6) Warrant Investments 10,968 Market Comparable Companies EBITDA Multiple (2) 11.5 x - 11.5 x 11.5 x Revenue Multiple (2) 0.6 x - 9.3 x 3.6 x Discount for Lack of Marketability (3) 0.00 % - 32.7 % 21.35 % 6,671 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.29 )% - 10.57 % ( 18.68 )% — Liquidation Revenue Multiple (2) 7.1 x - 7.1 x 7.1 x Discount for Lack of Marketability (3) 90.00 % - 90.00 % 90.00 % — Other (6) Total Level 3 $ 86,279 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 26,587 Market Comparable Companies EBITDA Multiple (2) 20.6 x - 20.6 x 20.6 x Revenue Multiple (2) 1.0 x - 18.4 x 11.8 x Tangible Book Value Multiple (2) 2.5 x - 2.5 x 2.5 x Discount for Lack of Marketability (3) 18.81 % - 34.69 % 25.53 % 24,910 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 88.67 )% - 47.22 % 0.81 % 11,990 Discounted Cash Flow Discount Rate (7) 15.93 % - 25.30 % 20.46 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 84.00 % - 84.00 % 84.00 % 27,920 Other (6) Warrant Investments 14,517 Market Comparable Companies EBITDA Multiple (2) 20.6 x - 26.0 x 20.7 x Revenue Multiple (2) 0.6 x - 9.5 x 4.5 x Discount for Lack of Marketability (3) 18.81 % - 37.35 % 26.93 % 11,914 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 88.67 )% - 47.22 % ( 7.76 )% 1,046 Other (6) Total Level 3 Warrant and Equity Investments $ 118,884 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument. As of September 30, 2022, the 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $ 23.48 per unit at par value. The par value at underwriting for the 2033 Notes was $ 25.00 per unit. Based on market quotations on or around September 30, 2022, the 2031 Asset-Backed Notes were quoted for 0.970 . The fair values of the SBA debentures, July 2024 Notes, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of September 30, 2022. The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 169,591 $ 153,614 $ — $ — $ 153,614 July 2024 Notes 104,459 99,364 — — 99,364 February 2025 Notes 49,723 45,739 — — 45,739 June 2025 Notes 69,555 63,834 — — 63,834 June 2025 3-Year Notes 49,577 47,626 — — 47,626 March 2026 A Notes 49,676 44,107 — — 44,107 March 2026 B Notes 49,647 44,181 — — 44,181 September 2026 Notes 321,112 261,406 — — 261,406 January 2027 Notes 344,271 286,885 — — 286,885 2031 Asset-Backed Notes 147,810 145,500 — 145,500 — 2033 Notes 38,799 37,568 — 37,568 — MUFG Bank Facility (1) 102,000 102,000 — — 102,000 SMBC Facility 25,000 25,000 — — 25,000 Total $ 1,521,220 $ 1,356,824 $ — $ 183,068 $ 1,173,756 (in thousands) December 31, 2021 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 145,498 $ 151,471 $ — $ — $ 151,471 2022 Notes 149,563 152,906 — 152,906 — July 2024 Notes 104,238 110,496 — — 110,496 February 2025 Notes 49,637 51,983 — — 51,983 June 2025 Notes 69,433 72,031 — — 72,031 March 2026 A Notes 49,605 52,646 — — 52,646 March 2026 B Notes 49,570 52,751 — — 52,751 September 2026 Notes 320,376 315,495 — — 315,495 2033 Notes 38,718 42,672 — 42,672 — 2022 Convertible Notes 229,740 236,049 — 236,049 — Union Bank Facility (1) — — — — — SMBC Facility 29,925 29,925 — — 29,925 Total $ 1,236,303 $ 1,268,425 $ — $ 431,627 $ 836,798 (1) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Schedule Of Investments [Abstract]
Investments	4. Investments Control and Affiliate Investments As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds. The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2022 and 2021. (in thousands) Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Portfolio Company (1) Type Fair Value as of September 30, 2022 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 400 $ — $ — $ ( 22 ) $ — $ — $ — $ ( 165 ) $ — Gibraltar Business Capital, LLC Control 37,662 853 18 ( 1,423 ) — 2,531 51 ( 6,228 ) — Hercules Adviser LLC Control 33,945 154 — ( 1,236 ) — 393 — 9,955 — Tectura Corporation Control 8,318 174 — 110 — 516 — 49 — Total Control Investments $ 80,325 $ 1,181 $ 18 $ ( 2,571 ) $ — $ 3,440 $ 51 $ 3,611 $ — Affiliate Investments Black Crow AI, Inc. (2) Affiliate $ — $ — $ — $ — $ — $ — $ — $ ( 120 ) $ 3,772 Pineapple Energy LLC (2) Affiliate — 81 — 4,631 ( 2,014 ) 1,204 — 4,209 ( 2,014 ) Total Affiliate Investments $ — $ 81 $ — $ 4,631 $ ( 2,014 ) $ 1,204 $ — $ 4,089 $ 1,758 Total Control & Affiliate Investments $ 80,325 $ 1,262 $ 18 $ 2,060 $ ( 2,014 ) $ 4,644 $ 51 $ 7,700 $ 1,758 (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Portfolio Company (1) Type Fair Value as of September 30, 2021 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Gibraltar Business Capital, LLC Control $ 40,737 $ 853 $ 15 $ ( 3,475 ) $ — $ 2,325 $ 38 $ ( 17,690 ) $ — Hercules Adviser LLC Control 16,804 45 — ( 219 ) — 59 — 10,669 — Tectura Corporation Control 8,294 174 5 ( 80 ) — 516 5 ( 306 ) — Total Control Investments $ 65,835 $ 1,072 $ 20 $ ( 3,774 ) $ — $ 2,900 $ 43 $ ( 7,327 ) $ — Affiliate Investments Black Crow AI, Inc. Affiliate $ 1,243 $ — $ — $ ( 66 ) $ — $ — $ — $ 2,028 $ — Pineapple Energy LLC Affiliate 8,469 1 — ( 52 ) — 3 — 9 — Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) Affiliate — — — — — — — 62,183 ( 62,143 ) Total Affiliate Investments $ 9,712 $ 1 $ — $ ( 118 ) $ — $ 3 $ — $ 64,220 $ ( 62,143 ) Total Control & Affiliate Investments $ 75,547 $ 1,073 $ 20 $ ( 3,892 ) $ — $ 2,903 $ 43 $ 56,893 $ ( 62,143 ) (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021 , there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2) As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act. Portfolio Composition The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 (in thousands) Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 2,607,006 92.3 % $ 2,156,709 88.6 % Unsecured Debt 54,393 1.9 % 52,890 2.2 % Preferred Stock 41,038 1.4 % 69,439 2.8 % Common Stock 93,096 3.3 % 115,271 4.7 % Warrants 27,159 1.0 % 38,399 1.6 % Investment Funds & Vehicles 3,046 0.1 % 1,814 0.1 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 % A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2022 and December 31, 2021 is shown as follows: September 30, 2022 December 31, 2021 (in thousands) Investments at Percentage of Investments at Percentage of United States $ 2,545,973 90.1 % $ 2,138,184 87.8 % United Kingdom 158,491 5.6 % 169,407 7.0 % Netherlands 88,174 3.1 % 82,925 3.4 % Canada 19,373 0.7 % 27,673 1.1 % Israel 9,005 0.3 % 8,980 0.4 % Ireland 3,313 0.1 % 5,459 0.2 % Germany 924 0.1 % 1,894 0.1 % Other 485 0.0 % — 0.0 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 % The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 December 31, 2021 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,091,827 38.6 % $ 967,383 39.7 % Software 680,216 24.1 % 585,622 24.1 % Internet Consumer & Business Services 489,968 17.3 % 395,506 16.3 % Healthcare Services, Other 203,599 7.2 % 121,003 5.0 % Communications & Networking 101,094 3.6 % 105,490 4.3 % Diversified Financial Services 72,061 2.5 % 65,073 2.7 % Information Services 59,735 2.1 % 74,417 3.1 % Manufacturing Technology 43,892 1.6 % 14,995 0.6 % Consumer & Business Products 25,497 0.9 % 28,099 1.2 % Semiconductors 20,621 0.7 % 22,498 0.9 % Medical Devices & Equipment 17,421 0.6 % 12,612 0.5 % Sustainable and Renewable Technology 15,683 0.6 % 39,387 1.6 % Electronics & Computer Hardware 2,498 0.1 % 1,040 0.0 % Surgical Devices 1,536 0.1 % 1,029 0.0 % Drug Delivery 90 0.0 % 368 0.0 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 % No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of September 30, 2022 or December 31, 2021. Concentrations of Credit Risk The Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development", "Software”, “Internet Consumer & Business Services”, “Healthcare Services, Other”, and “Communications & Networking" sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies. As of September 30, 2022 and December 31, 2021, the Company’s ten largest portfolio companies represented approximately 30.1 % and 30.5 % of the total fair value of the Company’s investments in portfolio companies, respectively. As of September 30, 2022 and December 31, 2021, the Company had eight and six portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of September 30, 2022, the Company had three equity investments representing approximately 36.6 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2021, the Company had six equity investments which represented approximately 49.6 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of such investments. Investment Collateral In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. As of September 30, 2022, approximately 77.4 % of the Company’s debt investments at fair value were in a senior secured first lien position, with 40.2 % secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 27.9 % secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property, and 9.3 % of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with a security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 20.6 % of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, and 2.0 % were unsecured. As of December 31, 2021, approximately 77.0 % of the Company’s debt investments at fair value were in a senior secured first lien position, with 37.5 % secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 31.6 % secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property and 7.9 % of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 20.6 % of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, and 2.4 % were unsecured.

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	5. Debt As of September 30, 2022 and December 31, 2021, the Company had the following available and outstanding debt: (in thousands) September 30, 2022 December 31, 2021 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures $ 175,000 $ 175,000 $ 169,591 $ 175,000 $ 150,500 $ 145,498 2022 Notes — — — 150,000 150,000 149,563 July 2024 Notes 105,000 105,000 104,459 105,000 105,000 104,238 February 2025 Notes 50,000 50,000 49,723 50,000 50,000 49,637 June 2025 Notes 70,000 70,000 69,555 70,000 70,000 69,433 June 2025 3-Year Notes 50,000 50,000 49,577 — — — March 2026 A Notes 50,000 50,000 49,676 50,000 50,000 49,605 March 2026 B Notes 50,000 50,000 49,647 50,000 50,000 49,570 September 2026 Notes 325,000 325,000 321,112 325,000 325,000 320,376 January 2027 Notes 350,000 350,000 344,271 — — — 2031 Asset-Backed Notes 150,000 150,000 147,810 — — — 2033 Notes 40,000 40,000 38,799 40,000 40,000 38,718 2022 Convertible Notes — — — 230,000 230,000 229,740 MUFG Bank Facility (2)(3) 545,000 102,000 102,000 400,000 — — SMBC Facility (2) 225,000 25,000 25,000 100,000 29,925 29,925 Total $ 2,185,000 $ 1,542,000 $ 1,521,220 $ 1,745,000 $ 1,250,425 $ 1,236,303 (1) Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 December 31, 2021 SBA Debentures $ 5,409 $ 5,002 2022 Notes — 300 July 2024 Notes 541 762 February 2025 Notes 277 363 June 2025 Notes 445 567 June 2025 3-Year Notes 423 — March 2026 A Notes 324 395 March 2026 B Notes 353 430 September 2026 Notes 3,888 4,624 January 2027 Notes 5,729 — 2031 Asset-Backed Notes 2,190 — 2033 Notes 1,201 1,282 2022 Convertible Notes — 149 MUFG Bank Facility (1) 1,346 1,239 SMBC Facility (1) 1,574 922 Total $ 23,700 $ 16,035 (1) The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30. For the three and nine months ended September 30, 2022, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,160 $ 148 $ — $ 1,308 $ 2,086 $ 2,848 $ 434 $ — $ 3,282 $ 2,835 2022 Notes — — — — — 1,011 50 — 1,061 2,293 July 2024 Notes 1,252 74 — 1,326 2,504 3,756 222 — 3,978 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 June 2025 3-Year Notes 750 38 — 788 — 817 42 — 859 — March 2026 A Notes 563 24 — 587 1,125 1,688 72 — 1,760 2,250 March 2026 B Notes 569 26 — 595 1,137 1,706 78 — 1,784 2,275 September 2026 Notes 2,174 204 — 2,378 4,266 6,523 612 — 7,135 8,532 January 2027 Notes 3,079 207 — 3,286 5,906 8,552 575 — 9,127 5,906 2031 Asset-Backed Notes 1,903 100 — 2,003 1,815 2,072 109 — 2,181 1,815 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 2022 Convertible Notes — — — — — 923 149 — 1,072 5,004 MUFG Bank Facility (2) 1,000 253 720 1,973 1,025 2,483 665 1,682 4,830 2,240 SMBC Facility 135 98 195 428 181 722 211 328 1,261 700 Total $ 14,499 $ 1,268 $ 915 $ 16,682 $ 21,740 $ 38,844 $ 3,507 $ 2,010 $ 44,361 $ 44,382 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the nine months ended September 30, 2022 , $ 23 thousand, $ 112 thousand, $ 125 thousand, $ 349 thousand, and $ 51 thousand related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. For the three and nine months ended September 30, 2021, the components of interest expense and related fees and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Description Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 114 $ 50 $ — $ 164 $ 183 $ 1,228 $ 367 $ — $ 1,595 $ 2,272 2022 Notes 1,776 90 — 1,866 — 5,327 270 — 5,597 3,469 July 2024 Notes 1,252 74 — 1,326 2,504 3,756 221 — 3,977 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 April 2025 Notes (3) — 1,477 — 1,477 667 1,969 1,667 — 3,636 2,635 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 March 2026 A Notes 563 24 — 587 1,125 1,688 70 — 1,758 1,875 March 2026 B Notes 569 26 — 595 1,138 1,308 59 — 1,367 1,138 September 2026 Notes 338 32 — 370 — 338 32 — 370 — 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 2027 Asset-Backed Notes (3) 1,344 72 — 1,416 1,348 4,593 922 — 5,515 4,677 2028 Asset-Backed Notes (3) 2,226 251 — 2,477 2,256 7,684 867 — 8,551 7,785 2022 Convertible Notes 2,683 223 — 2,906 5,031 8,050 669 — 8,719 10,062 Wells Facility (3) — 43 146 189 — — 132 460 592 — MUFG Bank Facility (4) 290 314 458 1,062 327 625 968 1,404 2,997 540 Total $ 13,069 $ 2,772 $ 604 $ 16,445 $ 16,274 $ 42,309 $ 6,532 $ 1,864 $ 50,705 $ 44,985 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2021 of $ 41 thousand, $ 168 thousand, and $ 6 thousand, for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes for the nine months ended September 30, 2021 , $ 123 thousand, $ 504 thou sand, and $ 6 thousand for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. (2) “Amortization of debt issuance cost (loan fees)” includes $ 1,477 thousand, $ 28 thousand, and $ 197 thousand related to debt extinguishment costs for the April (3) The April 2025 Notes, 2027 Asset-Backed Notes and 2028 Asset-Backed Notes were retired on July 1, 2021 and October 20, 2021 , respectively. The Wells November 29, 2021 . (4) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. As of September 30, 2022 and December 31, 2021, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company’s debt. SBA Debentures The Company reported the following SBA debentures outstanding principal balances as of September 30, 2022 and December 31, 2021: (in thousands) Maturity Date Interest Rate (1) September 30, 2022 December 31, 2021 March 26, 2021 September 1, 2031 1.58 % $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58 % 16,200 16,200 July 28, 2021 September 1, 2031 1.58 % 5,400 5,400 August 20, 2021 September 1, 2031 1.58 % 5,400 5,400 October 21, 2021 March 1, 2032 3.21 % 14,000 14,000 November 1, 2021 March 1, 2032 3.21 % 21,000 21,000 November 15, 2021 March 1, 2032 3.21 % 5,200 5,200 November 30, 2021 March 1, 2032 3.21 % 20,800 20,800 December 20, 2021 March 1, 2032 3.21 % 10,000 10,000 December 23, 2021 March 1, 2032 3.21 % 10,000 10,000 December 28, 2021 March 1, 2032 3.21 % 5,000 5,000 January 14, 2022 March 1, 2032 3.21 % 4,500 — January 21, 2022 March 1, 2032 3.21 % 20,000 — Total SBA Debentures $ 175,000 $ 150,500 (1) Interest rates are fixed rates set based on the pooling date of each debenture. The rates shown above are inclusive of annual SBA charges. SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs compliance with SBA regulations. Our SBIC was in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of September 30, 2022 and December 31, 2021. HC IV received its license to operate as a SBIC on October 27, 2020. The license has a 10-year term. Through the license, HC IV has access to $ 175.0 million of capital through the SBA debenture program, that is in addition to the Company’s regulatory capital commitment of $ 87.5 million to HC IV. As of September 30, 2022, HC IV has issued a total of $ 175.0 million in SBA guaranteed debentures and has paid the SBA commitment fees and facility fe es of approximately $ 1.75 million and $ 4.2 million, respectively. As of September 30, 2022, the Company held investments in HC IV in 18 companies with a fair value of approximately $ 277.1 million, accounting for approximately 9.8 % of the Company’s total investment portfolio. Further, HC IV held approximately $ 287.6 million in tangible assets which accounted for approximately 9.8 % of the Company’s total assets as of September 30, 2022. 2022 Notes On October 23, 2017, the Company issued $ 150.0 million in aggregate principal amount of 4.625 % interest-bearing unsecured notes that mature on October 23, 2022 (the “2022 Notes”), unless repurchased in accordance with their terms . Interest on the 2022 Notes is due semiannually in arrears on April 23 and October 23 of each year, commencing on April 23, 2018. On February 22, 2022, pursuant to the redemption terms of the 2025 Notes indenture, the Company fully repaid the aggregate outstanding $ 150.0 million of principal and $ 2.3 million of accrued interest. In addition, the Company paid $ 3.3 million of prepayment premium fees, which together with the accelerated recognition of $ 0.3 million of debt issuance costs was recognized as a realized loss on extinguishment of the debt. 2022 Convertible Notes On January 25, 2017, the Company issued $ 230.0 million in aggregate principal amount of 4.375 % interest-bearing unsecured notes due on February 1, 2022 (the “2022 Convertible Notes”), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2022 Convertible Notes . The $ 230.0 million issued aggregate principal of the 2022 Convertible Notes includes an additional $ 30.0 million aggregate principal amount issued pursuant to the initial purchaser’s exercise in full of its overallotment option. Interest on the 2022 Convertible Notes is due semiannually in arrears on February 1 and August 1 of each year . On February 1, 2022, the Company fully repaid the aggregate outstanding $ 230.0 million principal, $ 5.0 million of accrued interest and fees, and issued 981,169 shares related to noteholders who elected to convert pursuant to the redemption terms of the 2022 Convertible Notes indenture. July 2024 Notes On July 16, 2019, the Company issued $ 105.0 million in aggregate principal amount of 4.77 % interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering . Interest on the July 2024 Notes is due semiannually . The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. February 2025 Notes On February 5, 2020, the Company issued $ 50.0 million in aggregate principal amount of 4.28 % interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is due semiannually . The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 Notes On June 3, 2020, the Company issued $ 70.0 million in aggregate principal amount of 4.31 % interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 3-Year Notes On June 23, 2022, the Company issued $ 50.0 million in aggregate principal amount of 6.00 % interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes is due semiannually. The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 A Notes On November 4, 2020, the Company issued $ 50.0 million in aggregate principal amount of 4.5 % interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering . Interest on the March 2026 A Notes is due semiannually . The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 B Notes On March 4, 2021, the Company issued $ 50.0 million in aggregate principal amount of 4.55 % interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. The sale of the March 2026 B Notes generated net proceeds of approximately $ 49.5 million. Aggregate offering expenses in connection with the transaction, including fees and commissions, were approximately $ 0.5 million. Interest on the March 2026 B Notes is due semiannually . The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. September 2026 Notes On September 16, 2021, the Company issued $ 325.0 million in aggregate principal amount of 2.625 % interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. The issuance of the September 2026 Notes generated net proceeds of approximately $ 320.1 million. The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $ 4.1 million of costs and $ 0.8 million related to the discount. Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year, commencing on March 16, 2022 . The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture. January 2027 Notes On January 20, 2022, the Company issued $ 350.0 million in aggregate principal amount of 3.375 % interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Note s”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. The issuance of the January 2027 Notes generated net proceeds of approximately $ 343.4 million. The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $ 4.1 million of costs and $ 2.5 million related to the discount. Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year, commencing on July 20, 2022 . The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture. 2031 Asset-Backed Notes On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $ 150.0 million in aggregate principal amount of 4.95 % interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available. Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of September 30, 2022, there was approximately $ 8.3 million and none as of December 31, 2021 of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. 2033 Notes On September 24, 2018, the Company issued $ 40.0 million in aggregate principal amount of 6.25 % interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year . The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes Indenture after October 30, 2023. Credit Facilities As of September 30, 2022 and December 31, 2021, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the nine months ended September 30, 2022 and year ended December 31, 2021, the weighted average interest rate was 3.70 % and 2.54 % , respectively, and the average debt outstanding under the Credit Facilities was $ 115.6 million and $ 28.8 million, respectively. MUFG Bank Facility On June 10, 2022, the Company entered into a second amended credit facility agreement, which amends the agreement dated as of February 20, 2020. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. (formerly MUFG Union Bank and known as the “Union Bank Facility”) as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time. Under the MUFG Bank Facility, the lenders have made commitments of $ 545.0 million, which is an increase from $ 400.0 million as of December 31, 2021. The MUFG Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $ 600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. Debt under the MUFG Bank Facility generally bears interest at a rate per annum equal to SOFR plus 2.60 % for SOFR loans with a one-month interest period and 2.65 % for SOFR loans with a three-month interest period. The MUFG Bank Facility matures on February 22, 2024 , unless sooner terminated in accordance with its terms. The MUFG Bank Facility is secured by all of the assets of Hercules Funding IV. The MUFG Bank Facility requires payment of a non-use fee during the revolving credit availability period. The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of $ 723.0 million. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy. SMBC Facility On June 14, 2022, the Company entered into a second amendment to a revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of September 30, 2022 , the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $ 225.0 million, from which the Company may access subject to certain conditions. As of December 31, 2021, the Company had access to $ 100.0 million, subject to certain conditions. Additionally, the SMBC Facility provides for the issuance of letters of credit on the account of the Company or its designee in U.S. dollars and certain agreed upon foreign currencies in an aggregate face amount not to exceed $ 15.0 million. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder. Availability under the SMBC Facility will terminate on November 7, 2025 , and the outstanding loans under the SMBC Facility will mature on November 9, 2026 . Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. Interest under the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CDOR, or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 0.875 % to 2.0 % per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375 % per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility. The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders. As previously noted, federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Also, income is required to be recognized for tax purposes no later than when recognized for financial reporting purposes, with certain exceptions. As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years (the “Excise Tax Avoidance Requirement”). The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains). Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. The Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal corporate tax rates based on its taxable income. Taxable income for the three months ended September 30, 2022, was approximately $ 49.1 million or $ 0.39 per share. Taxable net realized losses for the same period were $( 2.0 ) million or approximately $( 0.02 ) per share. Taxable income for the three months ended September 30, 2021, was approximately $ 43.3 million or $ 0.38 per share. Taxable net realized gains for the same period were $ 23.0 million or approximately $ 0.20 per share. Taxable income for the nine months ended September 30, 2022, was approximately $ 122.2 million or $ 0.99 per share. Taxable net realized losses for the same period were $( 0.1 ) million or approximately $( 0.00 ) per share. Taxable income for the nine months ended September 30, 2021, was approximately $ 125.3 million or $ 1.09 per share. Taxable net realized gains for the same period were $ 80.5 million or approximately $ 0.70 per share. For the three and nine months ended September 30, 2022, the Company paid approximately $ 0.1 million and $ 7.3 million of income tax, respectively, including excise tax, and had $ 4.0 million of accrued but unpaid tax expense as of September 30, 2022. For the three and nine months ended September 30, 2021, the Company paid approximately $ 0.1 million and $ 3.7 million of income tax, including excise tax, and had $ 4.9 million of accrued but unpaid tax expense as of September 30, 2021. The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax. During the three and nine months ended September 30, 2022, the Company declared and paid distributions of $ 0.50 and $ 1.46 per share, respectively. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s taxable year generally based upon its taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. If the Company had determined the tax attributes of its distributions taxable year-to-date as of September 30, 2022, 100 % would be from its current and accumulated earnings and profits. How ever, there can be no certainty to stockholders that this determination is representative of what the actual tax attributes of the Company’s fiscal year of 2022 distributions to stockholders will be.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity On May 9, 2022, the Company entered into an At-The-Market (“ATM”) equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jeffries”) (the “2022 Equity Distribution Agreement”). The 2022 Equity Distribution Agreement provides that the Company may offer and sell up to 17.5 million shares of its common stock from time to time through JMP or Jeffries, as its sales agents. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The 2022 Equity Distribution Agreement replaces the ATM equity distribution agreement between the Company and JMP executed on July 2, 2020 (the “2020 Equity Distribution Agreement”). Under the 2020 Equity Distribution Agreement, the Company sold no shares and approximately 5.6 million shares, respectively, of common stock during the three and nine months ended September 30, 2022. From the sale of shares under the 2020 Equity Distribution Agreement during the nine months ended September 30, 2022, the Company received total accumulated net proceeds of approximately $ 98.5 million, including $ 1.1 million of offering expenses. Under the 2022 Equity Distribution agreement, the Company sold common stock shares of approximately 2.9 million and 6.2 million for the three and nine months ended September 30, 2022. From the sale of shares, the Company received total accumulated net proceeds of approximately $ 42.9 million and $ 91.5 million including $ 0.4 million and $ 1.0 million of offering expenses for the three and nine months ended September 30, 2022. During the three and nine months ended September 30, 2021, there were no shares sold under the existing equity distribution agreement. The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of September 30, 2022, approximately 11.3 million shares remain available for issuance and sale under the 2022 Equity Distribution Agreement. The 2020 Equity Distribution Agreement is no longer effective. The Company has issued stock options for common stock subject to future issuance, of which 207,794 and 210,569 were outstanding as of September 30, 2022 and December 31, 2021 , respectively.

Equity Incentive Plan

Equity Incentive Plan	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	8. Equity Incentive Plans The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018, and authorize us to issue up to 18.7 million shares of common stock and 300,000 shares of restricted stock under the 2018 Plan and Director Plan, respectively. Unless earlier terminated by the Board, the 2018 Plan and Director Plan will terminate on May 12, 2028. Outstanding awards issued under plans that precede the 2018 Plan and Director Plan remain outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with their terms. The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock. The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-based awards in the period they are forfeited. For the three months ended September 30, 2022, and 2021, the Company recognized $ 2.5 million and $ 3.3 million of stock based compensation expense in the Consolidated Statement of Operations, respectively. For the nine months ended September 30, 2022, and 2021, the Company recognized $ 10.6 million and $ 9.0 million of stock based compensation expense in the Consolidated Statement of Operations, respectively. As of September 30, 2022, and 2021, approximately $ 16.0 million and $ 18.3 million of total unrecognized compensation costs expected to be recognized over the next 1.8 and 1.9 years, respectively. Service-Vesting Awards The Company grants equity-based awards which have service conditions, and generally begin to vest one-third after one year after the date of grant and ratably over the succeeding 2 years in accordance with the individual award terms (the “Service Vesting Awards”). The grant date fair value of Service Vesting Awards granted during the nine months ended September 30, 2022, and 2021, were approximately $ 11.1 million, and $ 11.2 million, respectively. The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the nine months ended September 30, 2022, and 2021, are summarized below: Nine Months Ended September 30, 2022 2021 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 1,037,848 $ 14.51 989,100 $ 13.69 Granted 632,831 $ 17.24 748,519 $ 14.80 Vested (1) ( 578,579 ) $ 14.39 ( 517,076 ) $ 13.71 Forfeited ( 25,407 ) $ 15.99 ( 71,020 ) $ 14.16 Unvested Shares End of Period 1,066,693 $ 16.16 1,149,523 $ 14.42 (1) With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period. In addition to the restricted stock equity based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the nine months ended September 30, 2022 and 2021, was approximately $ 143,000 and $ 123,000 , respectively. During the nine months ended September 30, 2022 and 2021, approximately $ 52,000 , and $ 23,000 , of share-based cost due to stock option grants was expensed, respectively. Performance-Vesting Awards The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date using a Monte-Carlo simulation multiplied by the target payout level and is recognized over the service period. During the nine months ended September 30, 2022 , all 487,409 Performance Award shares vested. Additionally, 241,770 distribution equivalent units (“DEUs”) were issued with a grant date fair value of $ 4.0 million. During the nine months ended September 30, 2021, there were no Performance Awards or DEUs granted or vested. As of September 30, 2022 and 2021 , there were no shares and 487,409 shares of unvested Performance Awards. Liability Classified Awards The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). The remaining maximum total potential value of the Liability Awards granted is $ 4.3 millio n, which assumes all performance conditions are met for each Liability award. If the performance conditions are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The awards are recorded as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statement of Assets and Liabilities. Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. As of September 30, 2022 , the Company determined that the weighted average expected probability of the performance conditions being met within each Liability Award was 100 %. The expected probability is re-evaluated each period, and may be adjusted to reflect changes in this assumption. These other Liability Awards vest over a three year service term. As of September 30, 2022, all Liability Awards are unvested and there was approximately $ 2.3 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 1.6 years. For the nine months ended September 30, 2022, there was approximately $ 2.3 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $ 2.0 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. During the nine months ended September 30, 2022 and 2021, $ 6.0 million and $ 0 of the Liability Awards vested. As of September 30, 2021, all Liability Awards are unvested and there was approximately $ 4.2 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 2.2 years. For the nine months ended September 30, 2021, there was approximately $ 1.3 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $ 5.3 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. No Liability Awards vested during the periods presented.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	9. Earnings Per Share Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2022 2021 2022 2021 Numerator Net increase in net assets resulting from operations $ 53,202 $ 23,549 $ 39,548 $ 170,443 Less: Distributions declared-common and restricted shares ( 63,950 ) ( 45,190 ) ( 181,825 ) ( 133,143 ) (Over-)Undistributed earnings (loss) ( 10,748 ) ( 21,641 ) ( 142,277 ) 37,300 Undistributed earnings-common shares ( 10,748 ) ( 21,641 ) ( 142,277 ) 36,931 Add: Distributions declared-common shares 63,421 44,770 180,114 131,829 Numerator for basic and diluted change in net assets per common share $ 52,673 $ 23,129 $ 37,837 $ 168,760 Denominator Basic weighted average common shares outstanding 127,484 114,805 123,379 114,590 Incremental shares from assumed conversion of 2022 Convertible Notes — 661 — 293 Common shares issuable 1,850 773 1,388 667 Weighted average common shares outstanding assuming dilution 129,334 116,239 124,767 115,550 Change in net assets per common share Basic $ 0.41 $ 0.20 $ 0.31 $ 1.47 Diluted $ 0.41 $ 0.20 $ 0.30 $ 1.46 In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share. As disclosed in “Note 5 – Debt”, on February 1, 2022, the Company fully repaid the 2022 Convertible Notes. As these notes were fully repaid, there is no dilutive impact for the current period ended September 30, 2022. In July 2021, the Company irrevocably elected combination settlement for the 2022 Convertible Notes. Therefore the dilutive impact of the 2022 Convertible Notes, was calculated for only the portion expected to be settled in stock as it relates to the diluted shares outstanding for the three and nine months ended September 30, 2021. The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2022, and 2021, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three months ended September 30, Nine Months Ended September 30, Anti-dilutive Securities 2022 2021 2022 2021 2022 Convertible Notes — — — — Unvested common stock options 865 198 1,725 88 Restricted stock units* — — — — Unvested restricted stock awards 3,982 710 1,611 720 Performance awards* — — — — * Included in these amounts are shares related to certain equity-based awards, which are fully-vested but have not been delivered and thus not outstanding for purposes of calculating earnings per share. As of both September 30, 2022 and December 31, 2021 , the Company was authorized to issue 200.0 million shares of common stock with a par value of $ 0.001 . Each share of common stock entitles the holder to one vote.

Financial Highlights

Financial Highlights	9 Months Ended
	Sep. 30, 2022
Investment Company Financial Highlights [Abstract]
Financial Highlights	10. Financial Highlights Following is a schedule of financial highlights for the nine months ended September 30, 2022 and 2021: (in thousands, except per share data and ratios) Nine Months Ended September 30, 2022 2021 Per share data (1) : Net asset value at beginning of period $ 11.22 $ 11.26 Net investment income 1.01 0.95 Net realized gain (loss) 0.01 0.12 Net unrealized appreciation (depreciation) ( 0.71 ) 0.40 Total from investment operations 0.31 1.47 Net increase (decrease) in net assets from capital share transactions (1) 0.31 ( 0.11 ) Distributions of net investment income (6) ( 1.11 ) ( 1.06 ) Distributions of capital gains (6) ( 0.35 ) ( 0.09 ) Stock-based compensation expense included in investment income (2) 0.09 0.07 Net asset value at end of period $ 10.47 $ 11.54 Ratios and supplemental data: Per share market value at end of period $ 11.58 $ 16.61 Total return (3) ( 24.34 )% 23.05 % Shares outstanding at end of period 130,191 115,925 Weighted average number of common shares outstanding 123,379 114,590 Net assets at end of period $ 1,362,718 $ 1,337,532 Ratio of total expense to average net assets (4) 9.51 % 9.93 % Ratio of net investment income before investment gains and losses to average net assets (4) 12.53 % 11.01 % Portfolio turnover rate (5) 14.12 % 33.14 % Weighted average debt outstanding $ 1,430,814 $ 1,246,769 Weighted average debt per common share $ 11.60 $ 10.88 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC Topic 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital. (3) The total return for the nine months ended September 30, 2022, and 2021 , equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the nine months ended September 30, 2022, and 2021 , equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of September 30, 2022, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect its financial condition or business outlook. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones. As of September 30, 2022, and December 31, 2021, the Company had approximately $ 659.0 million and $ 286.8 million, respectively, of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. These amounts also exclude unfunded commitments related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions". The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements. As of September 30, 2022, and December 31, 2021, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2022 December 31, 2021 Debt Investments: Phathom Pharmaceuticals, Inc. $ 66,500 $ 43,250 Oak Street Health, Inc. 44,250 — Axsome Therapeutics, Inc. 42,000 — Thumbtack, Inc. 40,000 — Vida Health 40,000 — Skydio, Inc. 37,500 37,500 HilleVax, Inc. 36,000 — Automation Anywhere, Inc. 29,400 — Iveric Bio Gene Therapy LLC 24,750 — Brain Corporation 20,020 20,000 Aryaka Networks, Inc. 20,000 — Finch Therapeutics Group, Inc. 20,000 — G1 Therapeutics, Inc. 19,375 19,375 Tarsus Pharmaceuticals, Inc. 18,563 — Locus Robotics Corporation 18,281 — Alladapt Immunotherapeutics Inc. 15,000 — ATAI Life Sciences N.V. 14,000 — Dronedeploy, Inc. 12,500 — Carbon Health Technologies, Inc. 11,625 11,625 Nuvolo Technologies Corporation 10,200 — AppDirect, Inc. 10,000 — Blue Sprig Pediatrics, Inc. 10,000 30,000 Dashlane, Inc. 10,000 19,300 RVShare, LLC 8,500 13,500 Viridian Therapeutics, Inc. 8,000 — Elation Health, Inc. 7,500 — Gritstone Bio, Inc. 7,500 — Ouster, Inc. 7,000 — Akero Therapeutics, Inc. 5,000 — Alamar Biosciences, Inc. 5,000 — Fulfil Solutions, Inc. 5,000 — Demandbase, Inc. 3,750 9,375 Signal Media Limited 3,750 — Riviera Partners LLC 3,500 — Yipit, LLC 2,250 2,250 Khoros (p.k.a Lithium Technologies) 1,812 1,812 Ceros, Inc. 1,707 3,845 ThreatConnect, Inc. 1,600 1,600 Dispatch Technologies, Inc. 1,250 — LogicSource 1,209 — Zimperium, Inc. 1,088 — Ikon Science Limited 1,050 1,050 Omeda Holdings, LLC 938 — Alchemer LLC 890 — Agilence, Inc. 800 800 Mobile Solutions Services 742 424 3GTMS, LLC 725 1,583 Constructor.io Corporation 625 — Cybermaxx Intermediate Holdings, Inc. 471 471 Enmark Systems, Inc. 457 457 Annex Cloud 386 — Gryphon Networks Corp. 268 268 Cytracom Holdings LLC 225 225 Syndax Pharmaceutics Inc. — 30,000 Equality Health, LLC — 17,500 Bicycle Therapeutics PLC — 10,000 Better Therapeutics, Inc. — 4,000 Logicworks — 2,000 ShadowDragon, LLC — 333 ePayPolicy Holdings, LLC — 250 Pineapple Energy LLC — 120 Total Unfunded Debt Commitments: 652,957 282,913 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 3,187 3,839 Forbion Growth Opportunities Fund II C.V. 2,826 — Total Unfunded Commitments in Investment Funds & Vehicles: 6,013 3,839 Total Unfunded Commitments $ 658,970 $ 286,752 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions". (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds. The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) September 30, 2022 December 31, 2021 Unfunded Debt Commitments: Expiring during: 2022 $ 198,281 $ 199,681 2023 312,457 43,675 2024 121,586 25,800 2025 1,694 2,232 2026 9,053 11,525 2027 7,745 — 2028 2,141 — Total Unfunded Debt Commitments 652,957 282,913 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 3,187 3,839 2032 2,826 — Total Unfunded Commitments in Investment Funds & Vehicles 6,013 3,839 Total Unfunded Commitments $ 658,970 $ 286,752 The following tables provide the Company’s contractual obligations as of September 30, 2022 and December 31, 2021: As of September 30, 2022: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,542,000 $ — $ 377,000 $ 800,000 $ 365,000 Lease and License Obligations (4) 6,821 3,060 1,908 1,853 — Total $ 1,548,821 $ 3,060 $ 378,908 $ 801,853 $ 365,000 As of December 31, 2021: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,250,425 $ 380,000 $ 105,000 $ 574,925 $ 190,500 Lease and License Obligations (4) 8,283 3,120 2,958 1,427 778 Total $ 1,258,708 $ 383,120 $ 107,958 $ 576,352 $ 191,278 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of September 30, 2022. There was also $ 25.0 million outstanding under the SMBC Facility and $ 102.0 million outstanding under the MUFG Bank Facility as of September 30, 2022 . (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $ 150.5 million in principal outstanding under the SBA Debentures, $ 150.0 million of the 2022 Notes, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes, and $ 230.0 million of the 2022 Convertible Notes as of December 31, 2021. There was also $ 29.9 million outstanding under the SMBC Facility and no amounts outstanding under the Union Facility as of December 31, 2021 . Certain premises are leased or licensed under agreements which expire at various dates through December 2028. For the three and nine months ended September 30, 2022, total rent expense, including short-term leases, amounted to approximately $ 0.8 million and $ 2.4 million, respectively. For the three and nine months ended September 30, 2021, total rent expense, including short-term leases, amounted to approximately $ 0.8 million and $ 2.4 million, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset. The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2022, and 2021: (in thousands) Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 Total operating lease cost $ 744 $ 724 $ 2,185 $ 2,196 Cash paid for amounts included in the measurement of lease liabilities $ 642 $ 578 $ 2,411 $ 1,733 As of September 30, 2022 As of September 30, 2021 Weighted-average remaining lease term (in years) 4.17 4.37 Weighted-average discount rate 4.53 % 4.87 % The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2022: (in thousands) As of September 30, 2022 2022 $ 652 2023 2,500 2024 848 2025 887 Thereafter 1,804 Total lease payments 6,691 Less: imputed interest ( 599 ) Total operating lease liability $ 6,092 The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions As disclosed in “Note 2 – Summary of Significant Accounting Policies”, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. Refer to “Note 4 – Investments” for information related to income, gains and losses recognized related to the Company’s investment. In 2021, the Adviser Subsidiary entered into investment management agreements with its privately-offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds and may receive incentive fees based on the performance of the Adviser Funds. Additionally, the Company entered into a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary will utilize human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology) of the Company. Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three and nine months ended September 30, 2022, are net of expenses allocated to the Adviser Subsidiary of $ 1.9 million and $ 6.3 million, respectively. As of September 30, 2022, the Adviser Subsidiary owed $ 0.5 million to the Company. The Company’s total expenses for the three and nine months ended September 30, 2021, are net of expenses allocated to the Adviser Subsidiary of $ 1.3 million and $ 3.5 million, respectively. As of December 31, 2021, there was $ 0.1 million receivable from the Adviser Subsidiary. In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. During the nine months ended September 30, 2022, $ 610.9 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds. During the nine months ended September 30, 2022, fundings of $ 247.8 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $ 114.9 million from the Adviser Funds relating to the assigned investments during the nine months ended September 30, 2022. Additionally, on May 31, 2022, the Company sold $ 73.5 million of assets to the Adviser Funds and realized a $ 0.1 million gain. During the nine months ended September 30, 2021, $ 204.5 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds, respectively. During the nine months ended September 30, 2021, fundings of $ 139.6 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $ 107.6 million from the Adviser Funds relating to the assigned investments during the nine months ended September 30, 2021 .

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Dividend Distribution Declaration On October 13, 2022 , the Board declared a cash distribution of $ 0.36 per share to be paid on November 17, 2022 to stockholders of record as of November 10, 2022 . In addition to the cash distribution, and as part of the declared supplemental cash distribution of $ 0.60 per share to be paid in four quarterly distributions of $ 0.15 , the Board declared a supplemental cash distribution of $ 0.15 per share to be paid on November 17, 2022 to stockholders of record as of November 10, 2022 . Including the $ 0.15 per share supplemental cash distributions paid to stockholders of record as of March 9, 2022, May 17, 2022, and August 9, 2022, the Board has declared the full $ 0.60 per share supplemental cash distribution declared on February 16, 2022 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated.
Use of Estimates	Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and Variable Interest Entities (“VIE”) for which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. As of September 30, 2022, the Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The Company held no interests in a VIE as of December 31, 2021 . The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.
Fair Value Measurements	Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.
Valuation of Investments	Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. As of September 30, 2022, approximately 96.6 % of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of September 30, 2022, the Company held $ 679 thousa nd (Cost basis $ 726 thousand) of foreign cash. As of December 31, 2021, the Company held $ 95 thousand (Cost basis $ 93 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to our 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).
Other Assets	Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivables.
Escrow Receivables	Escrow Receivables Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. As of both September 30, 2022 and December 31, 2021, there were no material past due escrow receivables. The approximate fair value in accordance with ASC Topic 820 of the escrow receivable balance as of September 30, 2022 and December 31, 2021 was $ 1.3 million and $ 0.6 million, respectively.
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right of use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.
Income Recognition	Income Recognition The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal. Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $ 53.6 million of unamortized fees as of September 30, 2022, of which approximately $ 42.1 million was included as an offset to the cost basis of its current debt investments and approximately $ 11.5 million was deferred contingent upon the occurrence of a funding or milestone. As of December 31, 2021, the Company had approximately $ 42.9 million of unamortized fees, of which approximately $ 36.5 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $ 6.4 million was deferred contingent upon the occurrence of a funding or milestone. The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default, waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $ 0.5 million and $ 1.7 million in one-time fee income during the three months ended September 30, 2022 and 2021, respectively. The Company recorded approximately $ 1.3 million and $ 6.2 million in one-time fee income during the nine months ended September 30, 2022 and 2021, respectively. In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of September 30, 2022, the Company had approximately $ 36.5 million in exit fees receivable, of which approximately $ 32.0 million was included as a component of the cost basis of its current debt investments and approximately $ 4.5 million was a deferred receivable related to expired commitments. As of December 31, 2021, the Company had approximately $ 35.0 million in exit fees receivable, of which approximately $ 29.6 million was included as a component of the cost basis of its current debt investments and approximately $ 5.4 million was a deferred receivable related to expired commitments. The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $ 4.9 million and $ 2.9 million in PIK income during the three months ended September 30, 2022 and 2021, respectively. The Company recorded approximately $ 14.9 million and $ 8.1 million in PIK income during the nine months ended September 30, 2022 and 2021, respectively. To maintain the Company’s RIC status for taxation purposes, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three and nine months ended September 30, 2022 and 2021 .
Equity Offering Expenses	Equity Offering Expenses The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.
Debt	Debt The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statement of Operations within net realized gains (losses) as a “Loss on debt extinguishment”. Debt Issuance Costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest , debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.
Stock Based Compensation	Stock Based Compensation The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.
Income Taxes	Income Taxes The Company intends to operate so as to qualify to be subject to tax as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance Requirement, as defined below. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains). Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax. Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and net realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future. Also, tax legislation requires that income be recognized for tax purposes no later than when recognized for financial reporting purposes, with certain exceptions.
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.
Comprehensive Income	Comprehensive Income The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did no t have other comprehensive income for the three and nine months ended September 30, 2022 or 2021 . The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.
Stockholders' Equity, Policy [Policy Text Block]	Distributions Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions. During the three and nine months ended September 30, 2022, the Company issued 62,726 shares and 184,197 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan. During the three and nine months ended September 30, 2021, the Company issued 55,413 shares and 189,356 shares, of common stock to stockholders in connection with the dividend reinvestment plan.
Segments	Segments The Company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single reportable segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2022, the FASB issued ASU 2022-02, “Financial Instruments  Credit Losses (Topic 326)”, which is intended to address issues identified during the post-implementation review of ASU 2016-13, “Financial Instruments  Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The amendment, among other things, eliminates the accounting guidance for troubled debt restructurings by creditors in Subtopic 310-40, “Receivables  Troubled Debt Restructurings by Creditors”, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. The new guidance is effective for interim and annual periods beginning after December 15, 2022. The Company does not anticipate the new standard will have a material impact to the consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820)  Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, which was issued to (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The new guidance is effective for interim and annual periods beginning after December 15, 2023. The Company does not anticipate the new standard will have a material impact to the consolidated financial statements and related disclosures.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Investments Measured at Fair Value on Recurring Basis	These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2022 and December 31, 2021. (in thousands) Balance as of Quoted Prices in Significant Significant Description 2022 (Level 1) (Level 2) (Level 3) Cash equivalents Money Market Fund $ 25,000 $ 25,000 $ — $ — Other assets Escrow Receivables $ 1,282 $ — $ — $ 1,282 Investments Senior Secured Debt $ 2,607,006 $ — $ — $ 2,607,006 Unsecured Debt 54,393 — — 54,393 Preferred Stock 41,038 — — 41,038 Common Stock 93,096 58,319 7,175 27,602 Warrants 27,159 — 9,520 17,639 $ 2,822,692 $ 58,319 $ 16,695 $ 2,747,678 Investment Funds & Vehicles measured at Net Asset Value (1) 3,046 Total Investments excluding cash equivalents $ 2,825,738 Total Investments including cash equivalents $ 2,850,738 (in thousands) Balance as of Quoted Prices in Significant Significant Description 2021 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 561 $ — $ — $ 561 Investments Senior Secured Debt $ 2,156,709 $ — $ — $ 2,156,709 Unsecured Debt 52,890 — — 52,890 Preferred Stock 69,439 — — 69,439 Common Stock 115,271 84,460 8,843 21,968 Warrants 38,399 — 10,922 27,477 $ 2,432,708 $ 84,460 $ 19,765 $ 2,328,483 Investment Funds & Vehicles measured at Net Asset Value (1) 1,814 Total Investments excluding cash equivalents $ 2,434,522 Total Investments including cash equivalents $ 2,434,522 (1) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities.
Summary of Reconciliation Changes for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2022 and 2021. (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (3) Gross (3) Balance as of Investments Senior Secured Debt $ 2,156,709 $ ( 1,883 ) $ ( 11,377 ) $ 854,978 $ ( 73,500 ) $ ( 314,417 ) $ — $ ( 3,504 ) $ 2,607,006 Unsecured Debt 52,890 — ( 1,880 ) 3,383 — — — — 54,393 Preferred Stock 69,439 7,966 ( 22,458 ) 3,614 ( 11,101 ) — — ( 6,422 ) 41,038 Common Stock 21,968 ( 74 ) 9,462 — ( 19 ) — 207 ( 3,942 ) 27,602 Warrants 27,477 992 ( 13,795 ) 6,127 ( 3,162 ) — — — 17,639 Other Assets Escrow Receivable 561 401 ( 328 ) 1,148 ( 500 ) — — — 1,282 Total $ 2,329,044 $ 7,402 $ ( 40,376 ) $ 869,250 $ ( 88,282 ) $ ( 314,417 ) $ 207 $ ( 13,868 ) $ 2,748,960 (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (4) Gross (4) Balance as of Investments Senior Secured Debt $ 2,079,465 $ ( 3,744 ) $ 7,066 $ 884,833 $ — $ ( 754,373 ) $ — $ — $ 2,213,247 Unsecured Debt 14,970 — ( 1,194 ) 36,519 — — — — 50,295 Preferred Stock 58,981 — 54,508 13,954 ( 61,732 ) — — ( 1,267 ) 64,444 Common Stock 27,398 ( 60,904 ) 15,592 4,371 60,900 — — ( 16,025 ) 31,332 Warrants 21,483 2,584 9,043 1,854 ( 4,630 ) — — ( 1,769 ) 28,565 Other Assets Escrow Receivable 65 584 ( 1,515 ) 2,473 ( 1,036 ) — — — 571 Total $ 2,202,362 $ ( 61,480 ) $ 83,500 $ 944,004 $ ( 6,498 ) $ ( 754,373 ) $ — $ ( 19,061 ) $ 2,388,454 (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the ac companying Consolidated Statements of Operations. (3) Transfers out of Level 3 during the nine months ended September 30, 2022 related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the nine months ended September 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares. (4) Transfers out of Level 3 during the nine months ended September 30, 2021, related to the initial public offerings of Proterra, Inc., 23andMe, Inc., Sprinklr, Inc., Century Therapeutics, Couchbase, Inc., and Xometry, Inc. There was no activity related to transfers into Level 3 during the nine months ended September 30, 2021 . (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
Schedule of Quantitative Information of Fair Value Measurements	The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2022 and December 31, 2021. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 37,851 Originated Within 4-6 Months Origination Yield 9.28 % - 10.26 % 10.16 % 982,922 Market Comparable Companies Hypothetical Market Yield 10.48 % - 18.10 % 13.17 % Premium/(Discount) ( 0.75 )% - 1.50 % 0.02 % Technology 43,732 Originated Within 4-6 Months Origination Yield 9.90 % - 12.53 % 10.41 % 910,488 Market Comparable Companies Hypothetical Market Yield 11.72 % - 17.52 % 14.22 % Premium/(Discount) ( 0.75 )% - 1.50 % 0.16 % 20,354 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.83 % 4,270 Liquidation (3) Probability weighting of alternative outcomes 15.00 % - 55.00 % 46.57 % Sustainable and Renewable Technology 2,961 Market Comparable Companies Hypothetical Market Yield 13.67 %- 13.67 % 13.67 % Premium/(Discount) 0.75 %- 0.75 % 0.75 % Medical Devices 14,835 Originated Within 4-6 Months Origination Yield 14.84 % - 14.84 % 14.84 % Premium/(Discount) 0.50 % - 0.50 % 0.50 % Lower Middle Market 25,595 Originated Within 4-6 Months Origination Yield 9.67 % - 9.67 % 9.67 % 308,155 Market Comparable Companies Hypothetical Market Yield 12.71 % - 17.82 % 13.94 % Premium/(Discount) ( 2.00 )% - 1.50 % ( 0.38 )% 8,318 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 130,945 Debt Investments originated within 3 months 77,801 Imminent Payoffs (4) 93,172 Debt Investments Maturing in Less than One Year $ 2,661,399 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” industries. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services, Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Fair Value as of Valuation Techniques/Methodologies Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 206,461 Originated Within 4-6 Months Origination Yield 11.23 % - 12.84 % 11.40 % 451,587 Market Comparable Companies Hypothetical Market Yield 9.69 % - 13.89 % 11.34 % Premium/(Discount) ( 0.50 )% - 0.75 % 0.06 % Technology 109,904 Originated Within 4-6 Months Origination Yield 11.12 % - 11.68 % 11.39 % 654,320 Market Comparable Companies Hypothetical Market Yield 8.98 % - 14.54 % 11.64 % Premium/(Discount) ( 0.50 )% - 0.75 % 0.12 % 2,608 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 50.00 % 40.48 % 20,425 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 35.00 % 32.95 % Sustainable and Renewable Technology 247 Convertible Note Analysis Probability weighting of alternative outcomes 40.00 % - 60.00 % 51.84 % 7,500 Expected Realizable Value (4) Probability weighting of alternative outcomes 100 % - 100 % 100.00 % Lower Middle Market 3,100 Originated Within 4-6 Months Origination Yield 5.17 % - 5.17 % 5.17 % 81,566 Market Comparable Companies Hypothetical Market Yield 12.23 % - 16.01 % 13.22 % Premium/(Discount) 0.00 % - 1.50 % 0.43 % 90,504 Expected Realizable Value (4) Probability weighting of alternative outcomes 30.00 % - 70.00 % 57.74 % Hypothetical Market Yield 10.64 % - 10.64 % 10.64 % Premium/(Discount) ( 1.00 )% - ( 1.00 )% ( 1.00 )% 8,269 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 441,524 Debt Investments originated within 3 months 131,584 Debt Investments Maturing in Less than One Year $ 2,209,599 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” industries. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services, Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries. (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 29,721 Market Comparable Companies EBITDA Multiple (2) 11.5 x - 11.5 x 11.5 x Revenue Multiple (2) 0.6 x - 15.4 x 6.6 x Tangible Book Value Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 7.19 % - 32.68 % 20.53 % 13,397 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.29 )% - 7.80 % ( 16.68 )% 21,945 Discounted Cash Flow Discount Rate (7) 17.08 % - 28.80 % 23.32 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 84.00 % - 84.00 % 84.00 % 3,577 Other (6) Warrant Investments 10,968 Market Comparable Companies EBITDA Multiple (2) 11.5 x - 11.5 x 11.5 x Revenue Multiple (2) 0.6 x - 9.3 x 3.6 x Discount for Lack of Marketability (3) 0.00 % - 32.7 % 21.35 % 6,671 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.29 )% - 10.57 % ( 18.68 )% — Liquidation Revenue Multiple (2) 7.1 x - 7.1 x 7.1 x Discount for Lack of Marketability (3) 90.00 % - 90.00 % 90.00 % — Other (6) Total Level 3 $ 86,279 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 26,587 Market Comparable Companies EBITDA Multiple (2) 20.6 x - 20.6 x 20.6 x Revenue Multiple (2) 1.0 x - 18.4 x 11.8 x Tangible Book Value Multiple (2) 2.5 x - 2.5 x 2.5 x Discount for Lack of Marketability (3) 18.81 % - 34.69 % 25.53 % 24,910 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 88.67 )% - 47.22 % 0.81 % 11,990 Discounted Cash Flow Discount Rate (7) 15.93 % - 25.30 % 20.46 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 84.00 % - 84.00 % 84.00 % 27,920 Other (6) Warrant Investments 14,517 Market Comparable Companies EBITDA Multiple (2) 20.6 x - 26.0 x 20.7 x Revenue Multiple (2) 0.6 x - 9.5 x 4.5 x Discount for Lack of Marketability (3) 18.81 % - 37.35 % 26.93 % 11,914 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 88.67 )% - 47.22 % ( 7.76 )% 1,046 Other (6) Total Level 3 Warrant and Equity Investments $ 118,884 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Schedule of Fair Value Hierarchy Of Outstanding Borrowings	The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 169,591 $ 153,614 $ — $ — $ 153,614 July 2024 Notes 104,459 99,364 — — 99,364 February 2025 Notes 49,723 45,739 — — 45,739 June 2025 Notes 69,555 63,834 — — 63,834 June 2025 3-Year Notes 49,577 47,626 — — 47,626 March 2026 A Notes 49,676 44,107 — — 44,107 March 2026 B Notes 49,647 44,181 — — 44,181 September 2026 Notes 321,112 261,406 — — 261,406 January 2027 Notes 344,271 286,885 — — 286,885 2031 Asset-Backed Notes 147,810 145,500 — 145,500 — 2033 Notes 38,799 37,568 — 37,568 — MUFG Bank Facility (1) 102,000 102,000 — — 102,000 SMBC Facility 25,000 25,000 — — 25,000 Total $ 1,521,220 $ 1,356,824 $ — $ 183,068 $ 1,173,756 (in thousands) December 31, 2021 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 145,498 $ 151,471 $ — $ — $ 151,471 2022 Notes 149,563 152,906 — 152,906 — July 2024 Notes 104,238 110,496 — — 110,496 February 2025 Notes 49,637 51,983 — — 51,983 June 2025 Notes 69,433 72,031 — — 72,031 March 2026 A Notes 49,605 52,646 — — 52,646 March 2026 B Notes 49,570 52,751 — — 52,751 September 2026 Notes 320,376 315,495 — — 315,495 2033 Notes 38,718 42,672 — 42,672 — 2022 Convertible Notes 229,740 236,049 — 236,049 — Union Bank Facility (1) — — — — — SMBC Facility 29,925 29,925 — — 29,925 Total $ 1,236,303 $ 1,268,425 $ — $ 431,627 $ 836,798 (1) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2022
Industry Sector
Investments in and Advances to Affiliates [Line Items]
Supplemental disclosure to the investment holdings table that specifically covers control and affiliate investments	The following table shows the fair value of the Company’s portfolio by industry sector as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 December 31, 2021 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,091,827 38.6 % $ 967,383 39.7 % Software 680,216 24.1 % 585,622 24.1 % Internet Consumer & Business Services 489,968 17.3 % 395,506 16.3 % Healthcare Services, Other 203,599 7.2 % 121,003 5.0 % Communications & Networking 101,094 3.6 % 105,490 4.3 % Diversified Financial Services 72,061 2.5 % 65,073 2.7 % Information Services 59,735 2.1 % 74,417 3.1 % Manufacturing Technology 43,892 1.6 % 14,995 0.6 % Consumer & Business Products 25,497 0.9 % 28,099 1.2 % Semiconductors 20,621 0.7 % 22,498 0.9 % Medical Devices & Equipment 17,421 0.6 % 12,612 0.5 % Sustainable and Renewable Technology 15,683 0.6 % 39,387 1.6 % Electronics & Computer Hardware 2,498 0.1 % 1,040 0.0 % Surgical Devices 1,536 0.1 % 1,029 0.0 % Drug Delivery 90 0.0 % 368 0.0 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 %
Geographic Location
Investments in and Advances to Affiliates [Line Items]
Supplemental disclosure to the investment holdings table that specifically covers control and affiliate investments	A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2022 and December 31, 2021 is shown as follows: September 30, 2022 December 31, 2021 (in thousands) Investments at Percentage of Investments at Percentage of United States $ 2,545,973 90.1 % $ 2,138,184 87.8 % United Kingdom 158,491 5.6 % 169,407 7.0 % Netherlands 88,174 3.1 % 82,925 3.4 % Canada 19,373 0.7 % 27,673 1.1 % Israel 9,005 0.3 % 8,980 0.4 % Ireland 3,313 0.1 % 5,459 0.2 % Germany 924 0.1 % 1,894 0.1 % Other 485 0.0 % — 0.0 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 %
Investment by Asset
Investments in and Advances to Affiliates [Line Items]
Supplemental disclosure to the investment holdings table that specifically covers control and affiliate investments	The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 (in thousands) Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 2,607,006 92.3 % $ 2,156,709 88.6 % Unsecured Debt 54,393 1.9 % 52,890 2.2 % Preferred Stock 41,038 1.4 % 69,439 2.8 % Common Stock 93,096 3.3 % 115,271 4.7 % Warrants 27,159 1.0 % 38,399 1.6 % Investment Funds & Vehicles 3,046 0.1 % 1,814 0.1 % Total $ 2,825,738 100.0 % $ 2,434,522 100.0 %
Investment, Affiliated Issuer [Member]
Investments in and Advances to Affiliates [Line Items]
Supplemental disclosure to the investment holdings table that specifically covers control and affiliate investments	The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2022 and 2021. (in thousands) Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Portfolio Company (1) Type Fair Value as of September 30, 2022 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 400 $ — $ — $ ( 22 ) $ — $ — $ — $ ( 165 ) $ — Gibraltar Business Capital, LLC Control 37,662 853 18 ( 1,423 ) — 2,531 51 ( 6,228 ) — Hercules Adviser LLC Control 33,945 154 — ( 1,236 ) — 393 — 9,955 — Tectura Corporation Control 8,318 174 — 110 — 516 — 49 — Total Control Investments $ 80,325 $ 1,181 $ 18 $ ( 2,571 ) $ — $ 3,440 $ 51 $ 3,611 $ — Affiliate Investments Black Crow AI, Inc. (2) Affiliate $ — $ — $ — $ — $ — $ — $ — $ ( 120 ) $ 3,772 Pineapple Energy LLC (2) Affiliate — 81 — 4,631 ( 2,014 ) 1,204 — 4,209 ( 2,014 ) Total Affiliate Investments $ — $ 81 $ — $ 4,631 $ ( 2,014 ) $ 1,204 $ — $ 4,089 $ 1,758 Total Control & Affiliate Investments $ 80,325 $ 1,262 $ 18 $ 2,060 $ ( 2,014 ) $ 4,644 $ 51 $ 7,700 $ 1,758 (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Portfolio Company (1) Type Fair Value as of September 30, 2021 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Gibraltar Business Capital, LLC Control $ 40,737 $ 853 $ 15 $ ( 3,475 ) $ — $ 2,325 $ 38 $ ( 17,690 ) $ — Hercules Adviser LLC Control 16,804 45 — ( 219 ) — 59 — 10,669 — Tectura Corporation Control 8,294 174 5 ( 80 ) — 516 5 ( 306 ) — Total Control Investments $ 65,835 $ 1,072 $ 20 $ ( 3,774 ) $ — $ 2,900 $ 43 $ ( 7,327 ) $ — Affiliate Investments Black Crow AI, Inc. Affiliate $ 1,243 $ — $ — $ ( 66 ) $ — $ — $ — $ 2,028 $ — Pineapple Energy LLC Affiliate 8,469 1 — ( 52 ) — 3 — 9 — Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) Affiliate — — — — — — — 62,183 ( 62,143 ) Total Affiliate Investments $ 9,712 $ 1 $ — $ ( 118 ) $ — $ 3 $ — $ 64,220 $ ( 62,143 ) Total Control & Affiliate Investments $ 75,547 $ 1,073 $ 20 $ ( 3,892 ) $ — $ 2,903 $ 43 $ 56,893 $ ( 62,143 ) (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021 , there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2) As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act.

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Schedule of Available and Outstanding Debt	As of September 30, 2022 and December 31, 2021, the Company had the following available and outstanding debt: (in thousands) September 30, 2022 December 31, 2021 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures $ 175,000 $ 175,000 $ 169,591 $ 175,000 $ 150,500 $ 145,498 2022 Notes — — — 150,000 150,000 149,563 July 2024 Notes 105,000 105,000 104,459 105,000 105,000 104,238 February 2025 Notes 50,000 50,000 49,723 50,000 50,000 49,637 June 2025 Notes 70,000 70,000 69,555 70,000 70,000 69,433 June 2025 3-Year Notes 50,000 50,000 49,577 — — — March 2026 A Notes 50,000 50,000 49,676 50,000 50,000 49,605 March 2026 B Notes 50,000 50,000 49,647 50,000 50,000 49,570 September 2026 Notes 325,000 325,000 321,112 325,000 325,000 320,376 January 2027 Notes 350,000 350,000 344,271 — — — 2031 Asset-Backed Notes 150,000 150,000 147,810 — — — 2033 Notes 40,000 40,000 38,799 40,000 40,000 38,718 2022 Convertible Notes — — — 230,000 230,000 229,740 MUFG Bank Facility (2)(3) 545,000 102,000 102,000 400,000 — — SMBC Facility (2) 225,000 25,000 25,000 100,000 29,925 29,925 Total $ 2,185,000 $ 1,542,000 $ 1,521,220 $ 1,745,000 $ 1,250,425 $ 1,236,303 (1) Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.
Schedule of Debt Issuance Costs, Net of Accumulated Amortization	Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2022 and December 31, 2021: (in thousands) September 30, 2022 December 31, 2021 SBA Debentures $ 5,409 $ 5,002 2022 Notes — 300 July 2024 Notes 541 762 February 2025 Notes 277 363 June 2025 Notes 445 567 June 2025 3-Year Notes 423 — March 2026 A Notes 324 395 March 2026 B Notes 353 430 September 2026 Notes 3,888 4,624 January 2027 Notes 5,729 — 2031 Asset-Backed Notes 2,190 — 2033 Notes 1,201 1,282 2022 Convertible Notes — 149 MUFG Bank Facility (1) 1,346 1,239 SMBC Facility (1) 1,574 922 Total $ 23,700 $ 16,035 (1) The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.
Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt	For the three and nine months ended September 30, 2022, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Description Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,160 $ 148 $ — $ 1,308 $ 2,086 $ 2,848 $ 434 $ — $ 3,282 $ 2,835 2022 Notes — — — — — 1,011 50 — 1,061 2,293 July 2024 Notes 1,252 74 — 1,326 2,504 3,756 222 — 3,978 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 June 2025 3-Year Notes 750 38 — 788 — 817 42 — 859 — March 2026 A Notes 563 24 — 587 1,125 1,688 72 — 1,760 2,250 March 2026 B Notes 569 26 — 595 1,137 1,706 78 — 1,784 2,275 September 2026 Notes 2,174 204 — 2,378 4,266 6,523 612 — 7,135 8,532 January 2027 Notes 3,079 207 — 3,286 5,906 8,552 575 — 9,127 5,906 2031 Asset-Backed Notes 1,903 100 — 2,003 1,815 2,072 109 — 2,181 1,815 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 2022 Convertible Notes — — — — — 923 149 — 1,072 5,004 MUFG Bank Facility (2) 1,000 253 720 1,973 1,025 2,483 665 1,682 4,830 2,240 SMBC Facility 135 98 195 428 181 722 211 328 1,261 700 Total $ 14,499 $ 1,268 $ 915 $ 16,682 $ 21,740 $ 38,844 $ 3,507 $ 2,010 $ 44,361 $ 44,382 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the nine months ended September 30, 2022 , $ 23 thousand, $ 112 thousand, $ 125 thousand, $ 349 thousand, and $ 51 thousand related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. For the three and nine months ended September 30, 2021, the components of interest expense and related fees and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Description Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 114 $ 50 $ — $ 164 $ 183 $ 1,228 $ 367 $ — $ 1,595 $ 2,272 2022 Notes 1,776 90 — 1,866 — 5,327 270 — 5,597 3,469 July 2024 Notes 1,252 74 — 1,326 2,504 3,756 221 — 3,977 5,008 February 2025 Notes 535 29 — 564 1,070 1,605 86 — 1,691 2,140 April 2025 Notes (3) — 1,477 — 1,477 667 1,969 1,667 — 3,636 2,635 June 2025 Notes 754 40 — 794 — 2,263 121 — 2,384 1,509 March 2026 A Notes 563 24 — 587 1,125 1,688 70 — 1,758 1,875 March 2026 B Notes 569 26 — 595 1,138 1,308 59 — 1,367 1,138 September 2026 Notes 338 32 — 370 — 338 32 — 370 — 2033 Notes 625 27 — 652 625 1,875 81 — 1,956 1,875 2027 Asset-Backed Notes (3) 1,344 72 — 1,416 1,348 4,593 922 — 5,515 4,677 2028 Asset-Backed Notes (3) 2,226 251 — 2,477 2,256 7,684 867 — 8,551 7,785 2022 Convertible Notes 2,683 223 — 2,906 5,031 8,050 669 — 8,719 10,062 Wells Facility (3) — 43 146 189 — — 132 460 592 — MUFG Bank Facility (4) 290 314 458 1,062 327 625 968 1,404 2,997 540 Total $ 13,069 $ 2,772 $ 604 $ 16,445 $ 16,274 $ 42,309 $ 6,532 $ 1,864 $ 50,705 $ 44,985 (1) Interest expense includes amortization of original issue discounts for the three months ended September 30, 2021 of $ 41 thousand, $ 168 thousand, and $ 6 thousand, for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes for the nine months ended September 30, 2021 , $ 123 thousand, $ 504 thou sand, and $ 6 thousand for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. (2) “Amortization of debt issuance cost (loan fees)” includes $ 1,477 thousand, $ 28 thousand, and $ 197 thousand related to debt extinguishment costs for the April (3) The April 2025 Notes, 2027 Asset-Backed Notes and 2028 Asset-Backed Notes were retired on July 1, 2021 and October 20, 2021 , respectively. The Wells November 29, 2021 . (4) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.
SBA Debentures
Schedule of Available and Outstanding Debt	The Company reported the following SBA debentures outstanding principal balances as of September 30, 2022 and December 31, 2021: (in thousands) Maturity Date Interest Rate (1) September 30, 2022 December 31, 2021 March 26, 2021 September 1, 2031 1.58 % $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58 % 16,200 16,200 July 28, 2021 September 1, 2031 1.58 % 5,400 5,400 August 20, 2021 September 1, 2031 1.58 % 5,400 5,400 October 21, 2021 March 1, 2032 3.21 % 14,000 14,000 November 1, 2021 March 1, 2032 3.21 % 21,000 21,000 November 15, 2021 March 1, 2032 3.21 % 5,200 5,200 November 30, 2021 March 1, 2032 3.21 % 20,800 20,800 December 20, 2021 March 1, 2032 3.21 % 10,000 10,000 December 23, 2021 March 1, 2032 3.21 % 10,000 10,000 December 28, 2021 March 1, 2032 3.21 % 5,000 5,000 January 14, 2022 March 1, 2032 3.21 % 4,500 — January 21, 2022 March 1, 2032 3.21 % 20,000 — Total SBA Debentures $ 175,000 $ 150,500 (1) Interest rates are fixed rates set based on the pooling date of each debenture. The rates shown above are inclusive of annual SBA charges.

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of unvested restricted stock equity	The activities for the Company's unvested restricted stock equity awards for each of the nine months ended September 30, 2022, and 2021, are summarized below: Nine Months Ended September 30, 2022 2021 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 1,037,848 $ 14.51 989,100 $ 13.69 Granted 632,831 $ 17.24 748,519 $ 14.80 Vested (1) ( 578,579 ) $ 14.39 ( 517,076 ) $ 13.71 Forfeited ( 25,407 ) $ 15.99 ( 71,020 ) $ 14.16 Unvested Shares End of Period 1,066,693 $ 16.16 1,149,523 $ 14.42

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2022 2021 2022 2021 Numerator Net increase in net assets resulting from operations $ 53,202 $ 23,549 $ 39,548 $ 170,443 Less: Distributions declared-common and restricted shares ( 63,950 ) ( 45,190 ) ( 181,825 ) ( 133,143 ) (Over-)Undistributed earnings (loss) ( 10,748 ) ( 21,641 ) ( 142,277 ) 37,300 Undistributed earnings-common shares ( 10,748 ) ( 21,641 ) ( 142,277 ) 36,931 Add: Distributions declared-common shares 63,421 44,770 180,114 131,829 Numerator for basic and diluted change in net assets per common share $ 52,673 $ 23,129 $ 37,837 $ 168,760 Denominator Basic weighted average common shares outstanding 127,484 114,805 123,379 114,590 Incremental shares from assumed conversion of 2022 Convertible Notes — 661 — 293 Common shares issuable 1,850 773 1,388 667 Weighted average common shares outstanding assuming dilution 129,334 116,239 124,767 115,550 Change in net assets per common share Basic $ 0.41 $ 0.20 $ 0.31 $ 1.47 Diluted $ 0.41 $ 0.20 $ 0.30 $ 1.46
Schedule of Number of Anti-diluted Shares As Calculated Based on Weighted Average Closing Price of Common Stock	The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and nine months ended September 30, 2022, and 2021, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three months ended September 30, Nine Months Ended September 30, Anti-dilutive Securities 2022 2021 2022 2021 2022 Convertible Notes — — — — Unvested common stock options 865 198 1,725 88 Restricted stock units* — — — — Unvested restricted stock awards 3,982 710 1,611 720 Performance awards* — — — — * Included in these amounts are shares related to certain equity-based awards, which are fully-vested but have not been delivered and thus not outstanding for purposes of calculating earnings per share.

Financial Highlights (Tables)

Financial Highlights (Tables)	9 Months Ended
	Sep. 30, 2022
Investment Company Financial Highlights [Abstract]
Schedule of Financial Highlights	Following is a schedule of financial highlights for the nine months ended September 30, 2022 and 2021: (in thousands, except per share data and ratios) Nine Months Ended September 30, 2022 2021 Per share data (1) : Net asset value at beginning of period $ 11.22 $ 11.26 Net investment income 1.01 0.95 Net realized gain (loss) 0.01 0.12 Net unrealized appreciation (depreciation) ( 0.71 ) 0.40 Total from investment operations 0.31 1.47 Net increase (decrease) in net assets from capital share transactions (1) 0.31 ( 0.11 ) Distributions of net investment income (6) ( 1.11 ) ( 1.06 ) Distributions of capital gains (6) ( 0.35 ) ( 0.09 ) Stock-based compensation expense included in investment income (2) 0.09 0.07 Net asset value at end of period $ 10.47 $ 11.54 Ratios and supplemental data: Per share market value at end of period $ 11.58 $ 16.61 Total return (3) ( 24.34 )% 23.05 % Shares outstanding at end of period 130,191 115,925 Weighted average number of common shares outstanding 123,379 114,590 Net assets at end of period $ 1,362,718 $ 1,337,532 Ratio of total expense to average net assets (4) 9.51 % 9.93 % Ratio of net investment income before investment gains and losses to average net assets (4) 12.53 % 11.01 % Portfolio turnover rate (5) 14.12 % 33.14 % Weighted average debt outstanding $ 1,430,814 $ 1,246,769 Weighted average debt per common share $ 11.60 $ 10.88 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC Topic 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital. (3) The total return for the nine months ended September 30, 2022, and 2021 , equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the nine months ended September 30, 2022, and 2021 , equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Other Commitments [Line Items]
Schedule of Unfunded Contractual Commitments and Unencumbered Unfunded Commitments	As of September 30, 2022, and December 31, 2021, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company September 30, 2022 December 31, 2021 Debt Investments: Phathom Pharmaceuticals, Inc. $ 66,500 $ 43,250 Oak Street Health, Inc. 44,250 — Axsome Therapeutics, Inc. 42,000 — Thumbtack, Inc. 40,000 — Vida Health 40,000 — Skydio, Inc. 37,500 37,500 HilleVax, Inc. 36,000 — Automation Anywhere, Inc. 29,400 — Iveric Bio Gene Therapy LLC 24,750 — Brain Corporation 20,020 20,000 Aryaka Networks, Inc. 20,000 — Finch Therapeutics Group, Inc. 20,000 — G1 Therapeutics, Inc. 19,375 19,375 Tarsus Pharmaceuticals, Inc. 18,563 — Locus Robotics Corporation 18,281 — Alladapt Immunotherapeutics Inc. 15,000 — ATAI Life Sciences N.V. 14,000 — Dronedeploy, Inc. 12,500 — Carbon Health Technologies, Inc. 11,625 11,625 Nuvolo Technologies Corporation 10,200 — AppDirect, Inc. 10,000 — Blue Sprig Pediatrics, Inc. 10,000 30,000 Dashlane, Inc. 10,000 19,300 RVShare, LLC 8,500 13,500 Viridian Therapeutics, Inc. 8,000 — Elation Health, Inc. 7,500 — Gritstone Bio, Inc. 7,500 — Ouster, Inc. 7,000 — Akero Therapeutics, Inc. 5,000 — Alamar Biosciences, Inc. 5,000 — Fulfil Solutions, Inc. 5,000 — Demandbase, Inc. 3,750 9,375 Signal Media Limited 3,750 — Riviera Partners LLC 3,500 — Yipit, LLC 2,250 2,250 Khoros (p.k.a Lithium Technologies) 1,812 1,812 Ceros, Inc. 1,707 3,845 ThreatConnect, Inc. 1,600 1,600 Dispatch Technologies, Inc. 1,250 — LogicSource 1,209 — Zimperium, Inc. 1,088 — Ikon Science Limited 1,050 1,050 Omeda Holdings, LLC 938 — Alchemer LLC 890 — Agilence, Inc. 800 800 Mobile Solutions Services 742 424 3GTMS, LLC 725 1,583 Constructor.io Corporation 625 — Cybermaxx Intermediate Holdings, Inc. 471 471 Enmark Systems, Inc. 457 457 Annex Cloud 386 — Gryphon Networks Corp. 268 268 Cytracom Holdings LLC 225 225 Syndax Pharmaceutics Inc. — 30,000 Equality Health, LLC — 17,500 Bicycle Therapeutics PLC — 10,000 Better Therapeutics, Inc. — 4,000 Logicworks — 2,000 ShadowDragon, LLC — 333 ePayPolicy Holdings, LLC — 250 Pineapple Energy LLC — 120 Total Unfunded Debt Commitments: 652,957 282,913 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 3,187 3,839 Forbion Growth Opportunities Fund II C.V. 2,826 — Total Unfunded Commitments in Investment Funds & Vehicles: 6,013 3,839 Total Unfunded Commitments $ 658,970 $ 286,752 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions". (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.
Schedule of Contractual Obligations	The following tables provide the Company’s contractual obligations as of September 30, 2022 and December 31, 2021: As of September 30, 2022: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,542,000 $ — $ 377,000 $ 800,000 $ 365,000 Lease and License Obligations (4) 6,821 3,060 1,908 1,853 — Total $ 1,548,821 $ 3,060 $ 378,908 $ 801,853 $ 365,000 As of December 31, 2021: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,250,425 $ 380,000 $ 105,000 $ 574,925 $ 190,500 Lease and License Obligations (4) 8,283 3,120 2,958 1,427 778 Total $ 1,258,708 $ 383,120 $ 107,958 $ 576,352 $ 191,278 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of September 30, 2022. There was also $ 25.0 million outstanding under the SMBC Facility and $ 102.0 million outstanding under the MUFG Bank Facility as of September 30, 2022 . (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $ 150.5 million in principal outstanding under the SBA Debentures, $ 150.0 million of the 2022 Notes, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes, and $ 230.0 million of the 2022 Convertible Notes as of December 31, 2021. There was also $ 29.9 million outstanding under the SMBC Facility and no amounts outstanding under the Union Facility as of December 31, 2021 .
Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases	The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2022, and 2021: (in thousands) Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 Total operating lease cost $ 744 $ 724 $ 2,185 $ 2,196 Cash paid for amounts included in the measurement of lease liabilities $ 642 $ 578 $ 2,411 $ 1,733 As of September 30, 2022 As of September 30, 2021 Weighted-average remaining lease term (in years) 4.17 4.37 Weighted-average discount rate 4.53 % 4.87 %
Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability	The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2022: (in thousands) As of September 30, 2022 2022 $ 652 2023 2,500 2024 848 2025 887 Thereafter 1,804 Total lease payments 6,691 Less: imputed interest ( 599 ) Total operating lease liability $ 6,092
Unfunded Debt Commitments
Other Commitments [Line Items]
Schedule of Unfunded Contractual Commitments and Unencumbered Unfunded Commitments	The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) September 30, 2022 December 31, 2021 Unfunded Debt Commitments: Expiring during: 2022 $ 198,281 $ 199,681 2023 312,457 43,675 2024 121,586 25,800 2025 1,694 2,232 2026 9,053 11,525 2027 7,745 — 2028 2,141 — Total Unfunded Debt Commitments 652,957 282,913 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 3,187 3,839 2032 2,826 — Total Unfunded Commitments in Investment Funds & Vehicles 6,013 3,839 Total Unfunded Commitments $ 658,970 $ 286,752

Schedule 12-14s - Summary of sc

Schedule 12-14s - Summary of schedule of investment (Tables)	9 Months Ended
	Sep. 30, 2022
Investments in and Advances to Affiliates [Abstract]
Schedule of Investments in and Advances to Affiliates	(in thousands) Investment (1) Amount of Interest and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of September 30, 2022 Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC (10) Preferred Stock $ — $ — $ 500 $ — $ — $ ( 109 ) $ 391 Common Stock — — 65 — — ( 56 ) 9 Gibraltar Business Capital, LLC (5) Unsecured Debt 2,581 — 23,212 60 — ( 1,233 ) 22,039 Preferred Stock — — 19,393 — — ( 4,904 ) 14,489 Common Stock — — 1,225 — — ( 91 ) 1,134 Hercules Adviser LLC (6) Unsecured Debt 393 — 8,850 3,150 — — 12,000 Member Units — — 11,990 — — 9,955 21,945 Total Majority Owned Control Investments $ 2,974 $ — $ 65,235 $ 3,210 $ — $ 3,562 $ 72,007 Other Control Investments Tectura Corporation (7) Senior Debt $ 516 $ — $ 8,269 $ — $ — $ 49 $ 8,318 Preferred Stock — — — — — — — Common Stock — — — — — — — Total Other Control Investments $ 516 $ — $ 8,269 $ — $ — $ 49 $ 8,318 Total Control Investments $ 3,490 $ — $ 73,504 $ 3,210 $ — $ 3,611 $ 80,325 Affiliate Investments Black Crow AI, Inc. (8) Preferred Stock $ — $ 3,772 $ 1,120 $ — $ ( 1,000 ) $ ( 120 ) $ — Pineapple Energy LLC (9) Senior Debt 1,204 ( 2,014 ) 7,747 — ( 7,780 ) 33 — Common Stock — — 591 — ( 4,767 ) 4,176 — Total Affiliate Investments $ 1,204 $ 1,758 $ 9,458 $ — $ ( 13,547 ) $ 4,089 $ — Total Control and Affiliate Investments $ 4,694 $ 1,758 $ 82,962 $ 3,210 $ ( 13,547 ) $ 7,700 $ 80,325 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. (6) Hercules Adviser LLC is a wholly owned subsidiary providing investment management and other services to the Adviser Funds and other External Parties. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. (8) During the nine months ended September 30, 2022 , the Company sold its investments in Black Crow AI, Inc., as a result it is no longer an affiliate investment. (9) During the three months ended September 30, 2022, the Company sold a portion of its investments in Pineapple Energy LLC, as a result it is no longer an affiliate investment.. (10) As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES For the Nine Months Ended September 30, 2021 (unaudited) (in thousands) Investment (1) Amount of Interest and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of Portfolio Company Control Investments Majority Owned Control Investments Gibraltar Business Capital, LLC (5) Unsecured Debt $ 2,363 $ — $ 14,970 $ 9,627 $ — $ ( 1,194 ) $ 23,403 Preferred Stock — — 31,554 — — ( 15,386 ) 16,168 Common Stock — — 2,276 — — ( 1,110 ) 1,166 Hercules Adviser LLC (6) Unsecured Debt 59 — — 6,100 — — 6,100 Member Units — — — 35 — 10,669 10,704 Total Majority Owned Control Investments $ 2,422 $ — $ 48,800 $ 15,762 $ — $ ( 7,021 ) $ 57,541 Other Control Investments Tectura Corporation (7) Senior Debt $ 521 $ — $ 8,600 $ — $ — $ ( 306 ) $ 8,294 Preferred Stock — — — — — — — Common Stock — — — — — — — Total Other Control Investments $ 521 $ — $ 8,600 $ — $ — $ ( 306 ) $ 8,294 Total Control Investments $ 2,943 $ — $ 57,400 $ 15,762 $ — $ ( 7,327 ) $ 65,835 Affiliate Investments Black Crow AI, Inc. (8) Preferred Stock $ — $ — $ — $ 1,000 $ — $ 243 $ 1,243 Convertible Debt — — — 2,208 ( 3,993 ) 1,785 — Pineapple Energy LLC (9) Senior Debt 3 — 7,500 120 — — 7,620 Common Stock — — 840 — — 9 849 Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) (10) Senior Debt — ( 641 ) — — ( 681 ) 681 — Common Stock — ( 61,502 ) — — ( 61,502 ) 61,502 — Total Affiliate Investments $ 3 $ ( 62,143 ) $ 8,340 $ 3,328 $ ( 66,176 ) $ 64,220 $ 9,712 Total Control and Affiliate Investments $ 2,946 $ ( 62,143 ) $ 65,740 $ 19,090 $ ( 66,176 ) $ 56,893 $ 75,547 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. (6) Hercules Adviser LLC is a wholly-owned subsidiary providing investment management and other services to External Parties. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the (8) As of March 23, 2021, the Company's investment in Black Crow AI, Inc. became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the (9) As of December 11, 2020, the Company’s investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of (10) As of June 30, 2021, the Company’s investments in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) were written off for a realized loss. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of September 30, 2022 (unaudited) (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal or Shares Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 391 Medical Devices & Equipment Common Stock 180,000 — 9 Total Coronado Aesthetics, LLC $ 250 $ 400 Gibraltar Business Capital, LLC Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 14.50 % $ 15,000 $ 14,701 $ 13,033 Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.50 % $ 10,000 9,844 9,006 Diversified Financial Services Preferred Series A Equity 10,602,752 26,122 14,489 Diversified Financial Services Common Stock 830,000 1,884 1,134 Total Gibraltar Business Capital, LLC $ 52,551 $ 37,662 Hercules Adviser LLC Unsecured Debt June 2025 Interest rate FIXED 5.00 % $ 12,000 $ 12,000 $ 12,000 Member Units 1 35 21,945 Total Hercules Adviser LLC $ 12,035 $ 33,945 Total Majority Owned Control Investments ( 5.28 %)* $ 64,836 $ 72,007 Other Control Investments Tectura Corporation Internet Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 10,680 $ 240 $ — Internet Consumer & Business Services Senior Secured Debt July 2024 Interest rate FIXED 8.25 % $ 8,250 8,250 8,250 Internet Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 13,023 13,023 68 Internet Consumer & Business Services Preferred Series BB Equity 1,000,000 — — Internet Consumer & Business Services Common Stock 414,994,863 900 — Total Tectura Corporation $ 22,413 $ 8,318 Total Other Control Investments ( 0.61 %)* $ 22,413 $ 8,318 Total Control Investments ( 5.89 %)* $ 87,249 $ 80,325 Total Control and Affiliate Investments ( 5.89 %)* $ 87,249 $ 80,325 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. (10) Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of and for the year ended December 31, 2021 (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal or Shares Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 500 Medical Devices & Equipment Common Stock 180,000 — 65 Total Coronado Aesthetics, LLC $ 250 $ 565 Gibraltar Business Capital, LLC Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 14.50 % $ 15,000 $ 14,662 $ 13,818 Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.50 % $ 10,000 9,823 9,394 Diversified Financial Services Preferred Series A Equity 10,602,752 26,122 19,393 Diversified Financial Services Common Stock 830,000 1,884 1,225 Total Gibraltar Business Capital, LLC $ 52,491 $ 43,830 Hercules Adviser LLC Diversified Financial Services Unsecured Debt May 2023 Interest rate FIXED 5.00 % $ 8,850 $ 8,850 $ 8,850 Diversified Financial Services Member Units 1 35 11,990 Total Hercules Adviser LLC $ 8,885 $ 20,840 Total Majority Owned Control Investments ( 4.99 %)* $ 61,626 $ 65,235 Other Control Investments Tectura Corporation Internet Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 10,680 $ 240 $ — Internet Consumer & Business Services Senior Secured Debt July 2024 Interest rate FIXED 8.25 % $ 8,250 8,250 8,250 Internet Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 13,023 13,023 19 Internet Consumer & Business Services Preferred Series BB Equity 1,000,000 — — Internet Consumer & Business Services Common Stock 414,994,863 900 — Total Tectura Corporation $ 22,413 $ 8,269 Total Other Control Investments ( 0.63 %)* $ 22,413 $ 8,269 Total Control Investments ( 5.62 %)* $ 84,039 $ 73,504 Affiliate Investments Black Crow AI, Inc. Internet Consumer & Business Services Preferred Series Seed 872,797 $ 1,000 $ 1,120 Pineapple Energy LLC Sustainable and Renewable Technology Senior Secured Debt December 2023 PIK Interest 10.00 % $ 7,500 7,500 7,500 Sustainable and Renewable Technology Senior Secured Debt January 2022 Interest rate FIXED 10.00 % $ 280 280 247 Sustainable and Renewable Technology Common Stock 3,000,000 4,767 591 Total Pineapple Energy LLC $ 12,547 $ 8,338 Total Affiliate Investments ( 0.72 %)* $ 13,547 $ 9,458 Total Control and Affiliate Investments ( 6.34 %)* $ 97,586 $ 82,962 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

Description of Business - Addit

Description of Business - Additional Information (Details)	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Investment Company, Regulated Status [true false]	true

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total asset investment, Percentage	96.60%		96.60%
Cash, Held in Foreign Currency, Acquisition Cost			$ 726		$ 93
Cash, Held in Foreign Currency	$ 679		679		95
Escrow receivable	1,300		1,300		600
Unamortized fees	53,600		53,600		42,900
Fee Income	2,821	$ 6,881	9,110	$ 20,111
Exit fees receivables	36,500		36,500		35,000
Interest Income	81,408	63,312	212,391	188,400
Income from advisory services	$ 0	$ 0	$ 0	$ 0
Stock issued during period, shares, dividend reinvestment plan	62,726	55,413	184,197	189,356
Other comprehensive income	$ 0	$ 0	$ 0	$ 0
Investment Company, Accounting and Reporting under Topic 946 [true false]			true
PIK [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest Income	4,900	2,900	$ 14,900	8,100
One Time Fee [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fee Income	500	$ 1,700	1,300	$ 6,200
Deferred Fees [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unamortized fees	11,500		11,500		6,400
Exit fees receivables	4,500		4,500		5,400
Included in Cost [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Unamortized fees	42,100		42,100		36,500
Exit fees receivables	$ 32,000		$ 32,000		$ 29,600

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Investments Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		$ 2,822,692	$ 2,432,708
Money Market Fund
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value disclosure		25,000
Escrow Receivables
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets		1,282	561
Senior Secured
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		2,607,006	2,156,709
Unsecured Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		54,393	52,890
Private Equity Funds, Non-US
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments	[1]	3,046	1,814
Excluding Cash And Cash Equivalent
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		2,825,738	2,434,522
Including Cash And Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		2,850,738	2,434,522
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		58,319	84,460
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Fund
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents, fair value disclosure		25,000
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		16,695	19,765
Level 3 significant unobservable inputs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		2,747,678	2,328,483
Level 3 significant unobservable inputs | Escrow Receivables
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets		1,282	561
Level 3 significant unobservable inputs | Senior Secured
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		2,607,006	2,156,709
Level 3 significant unobservable inputs | Unsecured Debt
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		54,393	52,890
Preferred Note
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		41,038	69,439
Preferred Note | Level 3 significant unobservable inputs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		41,038	69,439
Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		93,096	115,271
Common Stock | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		58,319	84,460
Common Stock | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		7,175	8,843
Common Stock | Level 3 significant unobservable inputs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		27,602	21,968
Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		27,159	38,399
Warrant | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		9,520	10,922
Warrant | Level 3 significant unobservable inputs
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments		$ 17,639	$ 27,477
[1] In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities.

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - Level 3 significant unobservable inputs - USD ($)		9 Months Ended
		Sep. 30, 2022		Sep. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		$ 2,329,044,000		$ 2,202,362,000
Net Realized Gains (Losses)	[1]	7,402,000		(61,480,000)
Net Change in Unrealized Appreciation (Depreciation)	[2]	(40,376,000)		83,500,000
Purchases	[3]	869,250,000		944,004,000
Sales		88,282,000		6,498,000
Repayments	[4]	314,417,000		754,373,000
Gross Transfers into Level 3	[5]	207,000
Gross Transfers out of Level 3		13,868,000	[5]	19,061,000	[6]
Ending Balance		2,748,960,000		2,388,454,000
Senior Secured
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		2,156,709,000		2,079,465,000
Net Realized Gains (Losses)	[1]	(1,883,000)		(3,744,000)
Net Change in Unrealized Appreciation (Depreciation)	[2]	(11,377,000)		7,066,000
Purchases	[3]	854,978,000		884,833,000
Sales		73,500,000
Repayments	[4]	314,417,000		754,373,000
Gross Transfers out of Level 3	[5]	3,504,000
Ending Balance		2,607,006,000		2,213,247,000
Escrow Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		561,000		65,000
Net Realized Gains (Losses)	[1]	401,000		584,000
Net Change in Unrealized Appreciation (Depreciation)	[2]	(328)		(1,515,000)
Purchases	[3]	1,148,000		2,473,000
Sales		500,000		1,036,000
Ending Balance		1,282,000		571,000
Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		52,890,000		14,970,000
Net Change in Unrealized Appreciation (Depreciation)	[2]	(1,880,000)		(1,194,000)
Purchases	[3]	3,383,000		36,519,000
Ending Balance		54,393,000		50,295,000
Preferred Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		69,439,000		58,981,000
Net Realized Gains (Losses)	[1]	7,966,000
Net Change in Unrealized Appreciation (Depreciation)	[2]	(22,458,000)		54,508,000
Purchases	[3]	3,614,000		13,954,000
Sales		11,101,000		61,732,000
Gross Transfers out of Level 3		6,422,000	[5]	1,267,000	[6]
Ending Balance		41,038,000		64,444,000
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		21,968,000		27,398,000
Net Realized Gains (Losses)	[1]	(74,000)		(60,904,000)
Net Change in Unrealized Appreciation (Depreciation)	[2]	9,462,000		15,592,000
Purchases	[3]			4,371,000
Sales		19		(60,900,000)
Gross Transfers into Level 3	[5]	207,000
Gross Transfers out of Level 3		3,942,000	[5]	16,025,000	[6]
Ending Balance		27,602,000		31,332,000
Warrant
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		27,477,000		21,483,000
Net Realized Gains (Losses)	[1]	992,000		2,584,000
Net Change in Unrealized Appreciation (Depreciation)	[2]	(13,795,000)		9,043,000
Purchases	[3]	6,127,000		1,854,000
Sales		3,162,000		4,630,000
Gross Transfers out of Level 3	[6]			1,769,000
Ending Balance		$ 17,639,000		$ 28,565,000
[1] Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. Included in net change in unrealized appreciation (depreciation) in the ac companying Consolidated Statements of Operations. Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. Transfers out of Level 3 during the nine months ended September 30, 2022 related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the nine months ended September 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares. Transfers out of Level 3 during the nine months ended September 30, 2021, related to the initial public offerings of Proterra, Inc., 23andMe, Inc., Sprinklr, Inc., Century Therapeutics, Couchbase, Inc., and Xometry, Inc. There was no activity related to transfers into Level 3 during the nine months ended September 30, 2021 .

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 24, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments	$ (2,089)	$ (35,651)	$ (87,147)	$ 46,231
2033 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value	$ 23.48		$ 23.48
2031 Asset-Backed Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value	$ 0.970		$ 0.970
Debt | Unobservable Inputs Level 3 | Depreciation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			$ (12,200)
Debt | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments				400
Warrant Investment [Member] | Unobservable Inputs Level 3 | Depreciation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			(13,400)
Warrant Investment [Member] | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments				8,000
Common Stock Investment [Member] | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			9,500	15,600
Preferred Stock Investment Member | Unobservable Inputs Level 3 | Depreciation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			$ (23,200)	$ (6,500)
Underwriting | 2033 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value					$ 25

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Level 3 significant unobservable inputs $ in Thousands		Sep. 30, 2022 USD ($)		Dec. 31, 2021 USD ($)
Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 2,661,399		$ 2,209,599
Equity and Warrant Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		86,279		118,884
Debt Maturing Within One Year | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		93,172		131,584
Debt Investments - Imminent Payoff | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[1]	77,801
Valuation Cost Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		130,945		441,524
Valuation Market Approach | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		29,721		26,587
Valuation Market Approach | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 10,968		$ 14,517
Valuation Market Approach | Minimum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[2]	0
Valuation Market Approach | Maximum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[2]	0.327
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3]	20.6	[4]
Market Comparable Companies | Minimum | EBITDA Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3],[5]	20.6	[4]
Market Comparable Companies | Minimum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.6	[3]	1	[4]
Market Comparable Companies | Minimum | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.6	[3]	0.6	[4]
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[3]	2.5	[4]
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]	0.0719		0.1881
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]			0.1881
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3]	20.6	[4]
Market Comparable Companies | Maximum | EBITDA Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3],[5]	26	[4]
Market Comparable Companies | Maximum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		15.4	[3]	18.4	[4]
Market Comparable Companies | Maximum | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		9.3	[3]	9.5	[4]
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[3]	2.5	[4]
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]	0.3268		0.3469
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]			0.3735
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3],[7]	20.6	[4],[8]
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		11.5	[3],[5],[7]	20.7	[4],[8]
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		6.6	[3],[7]	11.8	[4],[8]
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		3.6	[3],[7]	4.5	[4],[8]
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[3],[7]	2.5	[4],[8]
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2053	[2],[7]	0.2553	[6],[8]
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2135	[2],[7]	0.2693	[6],[8]
Liquidation | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 0		$ 0
Liquidation | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 0
Liquidation | Minimum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		2.1	[3]	2.1	[4]
Liquidation | Minimum | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3]	7.1
Liquidation | Minimum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]	0.8400		0.8400
Liquidation | Minimum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]	0.9000
Liquidation | Maximum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		2.1	[3]	2.1	[4]
Liquidation | Maximum | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3]	7.1
Liquidation | Maximum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[6]	0.8400		0.8400
Liquidation | Maximum | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[2]	0.9000
Liquidation | Weighted Average | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		2.1	[3],[7]	2.1	[4],[8]
Liquidation | Weighted Average | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.8400	[2],[7]	0.8400	[6],[8]
Liquidation | Weighted Average | Discount for Lack of Marketability | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[2],[7]	0.9000
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[9]			(0.8867)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[9]			0.4722
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[8],[9]			0.0081
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[8],[9]			(0.0776)
Market Adjusted OPM Backsolve | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 13,397		$ 24,910
Market Adjusted OPM Backsolve | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 6,671		$ 11,914
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[9]	(0.9729)		(0.8867)
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[10]	(0.9729)
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[9]	0.0780		0.4722
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[10]	0.1057
Market Adjusted OPM Backsolve | Weighted Average | Revenue Multiple | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3],[7]	7.1
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[7],[9]	(0.1668)
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[7],[9]	(0.1868)
Discounted Cash Flow | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 21,945		$ 11,990
Discounted Cash Flow | Minimum | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1708	[11]	0.1593	[12]
Discounted Cash Flow | Maximum | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2880	[11]	0.2530	[12]
Discounted Cash Flow | Weighted Average | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2332	[7],[11]	0.2046	[8],[12]
Other | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 3,577	[5]	$ 27,920	[13]
Other | Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		0	[5]	1,046	[13]
Pharmaceuticals | Valuation Cost Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 37,851		$ 206,461
Pharmaceuticals | Valuation Cost Approach | Minimum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0928		0.1123
Pharmaceuticals | Valuation Cost Approach | Maximum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1026		0.1284
Pharmaceuticals | Valuation Cost Approach | Weighted Average | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1016	[14]	0.1140	[15]
Pharmaceuticals | Valuation Market Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 982,922
Pharmaceuticals | Market Comparable Companies | Minimum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1048		0.0969
Pharmaceuticals | Market Comparable Companies | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				(0.0050)
Pharmaceuticals | Market Comparable Companies | Maximum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1810		0.1389
Pharmaceuticals | Market Comparable Companies | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0150		0.0075
Pharmaceuticals | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]	0.1317		0.1134
Pharmaceuticals | Market Comparable Companies | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0002	[14]	0.0006	[15]
Pharmaceuticals | Market Yield Analysis | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				$ 451,587
Technology | Valuation Cost Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				$ 109,904
Technology | Valuation Cost Approach | Origination Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 43,732
Technology | Valuation Cost Approach | Minimum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0990		0.1112
Technology | Valuation Cost Approach | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.0100
Technology | Valuation Cost Approach | Maximum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1253		0.1168
Technology | Valuation Cost Approach | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.3500
Technology | Valuation Cost Approach | Weighted Average | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1041	[14]	0.1139	[15]
Technology | Valuation Cost Approach | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]			0.3295
Technology | Valuation Market Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 910,488
Technology | Market Comparable Companies | Minimum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1172		0.0898
Technology | Market Comparable Companies | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.0075)		(0.0050)
Technology | Market Comparable Companies | Maximum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1752		0.1454
Technology | Market Comparable Companies | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0150		0.0075
Technology | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1422	[14]	0.1164	[15]
Technology | Market Comparable Companies | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0016	[14]	0.0012	[15]
Technology | Market Yield Analysis | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				$ 654,320
Technology | Liquidation | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 4,270		$ 2,608	[16]
Technology | Liquidation | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1500		0.2000	[16]
Technology | Liquidation | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.5500		0.5000	[16]
Technology | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[16]	0.4657	[14]	0.4048	[15]
Technology | Valuation Income Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 20,354		$ 20,425
Technology | Valuation Income Approach | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0100
Technology | Valuation Income Approach | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.5000
Technology | Valuation Income Approach | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.3583
Medical Devices | Valuation Cost Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 14,835
Medical Devices | Valuation Cost Approach | Minimum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1484
Medical Devices | Valuation Cost Approach | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0050
Medical Devices | Valuation Cost Approach | Maximum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1484
Medical Devices | Valuation Cost Approach | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		50
Medical Devices | Valuation Cost Approach | Weighted Average | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.1484
Medical Devices | Valuation Cost Approach | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]	0.0050
Lower Middle Market | Valuation Cost Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 25,595		$ 3,100
Lower Middle Market | Valuation Cost Approach | Minimum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0967		0.0517
Lower Middle Market | Valuation Cost Approach | Maximum | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0967		0.0517
Lower Middle Market | Valuation Cost Approach | Weighted Average | Measurement Input, Discount Rate | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0967	[14]	0.0517	[15]
Lower Middle Market | Valuation Market Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 308,155
Lower Middle Market | Market Comparable Companies | Minimum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1271		0.1223
Lower Middle Market | Market Comparable Companies | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.0200)		0
Lower Middle Market | Market Comparable Companies | Maximum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1782		0.1601
Lower Middle Market | Market Comparable Companies | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0150		0.0150
Lower Middle Market | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1394	[14]	0.1322	[15]
Lower Middle Market | Market Comparable Companies | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.0038)	[14]	0.0043	[15]
Lower Middle Market | Market Yield Analysis | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				$ 81,566
Lower Middle Market | Liquidation | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 8,318		$ 8,269	[16]
Lower Middle Market | Liquidation | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2000		0.2000	[16],[17]
Lower Middle Market | Liquidation | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.8000		0.8000	[1]
Lower Middle Market | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.8000	[14],[18]	0.8000	[15],[16]
Lower Middle Market | Expected Realizable Value | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[1]			$ 90,504
Lower Middle Market | Expected Realizable Value | Minimum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.1064
Lower Middle Market | Expected Realizable Value | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				(0.0100)
Lower Middle Market | Expected Realizable Value | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[1]			0.3000
Lower Middle Market | Expected Realizable Value | Maximum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.1064
Lower Middle Market | Expected Realizable Value | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				(0.0100)
Lower Middle Market | Expected Realizable Value | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[1]			0.7000
Lower Middle Market | Expected Realizable Value | Weighted Average | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]			0.1064
Lower Middle Market | Expected Realizable Value | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]			(0.0100)
Lower Middle Market | Expected Realizable Value | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[1],[15]			0.5774
Sustainable And Renewable Technology | Valuation Cost Approach | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.4000
Sustainable And Renewable Technology | Valuation Cost Approach | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.6000
Sustainable And Renewable Technology | Valuation Cost Approach | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15]			0.5184
Sustainable And Renewable Technology | Valuation Market Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 2,961
Sustainable And Renewable Technology | Market Comparable Companies | Minimum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1367
Sustainable And Renewable Technology | Market Comparable Companies | Minimum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0075
Sustainable And Renewable Technology | Market Comparable Companies | Maximum | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1367
Sustainable And Renewable Technology | Market Comparable Companies | Maximum | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0075
Sustainable And Renewable Technology | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.1367
Sustainable And Renewable Technology | Market Comparable Companies | Weighted Average | Premium/(Discount) | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.0075
Sustainable And Renewable Technology | Valuation Income Approach | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				$ 247
Sustainable And Renewable Technology | Expected Realizable Value | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[17]			$ 7,500
Sustainable And Renewable Technology | Expected Realizable Value | Minimum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[17]			1
Sustainable And Renewable Technology | Expected Realizable Value | Maximum | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[17]			1
Sustainable And Renewable Technology | Expected Realizable Value | Weighted Average | Probability weighting of alternative outcomes | Debt Investment
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[15],[17]			1
[1] Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. Weighted averages are calculated based on the fair market value of each investment. Weighted averages are calculated based on the fair market value of each investment. Represents the range of changes in industry valuations since the portfolio company's last external valuation event. Represents the range of changes in industry valuations since the portfolio company's last external valuation event. The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The fair market value of these investments is derived based on recent market transactions. The weighted averages are calculated based on the fair market value of each investment. The weighted averages are calculated based on the fair market value of each investment. The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy Of Outstanding Borrowings (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		$ 1,521,220	$ 1,236,303
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		1,521,220	1,236,303
Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		1,356,824	1,268,425
SBA Debentures | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		169,591	145,498
SBA Debentures | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		153,614	151,471
July 2024 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		104,459	104,238
July 2024 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		99,364	110,496
February 2025 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,723	49,637
February 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		45,739	51,983
June 2025 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		69,555	69,433
June 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		63,834	72,031
June 2025 3-Year Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,577
June 2025 3-Year Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,626
March 2026 A Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,676	49,605
March 2026 A Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		44,107	52,646
March 2026 B Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,647	49,570
March 2026 B Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		44,181	52,751
September 2026 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		321,112	320,376
September 2026 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		261,406	315,495
January 2027 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		344,271
January 2027 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		286,885
2031 Asset-Backed Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		147,810
2031 Asset-Backed Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		145,500
2033 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		38,799	38,718
2033 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		37,568	42,672
MUFG Bank Facility | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt	[1]	102,000
MUFG Bank Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value	[1]	102,000
SMBC Facility | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		25,000	29,925
SMBC Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		25,000	29,925
2022 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt			149,563
2022 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value			152,906
2022 Convertible Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt			229,740
2022 Convertible Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value			236,049
Observable Inputs Level 2 | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		183,068	431,627
Observable Inputs Level 2 | 2031 Asset-Backed Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		145,500
Observable Inputs Level 2 | 2033 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		37,568	42,672
Observable Inputs Level 2 | 2022 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value			152,906
Observable Inputs Level 2 | 2022 Convertible Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value			236,049
Unobservable Inputs Level 3 | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		1,173,756	836,798
Unobservable Inputs Level 3 | SBA Debentures | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		153,614	151,471
Unobservable Inputs Level 3 | July 2024 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		99,364	110,496
Unobservable Inputs Level 3 | February 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		45,739	51,983
Unobservable Inputs Level 3 | June 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		63,834	72,031
Unobservable Inputs Level 3 | June 2025 3-Year Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,626
Unobservable Inputs Level 3 | March 2026 A Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		44,107	52,646
Unobservable Inputs Level 3 | March 2026 B Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		44,181	52,751
Unobservable Inputs Level 3 | September 2026 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		261,406	315,495
Unobservable Inputs Level 3 | January 2027 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		286,885
Unobservable Inputs Level 3 | MUFG Bank Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value	[1]	102,000
Unobservable Inputs Level 3 | SMBC Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		$ 25,000	$ 29,925
[1] The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments - Additional Inform

Investments - Additional Information (Details) - Firm	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Investments [Line Items]
Percentage of portfolio investment fair value	0%	0%
Percentage of fair value investment in portfolio companies	30.10%	30.50%
Count greater five percent fair value equity	3	6
Percentage of equity investments held in portfolio companies	36.60%	49.60%
Concentrations of Credit Risk
Schedule Of Investments [Line Items]
Number of portfolio companies	8	6
Senior Secured First Lien | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	77.40%	77%
First Lien IP | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	40.20%	37.50%
First Lien All Assets | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	27.90%	31.60%
Second Lien | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	20.60%	20.60%
First Lien last-out Senior Secured | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	9.30%	7.90%
Unsecured Debt | Revenue Benchmark | Collateral Type Concentration Risk
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	2%	2.40%

Investments - Schedule of Reali

Investments - Schedule of Realized Gains and Losses and Changes in Unrealized Appreciation and Depreciation on Control and Affiliate investments (Details) - USD ($) $ in Thousands		3 Months Ended				9 Months Ended
		Sep. 30, 2022		Sep. 30, 2021		Sep. 30, 2022		Sep. 30, 2021		Dec. 31, 2021		Dec. 31, 2020
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)		$ 2,825,738				$ 2,825,738				$ 2,434,522
Interest Income		81,408		$ 63,312		212,391		$ 188,400
Fee Income		2,821		6,881		9,110		20,111
Total net change in unrealized appreciation (depreciation)		(2,089)		(35,651)		(87,147)		46,231
Total net realized gain (loss)		5,289		21,111		775		14,599
Investment, Affiliated Issuer [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)		80,325	[1]	75,547		80,325	[1]	75,547		82,962	[2]	$ 65,740
Total net change in unrealized appreciation (depreciation)						7,700		56,893
Total net realized gain (loss)						1,758		(62,143)
Investment, Affiliated Issuer [Member] | Control & Affiliate Investments
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	80,325		75,547		80,325		75,547
Interest Income	[3]	1,262		1,073		4,644		2,903
Fee Income	[3]	18		20		51		43
Total net change in unrealized appreciation (depreciation)	[3]	2,060		(3,892)		7,700		56,893
Total net realized gain (loss)	[3]	(2,014)		0		1,758		(62,143)
Investment, Affiliated Issuer, Controlled [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)		80,325	[1]	65,835		80,325	[1]	65,835		73,504	[2]	57,400
Interest Income		1,181		1,072		3,440		2,900
Fee Income		18		20		51		43
Total net change in unrealized appreciation (depreciation)		(2,571)		(3,774)		3,611		(7,327)
Total net realized gain (loss)						0		0
Investment, Affiliated Issuer, Controlled [Member] | Control Investments
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	80,325		65,835		80,325		65,835
Interest Income	[3]	1,181		1,072		3,440		2,900
Fee Income	[3]	18		20		51		43
Total net change in unrealized appreciation (depreciation)	[3]	(2,571)		(3,774)		3,611		(7,327)
Total net realized gain (loss)	[3]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics, LLC
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	400				400
Interest Income	[3]	0				0
Fee Income	[3]	0				0
Total net change in unrealized appreciation (depreciation)	[3]	(22)				(165)
Total net realized gain (loss)	[3]	0				0
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital, LLC
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	37,662		40,737		37,662		40,737
Interest Income	[3]	853		853		2,531		2,325
Fee Income	[3]	18		15		51		38
Total net change in unrealized appreciation (depreciation)	[3]	(1,423)		(3,475)		(6,228)		(17,690)
Total net realized gain (loss)	[3]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser LLC
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	33,945		16,804		33,945		16,804
Interest Income	[3]	154		45		393		59
Fee Income	[3]	0		0		0		0
Total net change in unrealized appreciation (depreciation)	[3]	(1,236)		(219)		9,955		10,669
Total net realized gain (loss)	[3]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	8,318		8,294		8,318		8,294
Interest Income	[3]	174		174		516		516
Fee Income	[3]	0		5		0		5
Total net change in unrealized appreciation (depreciation)	[3]	110		(80)		49		(306)
Total net realized gain (loss)	[3]	0		0		0		0
Investment, Affiliated Issuer, Noncontrolled [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)		0		9,712		0		9,712		9,458	[2]	$ 8,340
Interest Income		81		1		1,204		3
Total net change in unrealized appreciation (depreciation)		4,631		(118)		4,089		64,220
Total net realized gain (loss)		(2,014)		0		1,758		(62,143)
Investment, Affiliated Issuer, Noncontrolled [Member] | Affiliate Investments
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	0		9,712		0		9,712
Interest Income	[3]	81		1		1,204		3
Fee Income	[3]	0		0		0		0
Total net change in unrealized appreciation (depreciation)	[3]	4,631		(118)		4,089		64,220
Total net realized gain (loss)	[3]	(2,014)		0		1,758		(62,143)
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow AI, Inc. affiliates
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]	0	[4]	1,243		0	[4]	1,243
Interest Income	[3]	0	[4]	0		0	[4]	0
Fee Income	[3]	0	[4]	0		0	[4]	0
Total net change in unrealized appreciation (depreciation)	[3]	0	[4]	(66)		(120)	[4]	2,028
Total net realized gain (loss)	[3]	0	[4]	0		3,772	[4]	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy LLC
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)		0	[3],[4]	8,469	[3]	0	[3],[4]	8,469	[3]	$ 8,338	[2]
Interest Income	[3]	81	[4]	1		1,204	[4]	3
Fee Income	[3]	0	[4]	0		0	[4]	0
Total net change in unrealized appreciation (depreciation)	[3]	4,631	[4]	(52)		4,209	[4]	9
Total net realized gain (loss)	[3]	$ (2,014)	[4]	0		$ (2,014)	[4]	0
Investment, Affiliated Issuer, Noncontrolled [Member] | Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Schedule Of Investments [Line Items]
Total investments, at fair value (cost of $2,869,469 and $2,390,984, respectively; fair value amounts related to a VIE $236,826 and $0, respectively)	[3]			0				0
Interest Income	[3]			0				0
Fee Income	[3]			0				0
Total net change in unrealized appreciation (depreciation)	[3]			0				62,183
Total net realized gain (loss)	[3]			$ 0				$ (62,143)
[1] All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021 , there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act.

Investments - Schedule of Fair

Investments - Schedule of Fair Value Portfolio of Investments by Asset Class (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 2,825,738	$ 2,434,522
Investment Funds And Vehicles
Schedule Of Investments [Line Items]
Investments at Fair Value	3,046	1,814
Senior Secured
Schedule Of Investments [Line Items]
Investments at Fair Value	2,607,006	2,156,709
Unsecured Debt
Schedule Of Investments [Line Items]
Investments at Fair Value	54,393	52,890
Preferred Note
Schedule Of Investments [Line Items]
Investments at Fair Value	41,038	69,439
Common Stock
Schedule Of Investments [Line Items]
Investments at Fair Value	93,096	115,271
Warrant
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 27,159	$ 38,399
Investment Type Concentration Risk | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Investment Type Concentration Risk | Revenue Benchmark | Investment Funds And Vehicles
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0.10%
Investment Type Concentration Risk | Revenue Benchmark | Senior Secured
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	92.30%	88.60%
Investment Type Concentration Risk | Revenue Benchmark | Unsecured Debt
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.90%	2.20%
Investment Type Concentration Risk | Revenue Benchmark | Preferred Note
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.40%	2.80%
Investment Type Concentration Risk | Revenue Benchmark | Common Stock
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3.30%	4.70%
Investment Type Concentration Risk | Revenue Benchmark | Warrant
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1%	1.60%
Geographic Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%

Investments - Schedule of Fai_2

Investments - Schedule of Fair Value Portfolio of Investments by Geographic Location (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 2,825,738	$ 2,434,522
United States
Schedule Of Investments [Line Items]
Investments at Fair Value	2,545,973	2,138,184
United Kingdom
Schedule Of Investments [Line Items]
Investments at Fair Value	158,491	169,407
Netherlands
Schedule Of Investments [Line Items]
Investments at Fair Value	88,174	82,925
Canada
Schedule Of Investments [Line Items]
Investments at Fair Value	19,373	27,673
Israel
Schedule Of Investments [Line Items]
Investments at Fair Value	9,005	8,980
Ireland
Schedule Of Investments [Line Items]
Investments at Fair Value	3,313	5,459
Germany
Schedule Of Investments [Line Items]
Investments at Fair Value	924	1,894
Other
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 485	$ 0
Geographic Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Geographic Concentration Risk [Member] | Revenue Benchmark | United States
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	90.10%	87.80%
Geographic Concentration Risk [Member] | Revenue Benchmark | United Kingdom
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	5.60%	7%
Geographic Concentration Risk [Member] | Revenue Benchmark | Netherlands
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3.10%	3.40%
Geographic Concentration Risk [Member] | Revenue Benchmark | Canada
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.70%	1.10%
Geographic Concentration Risk [Member] | Revenue Benchmark | Israel
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.30%	0.40%
Geographic Concentration Risk [Member] | Revenue Benchmark | Ireland
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0.20%
Geographic Concentration Risk [Member] | Revenue Benchmark | Germany
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0.10%
Geographic Concentration Risk [Member] | Revenue Benchmark | Other
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0%

Investments - Schedule of Fai_3

Investments - Schedule of Fair Value Portfolio By Industry Sector (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 2,825,738	$ 2,434,522
Drug Discovery & Development
Schedule Of Investments [Line Items]
Investments at Fair Value	1,091,827	967,383
Software
Schedule Of Investments [Line Items]
Investments at Fair Value	680,216	585,622
Internet Consumer And Business Services
Schedule Of Investments [Line Items]
Investments at Fair Value	489,968	395,506
Healthcare Services Other
Schedule Of Investments [Line Items]
Investments at Fair Value	203,599	121,003
Communications & Networking
Schedule Of Investments [Line Items]
Investments at Fair Value	101,094	105,490
Diversified Financial Services
Schedule Of Investments [Line Items]
Investments at Fair Value	72,061	65,073
Information Services
Schedule Of Investments [Line Items]
Investments at Fair Value	59,735	74,417
Manufacturing Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	43,892	14,995
Consumer & Business Products
Schedule Of Investments [Line Items]
Investments at Fair Value	25,497	28,099
Sustainable And Renewable Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	15,683	39,387
Semiconductors
Schedule Of Investments [Line Items]
Investments at Fair Value	20,621	22,498
Medical Devices & Equipment
Schedule Of Investments [Line Items]
Investments at Fair Value	17,421	12,612
Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Investments at Fair Value	2,498	1,040
Surgical Devices
Schedule Of Investments [Line Items]
Investments at Fair Value	1,536	1,029
Drug Delivery
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 90	$ 368
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Discovery & Development
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	38.60%	39.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Software
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	24.10%	24.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Internet Consumer And Business Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	17.30%	16.30%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Healthcare Services Other
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	7.20%	5%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Communications & Networking
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3.60%	4.30%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Diversified Financial Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	2.50%	2.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Information Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	2.10%	3.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Manufacturing Technology
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.60%	0.60%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Consumer & Business Products
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.90%	1.20%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Sustainable And Renewable Technology
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.60%	1.60%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Semiconductors
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.70%	0.90%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Medical Devices & Equipment
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.60%	0.50%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Surgical Devices
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Delivery
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0%

Debt - Schedule of Available an

Debt - Schedule of Available and Outstanding Debt (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021	Oct. 23, 2017	Jan. 25, 2017
Debt Instrument [Line Items]
Outstanding balance		$ 2,185,000	$ 1,745,000	$ 150,000
Principal		1,542,000	1,250,425
Carrying Value	[1]	1,521,220	1,236,303
SBA Debentures
Debt Instrument [Line Items]
Outstanding balance		175,000	175,000
Principal		175,000	150,500
Carrying Value	[1]	169,591	145,498
2022 Notes
Debt Instrument [Line Items]
Outstanding balance		0	150,000
Principal		0	150,000
Carrying Value	[1]	0	149,563
July 2024 Notes
Debt Instrument [Line Items]
Outstanding balance		105,000	105,000
Principal		105,000	105,000
Carrying Value	[1]	104,459	104,238
February 2025 Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,723	49,637
June 2025 Notes
Debt Instrument [Line Items]
Outstanding balance		70,000	70,000
Principal		70,000	70,000
Carrying Value	[1]	69,555	69,433
June 2025 3-Year Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	0
Principal		50,000	0
Carrying Value	[1]	49,577	0
March 2026 A Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,676	49,605
March 2026 B Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,647	49,570
September 2026 Notes
Debt Instrument [Line Items]
Outstanding balance		325,000	325,000
Principal		325,000	325,000
Carrying Value	[1]	321,112	320,376
January 2027 Notes
Debt Instrument [Line Items]
Outstanding balance		350,000	0
Principal		350,000	0
Carrying Value	[1]	344,271	0
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Outstanding balance		150,000	0
Principal		150,000	0
Carrying Value	[1]	147,810	0
2033 Notes
Debt Instrument [Line Items]
Outstanding balance		40,000	40,000
Principal		40,000	40,000
Carrying Value	[1]	38,799	38,718
2022 Convertible Notes
Debt Instrument [Line Items]
Outstanding balance		0	230,000		$ 230,000
Principal		0	230,000
Carrying Value	[1]	0	229,740
MUFG Bank Facility
Debt Instrument [Line Items]
Outstanding balance	[2],[3]	545,000	400,000
Principal	[2],[3]	102,000	0
Carrying Value	[1],[2],[3]	102,000	0
SMBC Facility
Debt Instrument [Line Items]
Outstanding balance	[2]	225,000	100,000
Principal	[2]	25,000	29,925
Carrying Value	[1],[2]	$ 25,000	$ 29,925
[1] Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. Availability subject to the Company meeting the borrowing base requirements. The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Debt - Schedule of Debt Issuanc

Debt - Schedule of Debt Issuance Costs, Net of accumulated Amortization (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Net of debt issuance costs		$ 23,700	$ 16,035
SBA Debentures
Debt Instrument [Line Items]
Net of debt issuance costs		5,409	5,002
2022 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		0	300
July 2024 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		541	762
February 2025 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		277	363
June 2025 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		445	567
June 2025 3-Year Notes
Debt Instrument [Line Items]
Net of debt issuance costs		423	0
March 2026 A Notes
Debt Instrument [Line Items]
Net of debt issuance costs		324	395
March 2026 B Notes
Debt Instrument [Line Items]
Net of debt issuance costs		353	430
September 2026 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		3,888	4,624
January 2027 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		5,729	0
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Net of debt issuance costs		2,190	0
2033 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		1,201	1,282
2022 Convertible Notes
Debt Instrument [Line Items]
Net of debt issuance costs		0	149
MUFG Bank Facility
Debt Instrument [Line Items]
Net of debt issuance costs	[1]	1,346	1,239
SMBC Facility
Debt Instrument [Line Items]
Net of debt issuance costs	[1]	$ 1,574	$ 922
[1] The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.

Debt - Components of Interest E

Debt - Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt (Details) - USD ($) $ in Thousands		3 Months Ended				9 Months Ended
		Sep. 30, 2022		Sep. 30, 2021		Sep. 30, 2022		Sep. 30, 2021
Debt Instrument [Line Items]
Interest Expense, Total		$ 16,682		$ 16,445		$ 44,361		$ 50,705
Amortization of debt issuance costs		1,268		2,772	[1]	3,507		6,532	[1]
Interest Expense Debt		14,499	[2]	13,069	[2]	38,844	[3]	42,309	[2]
Cash paid for interest expense		21,740		16,274		44,382		44,985
Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		915		604		2,010		1,864
SBA Debentures
Debt Instrument [Line Items]
Interest Expense, Total		1,308		164		3,282		1,595
Amortization of debt issuance costs		148		50	[1]	434		367	[1]
Interest Expense Debt		1,160	[3]	114	[2]	2,848	[3]	1,228	[2]
Cash paid for interest expense		2,086		183		2,835		2,272
SBA Debentures | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2022 Notes
Debt Instrument [Line Items]
Interest Expense, Total		0		1,866		1,061		5,597
Amortization of debt issuance costs		0		90	[1]	50		270	[1]
Interest Expense Debt		0	[4]	1,776	[2]	1,011	[3]	5,327	[2]
Cash paid for interest expense		0		0		2,293		3,469
2022 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
July 2024 Notes
Debt Instrument [Line Items]
Interest Expense, Total		1,326		1,326		3,978		3,977
Amortization of debt issuance costs		74		74	[1]	222		221	[1]
Interest Expense Debt		1,252	[3]	1,252	[2]	3,756	[3]	3,756	[2]
Cash paid for interest expense		2,504		2,504		5,008		5,008
July 2024 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
February 2025 Notes
Debt Instrument [Line Items]
Interest Expense, Total		564		564		1,691		1,691
Amortization of debt issuance costs		29		29	[1]	86		86	[1]
Interest Expense Debt		535	[3]	535	[2]	1,605	[3]	1,605	[2],[5]
Cash paid for interest expense		1,070		1,070		2,140		2,140
February 2025 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
June 2025 Notes
Debt Instrument [Line Items]
Interest Expense, Total		794		794		2,384		2,384
Amortization of debt issuance costs		40		40	[1]	121		121	[1]
Interest Expense Debt		754	[3]	754	[2]	2,263	[3]	2,263	[2]
Cash paid for interest expense		0		0		1,509		1,509
June 2025 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
June 2025 3-Year Notes
Debt Instrument [Line Items]
Interest Expense, Total		788				859
Amortization of debt issuance costs		38				42
Interest Expense Debt	[3]	750				817
Cash paid for interest expense		0				0
June 2025 3-Year Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0				0
March 2026 A Notes
Debt Instrument [Line Items]
Interest Expense, Total		587		587		1,760		1,758
Amortization of debt issuance costs		24		24	[1]	72		70	[1]
Interest Expense Debt		563	[3]	563	[2]	1,688	[3]	1,688	[2]
Cash paid for interest expense		1,125		1,125		2,250		1,875
March 2026 A Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
March 2026 B Notes
Debt Instrument [Line Items]
Interest Expense, Total		595		595		1,784		1,367
Amortization of debt issuance costs		26		26	[1]	78		59	[1]
Interest Expense Debt		569	[3]	569	[2]	1,706	[3]	1,308	[2]
Cash paid for interest expense		1,137		1,138		2,275		1,138
March 2026 B Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
September 2026 Notes
Debt Instrument [Line Items]
Interest Expense, Total		2,378		370		7,135		370
Amortization of debt issuance costs		204		32	[1]	612		32	[1]
Interest Expense Debt		2,174	[3]	338	[2]	6,523	[3]	338	[2]
Cash paid for interest expense		4,266		0		8,532		0
September 2026 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
January 2027 Notes
Debt Instrument [Line Items]
Interest Expense, Total		3,286				9,127
Amortization of debt issuance costs		207				575
Interest Expense Debt	[3]	3,079				8,552
Cash paid for interest expense		5,906				5,906
January 2027 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0				0
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Interest Expense, Total		2,003				2,181
Amortization of debt issuance costs		100				109
Interest Expense Debt		1,903	[2]			2,072	[3]
Cash paid for interest expense		1,815				1,815
2031 Asset-Backed Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0				0
2033 Notes
Debt Instrument [Line Items]
Interest Expense, Total		652		652		1,956		1,956
Amortization of debt issuance costs		27		27	[1]	81		81	[1]
Interest Expense Debt		625	[2]	625	[2]	1,875	[3]	1,875	[2]
Cash paid for interest expense		625		625		1,875		1,875
2033 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2022 Convertible Notes
Debt Instrument [Line Items]
Interest Expense, Total		0		2,906		1,072		8,719
Amortization of debt issuance costs		0		223	[1]	149		669	[1]
Interest Expense Debt		0	[2]	2,683	[2]	923	[3]	8,050	[2]
Cash paid for interest expense		0		5,031		5,004		10,062
2022 Convertible Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
MUFG Bank Facility
Debt Instrument [Line Items]
Interest Expense, Total		1,973	[6]	1,062	[7]	4,830	[6]	2,997	[7]
Amortization of debt issuance costs		253	[4]	314	[1],[7]	665	[6]	968	[1],[7]
Interest Expense Debt		1,000	[2],[4]	290	[2],[7]	2,483	[3],[6]	625	[2],[7]
Cash paid for interest expense		1,025	[6]	327	[7]	2,240	[6]	540	[7]
MUFG Bank Facility | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		720	[6]	458	[7]	1,682	[6]	1,404	[7]
SMBC Facility
Debt Instrument [Line Items]
Interest Expense, Total		428				1,261
Amortization of debt issuance costs		98				211
Interest Expense Debt		135	[2]			722	[3]
Cash paid for interest expense		181				700
SMBC Facility | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		$ 195				$ 328
April 2025 Notes
Debt Instrument [Line Items]
Interest Expense, Total	[5]			1,477				3,636
Amortization of debt issuance costs	[1],[5]			1,477				1,667
Interest Expense Debt				0				1,969	[2],[5]
Cash paid for interest expense	[5]			667				2,635
April 2025 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)				0				0
2027 Asset-Backed Notes
Debt Instrument [Line Items]
Interest Expense, Total	[5]			1,416				5,515
Amortization of debt issuance costs	[1],[5]			72				922
Interest Expense Debt	[2],[5]			1,344				4,593
Cash paid for interest expense	[5]			1,348				4,677
2027 Asset-Backed Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)				0				0
2028 Asset-Backed Notes
Debt Instrument [Line Items]
Interest Expense, Total	[5]			2,477				8,551
Amortization of debt issuance costs	[1],[5]			251				867
Interest Expense Debt	[2],[5]			2,226				7,684
Cash paid for interest expense	[5]			2,256				7,785
2028 Asset-Backed Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)				0				0
Wells Facility
Debt Instrument [Line Items]
Interest Expense, Total	[5]			189				592
Amortization of debt issuance costs	[1],[5]			43				132
Interest Expense Debt				0				0
Cash paid for interest expense				0				0
Wells Facility | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)	[5]			$ 146				$ 460
[1] “Amortization of debt issuance cost (loan fees)” includes $ 1,477 thousand, $ 28 thousand, and $ 197 thousand related to debt extinguishment costs for the April Interest expense includes amortization of original issue discounts for the three months ended September 30, 2021 of $ 41 thousand, $ 168 thousand, and $ 6 thousand, for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes for the nine months ended September 30, 2021 , $ 123 thousand, $ 504 thou sand, and $ 6 thousand for the 2022 Notes, 2022 Convertible Notes, and September 2026 Notes, respectively. Interest expense includes amortization of original issue discounts for the three months ended September 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the nine months ended September 30, 2022 , $ 23 thousand, $ 112 thousand, $ 125 thousand, $ 349 thousand, and $ 51 thousand related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. The April 2025 Notes, 2027 Asset-Backed Notes and 2028 Asset-Backed Notes were retired on July 1, 2021 and October 20, 2021 , respectively. The Wells November 29, 2021 . The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Debt - Components of Interest_2

Debt - Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt (Parentheticals) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Instrument [Line Items]
Debt retired			Oct. 23, 2022
Line of credit facility, termination date			Nov. 09, 2026
September 2026 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	$ 42	$ 6	$ 125	$ 6
January 2027 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	126		349
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	$ 47		51
2022 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts		41	23	123
2022 Convertible Notes
Debt Instrument [Line Items]
Amortization of original issue discounts		168	$ 112	504
Debt retired			Feb. 01, 2022
April 2025 Notes
Debt Instrument [Line Items]
Debt extinguishment costs		1,477		$ 1,477
Date retired				Jul. 01, 2021
2027 Asset-Backed Notes
Debt Instrument [Line Items]
Debt extinguishment costs		28		$ 28
Date retired				Oct. 20, 2021
2028 Asset-Backed Notes
Debt Instrument [Line Items]
Debt extinguishment costs		$ 197		$ 197
Date retired				Oct. 20, 2021
Wells Facility
Debt Instrument [Line Items]
Line of credit facility, termination date				Nov. 29, 2021

Debt - Schedule of SBA Debentur

Debt - Schedule of SBA Debentures Outstanding Principal Balances (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Maturity Date		Oct. 23, 2022
Interest Rate		4.625%
Outstanding Principal Balances		$ 1,542,000	$ 1,250,425
SBA Debentures Issued on March 26, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Mar. 26, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 37,500	37,500
SBA Debentures Issued on June 25, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Jun. 25, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 16,200	16,200
SBA Debentures Issued on July 28, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Jul. 28, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 5,400	5,400
SBA Debentures Issued on August 20, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Aug. 20, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 5,400	5,400
SBA Debentures Issued on October 21, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Oct. 21, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 14,000	14,000
SBA Debentures Issued on November 1, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 01, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 21,000	21,000
SBA Debentures Issued on November 15, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 15, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 5,200	5,200
SBA Debentures Issued on November 30, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 30, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 20,800	20,800
SBA Debentures Issued on December 20, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 20, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 10,000	10,000
SBA Debentures Issued on December 23, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 23, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 10,000	10,000
SBA Debentures Issued on December 28, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 28, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 5,000	5,000
SBA Debentures Issued on January 14, 2022
Debt Instrument [Line Items]
Issuance/Pooling Date		Jan. 14, 2022
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 4,500	0
SBA Debentures Issued on January 21, 2022
Debt Instrument [Line Items]
Issuance/Pooling Date		Jan. 21, 2022
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 20,000	0
SBA Debentures
Debt Instrument [Line Items]
Outstanding Principal Balances		$ 175,000	$ 150,500
[1] Interest rates are fixed rates set based on the pooling date of each debenture. The rates shown above are inclusive of annual SBA charges.

Debt - Additional Information (

Debt - Additional Information (Details) $ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Jun. 23, 2022 USD ($)

Feb. 22, 2022 USD ($)

Jan. 20, 2022 USD ($)

Sep. 16, 2021 USD ($)

Mar. 04, 2021 USD ($)

Oct. 27, 2020 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Sep. 30, 2022 USD ($) Firm

Sep. 30, 2021 USD ($)

Dec. 31, 2021 USD ($)

Jun. 22, 2022 USD ($)

Feb. 01, 2022 USD ($) shares

Nov. 04, 2020 USD ($)

Jun. 03, 2020 USD ($)

Feb. 05, 2020 USD ($)

Jul. 16, 2019 USD ($)

Sep. 24, 2018 USD ($)

Oct. 23, 2017 USD ($)

Jan. 25, 2017 USD ($)

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 2,185,000

$ 2,185,000

$ 1,745,000

$ 150,000

Investment Owned At Fair Value

$ 2,825,738

$ 2,825,738

2,434,522

Debt instrument, interest rate

4.625%

4.625%

Debt Instrument Maturity Date

Oct. 23, 2022

Debt Instrument, redemption, description

On October 23, 2017, the Company issued $150.0 million in aggregate principal amount of 4.625% interest-bearing unsecured notes that mature on October 23, 2022 (the “2022 Notes”), unless repurchased in accordance with their terms

Repayment of debt

$ 150,000

Interest payable

2,300

Gain (loss) on extinguishment of debt

$ 0

$ (1,702)

$ (3,686)

$ (1,702)

Restricted cash (amounts related to a VIE $8,346 and $0, respectively)

8,346

$ 13,509

$ 8,346

$ 13,509

3,150

Line of credit facility, termination date

Nov. 09, 2026

Line of Credit Facility, Description

Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026.

Variable Interest Entity Primary Beneficiary [Member]

Debt Instrument [Line Items]

Restricted cash (amounts related to a VIE $8,346 and $0, respectively)

8,346

$ 8,346

0

MUFG Bank Facility

Debt Instrument [Line Items]

Line of Credit Facility, Covenant Terms

these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of $723.0 million.

Line of credit facility, termination date

Feb. 22, 2024

Minimum tangible net worth amount

723,000

$ 723,000

Maximum borrowing capacity

545,000

$ 545,000

Line of Credit Facility, Description

The MUFG Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions.

MUFG Bank Facility | Maximum

Debt Instrument [Line Items]

Maximum borrowing capacity

600,000

$ 600,000

MUFG Bank Facility | One-month interest period

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

2.60%

MUFG Bank Facility | Three-month interest period

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

2.65%

MUFG Bank Facility | Lender [Member]

Debt Instrument [Line Items]

Maximum borrowing capacity

400,000

S M B C Facility [Member]

Debt Instrument [Line Items]

Line of credit facility, termination date

Nov. 07, 2025

Maximum borrowing capacity

225,000

$ 225,000

100,000

Line of Credit Facility, Description

the SMBC Facility provides for the issuance of letters of credit on the account of the Company or its designee in U.S. dollars and certain agreed upon foreign currencies in an aggregate face amount not to exceed $15.0 million.

Line of credit facility, unused capacity, commitment fee percentage

0.375%

S M B C Facility [Member] | Minimum

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

0.875%

S M B C Facility [Member] | Maximum

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

2%

Credit Facility [Member]

Debt Instrument [Line Items]

Debt average amount outstanding

$ 115,600

$ 28,800

Line of credit interest rate

3.70%

2.54%

Debt Issuance Cost

Debt Instrument [Line Items]

Gain (loss) on extinguishment of debt

(300)

Prepayment Fees

Debt Instrument [Line Items]

Gain (loss) on extinguishment of debt

$ (3,300)

Foreign Currency Borrowing Member | S M B C Facility [Member] | Maximum

Debt Instrument [Line Items]

Maximum borrowing capacity

15,000

$ 15,000

2022 Convertible Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 0

$ 0

$ 230,000

$ 230,000

Debt instrument, interest rate

4.375%

4.375%

Debt Instrument Maturity Date

Feb. 01, 2022

Debt Instrument, redemption, description

On January 25, 2017, the Company issued $230.0 million in aggregate principal amount of 4.375% interest-bearing unsecured notes due on February 1, 2022 (the “2022 Convertible Notes”), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2022 Convertible Notes

Repayment of debt

$ 230,000

Interest payable

$ 5,000

Debt instrument, payment terms, description

Interest on the 2022 Convertible Notes is due semiannually in arrears on February 1 and August 1 of each year

Convertible Debt Redemption Shares Issued on Redemption | shares

981,169

2022 Convertible Notes | Additional Face Amount [Member]

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 30,000

July 2024 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 105,000

Debt instrument, interest rate

4.77%

4.77%

Debt Instrument Maturity Date

Jul. 16, 2024

Debt Instrument, redemption, description

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the July 2024 Notes is due semiannually

Debt Instrument, Collateral

The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

February 2025 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 50,000

Debt instrument, interest rate

4.28%

4.28%

Debt Instrument Maturity Date

Feb. 05, 2025

Debt Instrument, redemption, description

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the February 2025 Notes is due semiannually

Debt Instrument, Collateral

The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 70,000

Debt instrument, interest rate

4.31%

4.31%

Debt Instrument Maturity Date

Jun. 03, 2025

Debt Instrument, redemption, description

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the June 2025 Notes is due semiannually.

Debt Instrument, Collateral

The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 3-Year Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 50,000

Debt instrument, interest rate

6%

6%

Debt Instrument Maturity Date

Jun. 23, 2025

Debt Instrument, redemption, description

On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.00% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the June 2025 3-Year Notes is due semiannually.

Debt Instrument, Collateral

The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 A Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 50,000

Debt instrument, interest rate

4.50%

4.50%

Debt Instrument Maturity Date

Mar. 04, 2026

Debt Instrument, redemption, description

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.5% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the March 2026 A Notes is due semiannually

Debt Instrument, Collateral

The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 B Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 50,000

Debt instrument, interest rate

4.55%

4.55%

Debt Instrument Maturity Date

Mar. 04, 2026

Debt Instrument, redemption, description

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering.

Debt instrument, payment terms, description

Interest on the March 2026 B Notes is due semiannually

Net proceeds from sale of Notes

49,500

Aggregate Debt Issuance Cost

$ 500

Debt Instrument, Collateral

The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

September 2026 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 325,000

Debt instrument, interest rate

2.625%

2.625%

Debt Instrument Maturity Date

Sep. 16, 2026

Debt Instrument, redemption, description

The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture.

Debt instrument, payment terms, description

Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year, commencing on March 16, 2022

Net proceeds from sale of Notes

320,100

Aggregate Debt Issuance Cost

4,100

Aggregate Discount On Issuance

$ 800

Debt Instrument, Collateral

The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

January 2027 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 350,000

Debt instrument, interest rate

3.375%

3.375%

Debt Instrument Maturity Date

Jan. 20, 2027

Debt Instrument, redemption, description

The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.

Debt instrument, payment terms, description

Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year, commencing on July 20, 2022

Net proceeds from sale of Notes

343,400

Aggregate Debt Issuance Cost

4,100

Aggregate Discount On Issuance

$ 2,500

Debt Instrument, Collateral

The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

2031 Asset-Backed Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 150,000

Debt instrument, interest rate

4.95%

4.95%

Debt Instrument Maturity Date

Jul. 20, 2031

Debt instrument, payment terms, description

Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.

2031 Asset-Backed Notes | Variable Interest Entity Primary Beneficiary [Member]

Debt Instrument [Line Items]

Restricted cash (amounts related to a VIE $8,346 and $0, respectively)

$ 8,300

$ 8,300

$ 0

2033 Notes

Debt Instrument [Line Items]

Debt Instrument Face Amount

$ 40,000

Debt instrument, interest rate

6.25%

6.25%

Debt Instrument Maturity Date

Oct. 30, 2033

Debt Instrument, redemption, description

The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes Indenture after October 30, 2023.

Debt instrument, payment terms, description

Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year

Debt Instrument, Collateral

The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

HC IV

Debt Instrument [Line Items]

License term

10 years

Debt Instrument, license description

HC IV received its license to operate as a SBIC on October 27, 2020. The license has a 10-year term.

Regulatory capital commitment amount

$ 87,500

Debt Instrument Face Amount

$ 175,000

$ 175,000

Investments held by number of companies | Firm

18

Investment Owned At Fair Value

$ 277,100

$ 277,100

Percentage of total investment portfolio

9.80%

9.80%

Tangible Assets

$ 287,600

$ 287,600

Percentage of total assets held

9.80%

9.80%

Maximum borrowing capacity

$ 175,000

HC IV | SBA Commitment Fee [Member]

Debt Instrument [Line Items]

Debt issuance cost

$ 1,750

$ 1,750

HC IV | SBA Facility Fee [Member]

Debt Instrument [Line Items]

Debt issuance cost

$ 4,200

$ 4,200

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Taxable income	$ 49,100	$ (43,300)	$ 122,200	$ 125,300
Taxable income per share	$ 0.39	$ 0.38	$ 0.99	$ 1.09
Taxable net realized gains	$ 2,000	$ (23,000)	$ 100	$ (80,500)
Taxable net realized gains per share	$ (0.02)	$ 0.20	$ 0	$ 0.70
Income Taxes Paid, Net, Total	$ 100	$ 100	$ 7,341	$ 3,731
Taxes payable	$ 4,000	$ 4,900	$ 4,000	$ 4,900
Common Stock, Dividends, Per Share, Declared	$ 0.50		$ 1.46
Investment company dividend distribution percentage distributable earnings	100%		100%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	May 09, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Accumulated proceeds from issuance of shares	$ 42,854	$ (10)	$ 189,958	$ (208)
Offering expenses on issuance of shares			$ 2,053	$ 208
Common Stock
Class Of Stock [Line Items]
Shares issued and sold	2,866,000		11,787,000
Accumulated proceeds from issuance of shares	$ 3		$ 12
Equity distribution agreement remaining available shares 2022	11,300,000		11,300,000
Common stock, reserved for future issuance	207,794		207,794			210,569
2022 Equity Distribution Agreement [Member]
Class Of Stock [Line Items]
Accumulated proceeds from issuance of shares	$ 42,900		$ 91,500
Offering expenses on issuance of shares	$ 400		$ 1,000
2022 Equity Distribution Agreement [Member] | Common Stock
Class Of Stock [Line Items]
Shares issued and sold	2,900,000		6,200,000
Equity distribution agreement available shares					17,500,000
2020 Equity Distribution Agreement [Member]
Class Of Stock [Line Items]
Accumulated proceeds from issuance of shares			$ 98,500
Offering expenses on issuance of shares			$ 1,100
2020 Equity Distribution Agreement [Member] | Common Stock
Class Of Stock [Line Items]
Shares issued and sold	0		5,600,000

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional information (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Jun. 28, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation		$ 2,500,000	$ 3,300,000	$ 10,600,000	$ 9,000,000
Unrecognized compensation costs		$ 16,000,000	$ 18,300,000	$ 16,000,000	$ 18,300,000
Total unrecognized compensation costs expected to be recognized, Period				1 year 9 months 18 days	1 year 10 months 24 days
Performance Award shares vested	[1]			578,579	517,076
Distribution equivalent units				632,831	748,519
Unvested Performance Awards		1,066,693	1,149,523	1,066,693	1,149,523	1,037,848	989,100
Employee Stock option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 52,000	$ 23,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted				143,000	123,000
Service vesting awards granted				$ 143,000	123,000
Service-Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards				2 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted				$ 11,100,000	11,200,000
Service vesting awards granted				$ 11,100,000	11,200,000
Performance Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards				The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted.
Performance Award shares vested				487,409
Distribution equivalent units				241,770
Distribution equivalent units (“DEUs”) were issued with a grant date fair value					$ 4,000,000
Unvested Performance Awards		0	487,409	0	487,409
Liability Classified Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 2,300,000	$ 1,300,000
Unrecognized compensation costs		$ 2,300,000	$ 4,200,000	$ 2,300,000	$ 4,200,000
Total unrecognized compensation costs expected to be recognized, Period				1 year 7 months 6 days	2 years 2 months 12 days
Remaining max award value		$ 4,300,000		$ 4,300,000
Weighted average performance conditions in liability		100%		100%
Accounts payable and accrued liabilities		$ 2,000,000	$ 5,300,000	$ 2,000,000	$ 5,300,000
Liability award vested				$ 6,000,000	$ 0
Two Thousand Eighteen Plan And Director Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								18,700,000
Two Thousand Eighteen Plan And Director Plan | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								300,000
[1] With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.

Equity Incentive Plans - Unvest

Equity Incentive Plans - Unvested Restricted Stock Equity Awards (Details) - $ / shares		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Unvested Shares Beginning of Period		1,037,848	989,100
Granted		632,831	748,519
Vested (1)	[1]	(578,579)	(517,076)
Forfeited		(25,407)	(71,020)
Unvested Shares End of Period		1,066,693	1,149,523
Unvested Shares Beginning of Period		$ 14.51	$ 13.69
Granted		17.24	14.80
Vested (1)	[1]	14.39	13.71
Forfeited		15.99	14.16
Unvested Shares End of Period		$ 16.16	$ 14.42
[1] With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator
Net increase in net assets resulting from operations	$ 53,202	$ 23,549	$ 39,548	$ 170,443
Less: Distributions declared-common and restricted shares	63,950	45,190	181,825	133,143
(Over-)Undistributed earnings (loss)	(10,748)	(21,641)	(142,277)	37,300
Add: Distributions declared-common shares	(63,950)	(45,190)	(181,825)	(133,143)
Numerator for basic and diluted change in net assets per common share	$ 52,673	$ 23,129	$ 37,837	$ 168,760
Denominator
Basic	127,484	114,805	123,379	114,590
Incremental shares from assumed conversion of 2022 Convertible Notes	0	661	0	293
Common shares issuable	1,850	773	1,388	667
Weighted average common shares outstanding assuming dilution	129,334	116,239	124,767	115,550
Change in net assets per common share
Basic	$ 0.41	$ 0.20	$ 0.31	$ 1.47
Diluted	$ 0.41	$ 0.20	$ 0.30	$ 1.46
Common Stock [Member]
Numerator
Less: Distributions declared-common and restricted shares	$ 63,421	$ 44,770	$ 180,114	$ 131,829
(Over-)Undistributed earnings (loss)	(10,748)	(21,641)	(142,277)	36,931
Add: Distributions declared-common shares	$ (63,421)	$ (44,770)	$ (180,114)	$ (131,829)

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Number of Anti-diluted Shares As Calculated Based on Weighted Average Closing Price of Common Stock (Details) - shares		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
2022 Convertible Notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		0	0	0	0
Unvested Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		865	198	1,725	88
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	[1]	0	0	0	0
Unvested Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		3,982	710	1,611	720
Performance Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	[1]	0	0	0	0
[1] Included in these amounts are shares related to certain equity-based awards, which are fully-vested but have not been delivered and thus not outstanding for purposes of calculating earnings per share.

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Common Stock, Shares Authorized	200,000,000	200,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, voting rights	Each share of common stock entitles the holder to one vote.

Financial Highlights - Schedule

Financial Highlights - Schedule of Financial Highlights of the Company (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Net investment income before investment gains and losses per common share:
Net asset value at beginning of period				$ 11.22	$ 11.26
Net investment income before investment gains and losses per common share: Basic		$ 0.39	$ 0.33	1.01	0.95
Total from investment operations				0.31	1.47
Investment Company, Issuance of Shares, Per Share	[1]			0.31	(0.11)
Distributions of net investment income	[2]				(0.09)
Stock-based compensation expense included in investment income	[3]			0.09	0.07
Net asset value at end of period		10.47	11.54	10.47	11.54
Ratios and supplemental data (in thousands, except per share data):
Per share market value at end of period		$ 11.58	$ 16.61	$ 11.58	$ 16.61
Total return	[4]			(24.34%)	23.05%
Shares outstanding at end of period		130,191	115,925	130,191	115,925
Basic		127,484	114,805	123,379	114,590
Diluted		129,334	116,239	124,767	115,550
Net assets at end of period		$ (1,362,718)	$ (1,337,532)	$ (1,362,718)	$ (1,337,532)	$ (1,327,740)	$ (1,308,547)	$ (1,356,358)	$ (1,291,704)
Ratio of total expense to average net assets	[5]			9.51%	9.93%
Ratio of net investment income before investment gains and losses to average net assets	[5]			12.53%	11.01%
Investment Company, Portfolio Turnover	[6]			14.12%	33.14%
Weighted average debt outstanding				$ 1,430,814	$ 1,246,769
Weighted average debt per common share				$ 11.60	$ 10.88
Realized
Net investment income before investment gains and losses per common share:
Net gain (loss)				0.01	0.12
Unrealized
Net investment income before investment gains and losses per common share:
Net gain (loss)				(0.71)	0.40
Capital Gains Member
Net investment income before investment gains and losses per common share:
Distributions of net investment income	[2]			(0.35)
Ordinary Income
Net investment income before investment gains and losses per common share:
Distributions of net investment income	[2]			$ (1.11)	$ (1.06)
[1] All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. Includes distributions on unvested restricted stock awards. Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC Topic 718, net investment income includes the expense associated with the granting of stock options which is offset by a corresponding increase in paid-in capital. The total return for the nine months ended September 30, 2022, and 2021 , equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. The ratios are calculated based on weighted average net assets for the relevant period and are annualized. The portfolio turnover rate for the nine months ended September 30, 2022, and 2021 , equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Investment Company, Financial Commitment to Investee, Future Amount	[1]	$ 658,970		$ 658,970		$ 286,752
Total rent expense		$ 800	$ 800	$ 2,400	$ 2,400
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions".

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[1]	$ 658,970	$ 286,752
Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[1]	652,957	282,913
Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[1],[2]	6,013	3,839
Phathom Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		66,500	43,250
Vida Health | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		40,000	0
Skydio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		37,500	37,500
Oak Street Health, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		44,250	0
HilleVax, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		36,000	0
Axsome Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		42,000	0
Automation Anywhere, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		29,400	0
Iveric Bio Gene Therapy LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		24,750	0
Aryaka Networks, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		20,000	0
Blue Sprig Pediatrics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		10,000	30,000
Finch Therapeutics Group, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		20,000	0
G1 Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		19,375	19,375
Alladapt Immunotherapeutics Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		15,000	0
ATAI Life Sciences N.V. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		14,000	0
Syndax Pharmaceutics Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	30,000
Dronedeploy Incorporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		12,500	0
Carbon Health Technologies, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		11,625	11,625
Locus Robotics Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		18,281	0
R V Share Limited Liability Company | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		8,500	13,500
App Direct Incorporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		10,000	0
Nuvolo Technologies Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		10,200	0
Equality Health, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	17,500
Elation Health, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		7,500	0
Gritstone Bio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		7,500	0
Viridian Therapeutics Inc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		8,000	0
Tarsus Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		18,563	0
Dashlane, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		10,000	19,300
Ouster, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		7,000	0
Akero Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		5,000	0
Alamar Biosciences, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		5,000	0
Fulfil Solutions Inc [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		5,000	0
Brain Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		20,020	20,000
Ceros, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,707	3,845
Signal Media Limited | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		3,750	0
Demandbase, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		3,750	9,375
Riviera Partners LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		3,500	0
Yipit, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		2,250	2,250
Khoros (p.k.a Lithium Technologies) | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,812	1,812
ThreatConnect, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,600	1,600
Dispatch Technologies, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,250	0
Logic Source | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,209	0
Ikon Science Limited | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,050	1,050
Omeda Holdings, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		938	0
Alchemer LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		890	0
3GTMS, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		725	1,583
Agilence, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		800	800
Constructor.io Corporation [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		625	0
Mobile Solutions Services | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		742	424
Enmark Systems, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		457	457
Zimperium, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		1,088	0
Cybermaxx Intermediate Holdings, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		471	471
ShadowDragon, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	333
Gryphon Networks Corp. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		268	268
Cytracom Holdings LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		225	225
Annex Cloud | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		386	0
Thumbtack, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		40,000	0
Better Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	4,000
Logicworks | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	2,000
Pineapple Energy LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	120
E Pay Policy Holdings L L C | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	250
Bicycle Therapeutics PLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		0	10,000
Forbion Growth Opportunities Fund I C V | Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[2]	3,187	3,839
Forbion Growth Opportunities Fund I I C V | Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[2]	$ 2,826	$ 0
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions". For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Parenthetical) (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[1]	$ 658,970	$ 286,752
Adviser Funds
Loss Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount		$ 203,200	$ 34,900
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions".

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Additional Information on Unecumbered Unfunded Commitments (Details) - USD ($) $ in Thousands		Sep. 30, 2022	Dec. 31, 2021
Commitments And Contingencies [Line Items]
Investment Company, Financial Commitment to Investee, Future Amount	[1]	$ 658,970	$ 286,752
Debt Investments
Commitments And Contingencies [Line Items]
2022		198,281	199,681
2023		312,457	43,675
2024		121,586	25,800
2025		1,694	2,232
2026		9,053	11,525
2027		7,745	0
2028		2,141	0
Investment Company, Financial Commitment to Investee, Future Amount	[1]	652,957	282,913
Investment Funds And Vehicles
Commitments And Contingencies [Line Items]
2030		3,187	3,839
2032		2,826	0
Investment Company, Financial Commitment to Investee, Future Amount	[1],[2]	$ 6,013	$ 3,839
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 203.2 million and $ 34.9 million of unfunded commitments as of September 30, 2022, and December 31, 2021 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in "Note -12 Related Party Transactions". For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Contractual Obligations (Details) - USD ($) $ in Thousands		Sep. 30, 2022		Dec. 31, 2021
Commitments And Contingencies [Line Items]
Long-Term Debt, Total	[1]	$ 1,521,220		$ 1,236,303
Lessee, Operating Lease, Liability, to be Paid, Year One		2,500
Total lease payments		6,691
Contractual Obligation, to be Paid, Year One		3,060		383,120
Contractual Obligation, to be Paid, Year Two and Three		378,908		107,958
Contractual Obligation, to be Paid, Year Four and Five		801,853		576,352
Contractual Obligation Due After Fifth Year		365,000		191,278
Contractual Obligations, Total		1,548,821		1,258,708
Debt
Commitments And Contingencies [Line Items]
Long-Term Debt, Maturity, Year One	[2]	0	[3]	380,000	[4]
Long-Term Debt, Maturity, Year Two and Three	[2]	377,000	[3]	105,000	[4]
Long-Term Debt, Maturity, Year Four and Five	[2]	800,000	[3]	574,925	[4]
Long-Term Debt, Maturity, after Year Five	[2]	365,000	[3]	190,500	[4]
Long-Term Debt, Total	[2]	1,542,000	[3]	1,250,425	[4]
Lease and License Obligations
Commitments And Contingencies [Line Items]
Lessee, Operating Lease, Liability, to be Paid, Year One	[5]	3,060		3,120
Lessee, Operating Lease, Liability, to be Paid, Year Two and Three	[5]	1,908		2,958
Lessee, Operating Lease, Liability, to be Paid, Year Four and Five	[5]	1,853		1,427
Lessee, Operating Lease, Liability, to be Paid, after Year Five	[5]	0		778
Total lease payments	[5]	$ 6,821		$ 8,283
[1] Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of September 30, 2022. There was also $ 25.0 million outstanding under the SMBC Facility and $ 102.0 million outstanding under the MUFG Bank Facility as of September 30, 2022 . Includes $ 150.5 million in principal outstanding under the SBA Debentures, $ 150.0 million of the 2022 Notes, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes, and $ 230.0 million of the 2022 Convertible Notes as of December 31, 2021. There was also $ 29.9 million outstanding under the SMBC Facility and no amounts outstanding under the Union Facility as of December 31, 2021 . Facility leases and licenses including short-term leases.

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Contractual Obligations (Parenthetical) (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments And Contingencies [Line Items]
Principal	$ 1,542,000	$ 1,250,425
SMBC Facility
Commitments And Contingencies [Line Items]
Principal	25,000	29,900
MUFG Bank Facility
Commitments And Contingencies [Line Items]
Principal	102,000	0
SBA Debentures
Commitments And Contingencies [Line Items]
Principal	175,000	150,500
2022 Notes
Commitments And Contingencies [Line Items]
Principal	0	150,000
July 2024 Notes
Commitments And Contingencies [Line Items]
Principal	105,000	105,000
February 2025 Notes
Commitments And Contingencies [Line Items]
Principal	50,000	50,000
June 2025 Notes
Commitments And Contingencies [Line Items]
Principal	70,000	70,000
June 2025 3-Year Notes
Commitments And Contingencies [Line Items]
Principal	50,000	0
March 2026 A Notes
Commitments And Contingencies [Line Items]
Principal	50,000	50,000
March 2026 B Notes
Commitments And Contingencies [Line Items]
Principal	50,000	50,000
2031 Asset-Backed Notes
Commitments And Contingencies [Line Items]
Principal	150,000	0
2033 Notes
Commitments And Contingencies [Line Items]
Principal	40,000	40,000
September 2026 Notes
Commitments And Contingencies [Line Items]
Principal	325,000	325,000
January 2027 Notes
Commitments And Contingencies [Line Items]
Principal	350,000	0
2022 Convertible Notes
Commitments And Contingencies [Line Items]
Principal	$ 0	$ 230,000

Commitments and Contingencies_6

Commitments and Contingencies - Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Total operating lease cost	$ 744	$ 724	$ 2,185	$ 2,196
Cash paid for amounts included in the measurement of lease liabilities	$ 642	$ 578	$ 2,411	$ 1,733
Weighted-average remaining lease term (in years)	4 years 2 months 1 day	4 years 4 months 13 days	4 years 2 months 1 day	4 years 4 months 13 days
Weighted-average discount rate	4.53%	4.87%	4.53%	4.87%

Commitments and Contingencies_7

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
2022	$ 652
2023	2,500
2024	848
2025	887
Thereafter	1,804
Total lease payments	6,691
Less: imputed interest	(599)
Operating lease liability	$ 6,092	$ 7,382

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	May 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Adviser Subsidiary
Related Party Transaction [Line Items]
Related party transactions amount receivable or owed		$ 0.5		$ 0.5		$ 0.1
Related party transactions amount		$ 1.9	$ 1.3	6.3	$ 3.5
Adviser Funds
Related Party Transaction [Line Items]
Adviser subsidiary investment commitments				610.9	204.5
Adviser subsidiary investment funding				247.8	139.6
Related Party Transaction, Other Revenues from Transactions with Related Party	$ 0.1
Related party transactions amount	$ 73.5			$ 114.9	$ 107.6

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - $ / shares				7 Months Ended
	Nov. 17, 2022	Nov. 10, 2022	Oct. 13, 2022	Oct. 13, 2022	Mar. 09, 2022
Base Dividend
Subsequent Event [Line Items]
Dividends payable, date of record		Nov. 10, 2022
Supplemental Dividend
Subsequent Event [Line Items]
Cash distribution, per share					$ 0.15
Quarterly distribution, per share					$ 0.15
Subsequent Event [Member] | Base Dividend
Subsequent Event [Line Items]
Dividends payable, date to be paid	Nov. 17, 2022
Cash distribution, per share	$ 0.36
Quarterly distribution, per share	$ 0.36
Subsequent Event [Member] | Supplemental Dividend
Subsequent Event [Line Items]
Dividends payable, date declared				Feb. 16, 2022
Dividends payable, date to be paid	Nov. 17, 2022
Cash distribution, per share	$ 0.15
Quarterly distribution, per share	$ 0.15
Dividends payable, date of record		Nov. 10, 2022
Total Supplemental Dividends Amount to be Paid			$ 0.60
Supplemental Dividends Declared to Date				$ 0.60
Supplemental Dividends Amount to be Paid Each Quarter			$ 0.15
Subsequent Event [Member] | Base and Supplemental Dividend
Subsequent Event [Line Items]
Dividends payable, date declared			Oct. 13, 2022

Schedule 12-14s - Summary of _2

Schedule 12-14s - Summary of schedule of investment (Details) - USD ($)		3 Months Ended				9 Months Ended				12 Months Ended
		Sep. 30, 2022		Sep. 30, 2021		Sep. 30, 2022		Sep. 30, 2021		Dec. 31, 2021		Dec. 31, 2020
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating		$ 84,229,000		$ 70,193,000		$ 221,501,000		$ 208,511,000
Realized Gain (Loss)		5,289,000		21,111,000		775,000		14,599,000
Investment cost		2,869,469,000				2,869,469,000				$ 2,390,984,000
Investment Owned At Fair Value		2,825,738,000				2,825,738,000				2,434,522,000
Net Change in Unrealized Appreciation (Depreciation)		(2,089,000)		(35,651,000)		(87,147,000)		46,231,000
Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		93,096,000				93,096,000				115,271,000
Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		54,393,000				54,393,000				52,890,000
Senior Secured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		2,607,006,000				2,607,006,000				2,156,709,000
Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		41,038,000				41,038,000				69,439,000
Sustainable And Renewable Technology [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		15,683,000				15,683,000				39,387,000
Medical Devices And Equipment [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		17,421,000				17,421,000				12,612,000
Diversified Financial Services [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		72,061,000				72,061,000				65,073,000
Internet Consumer And Business Services [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned At Fair Value		489,968,000				489,968,000				395,506,000
Investment, Affiliated Issuer [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						4,694,000	[1]	2,946,000	[2]
Realized Gain (Loss)						1,758,000		(62,143,000)
Investment cost		87,249,000				87,249,000				97,586,000
Investment Owned At Fair Value		80,325,000	[3]	75,547,000		80,325,000	[3]	75,547,000		82,962,000	[4]	$ 65,740,000
Gross Additions						3,210,000	[5]	19,090,000	[6]
Gross reductions						(13,547,000)	[7]	66,176,000	[8]
Net Change in Unrealized Appreciation (Depreciation)						7,700,000		56,893,000
Investment, Affiliated Issuer, Controlled [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						3,490,000	[1]	2,943,000	[2]
Realized Gain (Loss)						0		0
Investment cost		87,249,000				87,249,000				84,039,000
Investment Owned At Fair Value		80,325,000	[3]	65,835,000		80,325,000	[3]	65,835,000		$ 73,504,000	[4]	57,400,000
Gross Additions						3,210,000	[5]	15,762,000	[6]
Gross reductions						0	[7]	0	[8]
Net Change in Unrealized Appreciation (Depreciation)		(2,571,000)		(3,774,000)		3,611,000		(7,327,000)
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	0		0		0		0
Investment Owned At Fair Value	[9]	33,945,000		16,804,000		33,945,000		16,804,000
Net Change in Unrealized Appreciation (Depreciation)	[9]	(1,236,000)		(219,000)		9,955,000		10,669,000
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	0				0
Investment Owned At Fair Value	[9]	400,000				400,000
Net Change in Unrealized Appreciation (Depreciation)	[9]	(22,000)				(165,000)
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	0		0		0		0
Investment Owned At Fair Value	[9]	8,318,000		8,294,000		8,318,000		8,294,000
Net Change in Unrealized Appreciation (Depreciation)	[9]	110,000		(80,000)		49,000		(306,000)
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	0		0		0		0
Investment Owned At Fair Value	[9]	37,662,000		40,737,000		37,662,000		40,737,000
Net Change in Unrealized Appreciation (Depreciation)	[9]	(1,423,000)		(3,475,000)		(6,228,000)		(17,690,000)
Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Shares										3,000,000
Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Senior Secured Tranche A [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Kind										10%
Maturity Date										2023-12
Investment, Affiliated Issuer, Controlled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Senior Secured Tranche B [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash										10%
Principal Amount										$ 280,000
Maturity Date										2022-01
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						2,974,000	[1]	2,422,000	[2]
Realized Gain (Loss)						0		0
Investment cost		64,836,000				64,836,000				$ 61,626,000
Investment Owned At Fair Value		72,007,000	[3]	57,541,000		72,007,000	[3]	57,541,000		65,235,000	[4]	48,800,000
Gross Additions						3,210,000	[5]	15,762,000	[6]
Gross reductions						0	[7]	0	[8]
Net Change in Unrealized Appreciation (Depreciation)						3,562,000		(7,021,000)
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Hercules Adviser L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		12,035,000				12,035,000				8,885,000
Investment Owned At Fair Value		$ 33,945,000	[3]			$ 33,945,000	[3]			20,840,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Hercules Adviser L L C [Member] | Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		5%				5%
Gross Investment Income, Operating						$ 393,000	[1],[10]	59,000	[2],[11]
Realized Gain (Loss)						0	[10]	0	[11]
Investment cost		$ 12,000,000				12,000,000
Principal Amount		12,000,000				$ 12,000,000
Maturity Date						2025-06
Investment Owned At Fair Value		12,000,000	[3],[10]	6,100,000	[11]	$ 12,000,000	[3],[10]	6,100,000	[11]	8,850,000	[10]	0	[11]
Gross Additions						3,150,000	[5],[10]	6,100,000	[6],[11]
Gross reductions						0	[7],[10]	0	[8],[11]
Net Change in Unrealized Appreciation (Depreciation)						0	[10]	0	[11]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Hercules Adviser L L C [Member] | Member Units [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[10]	0	[2],[11]
Realized Gain (Loss)						0	[10]	0	[11]
Investment cost		$ 35,000				$ 35,000
Shares		1				1
Investment Owned At Fair Value		$ 21,945,000	[3],[10]	10,704,000	[11]	$ 21,945,000	[3],[10]	10,704,000	[11]	11,990,000	[10]	0	[11]
Gross Additions						0	[5],[10]	35,000	[6],[11]
Gross reductions						0	[7],[10]	0	[8],[11]
Net Change in Unrealized Appreciation (Depreciation)						9,955,000	[10]	10,669,000	[11]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Coronado Aesthetics L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		250,000				250,000				250,000
Investment Owned At Fair Value		400,000	[3]			400,000	[3]			565,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Coronado Aesthetics L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[1],[12]					0
Realized Gain (Loss)	[12]					0
Investment Owned At Fair Value	[12]	9,000				9,000				65,000
Gross Additions	[5],[12]					0
Gross reductions	[7],[12]					0
Net Change in Unrealized Appreciation (Depreciation)	[12]					(56,000)
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Coronado Aesthetics L L C [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[1],[12]					0
Realized Gain (Loss)	[12]					0
Investment Owned At Fair Value	[12]	391,000				391,000				500,000
Gross Additions	[5],[12]					0
Gross reductions	[7],[12]					0
Net Change in Unrealized Appreciation (Depreciation)	[12]					(109,000)
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Gibraltar Business Capital L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		52,551,000				52,551,000				52,491,000
Investment Owned At Fair Value		37,662,000	[3]			37,662,000	[3]			43,830,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Gibraltar Business Capital L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[13]	0	[2],[14]
Realized Gain (Loss)						0	[13]	0	[14]
Investment Owned At Fair Value		1,134,000	[13]	1,166,000	[14]	1,134,000	[13]	1,166,000	[14]	1,225,000	[13]	2,276,000	[14]
Gross Additions						0	[5],[13]	0	[6],[14]
Gross reductions						0	[7],[13]	0	[8],[14]
Net Change in Unrealized Appreciation (Depreciation)						(91,000)	[13]	(1,110,000)	[14]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Gibraltar Business Capital L L C [Member] | Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						2,581,000	[1],[13]	2,363,000	[2],[14]
Realized Gain (Loss)	[14]							0
Investment Owned At Fair Value		22,039,000	[13]	23,403,000	[14]	22,039,000	[13]	23,403,000	[14]	23,212,000	[13]	14,970,000	[14]
Gross Additions						60,000	[5],[13]	9,627,000	[6],[14]
Gross reductions						0	[7],[13]	0	[8],[14]
Net Change in Unrealized Appreciation (Depreciation)						(1,233,000)	[13]	(1,194,000)	[14]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Gibraltar Business Capital L L C [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[13]	0	[2],[14]
Realized Gain (Loss)						0	[13]	0	[14]
Investment Owned At Fair Value		14,489,000	[13]	16,168,000	[14]	14,489,000	[13]	16,168,000	[14]	19,393,000	[13]	31,554,000	[14]
Gross Additions						0	[5],[13]	0	[6],[14]
Gross reductions						0	[7],[13]	0	[8],[14]
Net Change in Unrealized Appreciation (Depreciation)						(4,904,000)	[13]	(15,386,000)	[14]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Medical Devices And Equipment [Member] | Coronado Aesthetics L L C [Member] | Preferred Series A
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 250,000				$ 250,000				$ 250,000
Shares		5,000,000				5,000,000				5,000,000
Investment Owned At Fair Value		$ 391,000	[3]			$ 391,000	[3]			$ 500,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Medical Devices And Equipment [Member] | Coronado Aesthetics L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 0				$ 0				$ 0
Shares		180,000				180,000				180,000
Investment Owned At Fair Value		$ 9,000	[3]			$ 9,000	[3]			$ 65,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Hercules Adviser L L C [Member] | Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash										5%
Investment cost										$ 8,850,000
Principal Amount										$ 8,850,000
Maturity Date										2023-05
Investment Owned At Fair Value	[4]									$ 8,850,000
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Hercules Adviser L L C [Member] | Member Units [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost										$ 35,000
Shares										1,000
Investment Owned At Fair Value	[4]									$ 11,990,000
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Preferred Series A
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 26,122,000				$ 26,122,000				$ 26,122,000
Shares		10,602,752				10,602,752				10,602,752
Investment Owned At Fair Value		$ 14,489,000	[3]			$ 14,489,000	[3]			$ 19,393,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 1,884,000				$ 1,884,000				$ 1,884,000
Shares		830,000				830,000				830,000
Investment Owned At Fair Value		$ 1,134,000	[3]			$ 1,134,000	[3]			$ 1,225,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Unsecured Debt Eleven Point Five Zero Percentage [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		11.50%				11.50%				11.50%
Investment cost		$ 9,844,000				$ 9,844,000				$ 9,823,000
Principal Amount		10,000,000				$ 10,000,000				$ 10,000,000
Maturity Date						2026-09				2026-09
Investment Owned At Fair Value		$ 9,006,000	[3]			$ 9,006,000	[3]			$ 9,394,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Unsecured Debt Fourteen Point Five Zero Percentage [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		14.50%				14.50%				14.50%
Investment cost		$ 14,701,000				$ 14,701,000				$ 14,662,000
Principal Amount		15,000,000				$ 15,000,000				$ 15,000,000
Maturity Date						2026-09				2026-09
Investment Owned At Fair Value		13,033,000	[3]			$ 13,033,000	[3]			$ 13,818,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						516,000	[1]	521,000	[2]
Realized Gain (Loss)						0		0
Investment cost		22,413,000				22,413,000				22,413,000
Investment Owned At Fair Value		8,318,000	[3]	8,294,000		8,318,000	[3]	8,294,000		8,269,000	[4]	8,600,000
Gross Additions						0	[5]	0	[6]
Gross reductions						0	[7]	0	[8]
Net Change in Unrealized Appreciation (Depreciation)						49,000		(306,000)
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Tectura Corporation [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		22,413,000				22,413,000				22,413,000
Investment Owned At Fair Value		8,318,000	[3]			8,318,000	[3]			8,269,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Tectura Corporation [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[15]	0	[2],[16]
Realized Gain (Loss)						0	[15]	0	[16]
Investment Owned At Fair Value		0	[15]	0	[16]	0	[15]	0	[16]	0	[15]	0	[16]
Gross Additions						0	[5],[15]	0	[6],[16]
Gross reductions						0	[7],[15]	0	[8],[16]
Net Change in Unrealized Appreciation (Depreciation)						0	[15]	0	[16]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Tectura Corporation [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[15]	0	[2],[16]
Realized Gain (Loss)						0	[15]	0	[16]
Investment Owned At Fair Value		0	[15]	0	[16]	0	[15]	0	[16]	0	[15]	0	[16]
Gross Additions						0	[5],[15]	0	[6],[16]
Gross reductions						0	[7],[15]	0	[8],[16]
Net Change in Unrealized Appreciation (Depreciation)						0	[15]	0	[16]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Gibraltar Business Capital L L C [Member] | Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[13]					0
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Internet Consumer And Business Services [Member] | Tectura Corporation [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 900,000				$ 900,000				$ 900,000
Shares		414,994,863				414,994,863				414,994,863
Investment Owned At Fair Value		$ 0	[3]			$ 0	[3]			$ 0	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Internet Consumer And Business Services [Member] | Tectura Corporation [Member] | Senior Secured Tranche A [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Kind		5%				5%				5%
Investment cost		$ 240,000				$ 240,000				$ 240,000
Principal Amount		10,680,000				$ 10,680,000				$ 10,680,000
Maturity Date						2024-07				2024-07
Investment Owned At Fair Value		$ 0	[3]			$ 0	[3]			$ 0	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Internet Consumer And Business Services [Member] | Tectura Corporation [Member] | Senior Secured Tranche B [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		8.25%				8.25%				8.25%
Investment cost		$ 8,250,000				$ 8,250,000				$ 8,250,000
Principal Amount		8,250,000				$ 8,250,000				$ 8,250,000
Maturity Date						2024-07				2024-07
Investment Owned At Fair Value		$ 8,250,000	[3]			$ 8,250,000	[3]			$ 8,250,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Internet Consumer And Business Services [Member] | Tectura Corporation [Member] | Senior Secured Tranche C [Member]
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Kind		5%				5%				5%
Investment cost		$ 13,023,000				$ 13,023,000				$ 13,023,000
Principal Amount		13,023,000				$ 13,023,000				$ 13,023,000
Maturity Date						2024-07				2024-07
Investment Owned At Fair Value		68,000	[3]			$ 68,000	[3]			$ 19,000	[4]
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments | Internet Consumer And Business Services [Member] | Tectura Corporation [Member] | Preferred Series BB Equity
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 0				$ 0				$ 0
Shares		1,000,000				1,000,000				1,000,000
Investment Owned At Fair Value		$ 0	[3]			$ 0	[3]			$ 0	[4]
Investment, Affiliated Issuer, Controlled [Member] | Senior Debt [Member] | Other Control Investments | Tectura Corporation [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						516,000	[1],[15]	521,000	[2],[16]
Realized Gain (Loss)						0	[15]	0	[16]
Investment Owned At Fair Value		8,318,000	[15]	8,294,000	[16]	8,318,000	[15]	8,294,000	[16]	8,269,000	[15]	8,600,000	[16]
Gross Additions						0	[5],[15]	0	[6],[16]
Gross reductions						0	[7],[15]	0	[8],[16]
Net Change in Unrealized Appreciation (Depreciation)						49,000	[15]	(306,000)	[16]
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						1,204,000	[1]	3,000	[2]
Realized Gain (Loss)		(2,014,000)		0		1,758,000		(62,143,000)
Investment cost		0				0				13,547,000
Investment Owned At Fair Value		0		9,712,000		0		9,712,000		9,458,000	[4]	8,340,000
Gross Additions						0	[5]	3,328,000	[6]
Gross reductions						(13,547,000)	[7]	66,176,000	[8]
Net Change in Unrealized Appreciation (Depreciation)		4,631,000		(118,000)		4,089,000		64,220,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Solar Spectrum Holdings L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]			0				(62,143,000)
Investment Owned At Fair Value	[9]			0				0
Net Change in Unrealized Appreciation (Depreciation)	[9]			0				62,183,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Solar Spectrum Holdings L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[17]							0
Realized Gain (Loss)	[17]							(61,502,000)
Investment Owned At Fair Value	[17]			0				0				0
Gross Additions	[6],[17]							0
Gross reductions	[8],[17]							61,502,000
Net Change in Unrealized Appreciation (Depreciation)	[17]							61,502,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	(2,014,000)	[18]	0		(2,014,000)	[18]	0
Investment cost										12,547,000
Investment Owned At Fair Value		0	[9],[18]	8,469,000	[9]	0	[9],[18]	8,469,000	[9]	8,338,000	[4]
Net Change in Unrealized Appreciation (Depreciation)	[9]	4,631,000	[18]	(52,000)		4,209,000	[18]	9,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[19]	0	[2],[20]
Realized Gain (Loss)						0	[19]	0	[20]
Investment Owned At Fair Value		0	[19]	849,000	[20]	0	[19]	849,000	[20]	591,000	[19]	840,000	[20]
Gross Additions						0	[5],[19]	0	[6],[20]
Gross reductions						(4,767,000)	[7],[19]	0	[8],[20]
Net Change in Unrealized Appreciation (Depreciation)						4,176,000	[19]	9,000	[20]
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow A I Inc [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9]	0	[18]	0		3,772,000	[18]	0
Investment Owned At Fair Value	[9]	0	[18]	1,243,000		0	[18]	1,243,000
Net Change in Unrealized Appreciation (Depreciation)	[9]	0	[18]	(66,000)		(120,000)	[18]	2,028,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow A I Inc [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[1],[21]	0	[2],[22]
Realized Gain (Loss)						3,772,000	[21]	0	[22]
Investment Owned At Fair Value		0	[21]	1,243,000	[22]	0	[21]	1,243,000	[22]	1,120,000	[21]	0	[22]
Gross Additions						0	[5],[21]	1,000,000	[6],[22]
Gross reductions						(1,000,000)	[7],[21]	0	[8],[22]
Net Change in Unrealized Appreciation (Depreciation)						(120,000)	[21]	243,000	[22]
Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost										4,767,000
Investment Owned At Fair Value	[4]									591,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Senior Secured Tranche A [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost										7,500,000
Principal Amount										7,500,000
Investment Owned At Fair Value	[4]									7,500,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Sustainable And Renewable Technology [Member] | Pineapple Energy L L C [Member] | Senior Secured Tranche B [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost										280,000
Investment Owned At Fair Value	[4]									247,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Internet Consumer And Business Services [Member] | Black Crow A I Inc [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Investment cost										$ 1,000,000
Shares										872,797
Investment Owned At Fair Value	[4]									$ 1,120,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Senior Debt [Member] | Solar Spectrum Holdings L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[17]							0
Realized Gain (Loss)	[17]							(641,000)
Investment Owned At Fair Value	[17]			0				0				0
Gross Additions	[6],[17]							0
Gross reductions	[8],[17]							681,000
Net Change in Unrealized Appreciation (Depreciation)	[17]							681,000
Investment, Affiliated Issuer, Noncontrolled [Member] | Senior Debt [Member] | Pineapple Energy L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						1,204,000	[1],[19]	3,000	[2],[20]
Realized Gain (Loss)						(2,014,000)	[19]	0	[20]
Investment Owned At Fair Value		$ 0	[19]	7,620,000	[20]	0	[19]	7,620,000	[20]	$ 7,747,000	[19]	7,500,000	[20]
Gross Additions						0	[5],[19]	120,000	[6],[20]
Gross reductions						(7,780,000)	[7],[19]	0	[8],[20]
Net Change in Unrealized Appreciation (Depreciation)						$ 33,000	[19]	0	[20]
Investment, Affiliated Issuer, Noncontrolled [Member] | Convertible Debt [Member] | Black Crow A I Inc [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[22]							0
Realized Gain (Loss)	[22]							0
Investment Owned At Fair Value	[22]			$ 0				0				$ 0
Gross Additions	[6],[22]							2,208,000
Gross reductions	[8],[22]							3,993,000
Net Change in Unrealized Appreciation (Depreciation)	[22]							$ 1,785,000
[1] Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2022 and September 30, 2021 , there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. Hercules Adviser LLC is a wholly owned subsidiary providing investment management and other services to the Adviser Funds and other External Parties. Hercules Adviser LLC is a wholly-owned subsidiary providing investment management and other services to External Parties. As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company. As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the As of June 30, 2021, the Company’s investments in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) were written off for a realized loss. As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC are no longer affiliates as defined under the 1940 Act. During the three months ended September 30, 2022, the Company sold a portion of its investments in Pineapple Energy LLC, as a result it is no longer an affiliate investment.. As of December 11, 2020, the Company’s investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of During the nine months ended September 30, 2022 , the Company sold its investments in Black Crow AI, Inc., as a result it is no longer an affiliate investment. As of March 23, 2021, the Company's investment in Black Crow AI, Inc. became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the

Schedule 12-14s - Summary of _3

Schedule 12-14s - Summary of schedule of investment (Parenthetical) (Details)	Sep. 30, 2022	Dec. 31, 2021
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets		0.72%
Investment, Affiliated Issuer, Controlled [Member]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	5.89%	5.62%
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	0.61%	0.63%
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments [Member]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	5.28%	4.99%
Investment, Affiliated Issuer [Member]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	5.89%	6.34%

N-2

N-2	9 Months Ended
	Sep. 30, 2022
Cover [Abstract]
Entity Central Index Key	0001280784
Amendment Flag	false
Securities Act File Number	814-00702
Document Type	10-Q
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Address, Address Line One	400 Hamilton Ave
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	289-3060
Entity Emerging Growth Company	false
General Description of Registrant [Abstract]
Risk Factors [Table Text Block]	ITEM 1A. RISK FACTORS In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 22, 2022 (the “Annual Report”) and Part II, Item 1A “Risk Factors” of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 5, 2022. Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at September 30, 2022 that represent greater than 5% of our net assets: (in thousands) September 30, 2022 Fair Value Percentage of Net Assets Corium, Inc. $ 135,828 10.0 % Phathom Pharmaceuticals, Inc. $ 94,119 6.9 % Worldremit Group Limited $ 92,698 6.8 % SeatGeek, Inc. $ 87,812 6.4 % Rocket Lab Global Services, LLC $ 87,283 6.4 % Axsome Therapeutics, Inc. $ 85,438 6.3 % Convoy, Inc. $ 73,674 5.4 % uniQure B.V. $ 73,527 5.4 % • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Worldremit Group Limited is a global online money transfer business. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events. • Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches. • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Convoy, Inc. is a developer for on-demand shipment services. • uniQure B.V. is a leader in the field of gene therapy, developing proprietary therapies to treat patients with severe genetic diseases of the central nervous system and liver. Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.
Significant Portfolio Investment [Member]
General Description of Registrant [Abstract]
Risk [Text Block]	Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at September 30, 2022 that represent greater than 5% of our net assets: (in thousands) September 30, 2022 Fair Value Percentage of Net Assets Corium, Inc. $ 135,828 10.0 % Phathom Pharmaceuticals, Inc. $ 94,119 6.9 % Worldremit Group Limited $ 92,698 6.8 % SeatGeek, Inc. $ 87,812 6.4 % Rocket Lab Global Services, LLC $ 87,283 6.4 % Axsome Therapeutics, Inc. $ 85,438 6.3 % Convoy, Inc. $ 73,674 5.4 % uniQure B.V. $ 73,527 5.4 % • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Worldremit Group Limited is a global online money transfer business. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events. • Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches. • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Convoy, Inc. is a developer for on-demand shipment services. • uniQure B.V. is a leader in the field of gene therapy, developing proprietary therapies to treat patients with severe genetic diseases of the central nervous system and liver. Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.